<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Gonadotropin‐releasing hormone analogues for endometriosis - Veth, VB - 2023 | Cochrane Library</title> <meta content="Gonadotropin‐releasing hormone analogues for endometriosis - Veth, VB - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014788.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Gonadotropin‐releasing hormone analogues for endometriosis - Veth, VB - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014788.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD014788.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Gonadotropin‐releasing hormone analogues for endometriosis" name="citation_title"/> <meta content="Veerle B Veth" name="citation_author"/> <meta content="Maastricht University Medical Center (MUMC+)" name="citation_author_institution"/> <meta content="veerle.veth@mumc.nl" name="citation_author_email"/> <meta content="Majorie MA van de Kar" name="citation_author"/> <meta content="Laurentius Ziekenhuis" name="citation_author_institution"/> <meta content="James MN Duffy" name="citation_author"/> <meta content="The Fetal Medicine Research Institute" name="citation_author_institution"/> <meta content="Madelon van Wely" name="citation_author"/> <meta content="Amsterdam UMC, University of Amsterdam" name="citation_author_institution"/> <meta content="Velja Mijatovic" name="citation_author"/> <meta content="Amsterdam UMC" name="citation_author_institution"/> <meta content="Jacques WM Maas" name="citation_author"/> <meta content="Maastricht University Medical Center (MUMC+)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD014788.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/06/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014788.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014788.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014788.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Calcium; Calcium, Dietary; Danazol [therapeutic use]; *Drug-Related Side Effects and Adverse Reactions; Dysmenorrhea; *Dyspareunia [drug therapy, etiology]; *Endometriosis [complications, drug therapy]; Gestrinone; Gonadotropin-Releasing Hormone; Pelvic Pain [drug therapy, etiology]; Progestins [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014788.pub2&amp;doi=10.1002/14651858.CD014788.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZDBB8PHY";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD014788\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD014788\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014788\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014788\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","th","ms","fa","fr","hu","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD014788.pub2",title:"Gonadotropin\\u2010releasing hormone analogues for endometriosis",firstPublishedDate:"Jun 21, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014788.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014788.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD014788.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD014788.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014788.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD014788.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD014788.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD014788.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD014788.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD014788.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4501 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD014788.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-sec-0078"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-sec-0065"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/appendices#CD014788-sec-0083"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/supinfo/CD014788-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/supinfo/CD014788-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Gonadotropin‐releasing hormone analogues for endometriosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/information#CD014788-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Veerle B Veth</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/information#CD014788-cr-0005">Majorie MA van de Kar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/information#CD014788-cr-0006">James MN Duffy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/information#CD014788-cr-0007">Madelon van Wely</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/information#CD014788-cr-0008">Velja Mijatovic</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014788.pub2/information#CD014788-cr-0009">Jacques WM Maas</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/information/en#CD014788-sec-0091">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 June 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD014788.pub2">https://doi.org/10.1002/14651858.CD014788.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD014788-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014788-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014788-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014788-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014788-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD014788-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014788-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD014788-abs-0001" lang="en"> <section id="CD014788-sec-0001"> <h3 class="title" id="CD014788-sec-0001">Background</h3> <p>Endometriosis is a common gynaecological condition affecting 6 to 11% of reproductive‐age women and may cause dyspareunia, dysmenorrhoea, and infertility. One treatment strategy is medical therapy with gonadotrophin‐releasing hormone analogues (GnRHas) to reduce pain due to endometriosis. One of the adverse effects of GnRHas is a decreased bone mineral density. In addition to assessing the effect on pain, quality of life, most troublesome symptom and patients' satisfaction, the current review also evaluated the effect on bone mineral density and risk of adverse effects in women with endometriosis who use GnRHas versus other treatment options. </p> </section> <section id="CD014788-sec-0002"> <h3 class="title" id="CD014788-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of GnRH analogues (GnRHas) in the treatment of painful symptoms associated with endometriosis and to determine the effects of GnRHas on bone mineral density of women with endometriosis. </p> </section> <section id="CD014788-sec-0003"> <h3 class="title" id="CD014788-sec-0003">Search methods</h3> <p>We searched the Cochrane Gynaecology and Fertility (CGF) Group trials register, CENTRAL, MEDLINE, Embase, PsycINFO and the trial registries in May 2022 together with reference checking and contact with study authors and experts in the field to identify additional studies. </p> </section> <section id="CD014788-sec-0004"> <h3 class="title" id="CD014788-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) which compared GnRHas with other hormonal treatment options, including analgesics, danazol, intra‐uterine progestogens, oral or injectable progestogens, gestrinone and also GnRHas compared with no treatment or placebo. Trials comparing GnRHas versus GnRHas in conjunction with add‐back therapy (hormonal or non‐hormonal) or calcium‐regulation agents were also included in this review.  </p> </section> <section id="CD014788-sec-0005"> <h3 class="title" id="CD014788-sec-0005">Data collection and analysis</h3> <p>We used standard methodology as recommended by Cochrane. Primary outcomes are relief of overall pain and the objective measurement of bone mineral density. Secondary outcomes include adverse effects, quality of life, improvement in the most troublesome symptoms and patient satisfaction.  </p> <p>Due to high risk of bias associated with some of the studies, primary analyses of all review outcomes were restricted to studies at low risk of selection bias. Sensitivity analysis including all studies was then performed. </p> </section> <section id="CD014788-sec-0006"> <h3 class="title" id="CD014788-sec-0006">Main results</h3> <p>Seventy‐two studies involving 7355 patients were included. The evidence was very low to low quality: the main limitations of all studies were serious risk of bias due to poor reporting of study methods, and serious imprecision.  </p> <p><b>Trials comparing GnRHas versus no treatment </b> </p> <p>We did not identify any studies.</p> <p><b>Trials comparing GnRHas versus placebo</b> </p> <p>There may be a decrease in overall pain, reported as pelvic pain scores (RR 2.14; 95% CI 1.41 to 3.24, 1 RCT, n = 87, low‐certainty evidence), dysmenorrhoea scores (RR 2.25; 95% CI 1.59 to 3.16, 1 RCT, n = 85, low‐certainty evidence), dyspareunia scores (RR 2.21; 95% CI 1.39 to 3.54, 1 RCT, n = 59, low‐certainty evidence), and pelvic tenderness scores (RR 2.28; 95% CI 1.48 to 3.50, 1 RCT, n = 85, low‐certainty evidence) after three months of treatment. We are uncertain of the effect for pelvic induration, based on the results found after three months of treatment (RR 1.07; 95% CI 0.64 to 1.79, 1 RCT, n = 81, low‐certainty evidence). Besides, treatment with GnRHas may be associated with a greater incidence of hot flushes at three months of treatment (RR 3.08; 95% CI 1.89 to 5.01, 1 RCT, n = 100, low‐certainty evidence). </p> <p><b>Trials comparing GnRHas versus danazol</b> </p> <p>For overall pain, for women treated with either GnRHas or danazol, a subdivision was made between pelvic tenderness, partly resolved and completely resolved. We are uncertain about the effect on relief of overall pain, when a subdivision was made for overall pain (MD ‐0.30; 95% CI ‐1.66 to 1.06, 1 RCT, n = 41, very low‐certainty evidence), pelvic pain (MD 0.20; 95% CI ‐0.26 to 0.66, 1 RCT, n = 41, very low‐certainty evidence), dysmenorrhoea (MD 0.10; 95% CI ‐0.49 to 0.69, 1 RCT, n = 41, very low‐certainty evidence), dyspareunia (MD ‐0.20; 95% CI ‐0.77 to 0.37, 1 RCT, n = 41, very low‐certainty evidence), pelvic induration (MD ‐0.10; 95% CI ‐0.59 to 0.39, 1 RCT, n = 41, very low‐certainty evidence), and pelvic tenderness (MD ‐0.20; 95% CI ‐0.78 to 0.38, 1 RCT, n = 41, very low‐certainty evidence) after three months of treatment. For pelvic pain (MD 0.50; 95% CI 0.10 to 0.90, 1 RCT, n = 41, very low‐certainty evidence) and pelvic induration (MD 0.70; 95% CI 0.21 to 1.19, 1 RCT, n = 41, very low‐certainty evidence), the complaints may decrease slightly after treatment with GnRHas, compared to danazol, for six months of treatment. </p> <p><b>Trials comparing GnRHas versus analgesics </b> </p> <p>We did not identify any studies.</p> <p><b>Trials comparing GnRHas versus intra‐uterine progestogens</b> </p> <p>We did not identify any low risk of bias studies.</p> <p><b>Trials comparing GnRHas versus GnRHas in conjunction with calcium‐regulating agents</b> </p> <p>There may be a slight decrease in bone mineral density (BMD) after 12 months treatment with GnRHas, compared to GnRHas in conjunction with calcium‐regulating agents for anterior‐posterior spine (MD ‐7.00; 95% CI ‐7.53 to ‐6.47, 1 RCT, n = 41, very low‐certainty evidence) and lateral spine (MD ‐12.40; 95% CI ‐13.31 to ‐11.49, 1 RCT, n = 41, very low‐certainty evidence).  </p> </section> <section id="CD014788-sec-0007"> <h3 class="title" id="CD014788-sec-0007">Authors' conclusions</h3> <p>For relief of overall pain, there may be a slight decrease in favour of treatment with GnRHas compared to placebo or oral or injectable progestogens. We are uncertain about the effect when comparing GnRHas with danazol, intra‐uterine progestogens or gestrinone. For BMD, there may be a slight decrease when women are treated with GnRHas, compared to gestrinone. There was a bigger decrease of BMD in favour of GnRHas, compared to GnRHas in conjunction with calcium‐regulating agents. However, there may be a slight increase in adverse effects when women are treated with GnRHas, compared to placebo or gestrinone. </p> <p>Due to a very low to low certainty of the evidence, a wide range of outcome measures and a wide range of outcome measurement instruments, the results should be interpreted with caution.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD014788-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014788-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD014788-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD014788-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014788-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014788-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hu#CD014788-abs-0014">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ms#CD014788-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ro#CD014788-abs-0015">Română</a> </li> <li class="section-language"> <a class="" href="full/th#CD014788-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014788-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD014788-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD014788-abs-0002" lang="en"> <h3>Gonadotrophin‐releasing hormone analogues for pain associated with endometriosis</h3> <p>What are the benefits and risks of gonadotrophin‐releasing hormone analogues (GnRHas) for pain associated with endometriosis? </p> <p><b>Key messages</b> </p> <p>GnRHas offer more pain reduction compared to placebo or progestogens. However, the largest decrease in bone mineral density (BMD) was found when using GnRHas, compared to a different hormone called gestrinone and GnRHas together with calcium‐regulating agents (acting on bone).  </p> <p>Most adverse effects were hot flushes for patients treated with GnRHas or gestrinone (hormone) and weight gain when treated with danazol (hormone). </p> <p>Further, well‐designed research is needed to provide better understanding of the benefits and risks of using GnRHas and other hormonal treatment options for pain associated with endometriosis. </p> <p><b>What is endometriosis?</b> </p> <p>Endometriosis is a common condition, affecting women of childbearing age, and is usually due to the presence of endometrial‐like tissue in places other than the uterus. The most reported symptoms are pain and infertility. </p> <p><b>What are GnRHas?</b> </p> <p>GnRHas are a group of drugs often used to treat endometriosis. GnRHas are a synthetic form of the hormone gonadorelin, released by the hypothalamus in the brain. They stimulate the pituitary gland in the brain to produce luteinising hormone (LH) and follicle‐stimulating hormone (FSH), both reproductive hormones. These reproductive hormones further stimulate the production of progesterone and oestrogen in the ovaries, the hormones that control your menstrual cycle.  </p> <p>However, continued use of GnRHas results in a suppression of ovarian function and therefore reduces oestrogen and progesterone levels. This will in turn result in a decrease of endometrial tissue and therefore reduce complaints of endometriosis. </p> <p>Because GnRHas temporarily stop the production of reproductive hormones, they mimic symptoms of menopause, including a decrease in bone mineral density (the amount of calcium and other minerals present in your bones). </p> <p><b>What did we want to find out?</b> </p> <p>In the current review, we looked at women with endometriosis, who were treated with GnRHas, and compared this treatment with other forms of hormonal treatment. </p> <p>We wanted to find out if GnRHas were better than any other hormonal treatment to improve pain and to see their effect on bone mineral density. </p> <p>Additionally, we wanted to find out if GnRHas were associated with an improved quality of life and also unveil any unwanted effects. </p> <p><b>What did we do?</b> </p> <p>The review involved searching for studies that investigated the effect of GnRHas compared with placebo (dummy treatment) and other hormonal treatment in women with endometriosis. We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found 72 trials that involved 7355 women with endometriosis. </p> <p>‐ A difference in overall pain, reported as pain reduction was seen in favour of GnRHas compared to placebo. We also saw that women treated with GnRHas had less pelvic pain reduction and an increase in endometriotic lesions after six months of treatment, compared to danazol.  </p> <p>‐ After six months of treatment, there was a greater decrease of pain for women treated with GnRHas compared to gestrinone.  </p> <p>‐ No difference was seen in pain scores between women treated with GnRHas compared to other hormonal treatment options.  </p> <p>‐ Most adverse effects were seen in women treated with GnRHas compared to placebo (hot flushes), with danazol (weight gain) and gestrinone (hot flushes).  </p> <p>‐ A greater decrease in bone mineral density was found in GnRHas compared to gestrinone and GnRHas in conjunction with calcium‐regulating agents.  </p> <p>‐ For the other comparisons examined in the current review, we are uncertain of the effect between the examined groups. It should be noted, however, that the evidence was often of (very) low quality in the analyses undertaken for the other comparisons. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>The included studies were of low quality mainly due to poor reporting of study methods and the inaccuracy with which the results were reported. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>The evidence is up‐to‐date to May 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD014788-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD014788-sec-0078"></div> <h3 class="title" id="CD014788-sec-0079">Implications for practice</h3> <section id="CD014788-sec-0079"> <p>Women who have complaints of endometriosis can be treated in different ways. The current review suggests that, for relief of overall pain, there may be a decrease in favour of treatment with GnRHas compared to placebo or oral or injectable progestogens. We are uncertain about the effects when comparing GnRHas with danazol, intra‐uterine progestogens or gestrinone. Not all aspects of pain relief are discussed in all the trials and generalisability about the relief of specific aspects of pain may be difficult.  </p> <p>This review showed that there may be a slight decrease in BMD when women were treated with GnRHas, compared to gestrinone. There was also a greater decrease of BMD when women were treated with GnRHas alone, compared to GnRHas in conjunction with calcium‐regulating agents. Thus, there may be an increase in adverse effects when women are treated with GnRHas, compared to placebo or gestrinone. This must be taken into account in the decision‐making process together with the patient, as endometriosis is a common disease, with many different treatment options that need to be individualised to the wishes and stage of life of the individual patient.  </p> </section> <h3 class="title" id="CD014788-sec-0080">Implications for research</h3> <section id="CD014788-sec-0080"> <p>Due to the limited number of low‐risk studies and the high heterogeneity in the sensitivity analyses, we recommend further research into the effects of GnRHas and other hormonal treatment options on our stated outcome measures. We recommend considering a modern large study with low risk of bias to validate the practice that has become common practice. In addition, it remains important to clearly describe the method in future articles, so that more articles can be labelled as low risk of bias in future reviews. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD014788-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD014788-sec-0008"></div> <div class="table" id="CD014788-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">GnRHas compared to no treatment for relief of overall pain associated with endometriosis and its related adverse effects</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GnRHas compared to no treatment for relief of overall pain associated with endometriosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> Women with endometriosis<br/><b>Settings:</b> Gynaecology clinics<br/><b>Intervention:</b> GnRHas<br/><b>Comparison:</b> No treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>GnRHas</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies included for any outcomes</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD014788-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">GnRHas compared to placebo for relief of overall pain associated with endometriosis and its related adverse effects</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GnRHas compared to placebo for relief of overall pain associated with endometriosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> Women with endometriosis<br/><b>Settings:</b> Gynaecology clinic<br/><b>Intervention:</b> GnRHas<br/><b>Comparison:</b> Placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>GnRHas</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ reported as pelvic pain ‐ 3 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>372 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>796 per 1000</b> </p> <p>(525 to 1205)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.14</b> </p> <p>(1.41 to 3.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relief of overall pain ‐ reported as dysmenorrhoea ‐ 3 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>439 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>988 per 1000</b> </p> <p>(698 to 1387)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.25</b> </p> <p>(1.59 to 3.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ reported as dyspareunia ‐ 3 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>387 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>855 per 1000</b> </p> <p>(538 to 1370)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.21</b> </p> <p>(1.39 to 3.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ reported as pelvic tenderness scores‐ 3 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>357 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>814 per 1000</b> </p> <p>(529 to 1250)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.28</b> </p> <p>(1.48 to 3.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ reported as pelvic induration scores ‐ 3 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>405 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>434 per 1000</b> </p> <p>(259 to 726)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.07</b> </p> <p>(0.64 to 1.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Evidence based on a single trial </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014788-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">GnRHas compared to analgesics for relief of overall pain associated with endometriosis and its related adverse effects</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GnRHas compared to analgesics for relief of overall pain associated with endometriosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> Women with pain due to endometriosis<br/><b>Settings:</b> Gynaecological clinics<br/><b>Intervention:</b> GnRHas<br/><b>Comparison:</b> Analgesics </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Analgesics</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>GnRHas</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies included for any outcomes</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD014788-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">GnRHas compared to danazol for relief of overall pain associated with endometriosis and its related adverse effects</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GnRHas compared to danazol for relief of overall pain associated with endometriosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> Women with pain due to endometriosis<br/><b>Settings:</b> Gynaecological clinics<br/><b>Intervention:</b> GnRHas<br/><b>Comparison:</b> Danazol </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Danazol</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>GnRHas</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relief of overall pain ‐ reported as pelvic tenderness, partly resolved ‐ 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>316 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>363 per 1000</b><br/>(155 to 862) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.15</b><br/>(0.49 to 2.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relief of overall pain ‐ reported as pelvic tenderness, complete resolved ‐ 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>579 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>637 per 1000</b><br/>(388 to 1048) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10 </b><br/>(0.67 to 1.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of overall pain in the control groups was ‐4.6</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of overall pain in the intervention group was <b>0.4 higher</b> </p> <p>(‐0.86 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ reported as pelvic pain ‐ 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of pelvic pain in the control groups was ‐0.5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of pelvic pain in the intervention group was <b>0.5 higher</b> </p> <p>(0.10 to 0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ reported as dysmenorrhoea ‐ 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of dysmenorrhoea in the control groups was ‐2.4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of dysmenorrhoea in the intervention group was <b>0.4 higher</b> </p> <p>(‐0.12 to 0.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ reported as pelvic induration ‐ 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of pelvic induration in the control groups was ‐0.7</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of pelvic induration in the intervention group was <b>0.7 higher</b> </p> <p>(0.21 to 1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ reported as pelvic tenderness ‐ 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of pelvic tenderness in the control groups was ‐0.7</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of pelvic tenderness in the intervention group was <b>0.2 lower</b> </p> <p>(‐0.75 to 0.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Evidence based on a single trial </p> <p><sup>2</sup> Small number of events </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014788-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">GnRHas compared to intra‐uterine progestogens device for relief of overall pain associated with endometriosis and its related adverse effects</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GnRHas compared to intra‐uterine progestogens device for relief of overall pain associated with endometriosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> Women with pain due to endometriosis<br/><b>Settings:</b> Gynaecological clinics<br/><b>Intervention:</b> GnRHas<br/><b>Comparison: I</b>ntra‐uterine progestogens device </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intra‐uterine progestogens device</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>GnRHas</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies included with only low risk of bias</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD014788-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Effect of GnRHas versus other hormonal treatment on bone mineral density</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Effect of GnRHas versus other hormonal treatment on bone mineral density</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population</b>: Women with endometriosis, treated with GnRHas with effect on bone mineral density </p> <p><b>Settings</b>: Gynaecological clinics  </p> <p><b>Intervention</b>: GnRHas </p> <p><b>Comparison</b>: Other hormonal treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Illustrative comparative risks* 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Relative effect  </b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>No of participants</b> </p> <p><b>(studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Quality of the evidence</b> </p> <p><b>(GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Other hormonal treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>GnRHas</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GnRHas vs gestrinone</b> </p> <p><b>Percentage change values ‐ 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean percentage change in BMD in the control groups was 0.88</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean percentage change in BMD in the intervention group was <b>1.96 lower</b> </p> <p>(3.62 to 0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GnRHas vs gestrinone</b> </p> <p><b>Percentage change values ‐ 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean percentage change in BMD in the control groups was 2.06</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean percentage change in BMD in the intervention group was <b>5.10 lower</b> </p> <p>(7.39 to 2.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>GnRHas vs GnRHas in conjunction with calcium‐regulating agents</b> </p> <p><b>Anterior‐posterior spine ‐ 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in BMD in the control groups was 2.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in BMD in the intervention group was <b>7.00 lower</b> </p> <p>(7.53 to 6.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>GnRHas vs GnRHas in conjunction with calcium‐regulating agents</b> </p> <p><b>Lateral spine ‐ 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in BMD in the control groups was 7.5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of pelvic pain in the intervention group was <b>12.40</b> <b>lower</b> </p> <p>(13.31 to 11.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Evidence based on a single trial </p> <p><sup>2</sup> Small number of events </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD014788-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD014788-sec-0009"></div> <section id="CD014788-sec-0010"> <h3 class="title" id="CD014788-sec-0010">Description of the condition</h3> <p>Endometriosis is a common gynaecological condition. Endometriosis is characterised as an inflammatory condition leading to fibrotic tissue formation, predominantly found in the pelvic peritoneum, ovaries and rectovaginal septum (<a href="./references#CD014788-bbs2-0141" title="BurneyRO ,  GiudiceLC . Pathogenesis and pathophysiology of endometriosis. Fertility and Sterility2012;3:511-9. [DOI: 10.1016/j.fertnstert.2012.06.029]">Burney 2012</a>; <a href="./references#CD014788-bbs2-0170" title="ViganoP ,  CandianiM ,  MonnoA ,  GiacominiE ,  Vercellini P, SomiglianaE . Time to redefine endometriosis including its pro-fibrotic nature. Human Reproduction2018;1(33(3)):347-52. [PMID: https://pubmed.ncbi.nlm.nih.gov/29206943/]">Vigano 2018</a>). Endometriosis is associated with symptoms such as dysmenorrhoea, dyspareunia, abdominal pain and infertility (<a href="./references#CD014788-bbs2-0169" title="VercelliniP , ViganòP , SomiglianaE , FedeleL . Endometriosis: pathogenesis and treatment. Nature Reviews, Endocrinology2014;5:261-75. [DOI: 10.1038/nrendo.2013.255]">Vercellini 2014</a>). It affects 6% to 11% of women of reproductive age, but the prevalence increases in women with infertility or pelvic pain (<a href="./references#CD014788-bbs2-0143" title="DarwishA , Hassanin MS, Abou Sekkin IA. Epidemiology and risk factors associated with laparoscopicaly diagnosed typical and atypical endometriosis among Egyptian women. Middle East Fertility Society Journal2006;11:196-201.">Darwish 2006</a>; <a href="./references#CD014788-bbs2-0145" title="Eskenazi B, WarnerML . Epidemiology of endometriosis. Obstetrics and Gynecology Clinics of North America1997;24:235-58. [DOI: 10.1016/s0889-8545(05)70302-8 Abstract] [PMID: 9163765]">Eskenazi 1997</a>; <a href="./references#CD014788-bbs2-0157" title="MahmoodTA , TempletonA . Prevalence and genesis of endometriosis. Human Reproduction1991;6:544-9. [PMID: 1918305]">Mahmood 1991</a>; <a href="./references#CD014788-bbs2-0159" title="MeulemanC , VandenabeeleB , FieuwsS , SpiessendC , TimmermansD , D'HoogheT . High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners.. Fertility and Sterility2009;92(1):68-74. [DOI: 10.1016/j.fertnstert.2008.04.056]">Meuleman 2009</a>; <a href="./references#CD014788-bbs2-0172" title="WheelerJM . Epidemiology of endometriosis-associated infertility. Journal of Reproductive Medicine1989;34:41-6. [PMID: 2704007]">Wheeler 1989</a>). </p> <p>The precise pathogenesis of endometriosis remains unclear, however there are some hypotheses that have widely been accepted. Possible theorised mechanisms of the pathogenesis of endometriosis include induction, in situ development and retrograde menstruation or implantation (<a href="./references#CD014788-bbs2-0155" title="LevanderG ,  NormannP . The pathogenesis of endometriosis; an experimental study. Acta Obstetricia et Gynecologica Scandinavica1955;34(4):366-98. [DOI: 10.3109/00016345509158287]">Levander 1955</a>; <a href="./references#CD014788-bbs2-0162" title="SampsonJA . The development of the implantation theory for the origin of peritoneal endometriosis. American Journal of Obstetrics and Gynecology October 01, 1940;40(4):549-557. [DOI: 10.1016/S0002-9378(40)91238-8]">Sampson 1940</a>; <a href="./references#CD014788-bbs2-0167" title="van derLindenPJ . Theories on the pathogenesis of endometriosis. Human Reproduction1996;3:53-65. [DOI: 10.1093/humrep/11.suppl_3.53.]">Van der Linden 1997</a>). The 'induction theory', introduced by Levander and Normann in 1955, is based on the assumption that specific substances released during the degeneration of the endometrium induce endometriosis from omnipotent blastema, present in connective tissues (<a href="./references#CD014788-bbs2-0138" title="BontisJN , VavilisDT . Etiopathology of endometriosis. Annals of the New York Academy of Sciences 17-06-1997;816:305-9.">Bontis 1997</a>; <a href="./references#CD014788-bbs2-0155" title="LevanderG ,  NormannP . The pathogenesis of endometriosis; an experimental study. Acta Obstetricia et Gynecologica Scandinavica1955;34(4):366-98. [DOI: 10.3109/00016345509158287]">Levander 1955</a>). The ‘in‐situ development theory’ states that endometriosis develops from either the Wolffian duct or knob, or from Müllerian tissue (<a href="./references#CD014788-bbs2-0136" title="BattRE , SmithRA , Buck LouisGM , MartinDC , ChapronC , KoninckxPR , YehJ . Müllerianosis. Histology &amp; Histopathology 22-10-2007;10:1161-6.">Batt 2007</a>; <a href="./references#CD014788-bbs2-0167" title="van derLindenPJ . Theories on the pathogenesis of endometriosis. Human Reproduction1996;3:53-65. [DOI: 10.1093/humrep/11.suppl_3.53.]">Van der Linden 1997</a>). The most common hypothesis is based on retrograde menstruation; this theory proposes that endometriosis arises by the dissemination of endometrial‐like tissue to ectopic sites where implantation, hypertrophy and invasion of pelvic structures occurs (<a href="./references#CD014788-bbs2-0141" title="BurneyRO ,  GiudiceLC . Pathogenesis and pathophysiology of endometriosis. Fertility and Sterility2012;3:511-9. [DOI: 10.1016/j.fertnstert.2012.06.029]">Burney 2012</a>; <a href="./references#CD014788-bbs2-0161" title="Robboy, S J, &amp; Bean, S M. Pathogenesis of endometriosis. Reproductive Biomedicine Online 01-07-2010;21(1):4-5.">Robboy 2010</a>; <a href="./references#CD014788-bbs2-0162" title="SampsonJA . The development of the implantation theory for the origin of peritoneal endometriosis. American Journal of Obstetrics and Gynecology October 01, 1940;40(4):549-557. [DOI: 10.1016/S0002-9378(40)91238-8]">Sampson 1940</a>; <a href="./references#CD014788-bbs2-0171" title="ViganòP , ParazziniF , SomiglianaE , VercelliniP , . Endometriosis: epidemiology and aetiological factors. Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology2004;18(2):177-200. [DOI: 10.1016/j.bpobgyn.2004.01.007]">Viganò 2004</a>). This ectopic growth provokes an inflammatory response, resulting in the symptoms mentioned above (<a href="./references#CD014788-bbs2-0148" title="GiudiceLC . Clinical practice: endometriosis. New England Journal of Medicine2010;25:2389-98. [DOI: 10.1056/NEJMcp1000274]">Guidice 2010</a>). Endometriosis is generally believed to be an oestrogen‐dependent disorder (<a href="./references#CD014788-bbs2-0176" title="ZondervanKT , BeckerCM , MissmerSA . Endometriosis. New England Journal of Medicine 2020 Mar 26;382(13):1244-1256. [DOI: 10.1056/NEJMra1810764]">Zondervan 2020</a>). Local oestradiol stimulates the activation of pain fibres and promotes sprouting of nociceptors that contribute to persistent inflammatory pain, that often worsens over time (<a href="./references#CD014788-bbs2-0148" title="GiudiceLC . Clinical practice: endometriosis. New England Journal of Medicine2010;25:2389-98. [DOI: 10.1056/NEJMcp1000274]">Guidice 2010</a>). </p> <p>To treat chronic pelvic pain associated with endometriosis, repeated courses of medical therapy or surgical therapy (or both) are often required. Hormonal treatment, such as gonadotrophin‐releasing hormone analogues (GnRHas), suppress ovarian function and alter the endometrium as well as the endometriosis tissue, which in turn often results in amenorrhoea and relief of endometriosis‐related pain symptoms (<a href="./references#CD014788-bbs2-0166" title="StrattonP ,  BerkleyKJ . Chronic pelvic pain and endometriosis: translational evidence of the relationship and implications. Human Reproduction Update2011;17(3):327–46. [PMID: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072022/]">Stratton 2011</a>). In the current review, only the GnRH agonists are included, not the GnRH antagonists.  </p> </section> <section id="CD014788-sec-0011"> <h3 class="title" id="CD014788-sec-0011">Description of the intervention</h3> <p>The GnRHas are a family of compounds that differ from natural gonadotrophin‐releasing hormone (GnRH), a ten‐amino‐acid hormone (decapeptide), by modifications in the decapeptide at positions six and ten (<a href="./references#CD014788-bbs2-0164" title="ShawRW . GnRH analogues in the treatment of endometriosis -rationale and efficacy. London: Kluwer Academic Publishers, 1991.">Shaw 1991</a>). They may be administered intranasally, or by subcutaneous or intramuscular injection. Buserelin, goserelin, leuprorelin, nafarelin and triptorelin are some of the most common GnRHas. Hypo‐oestrogenic side effects (relating to low levels of oestrogen), such as hot flushes, mood swings, sleep disturbances and bone mass loss are common when prescribing GnRHas. This is considered significant as it could increase the risk of women developing osteoporosis and place them at risk of osteoporotic fractures. To prevent bone loss and other hypo‐oestrogenic symptoms, it is therefore recommended to prescribe hormonal add‐back therapy concomitantly.  </p> <p>Other common treatments for endometriosis‐associated symptoms (including infertility and pain), are analgesics, danazol and progestogens (<a href="./references#CD014788-bbs2-0139" title="Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database of Systematic Reviews2012, Issue 3. Art. No: CD002122. [DOI: 10.1002/14651858.CD002122.pub2]">Brown 2012</a>), including intra‐uterine systems, combined oral contraceptive pills (<a href="./references#CD014788-bbs2-0140" title="Brown J, Crawford TJ, Datta S, Prentice A. Oral contraceptives for pain associated with endometriosis. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD001019. [DOI: 10.1002/14651858.CD001019]">Brown 2018</a>) and surgical therapies (<a href="./references#CD014788-bbs2-0135" title="BafortC , BeebeejaunY , TomassettiC , BosteelsJ , DuffyJMN . Laparoscopic surgery for endometriosis. Cochrane Database of Systematic Reviews2020, Issue 10. Art. No: CD011031. [DOI: 10.1002/14651858.CD011031]">Bafort 2020</a>). A combination of surgery with hormonal treatment (pre‐surgical, post‐surgical or pre‐ and post‐surgical hormonal therapy), is also used as a treatment option for people with endometriosis. Only post‐surgical medical therapy provides a reduction in pain symptoms, reduced rate of recurrence and increased chance of pregnancy (<a href="./references#CD014788-bbs2-0142" title="ChenI , VethVB , ChoudhryAJ , MurjiA , ZakhariA , BlackAY , et al. Pre- and postsurgical medical therapy for endometriosis surgery. Cochrane Database of Systematic Reviews2020, Issue 11. Art. No: CD003678. [DOI: 10.1002/14651858.CD003678.pub3]">Chen 2020</a>) </p> <p>The European Society of Human Reproduction and Embryology (ESHRE) recommends the use of GnRHas (nafarelin, leuprorelin, buserelin, goserelin or triptorelin) as one of the options for reducing endometriosis‐associated pain, however, evidence is limited regarding dosage or duration of treatment (<a href="./references#CD014788-bbs2-0137" title="BeckerCM , BokorA , HeikinheimoO , HorneA , JansenF , KieselL , KingK , KvaskoffM , NapA ,  PetersenK , SaridoganE , TomassettiC , vanHanegemN , VulliemozN ,  VermeulenN , ESHRE Endometriosis Guideline Group. ESHRE guideline: management of women with endometriosis.. Human Reproduction Open2022;2:1-26. [DOI: 10.1093/hropen/hoac009]">Becker 2022</a>). In addition, clinicians are recommended to prescribe hormonal add‐back therapy to coincide with the start of GnRH agonist therapy, to prevent bone loss and hypo‐oestrogenic symptoms during treatment. It is recommended to give careful consideration to the use of GnRHas in young women and adolescents, since these individuals may not have reached maximum bone density (<a href="./references#CD014788-bbs2-0137" title="BeckerCM , BokorA , HeikinheimoO , HorneA , JansenF , KieselL , KingK , KvaskoffM , NapA ,  PetersenK , SaridoganE , TomassettiC , vanHanegemN , VulliemozN ,  VermeulenN , ESHRE Endometriosis Guideline Group. ESHRE guideline: management of women with endometriosis.. Human Reproduction Open2022;2:1-26. [DOI: 10.1093/hropen/hoac009]">Becker 2022</a>). </p> </section> <section id="CD014788-sec-0012"> <h3 class="title" id="CD014788-sec-0012">How the intervention might work</h3> <p>Non‐analgesic medical treatment of endometriosis aims to suppress the ectopic endometrium deposits in premenopausal women by inducing atrophy within the hormonally dependent ectopic endometrium, making the endometrial‐like tissue inactive. The observation that endometriosis is rarely diagnosed in hypo‐oestrogenic postmenopausal women led to the concept of medical treatment of endometriosis by induction of a pseudo‐menopause. </p> <p>Gonadotrophin‐releasing hormone analogues are a potent synthetic analogue of the hypothalamic hormone gonadorelin. This stimulates the pituitary gland to produce luteinising hormone (LH) and follicle‐stimulating hormone (FSH). However, with continued use, suppression occurs due to exhaustion and desensitivity of the gonadotrophic pituitary cells. This suppresses ovarian function and therefore reduces oestrogen and progesterone levels, introducing a hypogonadotropic hypogonadal state. </p> <p>In endometriosis, this treatment leads to a reduction in the endometriosis implants and induces atrophy within them (<a href="./references#CD014788-bbs2-0142" title="ChenI , VethVB , ChoudhryAJ , MurjiA , ZakhariA , BlackAY , et al. Pre- and postsurgical medical therapy for endometriosis surgery. Cochrane Database of Systematic Reviews2020, Issue 11. Art. No: CD003678. [DOI: 10.1002/14651858.CD003678.pub3]">Chen 2020</a>). By reducing the endometriosis implants, GnRHas can provide a reduction in pain and other endometriosis‐related complaints. </p> </section> <section id="CD014788-sec-0013"> <h3 class="title" id="CD014788-sec-0013">Why it is important to do this review</h3> <p>Endometriosis occurs in approximately one in every 10 women within the reproductive general population (<a href="./references#CD014788-bbs2-0156" title="Macer ML and TaylorHS . Endometriosis and Infertility: A review of the pathogenesis and treatment of endometriosis-associated infertility. Obstetrics and Gynecology Clinics of North America2013;39(4):535-549. [DOI: 10.1016/j.ogc.2012.10.002]">Macer 2012</a>). It is a chronic disease with severe pain that impacts negatively on physical, mental and social well‐being (<a href="./references#CD014788-bbs2-0153" title="KleinS , D'HoogheT ,  MeulemanC ,  DirksenC ,  DunselmanG ,  SimoensS . What is the societal burden of endometriosis-associated symptoms? a prospective Belgian study. Reproductive Biomedical Online2013;28(1):116-224. [DOI: 10.1016/j.rbmo.2013.09.020]">Klein 2014</a>). In addition, the cost of endometriosis is high in both economic and psychosocial terms (<a href="./references#CD014788-bbs2-0158" title="MathiasSD , KuppermannM ,  LibermanRF , Lipschutz RC ,  Steege JF . Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstetrics and Gynecology1996;87(3):321-7. [DOI: 10.1016/0029-7844(95)00458-0]">Matthias 1996</a>, <a href="./references#CD014788-bbs2-0165" title="SimoensS ,  DunselmanG ,  DirksenC ,  HummelshojL ,  BokorA ,  BrandesI ,  et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Human Reproduction2021;27(5):1292-9. [DOI: 10.1093/humrep/des073]">Simoens 2012</a>). </p> <p>Treatment availability is dependent upon available resources but also upon the preferences of the individual woman and the gynaecologist. This particularly relates to their decisions concerning the conservation of fertility or requirements for contraception. One of the available treatment options is treatment with GnRHas. While GnRHas are not free of side effects, it is important to know how well they perform in comparison to other medical treatments and placebo. </p> <p>This review will evaluate the effect of GnRHas specifically on the relief of pain and on bone mineral density in symptomatic women with endometriosis. This review is a combination of two previously published Cochrane Reviews on GnRHas for bone mineral density (<a href="./references#CD014788-bbs2-0178" title="FarmerJE , PrenticeA , BreezeA . Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001297. [DOI: 10.1002/14651858.CD001297]">Farmer 2003</a>) and for pain associated with endometriosis (<a href="./references#CD014788-bbs2-0177" title="BrownJ , PanA , HartRJ . Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database of Systematic Reviews2010, Issue 12. Art. No: CD008475. [DOI: 10.1002/14651858.CD008475.pub2]">Brown 2010</a>). It was decided to merge both reviews, in order to provide the best overview of the use of GnRHas in women with endometriosis. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD014788-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD014788-sec-0014"></div> <p>To assess the effectiveness and safety of GnRH analogues (GnRHas) in the treatment of painful symptoms associated with endometriosis and to determine the effects of GnRHas on bone mineral density of women with endometriosis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD014788-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD014788-sec-0015"></div> <section id="CD014788-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD014788-sec-0017"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) comparing the use of GnRHas in the treatment of symptomatic endometriosis were eligible for inclusion. Cross‐over trials were included in the review providing that data from before‐and‐after cross‐over were available; only the first‐arm data were used for analysis. We excluded trials that used self‐reporting of endometriosis, as well as quasi‐randomised and non‐randomised studies (case control studies, cohort studies). </p> </section> <section id="CD014788-sec-0018"> <h4 class="title">Types of participants</h4> <p>Premenopausal women with symptoms ascribed to endometriosis were eligible for inclusion. For a trial to be included, the clinical diagnosis of endometriosis must have been made by direct visualisation (laparoscopy or laparotomy) or from ultrasonographic imaging or magnetic resonance imaging (MRI). We excluded women with asymptomatic disease or infertility as the only presenting complaint. </p> </section> <section id="CD014788-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included RCTs reporting the following comparisons for relief of pain associated with endometriosis and its related adverse effects. </p> <p> <ul id="CD014788-list-0001"> <li> <p>GnRHas versus no treatment.</p> </li> <li> <p>GnRHas versus placebo.</p> </li> <li> <p>GnRHas versus analgesics.</p> </li> <li> <p>GnRHas versus danazol.</p> </li> <li> <p>GnRHas versus intra‐uterine progestogens.</p> </li> <li> <p>GnRHas versus oral or injectable progestogens.</p> </li> <li> <p>GnRHas versus gestrinone.</p> </li> </ul> </p> <p>We also included RCTs comparing the following for relief of pain associated with endometriosis and its related adverse effects. </p> <p> <ul id="CD014788-list-0002"> <li> <p>Different doses of GnRHas.</p> </li> <li> <p>Different treatment duration of GnRHas.</p> </li> <li> <p>Different routes of administration of GnRHas.</p> </li> <li> <p>Different treatment regimens of GnRHas.</p> </li> <li> <p>GnRHas versus GnRHas in conjunction with add‐back therapy (hormonal or non‐hormonal).</p> </li> <li> <p>GnRHas versus GnRHas in conjunction with calcium‐regulating agents.</p> </li> </ul> </p> <p>When we identified trials that assessed the effect of GnRHas on bone mineral density (BMD), we considered them for inclusion providing the treatment period exceeded six months. The reason for this decision is that shorter treatment periods do not seem to treat the disease effectively (<a href="./references#CD014788-bbs2-0134" title="AudebertA ,  DescampsP , MarretH ,  Ory-LavolleeL , BailleulF , HamamahS . Pre or post-operative medical treatment with nafarelin in stage III-IV endometriosis: a French multicenter study. European Journal of Obstetrics, Gynecology and Reproductive Biology1998;79(2):145-48. [DOI: 10.1016/s0301-2115(98)00028-1]">Audebert 1998</a>). </p> <p>The following trials were excluded from this review. </p> <p> <ul id="CD014788-list-0003"> <li> <p>Trials comparing GnRHas with surgical therapies, the combined oral contraceptive pill, progesterone receptor modulators or selective oestrogen receptor modulators (SERMs), as these are included in separate Cochrane Reviews (<a href="./references#CD014788-bbs2-0135" title="BafortC , BeebeejaunY , TomassettiC , BosteelsJ , DuffyJMN . Laparoscopic surgery for endometriosis. Cochrane Database of Systematic Reviews2020, Issue 10. Art. No: CD011031. [DOI: 10.1002/14651858.CD011031]">Bafort 2020</a>; <a href="./references#CD014788-bbs2-0140" title="Brown J, Crawford TJ, Datta S, Prentice A. Oral contraceptives for pain associated with endometriosis. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD001019. [DOI: 10.1002/14651858.CD001019]">Brown 2018</a>; <a href="./references#CD014788-bbs2-0147" title="Fu J, Song H, Zhou M, Zhu H, Wang Y, Chen H, Huang W. Progesterone receptor modulators for endometriosis. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD009881. [DOI: 10.1002/14651858.CD009881.pub2]">Fu 2017</a>; <a href="./references#CD014788-bbs2-0168" title="Van HoeselMH , ChenYL , ZhengA , WanQ , MouradSM . Selective oestrogen receptor modulators (SERMs) for endometriosis. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD011169. [DOI: 10.1002/14651858.CD011169.pub2]">Van Hoesel 2021</a>, respectively). </p> </li> <li> <p>Trials comparing GnRHas with gonadotrophin antagonists, as this is a registered title of a Cochrane Review to be conducted by Cochrane Gynaecology and Fertility (<a href="./references#CD014788-bbs2-0150" title="Houda  MR, Grant  NH. Gonadotrophin antagonists for pain associated with endometriosis. Cochrane Database of Systematic Reviews2014, Issue 12. Art. No: CD011446. [DOI: 10.1002/14651858.CD011446]">Houda 2014</a>). </p> </li> <li> <p>Trials comparing GnRHas with alternative and complementary medicine such as Chinese herbs or acupuncture, as these are addressed by published Cochrane Reviews (<a href="./references#CD014788-bbs2-0146" title="FlowerA , LiuJP , LewithG , LittleP , LiQ . Chinese herbal medicine for endometriosis. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006568. [DOI: 10.1002/14651858.CD006568.pub3]">Flower 2012</a>; <a href="./references#CD014788-bbs2-0175" title="ZhuX , HamiltonKD , McNicolED . Acupuncture for pain in endometriosis. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD007864. [DOI: 10.1002/14651858.CD007864.pub2]">Zhu 2011</a>, respectively). </p> </li> <li> <p>Trials where GnRHas were administered in post‐surgical participants as adjuvant therapy.</p> </li> </ul> </p> <p> </p> </section> <section id="CD014788-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>The choice of outcome measures is based on the core outcome set (COS) determined for endometriosis research (<a href="./references#CD014788-bbs2-0144" title="DuffyJMN , HirschM ,   Vercoe M, AbbottJ , BarkerC ,  ColluraB , et al. A core outcome set for future endometriosis research: an international consensus development study [A core outcome set for future endometriosis research: an international consensus development study]. British Journal of Obstetrics and Gynaecology2020;127(8):967-74. [DOI: 10.1111/1471-0528.16157] [PMID: 32227676]">Duffy 2020</a>). This COS was developed by conducting a systematic review and a widely‐supported Delphi study, in which it was determined which outcome measures in endometriosis research should definitely be assessed in endometriosis trials. The COS is expected to provide a more uniform way for conducting, performing and reporting endometriosis research. </p> <section id="CD014788-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD014788-list-0004"> <li> <p>Overall pain, defined by using both quantitative measures such as visual analogue scales or categorical outcomes, at the end of treatment and at three, six, nine, 12, 18 and 24 months' follow‐up, where possible </p> </li> <li> <p>The objective measurement of bone mineral density (BMD), including dual‐energy photon absorptiometry (DPA), dual‐energy X‐ray absorptiometry (DEXA), single‐energy photon absorptiometry (SPA), single‐energy X‐ray absorptiometry (SXA) and quantitative computed tomography (QCT). Measurements taken at the lumbar spine and femoral head will be considered, whilst those at the distal forearm will be excluded because these measurements are of cortical bone which is less affected by GnRHa therapy (<a href="./references#CD014788-bbs2-0173" title="WhitehouseRW , AdamsJE , BancroftK , Vaughan-WilliamsCA , ElsteinM . The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis.. Clinical Endocrinology1990;3(33):365-73. [PMID: MEDLINE: 91070821]">Whitehouse 1990</a>; <a href="./references#CD014788-bbs2-0174" title="YlikorkalaO , NilssonG , HirvonenE , ViinikkaL . Evidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis. Gynaecological Endocrinology1990;4(4):251-60. [PMID: MEDLINE: 91188927]">Ylikorkala 1990</a>). Bone density measurements at the end of treatment and in the follow‐up period will be included. Measurements will be grouped according to the anatomical location of measurements and the timing of measurements. </p> </li> </ul> </p> <p>For overall pain, we applied the core outcome set (COS). Overall pain is one of the outcome measures recommended with the COS. However, many studies still distinguish between different sub‐forms of pain, and do not use overall pain as an outcome measure. In the current review, it was decided to include both overall pain and other sub‐forms of pain, i.e. dysmenorrhoea, dyspareunia and pelvic pain. This is to provide as much useful information as possible for shared decision‐making with patients.  </p> </section> <section id="CD014788-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD014788-list-0005"> <li> <p>Adverse effects (e.g. hot flushes, insomnia, reduced libido, vaginal dryness and headaches), both short‐term (during therapy) and long‐term (extending beyond the treatment period) </p> </li> <li> <p>Quality of life and factors affecting quality of life (by quality of life scores)</p> </li> <li> <p>Improvement in the most troublesome symptoms</p> </li> <li> <p>Patients' satisfaction with treatment</p> </li> </ul> </p> <p>Cost‐effectiveness and pregnancy rates are not outcomes of this review.</p> </section> </section> </section> <section id="CD014788-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>The search strategy of Cochrane Gynaecology and Fertility was utilised to identify all publications that describe or might describe randomised trials of GnRHas in the treatment of symptomatic endometriosis. </p> <section id="CD014788-sec-0024"> <h4 class="title">Electronic searches</h4> <p>There were no language or date restrictions in the searches. The following electronic databases, trial registers and websites were searched: </p> <p> <ul id="CD014788-list-0006"> <li> <p>Cochrane Gynaecology and Fertility Group's specialised register of controlled trials; searched from inception to 26 May 2022, ProCite platform (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007807.pub4/appendices#CD007807-sec-0106" target="_blank">Appendix 1</a>); </p> </li> <li> <p>CENTRAL, via the Cochrane Register of Studies Online (CRSO); now containing output from two trials registries (clinicaltrials.gov https://clinicaltrials.gov/ and the International Clinical Trials Registry Platform (ICTRP) https://www.who.int/clinical‐trials‐registry‐platform) and CINAHL, searched 26 May 2022, Web platform (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007807.pub4/appendices#CD007807-sec-0107" target="_blank">Appendix 2</a>); </p> </li> <li> <p>MEDLINE, searched from 1946 to 26 May 2022, Ovid platform (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007807.pub4/appendices#CD007807-sec-0108" target="_blank">Appendix 3</a>); </p> </li> <li> <p>Embase, searched from 1980 to 26 May 2022, Ovid platform (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007807.pub4/appendices#CD007807-sec-0109" target="_blank">Appendix 4</a>); </p> </li> <li> <p>PsycINFO, searched from 1806 to 26 May 2022, Ovid platform (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007807.pub4/appendices#CD007807-sec-0110" target="_blank">Appendix 5</a>). </p> </li> </ul> </p> <p>The MEDLINE search was combined with the Cochrane highly sensitive search strategy for identifying randomised trials, which appears in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014788-bbs2-0154" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.  Available from training.cochrane.org/handbook.">Lefebvre 2011</a>). The Embase search was combined with the trial filter developed by the Scottish Intercollegiate Guidelines Network (SIGN) (<a href="https://www.sign.ac.uk/what-we-do/methodology/search-filters/" target="_blank">www.sign.ac.uk/what-we-do/methodology/search-filters/</a>). </p> <p>Other web‐based electronic sources of trials searched were:</p> <p> <ul id="CD014788-list-0007"> <li> <p>ISI Web of Science, for conference abstracts; </p> </li> <li> <p>LILACS database, as a source of trials from the Portuguese and Spanish regions;</p> </li> <li> <p>Clinical Study Results, for clinical trial results of marketed pharmaceuticals;</p> </li> <li> <p>OpenSIGLE database, for grey literature;</p> </li> <li> <p>Google, for grey literature and for trials that were not yet indexed in the major databases. </p> </li> </ul> </p> </section> <section id="CD014788-sec-0025"> <h4 class="title">Searching other resources</h4> <p>Any relevant journals and conference abstracts that were not covered in the Cochrane Gynaecology and Fertility specialised register were handsearched in liaison with the Group's Information Specialist, Marian Showell. </p> <p>The reference lists of relevant articles retrieved by the search were handsearched, and we personally communicated with experts in the field to obtain any additional trials. In addition, we approached all distributors of GnRHas for details of unpublished trials of GnRHas known to, or undertaken by, them or their parent companies. </p> </section> </section> <section id="CD014788-sec-0026"> <h3 class="title" id="CD014788-sec-0026">Data collection and analysis</h3> <section id="CD014788-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (VV and MK) independently scanned the search results for relevant titles and abstracts and removed those that were clearly irrelevant. The full texts of all potentially eligible studies were retrieved. Two review authors (VV and MK) independently examined the full‐text articles for compliance with the inclusion criteria. Authors corresponded with study investigators to clarify study eligibility. Communication with study authors was documented in the appendices. Where required, disagreements regarding study eligibility were resolved by consensus or by the assessment of a third review author (JM). </p> </section> <section id="CD014788-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was conducted independently by two review authors (VV and MK). Data extraction forms were developed and pilot‐tested by the authors. Where studies had multiple publications, the main trial report was used as the reference and additional details supplemented from secondary papers. Authors corresponded with study investigators in order to resolve any data queries, as required. When disagreements arose between the two review authors, a third review author was contacted to resolve the dispute (JM).   </p> </section> <section id="CD014788-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Assessment of the risk of bias in the included studies was undertaken by two of the review authors, using the Cochrane risk of bias tool (<a href="./references#CD014788-bbs2-0149" title="HigginsJPT , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook.">Higgins 2011</a>). The assessment is based on allocation (random sequence generation and allocation concealment), blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective reporting and other bias. Where uncertainty arose or there was a discrepancy between the two review authors (VV and MK), a third review author was contacted to make further assessment. When a study protocol was available, we assessed whether there are differences between the study protocol and published results. </p> <p>If necessary, additional information was sought from the principal investigator of the original trial. All judgements were fully described and the conclusions presented in the risk of bias table. </p> </section> <section id="CD014788-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For continuous data like pain and BMD (bone mineral density) scores, mean differences (MDs) with 95% confidence intervals (CIs) were reported using change‐from‐baseline scores.  When similar outcomes were reported on different scales we intended to calculate standardised mean differences (SMDs). Ordinal data (e.g. quality of life scores) were treated as continuous data. A summary statistic for each outcome was calculated using a fixed‐effect model and a 95% CI. For dichotomous data, we calculated for each study a Mantel‐Haenszel risk ratio (RR) with corresponding 95% CI. </p> </section> <section id="CD014788-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>Data were presented according to each woman randomised. In cross‐over trials only the first‐arm data were used for analysis where data were available, and where data were not available, we intended to contact the primary author. </p> </section> <section id="CD014788-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>The data were analysed on an intention‐to‐treat basis as far as possible, and attempts were made to obtain missing data from the original investigators. If studies reported sufficient detail to calculate MDs, but provided no information on an associated standard deviation (SD), the outcome was assumed to have an SD equal to the highest SD from other studies within the same analysis. For other outcomes, only the available data were analysed. </p> </section> <section id="CD014788-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>The review authors considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a meaningful summary. Statistical heterogeneity was assessed using the I<sup>2</sup> statistic (<a href="https://revman.cochrane.org/416510777407367429" target="_blank">Higgins 2019</a>). An I<sup>2</sup> measurement greater than 50% indicates substantial heterogeneity. Sensitivity analyses including all studies were conducted where it was taken into account if the quality of the studies contributed to the heterogeneity. </p> </section> <section id="CD014788-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. </p> </section> <section id="CD014788-sec-0035"> <h4 class="title">Data synthesis</h4> <p>When studies were sufficiently similar, the data from primary studies were combined using the fixed‐effect model. The primary analysis only included trials with a low risk of selection bias and no high risk of bias in other domains. </p> </section> <section id="CD014788-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Data derived in all outcome measurements were divided into subgroups by dosage (low or high, as defined by study); duration of treatment (three, six, nine, 12, 18 and 24 months); route of administration (intranasal, intramuscular, subcuticular or depot injection); and drug regimens. </p> </section> <section id="CD014788-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses were conducted for the primary outcomes to determine whether the conclusions were robust to arbitrary decisions made regarding the eligibility and analysis. These analyses included consideration of whether our conclusions differed in the following situations. </p> <p> <ul id="CD014788-list-0008"> <li> <p>If all studies were included in the analysis (studies with unclear risk of selection bias and high risk of bias in other domains).  </p> </li> <li> <p>If studies with outlying results were excluded.</p> </li> <li> <p>If alternative imputation strategies were adopted.</p> </li> <li> <p>If a random‐effects model was adopted.</p> </li> </ul> </p> </section> <section id="CD014788-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared a summary of findings table using GRADEpro GDT software and Cochrane methods (<a href="./references#CD014788-bbs2-0163" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , GuyattGH . Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook2021.">Schünemann 2021</a>). This table evaluated the overall quality of the body of evidence for the main review outcomes, namely overall pain, the objective measurement of BMD, and adverse effects, for the following main comparisons. </p> <p> <ul id="CD014788-list-0009"> <li> <p>GnRHas versus no treatment.</p> </li> <li> <p>GnRHas versus placebo.</p> </li> <li> <p>GnRHas versus danazol.</p> </li> </ul> </p> <p>Additional summary of findings tables were also prepared for the main review outcomes for other important comparisons (GnRHas versus analgesics; and GnRHas versus intra‐uterine progestogen devices). We assessed the quality of the evidence using GRADE criteria: risk of bias, consistency of effect, imprecision, indirectness and publication bias. Judgements about evidence quality (high, moderate, low or very low) were made by two review authors working independently, with disagreements resolved by discussion. Judgements were justified, documented, and incorporated into reporting of results for each outcome. We extracted study data, formatted our comparisons in data tables and prepared a summary of findings table before writing the results and conclusions of our review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD014788-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD014788-sec-0039"></div> <section id="CD014788-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD014788-sec-0041"> <h4 class="title">Results of the search</h4> <p>This is a combination of two previous reviews (<a href="./references#CD014788-bbs2-0177" title="BrownJ , PanA , HartRJ . Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database of Systematic Reviews2010, Issue 12. Art. No: CD008475. [DOI: 10.1002/14651858.CD008475.pub2]">Brown 2010</a>; <a href="./references#CD014788-bbs2-0178" title="FarmerJE , PrenticeA , BreezeA . Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001297. [DOI: 10.1002/14651858.CD001297]">Farmer 2003</a>). The inclusion and exclusion criteria, as well as the participants, differ slightly from the two previous reviews. <a href="./references#CD014788-bbs2-0177" title="BrownJ , PanA , HartRJ . Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database of Systematic Reviews2010, Issue 12. Art. No: CD008475. [DOI: 10.1002/14651858.CD008475.pub2]">Brown 2010</a> only included women with a clinical diagnosis of endometriosis, so the diagnosis had to be made by direct visualisation (laparoscopy). In this review, we also include women with a clinical diagnosis of endometriosis from ultrasonographic imaging or magnetic resonance imaging (MRI). <a href="./references#CD014788-bbs2-0178" title="FarmerJE , PrenticeA , BreezeA . Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001297. [DOI: 10.1002/14651858.CD001297]">Farmer 2003</a> included premenopausal women suffering from endometriosis diagnosed visually by laparoscopy or laparotomy, or presumptively, from symptom history. Here, too, the inclusion criteria differ slightly from each other. </p> <p>A total of seventy‐two studies were included. Two studies were still awaiting classification, however, as data were still not available at the current review, we also excluded these articles. A total of fifty‐six studies were excluded, and five are still awaiting classification. See study tables: "<a href="./references#CD014788-sec-0098" title="">Characteristics of included studies</a>", "<a href="./references#CD014788-sec-0099" title="">Characteristics of excluded studies</a>"; "<a href="./references#CD014788-sec-0100" title="">Characteristics of studies awaiting classification</a>". <a href="#CD014788-fig-0001">Figure 1</a> summarises the results of the search. </p> <div class="figure" id="CD014788-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD014788-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD014788-sec-0042"> <h4 class="title">Included studies</h4> <p>Seventy‐two randomised controlled trials met our eligibility criteria and were included in this review (<a href="./references#CD014788-bbs2-0001" title="AbdouAM , AmmarIMM , AlenmrAAA , AbdelrhmanAA . Dienogest versus leuprolide acetate for recurrent pelvic pain following laparoscopic treatment of endometriosis. Journal of Obstetrics and Gynecology of India Aug 2018;4:306-13. [PMID: DOI: 10.1007/s13224-018-1119-3]">Abdou 2018</a>; <a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>; <a href="./references#CD014788-bbs2-0003" title="AgarwalSK , HamrangC , HenzlMR , JuddHL . Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. Journal of Reproductive Medicine1997;42(7):413-23. ">Agarwal 1997</a>; <a href="./references#CD014788-bbs2-0004" title="AN Zoladex. Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(1):55-60. ">AN Zoladex 1996</a>; <a href="./references#CD014788-bbs2-0005" title="AudebertA , LucasC , Joubert-CollinM . Efficacy and safety of slow-release leuprorelin 3,75 mg compared to danazol treatment.  [Efficacite et tolerance de la leuproreline 3,75 MG a liberation prolongeedans le traitement de l'endometriose en comparaison au danazol]. References en Gynecologie Obstetrique1997;5(1):49-57. ">Audebert 1997</a>; <a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a>; <a href="./references#CD014788-bbs2-0007" title="BergqvistA , BerghT , HogstromL , MattssonS , NordenskjoldF , RasmussenC . Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertility &amp; Sterility1998;69(4):702-8. ">Bergqvist 1998</a>; <a href="./references#CD014788-bbs2-0008" title="Bergqvist A and SCANDET group. A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis. Gynecological Endocrinology Aug 2000;14:425-432. [DOI: https://doi.org/10.3109/09513590009167714]">Bergqvist 2000</a>; <a href="./references#CD014788-bbs2-0009" title="BurryKA , PattonPE , IllingworthDR . Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.. American Journal of Obstetrics &amp; Gynecology1989;160(6):1454-9; discussion 1459-61. ">Burry 1989</a>; <a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>; <a href="./references#CD014788-bbs2-0011" title="ChangSP , NgHT . A randomized comparative study of the effect of leuprorelin acetate depot and danazol in the treatment of endometriosis. Chung Hua i Hsueh Tsa Chih - Chinese Medical Journal1996;57(6):431-7. ">Chang 1996</a>; <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0014" title="CrosignaniPG , De CeccoL , GastaldiA , VenturiniPL , OldaniS , VegettiW , et al. Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study. Human Reproduction1996;11(12):2732-5. [DOI: 10.1093/oxfordjournals.humrep.a019199]">Crosignani 1996</a>; <a href="./references#CD014788-bbs2-0015" title="CrosignaniPG , LucianoA , RayA , BergqvistA . Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction Sep 2006;21:248-56. [DOI: 10.1093/humrep/dei290]">Crosignani 2006</a>; <a href="./references#CD014788-bbs2-0016" title="DawoodMY , RamosJ , Khan-DawoodF . Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertility &amp; Sterility1995;63:1177-1183. [DOI: 10.1016/s0015-0282(16)57593-1]">Dawood 1995</a>; <a href="./references#CD014788-bbs2-0017" title="DlugiAM , MillerJD , KnittleJ . Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertility &amp; Sterility1990;54(3):419-27. [DOI: 10.1016/s0015-0282(16)53755-8]">Dlugi 1990</a>; <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>; <a href="./references#CD014788-bbs2-0019" title="EdmondsDK , HowellR . Can hormone replacement therapy be used during medical therapy of endometriosis?British Journal of Obstetrics and Gynaecology May 1994;101:24-26. [DOI: 10.1111/j.1471-0528.1994.tb13681.x]">Edmonds 1994</a>; <a href="./references#CD014788-bbs2-0020" title="FedeleL , BianchiS , ArcainiL , VercelliniP , CandianiGB . Buserelin versus danazol in the treatment of endometriosis-associated infertility. American Journal of Obstetrics &amp; Gynecology1989;161(4):871-6. [DOI: 10.1016/0002-9378(89)90739-4]FedeleL , MarchiniM , BianchiS , BaglioniA , ZanottiF . Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fertility &amp; Sterility1993;59(6):1191-5. ">Fedele 1989</a>; <a href="./references#CD014788-bbs2-0021" title="FerreiraRA , VieiraC , Rosa-e-SilavaJ , Rosa-e-SilvaA , NogueiraA , FerrianiR . Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception2010;81:117-122. [DOI: 10.1016/j.contraception.2009.08.003]">Ferreira 2010</a>; <a href="./references#CD014788-bbs2-0022" title="FinkelsteinJS , KlibanskiA , ArnoldAL , TothTL , HornsteinMD , NeerRM . Prevention of estrogen deficiency–related bone loss with human parathyroid hormone–(1-34). Journal of the American Medical Association1998;280:1067-1073. [DOI: 10.1001/jama.280.12.1067]">Finkelstein 1998</a>; <a href="./references#CD014788-bbs2-0023" title="FinkelsteinJS , Arnold AL . Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. Journal of Clinical Endocrinology &amp; Metabolism1999;84:1214-1219. [DOI: 10.1210/jcem.84.4.5643]">Finkelstein 1999</a>; <a href="./references#CD014788-bbs2-0024" title="FrankeHR , Van der WeijerPHM , PenningsTMM , Van der MoorenMJ . Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertility &amp; Sterility Sept 2000;74:534-539. [DOI: 10.1016/s0015-0282(00)00690-7]">Franke 2000</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>; <a href="./references#CD014788-bbs2-0026" title="FreundlG , GödtkeK , GnothaC , GodehardtE , Kienle E. Steroidal ‘Add-Back’ Therapy in Patients Treated with GnRH Agonists. Gynecologic and Obstetric Investigation1998;45:22-30. [DOI: 10.1159/000052848]">Freundl 1998</a>; <a href="./references#CD014788-bbs2-0027" title="FukushimaM , ShindoM , SatoK . Hormone treatment related bone mineral content changes in Japanese women with endometriosis. Asia-Oceania Journal of Obstetrics and Gynaecology1993;19(3):299-307. [DOI: 10.1111/j.1447-0756.1993.tb00389.x]Fukushima M . Changes in bone mineral content following hormone treatment for endometriosis. . International Journal of Gynecology &amp; Obstetrics1995;50:S17-S21. [DOI: 10.1016/0020-7292(95)02510-j]">Fukushima 1993</a>; <a href="./references#CD014788-bbs2-0028" title="GnothC , GödtkeK , FreundlG , GodehardtE , KienleE . Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists. Gynecologic and Obstetric Investigation1999;47:37-41. [DOI: 10.1159/000010059]">Gnoth 1999</a>; <a href="./references#CD014788-bbs2-0029" title="GomesMK , FerrianiRA , Rosa e SilvaJC , Japur de Sa Rosa e SilvaAC , VieiraCS , Candido dos ReisFJ . The levonorgestrel-releasing intrauterine system and endometriosis staging. Fertility &amp; Sterility2007;87(5):1231-4. [DOI: 10.1016/j.fertnstert.2006.11.044]">Gomes 2007</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a>; <a href="./references#CD014788-bbs2-0032" title="HornsteinM , YuzpeA , BurryK , HeinrichsL , OrwollE . A prospective randomised double-blind trial of 3 versus 6 months nafarelin therapy for symptoms of endometriosis. Fertility &amp; Sterility1992;58:S84. HornsteinMD , YuzpeAA , BurryKA , HeinrichsLR , Buttram VL Jr, et al. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertility &amp; Sterility1995;63(5):955-62. [PMID: 7720940]">Hornstein 1995</a>; <a href="./references#CD014788-bbs2-0033" title="HornsteinMD , SurreyES , WeisbergGW , Casino LA LUPRON add-back study group. Leuprolide acetate depot and hormonal add-back in endometriosis: A 12- month study. Obstetrics and Gynecology Jan 1998;1:16-24. [DOI: 10.1016/s0029-7844(97)00620-0]">Hornstein 1998</a>; <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>; <a href="./references#CD014788-bbs2-0035" title="HurstBS , GardnerSC , TuckerKE , AwoniyiCA , SchlaffWD . Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. Journal of the Society of Laparoendoscopic Surgeons2000;4:97-101. [PMID: PMC3015370]">Hurst 2000</a>; <a href="./references#CD014788-bbs2-0036" title="IraharaM ,  UemuraH , YasuiT , KinoshitaH , YamadaM , TezukaM , et al. Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis. Gynecologic and Obstetric Investigation2001;52:217-222. [DOI: 10.1159/000052978]">Irahara 2001</a>; <a href="./references#CD014788-bbs2-0037" title="JelleyRY , MagillPJ . The effect of LHRH agonist therapy in the treatment of endometriosis (English experience). Progress in Clinical &amp; Biological Research1986;225:227-38. JelleyRY . Multicentre open comparative study of buserelin and danazol in the treatment of endometriosis. British Journal of Clinical Practice1986;48(Suppl):64-8. ">Jelley 1986</a>; <a href="./references#CD014788-bbs2-0038" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility June 1990;53(6):998-1003. [DOI: 10.1016/s0015-0282(16)53574-2]">Kennedy 1990</a>; <a href="./references#CD014788-bbs2-0039" title="KiilholmaP , TuimalaR , KivinenS , KorhonenM , Hagman E. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertility &amp; Sterility1995;64(5):903-908. [DOI: 10.1016/s0015-0282(16)57900-x]">Kiilholma 1995</a>; <a href="./references#CD014788-bbs2-0040" title="LemayA , MaheuxR , HuotC , BlanchetJ , FaureN . Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1988;158(2):233-6. [DOI: 10.1016/0002-9378(88)90128-7]LemayA , MaheuxR , QuesnelG , Bureau M, FaureN , MeratP . LH-RH agonist treatment of endometriosis. Contributions to Gynecology and Obstetrics1987;16:247-53. ">Lemay 1988</a>; <a href="./references#CD014788-bbs2-0041" title="LingFW . Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic pain study group. Obstetrics &amp; Gynecology1999;93(1):51-58. [DOI: 10.1016/s0029-7844(98)00341-x]">Ling 1999</a>; <a href="./references#CD014788-bbs2-0042" title="MakarainenL , RönnbergL , KauppilaA . Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertility &amp; Sterility1996;65(1):29-34. [DOI: 10.1016/s0015-0282(16)58023-6]">Mäkäräinen 1996</a>; <a href="./references#CD014788-bbs2-0043" title="MillerJD . Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. American Journal of Obstetrics &amp; Gynecology2000;182(6):1483-1488. [DOI: 10.1067/mob.2000.106846]">Miller 2000</a>; <a href="./references#CD014788-bbs2-0044" title="MinaguchiH , UemuraT , ShirasuK . Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis--multicenter trial in Japan. Progress in Clinical &amp; Biological Research1986;225:211-25. [PMID: 3097667]">Minaguchi 1986</a>; <a href="./references#CD014788-bbs2-0045" title="MoghissiKS , SchlaffWD , OliveDL , SkinnerMA , YinH . Goserelin acetate (Zoladex) with or without hormone replacement. Therapy for the treatment of endometriosis. Fertility &amp; Sterility June 1998;69(6):1056-1062. [DOI: 10.1016/s0015-0282(98)00086-7]">Moghissi 1998</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>; <a href="./references#CD014788-bbs2-0047" title="OdukoyaOA , BansalA , WilsonAP , WeetmanAP , CookeID . Serum-soluble CD23 in patients with endometriosis and the effect of treatment with danazol and leuprolide acetate depot injection. Human Reproduction1995;10(4):942-946. [DOI: 10.1093/oxfordjournals.humrep.a136067]">Odukoya 1995</a>; <a href="./references#CD014788-bbs2-0048" title="OrwollES , YuzpeAA , BurryKA , HeinrichsL , ButtramVC ,  HornsteinMD . Nafarelin therapy in endometriosis: long-term effects on bone mineral density. American Journal of Obstetrics and Gynecology Nov 1994;171(5):1221-1225. [DOI: 10.1016/0002-9378(94)90136-8]">Orwoll 1994</a>; <a href="./references#CD014788-bbs2-0049" title="OzakiR ,  KumakiriJ , JinushiM , IkumaS , MurakamiK , KawasakiY , et al. Comparison of effect of preoperative dienogest and gonadotropin‑releasing hormone agonist administration on laparoscopic cystectomy for ovarian endometriomas. Archives of Gynecology and Obstetrics  July 2020;302:969-976. [DOI: 10.1007/s00404-020-05691-3]">Ozaki 2020</a>; <a href="./references#CD014788-bbs2-0050" title="PalagianoA , CapuanoV . Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol. Minerva Ginecologica1994;46(4):173-7. [PMID: 8065590]">Palagiano 1994</a>; <a href="./references#CD014788-bbs2-0051" title="PettaCA , FerrianiRA , AbraoMS , HassanD , RosaESJC , PodgaecS , et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Human Reproduction2005;20(7):1993-8. [DOI: 10.1093/humrep/deh869]VieiraCS , FerreiraRA , Rosa e SilvaJC , Rosa e SilvaACJS , GomesMK , FerrianiRA . Comparative study of the influence of the levonorgestrel intra-uterine system and the GnRH analogues on cardiovascular risk markers in patients with endometriosis. Fertility &amp; Sterility2007;88(Suppl 1):211. deSa Rosa e SilvaAC , Rosa e SilvaJC , NogueiraAA , PettaCA , AbraoMS , FerrianiRA . The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis. Fertility &amp; Sterility2006;86(3):742-4. ">Petta 2005</a>; <a href="./references#CD014788-bbs2-0052" title="AllenTW . Zoladex versus danazol in endometriosis therapy. Journal of the American Osteopathic Association1993;93(10):1013. RockJA , TrugliaJA , CaplanRJ . Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstetrics &amp; Gynecology1993;82(2):198-205. [PMID: 8336864]RockJA . A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis . Fertility &amp; Sterility1991;56(pp.s49). ">Rock 1993</a>; <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>; <a href="./references#CD014788-bbs2-0054" title="RotondiM , LabriolaD , AmmaturoFP , AmatoG , CarellaC , IzzoA , et al. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. European Journal of Gynaecological Oncology2002;23(6):523-526. [PMID: 12556096]">Rotondi 2002</a>; <a href="./references#CD014788-bbs2-0055" title="RouxC , PelissierC , ListratV , KoltaS , SimonettaC , GuignardM , et al. Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. Osteoporosis International1995;5:185-190. [DOI: 10.1007/BF02106098]">Roux 1995</a>; <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>; <a href="./references#CD014788-bbs2-0057" title="ShawRW , MattaW . Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis - comparison of two dose regimens. Clinical Reproduction and Fertility1986;4(5):329-36. [PMID: 3100012]">Shaw 1986</a>; <a href="./references#CD014788-bbs2-0058" title="ShawRW . Nafarelin in the treatment of pelvic pain caused by endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):574-6. [DOI: 10.1016/0002-9378(90)90433-8]">Shaw 1990</a>; <a href="./references#CD014788-bbs2-0059" title="SillemM , ParvizM , WoitgeHW , KieselL , UlrichU , vonHolstT , et al. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. Experimental and Clinical Endocrinology &amp; Diabetes1999;107:379-385. [DOI: 10.1055/s-0029-1212129]">Sillem 1999</a>; <a href="./references#CD014788-bbs2-0060" title="SkrzypulecV , WalaszekA , DrosdzolA , NowosielskiK , PielaB , Rozmus-WarcholinskaW . Influence of GnRH analogue on the intensification of endometriosis symptoms and infertility treatment. Wiadomosci Lekarskie2004;57 Suppl 1:301-4. [PMID: 15884262]">Skrzypulec 2004</a>; <a href="./references#CD014788-bbs2-0061" title="StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. International Journal of Gynecology and Obstetrics2012;117(3):228-233. [DOI: 10.1016/j.ijgo.2012.01.009]StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Human Reproduction January 2010;25(3):633-641. [DOI: 10.1093/humrep/dep46]">Strowitzki 2012</a>; <a href="./references#CD014788-bbs2-0062" title="SurreyES , JuddHL . Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial. Journal of Clinical Endocrinology and Metabolism1992;75(2):558-563. [DOI: 10.1210/jcem.75.2.1386374]">Surrey 1992</a>; <a href="./references#CD014788-bbs2-0063" title="SurreyES , HornsteinMD . Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstetrics and Gynecology2002;99(5 Pt 1):709-719. [DOI: 10.1016/s0029-7844(02)01945-2]">Surrey 2002</a>; <a href="./references#CD014788-bbs2-0064" title='TaharaM , MatsuokaT , YokoiT , TasakaK , KurachiH , MurataY . Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy). Fertility &amp; Sterility2000;73(4):799-804. [DOI: 10.1016/s0015-0282(99)00636-6]'>Tahara 2000</a>; <a href="./references#CD014788-bbs2-0065" title="TangH , WuR , LiX , ZhouY , LiuZ , WangC , ChenY , et al. Curative effect of 1.88-mg and 3.75-mg gonadotrophin-releasing hormone agonist on stage III–IV endometriosis: Randomized controlled study. The Journal of Obstetrics and Gynaecology Research October 2017;43(10):1550-1554. [DOI: 10.1111/jog.13420]">Tang 2017</a>; <a href="./references#CD014788-bbs2-0066" title="TummonIS , AliA , PeppingME , RadwanskaE , BinorZ , DmowskiWP . Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertility &amp; Sterility May 1988;49(5):792-796. [PMID: 3129312]">Tummon 1988</a>; <a href="./references#CD014788-bbs2-0067" title="TummonIS , PeppingME , BinorZ , RadwanskaE , DmowskiWP . A randomized, prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis. Fertility &amp; Sterility1989;51(3):390-4. [DOI: 10.1016/s0015-0282(16)60542-3]">Tummon 1989</a>; <a href="./references#CD014788-bbs2-0068" title="VercelliniP , TrespidiL , PanazzaS , BramanteT , MauroF , CrosignaniPG . Very low dose danazol for relief of endometriosis-associated pelvic pain: a pilot study. Fertility &amp; Sterility1994;62(6):1136-42. [PMID: 7525359]">Vercellini 1994</a>; <a href="./references#CD014788-bbs2-0069" title="VercelliniP , SomaM , MoroGL . Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertility &amp; Sterility 196;66(6):911-919. [DOI: 10.1016/s0015-0282(16)58682-8]">Vercellini 1996</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>; <a href="./references#CD014788-bbs2-0071" title="WhitehouseRW , AdamsJE , BancroftK , Vaughan-WilliamsCA , ElsteinM . The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clinical Endocrinology1990;33(3):365-373. [DOI: 10.1016/s0015-0282(16)58682-8]">Whitehouse 1990</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>).  See <a href="./references#CD014788-sec-0098" title="">Characteristics of included studies</a> for description.  </p> <p>All the studies were randomised controlled trials and came from a variety of different countries:  </p> <p>Brazil: <a href="./references#CD014788-bbs2-0021" title="FerreiraRA , VieiraC , Rosa-e-SilavaJ , Rosa-e-SilvaA , NogueiraA , FerrianiR . Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception2010;81:117-122. [DOI: 10.1016/j.contraception.2009.08.003]">Ferreira 2010</a>; <a href="./references#CD014788-bbs2-0029" title="GomesMK , FerrianiRA , Rosa e SilvaJC , Japur de Sa Rosa e SilvaAC , VieiraCS , Candido dos ReisFJ . The levonorgestrel-releasing intrauterine system and endometriosis staging. Fertility &amp; Sterility2007;87(5):1231-4. [DOI: 10.1016/j.fertnstert.2006.11.044]">Gomes 2007</a>; <a href="./references#CD014788-bbs2-0051" title="PettaCA , FerrianiRA , AbraoMS , HassanD , RosaESJC , PodgaecS , et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Human Reproduction2005;20(7):1993-8. [DOI: 10.1093/humrep/deh869]VieiraCS , FerreiraRA , Rosa e SilvaJC , Rosa e SilvaACJS , GomesMK , FerrianiRA . Comparative study of the influence of the levonorgestrel intra-uterine system and the GnRH analogues on cardiovascular risk markers in patients with endometriosis. Fertility &amp; Sterility2007;88(Suppl 1):211. deSa Rosa e SilvaAC , Rosa e SilvaJC , NogueiraAA , PettaCA , AbraoMS , FerrianiRA . The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis. Fertility &amp; Sterility2006;86(3):742-4. ">Petta 2005</a> </p> <p>Canada: <a href="./references#CD014788-bbs2-0040" title="LemayA , MaheuxR , HuotC , BlanchetJ , FaureN . Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1988;158(2):233-6. [DOI: 10.1016/0002-9378(88)90128-7]LemayA , MaheuxR , QuesnelG , Bureau M, FaureN , MeratP . LH-RH agonist treatment of endometriosis. Contributions to Gynecology and Obstetrics1987;16:247-53. ">Lemay 1988</a> </p> <p>Egypt: <a href="./references#CD014788-bbs2-0001" title="AbdouAM , AmmarIMM , AlenmrAAA , AbdelrhmanAA . Dienogest versus leuprolide acetate for recurrent pelvic pain following laparoscopic treatment of endometriosis. Journal of Obstetrics and Gynecology of India Aug 2018;4:306-13. [PMID: DOI: 10.1007/s13224-018-1119-3]">Abdou 2018</a> </p> <p>France: <a href="./references#CD014788-bbs2-0005" title="AudebertA , LucasC , Joubert-CollinM . Efficacy and safety of slow-release leuprorelin 3,75 mg compared to danazol treatment.  [Efficacite et tolerance de la leuproreline 3,75 MG a liberation prolongeedans le traitement de l'endometriose en comparaison au danazol]. References en Gynecologie Obstetrique1997;5(1):49-57. ">Audebert 1997</a>; <a href="./references#CD014788-bbs2-0055" title="RouxC , PelissierC , ListratV , KoltaS , SimonettaC , GuignardM , et al. Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. Osteoporosis International1995;5:185-190. [DOI: 10.1007/BF02106098]">Roux 1995</a> </p> <p>Finland: <a href="./references#CD014788-bbs2-0039" title="KiilholmaP , TuimalaR , KivinenS , KorhonenM , Hagman E. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertility &amp; Sterility1995;64(5):903-908. [DOI: 10.1016/s0015-0282(16)57900-x]">Kiilholma 1995</a>; <a href="./references#CD014788-bbs2-0042" title="MakarainenL , RönnbergL , KauppilaA . Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertility &amp; Sterility1996;65(1):29-34. [DOI: 10.1016/s0015-0282(16)58023-6]">Mäkäräinen 1996</a> </p> <p>Germany: <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0026" title="FreundlG , GödtkeK , GnothaC , GodehardtE , Kienle E. Steroidal ‘Add-Back’ Therapy in Patients Treated with GnRH Agonists. Gynecologic and Obstetric Investigation1998;45:22-30. [DOI: 10.1159/000052848]">Freundl 1998</a>; <a href="./references#CD014788-bbs2-0028" title="GnothC , GödtkeK , FreundlG , GodehardtE , KienleE . Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists. Gynecologic and Obstetric Investigation1999;47:37-41. [DOI: 10.1159/000010059]">Gnoth 1999</a>; <a href="./references#CD014788-bbs2-0059" title="SillemM , ParvizM , WoitgeHW , KieselL , UlrichU , vonHolstT , et al. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. Experimental and Clinical Endocrinology &amp; Diabetes1999;107:379-385. [DOI: 10.1055/s-0029-1212129]">Sillem 1999</a>; <a href="./references#CD014788-bbs2-0061" title="StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. International Journal of Gynecology and Obstetrics2012;117(3):228-233. [DOI: 10.1016/j.ijgo.2012.01.009]StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Human Reproduction January 2010;25(3):633-641. [DOI: 10.1093/humrep/dep46]">Strowitzki 2012</a> </p> <p>International (multi‐centre): <a href="./references#CD014788-bbs2-0004" title="AN Zoladex. Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(1):55-60. ">AN Zoladex 1996</a>; <a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a>; <a href="./references#CD014788-bbs2-0008" title="Bergqvist A and SCANDET group. A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis. Gynecological Endocrinology Aug 2000;14:425-432. [DOI: https://doi.org/10.3109/09513590009167714]">Bergqvist 2000</a>; <a href="./references#CD014788-bbs2-0015" title="CrosignaniPG , LucianoA , RayA , BergqvistA . Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction Sep 2006;21:248-56. [DOI: 10.1093/humrep/dei290]">Crosignani 2006</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>; <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>;  <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a> </p> <p>Italy: <a href="./references#CD014788-bbs2-0014" title="CrosignaniPG , De CeccoL , GastaldiA , VenturiniPL , OldaniS , VegettiW , et al. Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study. Human Reproduction1996;11(12):2732-5. [DOI: 10.1093/oxfordjournals.humrep.a019199]">Crosignani 1996</a>; <a href="./references#CD014788-bbs2-0020" title="FedeleL , BianchiS , ArcainiL , VercelliniP , CandianiGB . Buserelin versus danazol in the treatment of endometriosis-associated infertility. American Journal of Obstetrics &amp; Gynecology1989;161(4):871-6. [DOI: 10.1016/0002-9378(89)90739-4]FedeleL , MarchiniM , BianchiS , BaglioniA , ZanottiF . Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fertility &amp; Sterility1993;59(6):1191-5. ">Fedele 1989</a>; <a href="./references#CD014788-bbs2-0050" title="PalagianoA , CapuanoV . Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol. Minerva Ginecologica1994;46(4):173-7. [PMID: 8065590]">Palagiano 1994</a>; <a href="./references#CD014788-bbs2-0054" title="RotondiM , LabriolaD , AmmaturoFP , AmatoG , CarellaC , IzzoA , et al. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. European Journal of Gynaecological Oncology2002;23(6):523-526. [PMID: 12556096]">Rotondi 2002</a>; <a href="./references#CD014788-bbs2-0068" title="VercelliniP , TrespidiL , PanazzaS , BramanteT , MauroF , CrosignaniPG . Very low dose danazol for relief of endometriosis-associated pelvic pain: a pilot study. Fertility &amp; Sterility1994;62(6):1136-42. [PMID: 7525359]">Vercellini 1994</a>; <a href="./references#CD014788-bbs2-0069" title="VercelliniP , SomaM , MoroGL . Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertility &amp; Sterility 196;66(6):911-919. [DOI: 10.1016/s0015-0282(16)58682-8]">Vercellini 1996</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a> </p> <p>Japan: <a href="./references#CD014788-bbs2-0027" title="FukushimaM , ShindoM , SatoK . Hormone treatment related bone mineral content changes in Japanese women with endometriosis. Asia-Oceania Journal of Obstetrics and Gynaecology1993;19(3):299-307. [DOI: 10.1111/j.1447-0756.1993.tb00389.x]Fukushima M . Changes in bone mineral content following hormone treatment for endometriosis. . International Journal of Gynecology &amp; Obstetrics1995;50:S17-S21. [DOI: 10.1016/0020-7292(95)02510-j]">Fukushima 1993</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0036" title="IraharaM ,  UemuraH , YasuiT , KinoshitaH , YamadaM , TezukaM , et al. Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis. Gynecologic and Obstetric Investigation2001;52:217-222. [DOI: 10.1159/000052978]">Irahara 2001</a>; <a href="./references#CD014788-bbs2-0044" title="MinaguchiH , UemuraT , ShirasuK . Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis--multicenter trial in Japan. Progress in Clinical &amp; Biological Research1986;225:211-25. [PMID: 3097667]">Minaguchi 1986</a>; <a href="./references#CD014788-bbs2-0049" title="OzakiR ,  KumakiriJ , JinushiM , IkumaS , MurakamiK , KawasakiY , et al. Comparison of effect of preoperative dienogest and gonadotropin‑releasing hormone agonist administration on laparoscopic cystectomy for ovarian endometriomas. Archives of Gynecology and Obstetrics  July 2020;302:969-976. [DOI: 10.1007/s00404-020-05691-3]">Ozaki 2020</a>; <a href="./references#CD014788-bbs2-0064" title='TaharaM , MatsuokaT , YokoiT , TasakaK , KurachiH , MurataY . Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy). Fertility &amp; Sterility2000;73(4):799-804. [DOI: 10.1016/s0015-0282(99)00636-6]'>Tahara 2000</a>; <a href="./references#CD014788-bbs2-0065" title="TangH , WuR , LiX , ZhouY , LiuZ , WangC , ChenY , et al. Curative effect of 1.88-mg and 3.75-mg gonadotrophin-releasing hormone agonist on stage III–IV endometriosis: Randomized controlled study. The Journal of Obstetrics and Gynaecology Research October 2017;43(10):1550-1554. [DOI: 10.1111/jog.13420]">Tang 2017</a> </p> <p>Netherlands: <a href="./references#CD014788-bbs2-0024" title="FrankeHR , Van der WeijerPHM , PenningsTMM , Van der MoorenMJ . Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertility &amp; Sterility Sept 2000;74:534-539. [DOI: 10.1016/s0015-0282(00)00690-7]">Franke 2000</a> </p> <p>Poland: <a href="./references#CD014788-bbs2-0060" title="SkrzypulecV , WalaszekA , DrosdzolA , NowosielskiK , PielaB , Rozmus-WarcholinskaW . Influence of GnRH analogue on the intensification of endometriosis symptoms and infertility treatment. Wiadomosci Lekarskie2004;57 Suppl 1:301-4. [PMID: 15884262]">Skrzypulec 2004</a> </p> <p>Sweden: <a href="./references#CD014788-bbs2-0007" title="BergqvistA , BerghT , HogstromL , MattssonS , NordenskjoldF , RasmussenC . Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertility &amp; Sterility1998;69(4):702-8. ">Bergqvist 1998</a> </p> <p>Taiwan: <a href="./references#CD014788-bbs2-0011" title="ChangSP , NgHT . A randomized comparative study of the effect of leuprorelin acetate depot and danazol in the treatment of endometriosis. Chung Hua i Hsueh Tsa Chih - Chinese Medical Journal1996;57(6):431-7. ">Chang 1996</a>; <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a> </p> <p>United Kingdom: <a href="./references#CD014788-bbs2-0019" title="EdmondsDK , HowellR . Can hormone replacement therapy be used during medical therapy of endometriosis?British Journal of Obstetrics and Gynaecology May 1994;101:24-26. [DOI: 10.1111/j.1471-0528.1994.tb13681.x]">Edmonds 1994</a>; <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>; <a href="./references#CD014788-bbs2-0037" title="JelleyRY , MagillPJ . The effect of LHRH agonist therapy in the treatment of endometriosis (English experience). Progress in Clinical &amp; Biological Research1986;225:227-38. JelleyRY . Multicentre open comparative study of buserelin and danazol in the treatment of endometriosis. British Journal of Clinical Practice1986;48(Suppl):64-8. ">Jelley 1986</a>; <a href="./references#CD014788-bbs2-0038" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility June 1990;53(6):998-1003. [DOI: 10.1016/s0015-0282(16)53574-2]">Kennedy 1990</a>; <a href="./references#CD014788-bbs2-0047" title="OdukoyaOA , BansalA , WilsonAP , WeetmanAP , CookeID . Serum-soluble CD23 in patients with endometriosis and the effect of treatment with danazol and leuprolide acetate depot injection. Human Reproduction1995;10(4):942-946. [DOI: 10.1093/oxfordjournals.humrep.a136067]">Odukoya 1995</a>; <a href="./references#CD014788-bbs2-0057" title="ShawRW , MattaW . Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis - comparison of two dose regimens. Clinical Reproduction and Fertility1986;4(5):329-36. [PMID: 3100012]">Shaw 1986</a>; <a href="./references#CD014788-bbs2-0058" title="ShawRW . Nafarelin in the treatment of pelvic pain caused by endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):574-6. [DOI: 10.1016/0002-9378(90)90433-8]">Shaw 1990</a>; <a href="./references#CD014788-bbs2-0071" title="WhitehouseRW , AdamsJE , BancroftK , Vaughan-WilliamsCA , ElsteinM . The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clinical Endocrinology1990;33(3):365-373. [DOI: 10.1016/s0015-0282(16)58682-8]">Whitehouse 1990</a> </p> <p>United States of America: <a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>; <a href="./references#CD014788-bbs2-0003" title="AgarwalSK , HamrangC , HenzlMR , JuddHL . Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. Journal of Reproductive Medicine1997;42(7):413-23. ">Agarwal 1997</a>; <a href="./references#CD014788-bbs2-0009" title="BurryKA , PattonPE , IllingworthDR . Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.. American Journal of Obstetrics &amp; Gynecology1989;160(6):1454-9; discussion 1459-61. ">Burry 1989</a>; <a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>; <a href="./references#CD014788-bbs2-0016" title="DawoodMY , RamosJ , Khan-DawoodF . Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertility &amp; Sterility1995;63:1177-1183. [DOI: 10.1016/s0015-0282(16)57593-1]">Dawood 1995</a>; <a href="./references#CD014788-bbs2-0017" title="DlugiAM , MillerJD , KnittleJ . Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertility &amp; Sterility1990;54(3):419-27. [DOI: 10.1016/s0015-0282(16)53755-8]">Dlugi 1990</a>; <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>; <a href="./references#CD014788-bbs2-0022" title="FinkelsteinJS , KlibanskiA , ArnoldAL , TothTL , HornsteinMD , NeerRM . Prevention of estrogen deficiency–related bone loss with human parathyroid hormone–(1-34). Journal of the American Medical Association1998;280:1067-1073. [DOI: 10.1001/jama.280.12.1067]">Finkelstein 1998</a>; <a href="./references#CD014788-bbs2-0023" title="FinkelsteinJS , Arnold AL . Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. Journal of Clinical Endocrinology &amp; Metabolism1999;84:1214-1219. [DOI: 10.1210/jcem.84.4.5643]">Finkelstein 1999</a>; <a href="./references#CD014788-bbs2-0032" title="HornsteinM , YuzpeA , BurryK , HeinrichsL , OrwollE . A prospective randomised double-blind trial of 3 versus 6 months nafarelin therapy for symptoms of endometriosis. Fertility &amp; Sterility1992;58:S84. HornsteinMD , YuzpeAA , BurryKA , HeinrichsLR , Buttram VL Jr, et al. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertility &amp; Sterility1995;63(5):955-62. [PMID: 7720940]">Hornstein 1995</a>; <a href="./references#CD014788-bbs2-0033" title="HornsteinMD , SurreyES , WeisbergGW , Casino LA LUPRON add-back study group. Leuprolide acetate depot and hormonal add-back in endometriosis: A 12- month study. Obstetrics and Gynecology Jan 1998;1:16-24. [DOI: 10.1016/s0029-7844(97)00620-0]">Hornstein 1998</a>; <a href="./references#CD014788-bbs2-0035" title="HurstBS , GardnerSC , TuckerKE , AwoniyiCA , SchlaffWD . Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. Journal of the Society of Laparoendoscopic Surgeons2000;4:97-101. [PMID: PMC3015370]">Hurst 2000</a>; <a href="./references#CD014788-bbs2-0041" title="LingFW . Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic pain study group. Obstetrics &amp; Gynecology1999;93(1):51-58. [DOI: 10.1016/s0029-7844(98)00341-x]">Ling 1999</a>; <a href="./references#CD014788-bbs2-0043" title="MillerJD . Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. American Journal of Obstetrics &amp; Gynecology2000;182(6):1483-1488. [DOI: 10.1067/mob.2000.106846]">Miller 2000</a>; <a href="./references#CD014788-bbs2-0045" title="MoghissiKS , SchlaffWD , OliveDL , SkinnerMA , YinH . Goserelin acetate (Zoladex) with or without hormone replacement. Therapy for the treatment of endometriosis. Fertility &amp; Sterility June 1998;69(6):1056-1062. [DOI: 10.1016/s0015-0282(98)00086-7]">Moghissi 1998</a>; <a href="./references#CD014788-bbs2-0048" title="OrwollES , YuzpeAA , BurryKA , HeinrichsL , ButtramVC ,  HornsteinMD . Nafarelin therapy in endometriosis: long-term effects on bone mineral density. American Journal of Obstetrics and Gynecology Nov 1994;171(5):1221-1225. [DOI: 10.1016/0002-9378(94)90136-8]">Orwoll 1994</a>; <a href="./references#CD014788-bbs2-0052" title="AllenTW . Zoladex versus danazol in endometriosis therapy. Journal of the American Osteopathic Association1993;93(10):1013. RockJA , TrugliaJA , CaplanRJ . Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstetrics &amp; Gynecology1993;82(2):198-205. [PMID: 8336864]RockJA . A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis . Fertility &amp; Sterility1991;56(pp.s49). ">Rock 1993</a>; <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>; <a href="./references#CD014788-bbs2-0062" title="SurreyES , JuddHL . Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial. Journal of Clinical Endocrinology and Metabolism1992;75(2):558-563. [DOI: 10.1210/jcem.75.2.1386374]">Surrey 1992</a>; <a href="./references#CD014788-bbs2-0063" title="SurreyES , HornsteinMD . Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstetrics and Gynecology2002;99(5 Pt 1):709-719. [DOI: 10.1016/s0029-7844(02)01945-2]">Surrey 2002</a>; <a href="./references#CD014788-bbs2-0066" title="TummonIS , AliA , PeppingME , RadwanskaE , BinorZ , DmowskiWP . Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertility &amp; Sterility May 1988;49(5):792-796. [PMID: 3129312]">Tummon 1988</a>; <a href="./references#CD014788-bbs2-0067" title="TummonIS , PeppingME , BinorZ , RadwanskaE , DmowskiWP . A randomized, prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis. Fertility &amp; Sterility1989;51(3):390-4. [DOI: 10.1016/s0015-0282(16)60542-3]">Tummon 1989</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a> </p> <p>The included studies comprised 7355 women having complaints of endometriosis. Where reported, ages ranged from 18 to 48 years. All women with endometriosis had a clinical diagnosis of endometriosis made by direct visualisation (laparoscopy or laparotomy) or from ultrasonographic imaging or magnetic resonance imaging (MRI). </p> <p>The following interventions were tested in the included trials: </p> <p> <ul id="CD014788-list-0010"> <li> <p>GnRHas versus placebo (five trials; <a href="./references#CD014788-bbs2-0007" title="BergqvistA , BerghT , HogstromL , MattssonS , NordenskjoldF , RasmussenC . Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertility &amp; Sterility1998;69(4):702-8. ">Bergqvist 1998</a>; <a href="./references#CD014788-bbs2-0017" title="DlugiAM , MillerJD , KnittleJ . Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertility &amp; Sterility1990;54(3):419-27. [DOI: 10.1016/s0015-0282(16)53755-8]">Dlugi 1990</a>; <a href="./references#CD014788-bbs2-0041" title="LingFW . Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic pain study group. Obstetrics &amp; Gynecology1999;93(1):51-58. [DOI: 10.1016/s0029-7844(98)00341-x]">Ling 1999</a>; <a href="./references#CD014788-bbs2-0043" title="MillerJD . Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. American Journal of Obstetrics &amp; Gynecology2000;182(6):1483-1488. [DOI: 10.1067/mob.2000.106846]">Miller 2000</a>; <a href="./references#CD014788-bbs2-0060" title="SkrzypulecV , WalaszekA , DrosdzolA , NowosielskiK , PielaB , Rozmus-WarcholinskaW . Influence of GnRH analogue on the intensification of endometriosis symptoms and infertility treatment. Wiadomosci Lekarskie2004;57 Suppl 1:301-4. [PMID: 15884262]">Skrzypulec 2004</a>) </p> </li> <li> <p>GnRHas versus danazol (twenty‐nine trials; <a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>; <a href="./references#CD014788-bbs2-0004" title="AN Zoladex. Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(1):55-60. ">AN Zoladex 1996</a>; <a href="./references#CD014788-bbs2-0005" title="AudebertA , LucasC , Joubert-CollinM . Efficacy and safety of slow-release leuprorelin 3,75 mg compared to danazol treatment.  [Efficacite et tolerance de la leuproreline 3,75 MG a liberation prolongeedans le traitement de l'endometriose en comparaison au danazol]. References en Gynecologie Obstetrique1997;5(1):49-57. ">Audebert 1997</a>; <a href="./references#CD014788-bbs2-0009" title="BurryKA , PattonPE , IllingworthDR . Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.. American Journal of Obstetrics &amp; Gynecology1989;160(6):1454-9; discussion 1459-61. ">Burry 1989</a>; <a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>; <a href="./references#CD014788-bbs2-0011" title="ChangSP , NgHT . A randomized comparative study of the effect of leuprorelin acetate depot and danazol in the treatment of endometriosis. Chung Hua i Hsueh Tsa Chih - Chinese Medical Journal1996;57(6):431-7. ">Chang 1996</a>; <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0016" title="DawoodMY , RamosJ , Khan-DawoodF . Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertility &amp; Sterility1995;63:1177-1183. [DOI: 10.1016/s0015-0282(16)57593-1]">Dawood 1995</a>; <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>; <a href="./references#CD014788-bbs2-0020" title="FedeleL , BianchiS , ArcainiL , VercelliniP , CandianiGB . Buserelin versus danazol in the treatment of endometriosis-associated infertility. American Journal of Obstetrics &amp; Gynecology1989;161(4):871-6. [DOI: 10.1016/0002-9378(89)90739-4]FedeleL , MarchiniM , BianchiS , BaglioniA , ZanottiF . Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fertility &amp; Sterility1993;59(6):1191-5. ">Fedele 1989</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>; <a href="./references#CD014788-bbs2-0027" title="FukushimaM , ShindoM , SatoK . Hormone treatment related bone mineral content changes in Japanese women with endometriosis. Asia-Oceania Journal of Obstetrics and Gynaecology1993;19(3):299-307. [DOI: 10.1111/j.1447-0756.1993.tb00389.x]Fukushima M . Changes in bone mineral content following hormone treatment for endometriosis. . International Journal of Gynecology &amp; Obstetrics1995;50:S17-S21. [DOI: 10.1016/0020-7292(95)02510-j]">Fukushima 1993</a>; <a href="./references#CD014788-bbs2-0028" title="GnothC , GödtkeK , FreundlG , GodehardtE , KienleE . Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists. Gynecologic and Obstetric Investigation1999;47:37-41. [DOI: 10.1159/000010059]">Gnoth 1999</a>; <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a>; <a href="./references#CD014788-bbs2-0037" title="JelleyRY , MagillPJ . The effect of LHRH agonist therapy in the treatment of endometriosis (English experience). Progress in Clinical &amp; Biological Research1986;225:227-38. JelleyRY . Multicentre open comparative study of buserelin and danazol in the treatment of endometriosis. British Journal of Clinical Practice1986;48(Suppl):64-8. ">Jelley 1986</a>; <a href="./references#CD014788-bbs2-0038" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility June 1990;53(6):998-1003. [DOI: 10.1016/s0015-0282(16)53574-2]">Kennedy 1990</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>; <a href="./references#CD014788-bbs2-0047" title="OdukoyaOA , BansalA , WilsonAP , WeetmanAP , CookeID . Serum-soluble CD23 in patients with endometriosis and the effect of treatment with danazol and leuprolide acetate depot injection. Human Reproduction1995;10(4):942-946. [DOI: 10.1093/oxfordjournals.humrep.a136067]">Odukoya 1995</a>; <a href="./references#CD014788-bbs2-0050" title="PalagianoA , CapuanoV . Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol. Minerva Ginecologica1994;46(4):173-7. [PMID: 8065590]">Palagiano 1994</a>; <a href="./references#CD014788-bbs2-0052" title="AllenTW . Zoladex versus danazol in endometriosis therapy. Journal of the American Osteopathic Association1993;93(10):1013. RockJA , TrugliaJA , CaplanRJ . Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstetrics &amp; Gynecology1993;82(2):198-205. [PMID: 8336864]RockJA . A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis . Fertility &amp; Sterility1991;56(pp.s49). ">Rock 1993</a>; <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>; <a href="./references#CD014788-bbs2-0054" title="RotondiM , LabriolaD , AmmaturoFP , AmatoG , CarellaC , IzzoA , et al. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. European Journal of Gynaecological Oncology2002;23(6):523-526. [PMID: 12556096]">Rotondi 2002</a>; <a href="./references#CD014788-bbs2-0058" title="ShawRW . Nafarelin in the treatment of pelvic pain caused by endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):574-6. [DOI: 10.1016/0002-9378(90)90433-8]">Shaw 1990</a>; <a href="./references#CD014788-bbs2-0066" title="TummonIS , AliA , PeppingME , RadwanskaE , BinorZ , DmowskiWP . Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertility &amp; Sterility May 1988;49(5):792-796. [PMID: 3129312]">Tummon 1988</a>; <a href="./references#CD014788-bbs2-0067" title="TummonIS , PeppingME , BinorZ , RadwanskaE , DmowskiWP . A randomized, prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis. Fertility &amp; Sterility1989;51(3):390-4. [DOI: 10.1016/s0015-0282(16)60542-3]">Tummon 1989</a>; <a href="./references#CD014788-bbs2-0068" title="VercelliniP , TrespidiL , PanazzaS , BramanteT , MauroF , CrosignaniPG . Very low dose danazol for relief of endometriosis-associated pelvic pain: a pilot study. Fertility &amp; Sterility1994;62(6):1136-42. [PMID: 7525359]">Vercellini 1994</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>; <a href="./references#CD014788-bbs2-0071" title="WhitehouseRW , AdamsJE , BancroftK , Vaughan-WilliamsCA , ElsteinM . The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clinical Endocrinology1990;33(3):365-373. [DOI: 10.1016/s0015-0282(16)58682-8]">Whitehouse 1990</a>) </p> </li> <li> <p>GnRHas versus intra‐uterine progestogens (three trials; <a href="./references#CD014788-bbs2-0021" title="FerreiraRA , VieiraC , Rosa-e-SilavaJ , Rosa-e-SilvaA , NogueiraA , FerrianiR . Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception2010;81:117-122. [DOI: 10.1016/j.contraception.2009.08.003]">Ferreira 2010</a>; <a href="./references#CD014788-bbs2-0029" title="GomesMK , FerrianiRA , Rosa e SilvaJC , Japur de Sa Rosa e SilvaAC , VieiraCS , Candido dos ReisFJ . The levonorgestrel-releasing intrauterine system and endometriosis staging. Fertility &amp; Sterility2007;87(5):1231-4. [DOI: 10.1016/j.fertnstert.2006.11.044]">Gomes 2007</a>; <a href="./references#CD014788-bbs2-0051" title="PettaCA , FerrianiRA , AbraoMS , HassanD , RosaESJC , PodgaecS , et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Human Reproduction2005;20(7):1993-8. [DOI: 10.1093/humrep/deh869]VieiraCS , FerreiraRA , Rosa e SilvaJC , Rosa e SilvaACJS , GomesMK , FerrianiRA . Comparative study of the influence of the levonorgestrel intra-uterine system and the GnRH analogues on cardiovascular risk markers in patients with endometriosis. Fertility &amp; Sterility2007;88(Suppl 1):211. deSa Rosa e SilvaAC , Rosa e SilvaJC , NogueiraAA , PettaCA , AbraoMS , FerrianiRA . The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis. Fertility &amp; Sterility2006;86(3):742-4. ">Petta 2005</a>) </p> </li> <li> <p>GnRHas versus  oral or injectable progestogens (seven trials; <a href="./references#CD014788-bbs2-0001" title="AbdouAM , AmmarIMM , AlenmrAAA , AbdelrhmanAA . Dienogest versus leuprolide acetate for recurrent pelvic pain following laparoscopic treatment of endometriosis. Journal of Obstetrics and Gynecology of India Aug 2018;4:306-13. [PMID: DOI: 10.1007/s13224-018-1119-3]">Abdou 2018</a>; <a href="./references#CD014788-bbs2-0015" title="CrosignaniPG , LucianoA , RayA , BergqvistA . Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction Sep 2006;21:248-56. [DOI: 10.1093/humrep/dei290]">Crosignani 2006</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0049" title="OzakiR ,  KumakiriJ , JinushiM , IkumaS , MurakamiK , KawasakiY , et al. Comparison of effect of preoperative dienogest and gonadotropin‑releasing hormone agonist administration on laparoscopic cystectomy for ovarian endometriomas. Archives of Gynecology and Obstetrics  July 2020;302:969-976. [DOI: 10.1007/s00404-020-05691-3]">Ozaki 2020</a>; <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>; <a href="./references#CD014788-bbs2-0061" title="StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. International Journal of Gynecology and Obstetrics2012;117(3):228-233. [DOI: 10.1016/j.ijgo.2012.01.009]StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Human Reproduction January 2010;25(3):633-641. [DOI: 10.1093/humrep/dep46]">Strowitzki 2012</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>)  </p> </li> <li> <p>GnRHas versus gestrinone (one trial; <a href="./references#CD014788-bbs2-0069" title="VercelliniP , SomaM , MoroGL . Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertility &amp; Sterility 196;66(6):911-919. [DOI: 10.1016/s0015-0282(16)58682-8]">Vercellini 1996</a>) </p> </li> <li> <p>Trials comparing different doses of GnRHas (eight trials; <a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>; <a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a>; <a href="./references#CD014788-bbs2-0009" title="BurryKA , PattonPE , IllingworthDR . Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.. American Journal of Obstetrics &amp; Gynecology1989;160(6):1454-9; discussion 1459-61. ">Burry 1989</a>; <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a>; <a href="./references#CD014788-bbs2-0044" title="MinaguchiH , UemuraT , ShirasuK . Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis--multicenter trial in Japan. Progress in Clinical &amp; Biological Research1986;225:211-25. [PMID: 3097667]">Minaguchi 1986</a>; <a href="./references#CD014788-bbs2-0057" title="ShawRW , MattaW . Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis - comparison of two dose regimens. Clinical Reproduction and Fertility1986;4(5):329-36. [PMID: 3100012]">Shaw 1986</a>; <a href="./references#CD014788-bbs2-0064" title='TaharaM , MatsuokaT , YokoiT , TasakaK , KurachiH , MurataY . Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy). Fertility &amp; Sterility2000;73(4):799-804. [DOI: 10.1016/s0015-0282(99)00636-6]'>Tahara 2000</a>; <a href="./references#CD014788-bbs2-0065" title="TangH , WuR , LiX , ZhouY , LiuZ , WangC , ChenY , et al. Curative effect of 1.88-mg and 3.75-mg gonadotrophin-releasing hormone agonist on stage III–IV endometriosis: Randomized controlled study. The Journal of Obstetrics and Gynaecology Research October 2017;43(10):1550-1554. [DOI: 10.1111/jog.13420]">Tang 2017</a>) </p> </li> <li> <p>Trials comparing different treatment duration of GnRHas (two trials; <a href="./references#CD014788-bbs2-0032" title="HornsteinM , YuzpeA , BurryK , HeinrichsL , OrwollE . A prospective randomised double-blind trial of 3 versus 6 months nafarelin therapy for symptoms of endometriosis. Fertility &amp; Sterility1992;58:S84. HornsteinMD , YuzpeAA , BurryKA , HeinrichsLR , Buttram VL Jr, et al. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertility &amp; Sterility1995;63(5):955-62. [PMID: 7720940]">Hornstein 1995</a>; <a href="./references#CD014788-bbs2-0048" title="OrwollES , YuzpeAA , BurryKA , HeinrichsL , ButtramVC ,  HornsteinMD . Nafarelin therapy in endometriosis: long-term effects on bone mineral density. American Journal of Obstetrics and Gynecology Nov 1994;171(5):1221-1225. [DOI: 10.1016/0002-9378(94)90136-8]">Orwoll 1994</a>) </p> </li> <li> <p>Trials comparing different route of administration of GnRHas (four trials; <a href="./references#CD014788-bbs2-0003" title="AgarwalSK , HamrangC , HenzlMR , JuddHL . Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. Journal of Reproductive Medicine1997;42(7):413-23. ">Agarwal 1997</a>; <a href="./references#CD014788-bbs2-0008" title="Bergqvist A and SCANDET group. A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis. Gynecological Endocrinology Aug 2000;14:425-432. [DOI: https://doi.org/10.3109/09513590009167714]">Bergqvist 2000</a>; <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>; <a href="./references#CD014788-bbs2-0040" title="LemayA , MaheuxR , HuotC , BlanchetJ , FaureN . Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1988;158(2):233-6. [DOI: 10.1016/0002-9378(88)90128-7]LemayA , MaheuxR , QuesnelG , Bureau M, FaureN , MeratP . LH-RH agonist treatment of endometriosis. Contributions to Gynecology and Obstetrics1987;16:247-53. ">Lemay 1988</a>) </p> </li> <li> <p>Trials comparing different GnRHas treatment regimens (one trial; <a href="./references#CD014788-bbs2-0014" title="CrosignaniPG , De CeccoL , GastaldiA , VenturiniPL , OldaniS , VegettiW , et al. Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study. Human Reproduction1996;11(12):2732-5. [DOI: 10.1093/oxfordjournals.humrep.a019199]">Crosignani 1996</a>) </p> </li> <li> <p>Trials comparing GnRHas versus GnRHas in conjunction with add‐back therapy (hormonal or non‐hormonal) (seventeen trials; <a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a>; <a href="./references#CD014788-bbs2-0019" title="EdmondsDK , HowellR . Can hormone replacement therapy be used during medical therapy of endometriosis?British Journal of Obstetrics and Gynaecology May 1994;101:24-26. [DOI: 10.1111/j.1471-0528.1994.tb13681.x]">Edmonds 1994</a>; <a href="./references#CD014788-bbs2-0024" title="FrankeHR , Van der WeijerPHM , PenningsTMM , Van der MoorenMJ . Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertility &amp; Sterility Sept 2000;74:534-539. [DOI: 10.1016/s0015-0282(00)00690-7]">Franke 2000</a>; <a href="./references#CD014788-bbs2-0026" title="FreundlG , GödtkeK , GnothaC , GodehardtE , Kienle E. Steroidal ‘Add-Back’ Therapy in Patients Treated with GnRH Agonists. Gynecologic and Obstetric Investigation1998;45:22-30. [DOI: 10.1159/000052848]">Freundl 1998</a>; <a href="./references#CD014788-bbs2-0028" title="GnothC , GödtkeK , FreundlG , GodehardtE , KienleE . Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists. Gynecologic and Obstetric Investigation1999;47:37-41. [DOI: 10.1159/000010059]">Gnoth 1999</a>; <a href="./references#CD014788-bbs2-0033" title="HornsteinMD , SurreyES , WeisbergGW , Casino LA LUPRON add-back study group. Leuprolide acetate depot and hormonal add-back in endometriosis: A 12- month study. Obstetrics and Gynecology Jan 1998;1:16-24. [DOI: 10.1016/s0029-7844(97)00620-0]">Hornstein 1998</a>; <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>; <a href="./references#CD014788-bbs2-0035" title="HurstBS , GardnerSC , TuckerKE , AwoniyiCA , SchlaffWD . Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. Journal of the Society of Laparoendoscopic Surgeons2000;4:97-101. [PMID: PMC3015370]">Hurst 2000</a>; <a href="./references#CD014788-bbs2-0036" title="IraharaM ,  UemuraH , YasuiT , KinoshitaH , YamadaM , TezukaM , et al. Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis. Gynecologic and Obstetric Investigation2001;52:217-222. [DOI: 10.1159/000052978]">Irahara 2001</a>; <a href="./references#CD014788-bbs2-0039" title="KiilholmaP , TuimalaR , KivinenS , KorhonenM , Hagman E. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertility &amp; Sterility1995;64(5):903-908. [DOI: 10.1016/s0015-0282(16)57900-x]">Kiilholma 1995</a>; <a href="./references#CD014788-bbs2-0042" title="MakarainenL , RönnbergL , KauppilaA . Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertility &amp; Sterility1996;65(1):29-34. [DOI: 10.1016/s0015-0282(16)58023-6]">Mäkäräinen 1996</a>; <a href="./references#CD014788-bbs2-0045" title="MoghissiKS , SchlaffWD , OliveDL , SkinnerMA , YinH . Goserelin acetate (Zoladex) with or without hormone replacement. Therapy for the treatment of endometriosis. Fertility &amp; Sterility June 1998;69(6):1056-1062. [DOI: 10.1016/s0015-0282(98)00086-7]">Moghissi 1998</a>; <a href="./references#CD014788-bbs2-0059" title="SillemM , ParvizM , WoitgeHW , KieselL , UlrichU , vonHolstT , et al. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. Experimental and Clinical Endocrinology &amp; Diabetes1999;107:379-385. [DOI: 10.1055/s-0029-1212129]">Sillem 1999</a>; <a href="./references#CD014788-bbs2-0062" title="SurreyES , JuddHL . Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial. Journal of Clinical Endocrinology and Metabolism1992;75(2):558-563. [DOI: 10.1210/jcem.75.2.1386374]">Surrey 1992</a>; <a href="./references#CD014788-bbs2-0063" title="SurreyES , HornsteinMD . Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstetrics and Gynecology2002;99(5 Pt 1):709-719. [DOI: 10.1016/s0029-7844(02)01945-2]">Surrey 2002</a>; <a href="./references#CD014788-bbs2-0068" title="VercelliniP , TrespidiL , PanazzaS , BramanteT , MauroF , CrosignaniPG . Very low dose danazol for relief of endometriosis-associated pelvic pain: a pilot study. Fertility &amp; Sterility1994;62(6):1136-42. [PMID: 7525359]">Vercellini 1994</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>) </p> </li> <li> <p>Trials comparing GnRHas versus GnRHas in conjunction with calcium‐regulating agents (three trials; <a href="./references#CD014788-bbs2-0022" title="FinkelsteinJS , KlibanskiA , ArnoldAL , TothTL , HornsteinMD , NeerRM . Prevention of estrogen deficiency–related bone loss with human parathyroid hormone–(1-34). Journal of the American Medical Association1998;280:1067-1073. [DOI: 10.1001/jama.280.12.1067]">Finkelstein 1998</a>; <a href="./references#CD014788-bbs2-0023" title="FinkelsteinJS , Arnold AL . Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. Journal of Clinical Endocrinology &amp; Metabolism1999;84:1214-1219. [DOI: 10.1210/jcem.84.4.5643]">Finkelstein 1999</a>;  <a href="./references#CD014788-bbs2-0055" title="RouxC , PelissierC , ListratV , KoltaS , SimonettaC , GuignardM , et al. Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. Osteoporosis International1995;5:185-190. [DOI: 10.1007/BF02106098]">Roux 1995</a>) </p> </li> <li> <p>Trials mentioning the effect of GnRHas on BMD (thirty trials; <a href="./references#CD014788-bbs2-0014" title="CrosignaniPG , De CeccoL , GastaldiA , VenturiniPL , OldaniS , VegettiW , et al. Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study. Human Reproduction1996;11(12):2732-5. [DOI: 10.1093/oxfordjournals.humrep.a019199]">Crosignani 1996</a>; <a href="./references#CD014788-bbs2-0015" title="CrosignaniPG , LucianoA , RayA , BergqvistA . Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction Sep 2006;21:248-56. [DOI: 10.1093/humrep/dei290]">Crosignani 2006</a>; <a href="./references#CD014788-bbs2-0016" title="DawoodMY , RamosJ , Khan-DawoodF . Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertility &amp; Sterility1995;63:1177-1183. [DOI: 10.1016/s0015-0282(16)57593-1]">Dawood 1995</a>; <a href="./references#CD014788-bbs2-0017" title="DlugiAM , MillerJD , KnittleJ . Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertility &amp; Sterility1990;54(3):419-27. [DOI: 10.1016/s0015-0282(16)53755-8]">Dlugi 1990</a>; <a href="./references#CD014788-bbs2-0019" title="EdmondsDK , HowellR . Can hormone replacement therapy be used during medical therapy of endometriosis?British Journal of Obstetrics and Gynaecology May 1994;101:24-26. [DOI: 10.1111/j.1471-0528.1994.tb13681.x]">Edmonds 1994</a>; <a href="./references#CD014788-bbs2-0022" title="FinkelsteinJS , KlibanskiA , ArnoldAL , TothTL , HornsteinMD , NeerRM . Prevention of estrogen deficiency–related bone loss with human parathyroid hormone–(1-34). Journal of the American Medical Association1998;280:1067-1073. [DOI: 10.1001/jama.280.12.1067]">Finkelstein 1998</a>; <a href="./references#CD014788-bbs2-0023" title="FinkelsteinJS , Arnold AL . Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. Journal of Clinical Endocrinology &amp; Metabolism1999;84:1214-1219. [DOI: 10.1210/jcem.84.4.5643]">Finkelstein 1999</a>; <a href="./references#CD014788-bbs2-0024" title="FrankeHR , Van der WeijerPHM , PenningsTMM , Van der MoorenMJ . Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertility &amp; Sterility Sept 2000;74:534-539. [DOI: 10.1016/s0015-0282(00)00690-7]">Franke 2000</a>; <a href="./references#CD014788-bbs2-0026" title="FreundlG , GödtkeK , GnothaC , GodehardtE , Kienle E. Steroidal ‘Add-Back’ Therapy in Patients Treated with GnRH Agonists. Gynecologic and Obstetric Investigation1998;45:22-30. [DOI: 10.1159/000052848]">Freundl 1998</a>; <a href="./references#CD014788-bbs2-0027" title="FukushimaM , ShindoM , SatoK . Hormone treatment related bone mineral content changes in Japanese women with endometriosis. Asia-Oceania Journal of Obstetrics and Gynaecology1993;19(3):299-307. [DOI: 10.1111/j.1447-0756.1993.tb00389.x]Fukushima M . Changes in bone mineral content following hormone treatment for endometriosis. . International Journal of Gynecology &amp; Obstetrics1995;50:S17-S21. [DOI: 10.1016/0020-7292(95)02510-j]">Fukushima 1993</a>; <a href="./references#CD014788-bbs2-0028" title="GnothC , GödtkeK , FreundlG , GodehardtE , KienleE . Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists. Gynecologic and Obstetric Investigation1999;47:37-41. [DOI: 10.1159/000010059]">Gnoth 1999</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0033" title="HornsteinMD , SurreyES , WeisbergGW , Casino LA LUPRON add-back study group. Leuprolide acetate depot and hormonal add-back in endometriosis: A 12- month study. Obstetrics and Gynecology Jan 1998;1:16-24. [DOI: 10.1016/s0029-7844(97)00620-0]">Hornstein 1998</a>; <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>; <a href="./references#CD014788-bbs2-0036" title="IraharaM ,  UemuraH , YasuiT , KinoshitaH , YamadaM , TezukaM , et al. Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis. Gynecologic and Obstetric Investigation2001;52:217-222. [DOI: 10.1159/000052978]">Irahara 2001</a>; <a href="./references#CD014788-bbs2-0045" title="MoghissiKS , SchlaffWD , OliveDL , SkinnerMA , YinH . Goserelin acetate (Zoladex) with or without hormone replacement. Therapy for the treatment of endometriosis. Fertility &amp; Sterility June 1998;69(6):1056-1062. [DOI: 10.1016/s0015-0282(98)00086-7]">Moghissi 1998</a>; <a href="./references#CD014788-bbs2-0048" title="OrwollES , YuzpeAA , BurryKA , HeinrichsL , ButtramVC ,  HornsteinMD . Nafarelin therapy in endometriosis: long-term effects on bone mineral density. American Journal of Obstetrics and Gynecology Nov 1994;171(5):1221-1225. [DOI: 10.1016/0002-9378(94)90136-8]">Orwoll 1994</a>; <a href="./references#CD014788-bbs2-0052" title="AllenTW . Zoladex versus danazol in endometriosis therapy. Journal of the American Osteopathic Association1993;93(10):1013. RockJA , TrugliaJA , CaplanRJ . Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstetrics &amp; Gynecology1993;82(2):198-205. [PMID: 8336864]RockJA . A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis . Fertility &amp; Sterility1991;56(pp.s49). ">Rock 1993</a>; <a href="./references#CD014788-bbs2-0055" title="RouxC , PelissierC , ListratV , KoltaS , SimonettaC , GuignardM , et al. Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. Osteoporosis International1995;5:185-190. [DOI: 10.1007/BF02106098]">Roux 1995</a>; <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>; <a href="./references#CD014788-bbs2-0059" title="SillemM , ParvizM , WoitgeHW , KieselL , UlrichU , vonHolstT , et al. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. Experimental and Clinical Endocrinology &amp; Diabetes1999;107:379-385. [DOI: 10.1055/s-0029-1212129]">Sillem 1999</a>; <a href="./references#CD014788-bbs2-0062" title="SurreyES , JuddHL . Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial. Journal of Clinical Endocrinology and Metabolism1992;75(2):558-563. [DOI: 10.1210/jcem.75.2.1386374]">Surrey 1992</a>; <a href="./references#CD014788-bbs2-0063" title="SurreyES , HornsteinMD . Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstetrics and Gynecology2002;99(5 Pt 1):709-719. [DOI: 10.1016/s0029-7844(02)01945-2]">Surrey 2002</a>; <a href="./references#CD014788-bbs2-0064" title='TaharaM , MatsuokaT , YokoiT , TasakaK , KurachiH , MurataY . Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy). Fertility &amp; Sterility2000;73(4):799-804. [DOI: 10.1016/s0015-0282(99)00636-6]'>Tahara 2000</a>; <a href="./references#CD014788-bbs2-0065" title="TangH , WuR , LiX , ZhouY , LiuZ , WangC , ChenY , et al. Curative effect of 1.88-mg and 3.75-mg gonadotrophin-releasing hormone agonist on stage III–IV endometriosis: Randomized controlled study. The Journal of Obstetrics and Gynaecology Research October 2017;43(10):1550-1554. [DOI: 10.1111/jog.13420]">Tang 2017</a>; <a href="./references#CD014788-bbs2-0066" title="TummonIS , AliA , PeppingME , RadwanskaE , BinorZ , DmowskiWP . Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertility &amp; Sterility May 1988;49(5):792-796. [PMID: 3129312]">Tummon 1988</a>; <a href="./references#CD014788-bbs2-0069" title="VercelliniP , SomaM , MoroGL . Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertility &amp; Sterility 196;66(6):911-919. [DOI: 10.1016/s0015-0282(16)58682-8]">Vercellini 1996</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>; <a href="./references#CD014788-bbs2-0071" title="WhitehouseRW , AdamsJE , BancroftK , Vaughan-WilliamsCA , ElsteinM . The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clinical Endocrinology1990;33(3):365-373. [DOI: 10.1016/s0015-0282(16)58682-8]">Whitehouse 1990</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>) </p> </li> </ul> </p> <p>No trials comparing GnRHas versus no treatment or trials comparing GnRH analogues versus analgesics were identified.   </p> <p>Six trials were included in two different comparisons, due to the fact that these trials included three different treatment groups, and therefore could be included in different comparisons (<a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>; <a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a>; <a href="./references#CD014788-bbs2-0009" title="BurryKA , PattonPE , IllingworthDR . Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.. American Journal of Obstetrics &amp; Gynecology1989;160(6):1454-9; discussion 1459-61. ">Burry 1989</a>; <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>; <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>). <a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>, <a href="./references#CD014788-bbs2-0009" title="BurryKA , PattonPE , IllingworthDR . Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.. American Journal of Obstetrics &amp; Gynecology1989;160(6):1454-9; discussion 1459-61. ">Burry 1989</a>, <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>, and <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a> compared varying dosage of GnRHas in addition to a comparison with danazol, and <a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a> compared varying dosage of GnRHas in addition to a comparison with add‐back therapy (hormonal or non‐hormonal). <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a> compared GnRHas with GnRHas in conjunction with add‐back, and compared GnRHas with oral or injectable progestogens.   </p> </section> <section id="CD014788-sec-0043"> <h4 class="title">Excluded studies</h4> <p>Of the fifty‐six studies that were excluded, ten studies did not have the stated outcome measures (<a href="./references#CD014788-bbs2-0073" title="AcienP , ShawRW , IrvineL , BurfordGRG . CA 125 levels in endometriosis patients before, during and after treatment with danazol or LHRH agonists. European Journal of Gynaecological Oncology1989;32(1):241-6. ">Acien 1989</a>; <a href="./references#CD014788-bbs2-0078" title="Calvo LugoGE , Sauceda GonzalezLF , Jimenez PereaML , Diaz AriasFJ . Treatment of pelvic endometriosis with goserelin acetate or nafarelin acetate. Comparative study. Ginecologia y Obstetricia de Mexico2000;68:7-14. ">Calvo 2000</a>;<a href="./references#CD014788-bbs2-0087" title="DonnezJ , Nisolle-PochetM , Clerckx-BraunF , SandowJ , Casanas-RouxF . Administration of nasal buserelin as compared with subcutaneous buserelin implant for endometriosis. Fertility &amp; Sterility1989;52(1):27-30. ">Donnez 1989</a>; <a href="./references#CD014788-bbs2-0090" title="el-RoeiyA , DmowskiWP , GleicherN , RadwanskaE , HarlowL , BinorZ , et al. Danazol but not gonadotropin-releasing hormone agonists suppresses autoantibodies in endometriosis. Fertility &amp; Sterility1988;50(6):864-71. ">el‐Roeiy 1988</a>; <a href="./references#CD014788-bbs2-0102" title="MaourisP , DowsettM , NicholsJ , RoseG , EdmondsDK . Pseudomenopause treatment for endometriosis: The endocrine effects of danazol compared with the use of the LH-RH agonist goserelin. Journal of Obstetrics &amp; Gynaecology1991;11:123-127. [DOI: 10.1016/s0015-0282(16)58023-6]MaourisP , DowsettM , RoseG , D E. Comparison of the endocrine effects of danazol and the LHRH agonist goserelin (Zoladex) in the treament of endometriosis. Silver Jubilee British Congress of Obstetrics and Gynaecology1989:61. ">Maouris 1991</a>; <a href="./references#CD014788-bbs2-0103" title="MatalliotakisIM , NeonakiMA , KoumantakiYG , GoumenouAG , KyriakouDS , KoumantakisEE . A randomized comparison of danazol and leuprolide acetate suppression of serum-soluble CD23 levels in endometriosis. Obstetrics &amp; Gynecology2000;95(6 Pt 1):810-813. [DOI: 10.1016/s0029-7844(99)00635-3]">Matalliotakis 2000</a>; <a href="./references#CD014788-bbs2-0120" title="TapanainenJ , HovattaO , JuntunenK , MartikainenH , RatsulaK , TuppalaM , et al. Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF: a randomized comparative study. Human Reproduction1993;8(12):2052-5. ">Tapanainen 1993</a>; <a href="./references#CD014788-bbs2-0123" title="ValimakiM , NilssonCG , RoineR , YlikorkalaO . Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis. The Journal of Clinical Endocrinology and Metabolism1989;69(6):1097-103. [DOI: 10.1210/jcem-69-6-1097]">Valimaki 1989</a>; <a href="./references#CD014788-bbs2-0126" title="WrightS , ValdesCT , DunnRC , FranklinRR . Short-term lupron or danazol therapy for pelvic endometriosis. Fertility &amp; Sterility1995;63(3):504-7. [PMID: 7851578]">Wright 1995</a>; <a href="./references#CD014788-bbs2-0127" title="YeeB . A preliminary report on the comparative use of buserelin (Hoe 766) and danazol in the treatment of endometriosis: the university of Southern California experience. Progress in Clinical &amp; Biological Research1986;225:175-88. ">Yee 1986</a>). Fifteen studies reported wrong comparisons, see 'Types of Interventions' for details (<a href="./references#CD014788-bbs2-0075" title="AgarwalAK , DanielsA , DrosmanSR , UdoffL , FosterWG ,  PikeMC ,  et al. Treatment of endometriosis with the GnRHa deslorelin and add-back estradiol and supplementary testosterone. BioMed Research International2015;2015:1-9. [PMID: 10.1155/2015/934164]">Agarwal 2015</a>; <a href="./references#CD014788-bbs2-0083" title="CookeID , ThomasEJ . The medical treatment of mild endometriosis. Acta Obstetricia et Gynecologica Scandinavica - Supplement1989;150:27-30. ">Cooke 1989</a>; <a href="./references#CD014788-bbs2-0085" title="DmowskiWP . Comparitive study of buserelin versus danazol in the management of endometriosis. Gynecological Endocrinology1989;3(Suppl 2):21-31. ">Dmowski 1989</a>; <a href="./references#CD014788-bbs2-0088" title="DonnezJ , DewartPJ , HedonB , PerinoA , SchindlerAE , BlumbergJ , et al. Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis. Fertility &amp; Sterility2004;81(2):297-304. ">Donnez 2004</a>; <a href="./references#CD014788-bbs2-0092" title="Fernandez H, LucasC , Hédon B , Meyer JL, Mayenga JM and Roux C. One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial. Human Reproduction April 2004;19:1465-1471. [DOI: 10.1093/humrep/deh250]">Fernandez 2004</a>; <a href="./references#CD014788-bbs2-0093" title="FerreroS , VenturiniPL , GillottDJ , RemorgidaV . Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial. Reproductive Biology and Endocrinology2011;9:1-7. [DOI: 10.1186/1477-7827-9-88]">Ferrero 2011</a>; <a href="./references#CD014788-bbs2-0098" title="ImaniR , Thai-CuartoD , JimenezR , BurkeJ , KrollR , O'BrienC . Petal study: Safety, tolerability and effectiveness of elagolix, an oral GnRH antagonist for endometriosis. In: Fertility &amp; Sterility. Vol. 92. 2009:S111-S112. [DOI: 10.1016/j.fertnstert.2009.07.1100]">Imani 2009</a>; <a href="./references#CD014788-bbs2-0100" title='LucianoAA . Leuprolide acetate in the management of endometriosis-associated pain: A multicenter, evaluator-blind, comparative clinical trial. Global Congress of Gynecologic Endoscopy 33rd Annual Meeting of the AAGL "Advancing Minimally Invasive Gynecology Worldwide"2004;11(Suppl 3):s5. '>Luciano 2004</a>; <a href="./references#CD014788-bbs2-0101" title="MaginiA , PellegriniS , TavellaK , FortiG , MassiGB , SerioM . Estrogenic suppression by different administration schedules of goserelin depot for treatment of endometriosis. Journal of Endocrinological Investigation1993;16(10):775-80. ">Magini 1993</a>; <a href="./references#CD014788-bbs2-0106" title="MillerJD . Leuprolide acetate for the treatment of endometriosis. Progress in Clinical &amp; Biological Research1990;323:337-41. ">Miller 1990</a>; <a href="./references#CD014788-bbs2-0108" title="NewtonC , SlotaD , YuzpeAA , TummonIS . Memory complaints associated with the use of gonadotropin-releasing hormone agonists: a preliminary study. Fertility &amp; Sterility1996;65(6):1253-5. ">Newton 1996</a>; <a href="./references#CD014788-bbs2-0112" title="ShawR , GarryR , McMillanL , SuttonC , WoodS , HarrisonR , et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecological Endoscopy2001;10(3):151-7. ">Shaw 2001</a>; <a href="./references#CD014788-bbs2-0117" title="SurreyES , FournetN , VoigtB , JuddHL . Effects of sodium etidronate in combination with low-dose norethindrone in patients administered a long-acting GnRH agonist: a preliminary report. Obstetrics &amp; Gynecology1993;81(4):581-6. ">Surrey 1993</a>; <a href="./references#CD014788-bbs2-0121" title="TaskinO , YalcinogluAI , KucukS , UryanI , BuhurA , F B. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Fertility &amp; Sterility1997;67(1):40-5. ">Taskin 1997</a>; <a href="./references#CD014788-bbs2-0122" title="ToomeyC , KraussB , HammerschlagR , BurryK . Endometriosis: traditional medicine vs hormone therapy. National Centre for Complementary and Alternative Medicine2003. ">Toomey 2003</a>; <a href="./references#CD014788-bbs2-0125" title="WarnockJK , BundrenJC , MorrisDW . Depressive symptoms associated with gonadotropin-releasing hormone agonists. Depression and Anxiety1998;7(4):171-7. ">Warnock 1998</a>). Four studies looked at the outcome in post‐surgical participants (<a href="./references#CD014788-bbs2-0074" title="AdiyonoW , AdisusiantoI . The impact of combination laparoscopic surgery and GNRH analog on quality of life endometriosis patients. In: XVIII FIGO World Congress of Gynecology and Obstetrics. Vol. 2. 5-10 November Kuala Lumpur, Malaysia, 2006:143. ">Adiyono 2006</a>; <a href="./references#CD014788-bbs2-0104" title="MatalliotakisIM , AriciA , GoumenouAG , KatassosT , KarkavitsasN , KoumantakisEE . Comparison of the effects of leuprorelin acetate and danazol treatments on serum CA-125 levels in women with endometriosis. International Journal of Fertility &amp; Womens Medicine2004;49(2):75-8. ">Matalliotakis 2004</a>; <a href="./references#CD014788-bbs2-0116" title="SoysalS , SoysalME , OzerS , GulN , GezginT . The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Human Reproduction2004;19(1):160-167. [DOI: 10.1093/humrep/deh035]">Soysal 2004</a>; <a href="./references#CD014788-bbs2-0119" title="TakaesuY , NishiH , KojimaJ , SasakiT , NagamitsuY , KatoR , et al. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis. The Journal of Obstetrics and Gynaecology Research Sept 2016;42(9):1152-1158. [DOI: 10.1111/jog.13023]">Takaesu 2013</a>); endometriosis was not the main condition discussed in eleven studies (<a href="./references#CD014788-bbs2-0076" title="Al-AzemiM , JonesG , SirkeciF , WaltersS , HoudmontM , LedgerW . Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain. British Journal of Obstetrics and Gynaecology2009;116:1646-1656. [DOI: 10.1111/j.1471-0528.2009.02319.x]">Al‐Azemi 2009</a>; <a href="./references#CD014788-bbs2-0086" title="DodinS , LemayA , MaheuxR , DumontM , Turcot-Lemay L. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. Obstetrics and Gynecology1991;77(3):410-415. [PMID: 1825135]">Dodin 1991</a>; <a href="./references#CD014788-bbs2-0089" title="EldredJM , HaynesPJ , ThomasEJ . A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone. Clinical Endocrinology1992;37:354-359. [DOI: 10.1111/j.1365-2265.1992.tb02338.x]">Eldred 1992</a>; <a href="./references#CD014788-bbs2-0095" title="FraserIS , HealyDL , TorodeH , SongJY , MamersP , WildeF . Depot goserelin and danazol pre-treatment before rollerball endometrial ablation for menorrhagia. Obstetrics &amp; Gynecology1996;87(4):544-50. ">Fraser 1996</a>; <a href="./references#CD014788-bbs2-0099" title="LindsayPC , ShawRW , BenninkHJC , KicovicP . The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (decapeptyl). Fertility &amp; Sterility1996;65(2):342-348. [DOI: 10.1016/s0015-0282(16)58096-0]">Lindsay 1996</a>; <a href="./references#CD014788-bbs2-0105" title="MattaW , ShawR . A comparative study between buserelin and danazol in the treatment of endometriosis. The British Journal of Clinical Practice1988;40(4):69-72. ">Matta 1988</a>;  <a href="./references#CD014788-bbs2-0107" title="MukherjeeT , BaradD , TurkR , ReemanR . A randomized, placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment. American Journal of Obstetrics and Gynecology 1997;175(1):105-109. [DOI: 10.1016/S0002-9378(96)70258-2]">Mukherjee 1996</a>; <a href="./references#CD014788-bbs2-0110" title="RippsBA , VanGilderK , MinhasB , WelfordM , MamishZ . Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy. The Journal of Reproductive Medicine October 2003 ;48(10):761-766. [PMID: 14619641]">Ripps 2003</a> <a href="./references#CD014788-bbs2-0113" title="SomekawaY , ChigughiM , HaradaM , IshibashiT . Use of vitamin K2 (Menatetrenone) and 1,25- dihydroxyvitamin D3 in the prevention of bone loss induced by leuprolide. The Journal of Clinical Endocrinology &amp; Metabolism Aug 1999;84(8):2700-2704. [DOI: 10.1210/jcem.84.8.5920]">Somekawa 1999</a>; <a href="./references#CD014788-bbs2-0114" title="SorensenSS , ColovNP , VejerslevLO . Pre- and postoperative therapy with GnRH agonist for endometrial resection. A prospective, randomized study. Acta Obstetricia et Gynecologica Scandinavica1997;76(4):340-4. ">Sorensen 1997</a>; <a href="./references#CD014788-bbs2-0115" title="SowterMC , BidgoodK , RichardsonJA . A prospective randomized trial of the effect of preoperative endometrial inhibition on the long-term outcome of transcervical endometrial resection. Gynaecological Endoscopy1997;6(1):33-7. ">Sowter 1997</a>; <a href="./references#CD014788-bbs2-0118" title='SurreyES , VoigtB , FournetN , JuddHL . Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy. Fertility &amp; Sterility1995;63(4):747-55. '>Surrey 1995</a>); and two studies had included a wrong population (<a href="./references#CD014788-bbs2-0111" title="ShawRW . A randomised comparative study of the effects of goserelin and danazol for the treatment of endometriosis. Gynecological Endocrinology1990;4(70 Suppl 2):45. ShawRW . An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Endometriosis Study Team. Fertility &amp; Sterility1992;58(2):265-272. [DOI: 10.1016/s0015-0282(16)55205-4]ShawRW . Goserelin depot: an analog of LHRH for the treatment of endometriosis. Drugs Under Experimental &amp; Clinical Research1990;16(Suppl):69-75. ">Shaw 1992</a>; <a href="./references#CD014788-bbs2-0128" title="YlikorkalaO , TiitinenA , HulkkoS , KivinenS , NummiS . Decrease in symptoms, blood loss and uterine size with nafarelin acetate before abdominal hysterectomy: a placebo-controlled, double-blind study. Human Reproduction1995;10(6):1470-4. ">Ylikorkala 1995</a>). Nine studies were not randomised controlled trials (<a href="./references#CD014788-bbs2-0077" title="Bergquist C. Effects of nafarelin versus danazol on lipids and calcium metabolism. American Journal of Obstetrics and Gynecology1990;162(2):589-591. [DOI: 10.1016/0002-9378(90)90438-d]">Bergqvist 1990</a>; <a href="./references#CD014788-bbs2-0081" title="ChoktanasiriW , RojanasakulA . Buserelin acetate implants in the treatment of pain in endometriosis. Journal of the Medical Association of Thailand2001;84(5):656-60. ">Choktanasiri 2001</a>; <a href="./references#CD014788-bbs2-0082" title="ClaessonB , BergquistC . Clinical experience treating endometriosis with nafarelin. Journal of Reproductive Medicine1989;34(12 Suppl):1025-1028. [PMID: 2533617]">Claesson 1989</a>; <a href="./references#CD014788-bbs2-0084" title="DawoodMY . A comparison of the efficacy and safety of buserelin vs danazol in the treatment of endometriosis. Current Concepts in Endometriosis1990:253-67. ">Dawood 1990</a>; <a href="./references#CD014788-bbs2-0091" title="FedeleL , BianchiS , BoccioloneL , Di NolaG , FranchiD . Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study. Fertility &amp; Sterility1993;59(3):516-21. ">Fedele 1993</a>; <a href="./references#CD014788-bbs2-0094" title="FranssenAM , van derHeijdenPF , ThomasCM , DoesburgWH , WillemsenWN , RollandR . On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol. Fertility &amp; Sterility1992;57(5):974-9. ">Franssen 1992</a>; <a href="./references#CD014788-bbs2-0096" title="HaradaT . Empirical leuprolide treatment of women with suspected endometriosis was effective in reducing chronic pain. Evidence-based Obstetrics and Gynecology2000;2:45. ">Harada 2000</a> <a href="./references#CD014788-bbs2-0109" title="PierceSJ , GazvaniRM , FarquharsonRG . Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up. Fertility &amp; Sterility Nov 2000;74(5):964-968. [DOI: 10.1016/s0015-0282(00)01537-5]">Pierce 2000</a>; <a href="./references#CD014788-bbs2-0124" title="VercelliniP , SomiglianaE , ViganoP , AbbiatiA , BarbaraG , CrosignaniPG . Endometriosis: current therapies and new pharmacological developments. Drugs2009;69(6):649-75. ">Vercellini 2009</a>). <a href="./references#CD014788-bbs2-0079" title="ChanCLK , SoonSB , LohFH . Comparative study of gestrinone, danazol and decapeptyl CR in the treatment of endometriosis. 2nd International Scientific Meeting of the Royal College of Obstetricians1993:82. ">Chan 1993</a> and <a href="./references#CD014788-bbs2-0080" title="Chen Q-Y, Bian M-L, QiaoJ , Zhang Z-Y, Lin J-F, Zuo Y-W. Randomized blind, parallel-controlled and multiple centre clinical trial on the effectiveness and safety of leuprolide acetate in the treatment of endometriosis. Chinese Journal of New Drugs - Zhongguo2009;18(9):797-801. ">Chen 2009</a> were both still awaiting assessment, as they were in the original review (<a href="./references#CD014788-bbs2-0177" title="BrownJ , PanA , HartRJ . Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database of Systematic Reviews2010, Issue 12. Art. No: CD008475. [DOI: 10.1002/14651858.CD008475.pub2]">Brown 2010</a>) and therefore they were excluded.  </p> <p>The other five studies have been placed under 'awaiting classification'. These are abstracts of articles that are not available in full text and do not contain enough information to enable us to make a decision about inclusion or exclusion. Therefore, we decided to place these five studies under 'awaiting classification' (<a href="./references#CD014788-bbs2-0129" title="AisakaK , NakagawaK , UesatoT , MiwaA , KoshinoT , OokaF , et al. Effectiveness of long term GN-RH agonist administration for treatment of endometriosis combined with estrogen-progestogen add back therapy. In: XVI FIGO World Congress of O &amp; G 2000. 2000. [DOI: doi.org/10.1016/S0020-7292(00)82576-X]">Aisaka 2000</a>; <a href="./references#CD014788-bbs2-0130" title="ArcherDF , LucianoA , CarsonS , VilosG  . New low dose depot medroxyprogesterone acetate subcutaneous injection is equivalent to leuprolide acetate for endometriosis-associated pain. In: Fertility &amp; Sterility. Oct 2004. [DOI: https://doi.org/10.1016/j.fertnstert.2004.07.182]">Archer 2004</a>; <a href="./references#CD014788-bbs2-0131" title="GregoriouO , KonidarisS , VitoratosN , PapadiasC , PapouliasI , ChryssicopoulosA . Gonadotropin-releasing hormone analoque (leuprolide) plus hormone replacement therapy for the treatment of endometriosis: a randomised controlled trial. Acta Obstetricia et Gynecologica Scandinavica1997;67:no pagination. [PMID: 9459084]">Gregoriou 1997</a>;  <a href="./references#CD014788-bbs2-0132" title="LongQ , Zhang S. A randomized clinical trial of GnRHa and add-back therapy in the treatment of endometriosis. In: International Journal of Gynecology and Obstetrics . Vol. 107. 2009:S247. [DOI: 10.1016/S0020-7292]">Long 2009</a>; <a href="./references#CD014788-bbs2-0133" title="VellaA , BrincatM , GaleaR , Muscat BaronY . Skin thickness and bone density: effect of add-back therapy in women on GnRh analogue. In: 27th British Congress of Obstetrics and Gynaecology. Vol. 155. 1995. ">Vella 1995</a>). </p> </section> </section> <section id="CD014788-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>Details on the quality of each individual study are described in the table <a href="./references#CD014788-sec-0098" title="">Characteristics of included studies</a> where the individual quality criteria were rated for each study. Authors have been contacted for more information when required.  </p> <p>Of the seventy‐two articles included, only three were at overall low risk of bias (<a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0041" title="LingFW . Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic pain study group. Obstetrics &amp; Gynecology1999;93(1):51-58. [DOI: 10.1016/s0029-7844(98)00341-x]">Ling 1999</a>; <a href="./references#CD014788-bbs2-0069" title="VercelliniP , SomaM , MoroGL . Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertility &amp; Sterility 196;66(6):911-919. [DOI: 10.1016/s0015-0282(16)58682-8]">Vercellini 1996</a>). Ten of these seventy‐two were indicated as having high risk of bias (<a href="./references#CD014788-bbs2-0004" title="AN Zoladex. Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(1):55-60. ">AN Zoladex 1996</a>; <a href="./references#CD014788-bbs2-0009" title="BurryKA , PattonPE , IllingworthDR . Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.. American Journal of Obstetrics &amp; Gynecology1989;160(6):1454-9; discussion 1459-61. ">Burry 1989</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0017" title="DlugiAM , MillerJD , KnittleJ . Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertility &amp; Sterility1990;54(3):419-27. [DOI: 10.1016/s0015-0282(16)53755-8]">Dlugi 1990</a>; <a href="./references#CD014788-bbs2-0019" title="EdmondsDK , HowellR . Can hormone replacement therapy be used during medical therapy of endometriosis?British Journal of Obstetrics and Gynaecology May 1994;101:24-26. [DOI: 10.1111/j.1471-0528.1994.tb13681.x]">Edmonds 1994</a>; <a href="./references#CD014788-bbs2-0027" title="FukushimaM , ShindoM , SatoK . Hormone treatment related bone mineral content changes in Japanese women with endometriosis. Asia-Oceania Journal of Obstetrics and Gynaecology1993;19(3):299-307. [DOI: 10.1111/j.1447-0756.1993.tb00389.x]Fukushima M . Changes in bone mineral content following hormone treatment for endometriosis. . International Journal of Gynecology &amp; Obstetrics1995;50:S17-S21. [DOI: 10.1016/0020-7292(95)02510-j]">Fukushima 1993</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>; <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>; <a href="./references#CD014788-bbs2-0063" title="SurreyES , HornsteinMD . Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstetrics and Gynecology2002;99(5 Pt 1):709-719. [DOI: 10.1016/s0029-7844(02)01945-2]">Surrey 2002</a>). The other fifty‐nine were assigned as having overall unclear risk of bias.  </p> <p>For selection bias, six studies reported low risk of bias, without high risk of bias on the other domains, and were therefore included in the main analysis (<a href="./references#CD014788-bbs2-0001" title="AbdouAM , AmmarIMM , AlenmrAAA , AbdelrhmanAA . Dienogest versus leuprolide acetate for recurrent pelvic pain following laparoscopic treatment of endometriosis. Journal of Obstetrics and Gynecology of India Aug 2018;4:306-13. [PMID: DOI: 10.1007/s13224-018-1119-3]">Abdou 2018</a>; <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0022" title="FinkelsteinJS , KlibanskiA , ArnoldAL , TothTL , HornsteinMD , NeerRM . Prevention of estrogen deficiency–related bone loss with human parathyroid hormone–(1-34). Journal of the American Medical Association1998;280:1067-1073. [DOI: 10.1001/jama.280.12.1067]">Finkelstein 1998</a>; <a href="./references#CD014788-bbs2-0040" title="LemayA , MaheuxR , HuotC , BlanchetJ , FaureN . Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1988;158(2):233-6. [DOI: 10.1016/0002-9378(88)90128-7]LemayA , MaheuxR , QuesnelG , Bureau M, FaureN , MeratP . LH-RH agonist treatment of endometriosis. Contributions to Gynecology and Obstetrics1987;16:247-53. ">Lemay 1988</a>; <a href="./references#CD014788-bbs2-0041" title="LingFW . Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic pain study group. Obstetrics &amp; Gynecology1999;93(1):51-58. [DOI: 10.1016/s0029-7844(98)00341-x]">Ling 1999</a>; <a href="./references#CD014788-bbs2-0047" title="OdukoyaOA , BansalA , WilsonAP , WeetmanAP , CookeID . Serum-soluble CD23 in patients with endometriosis and the effect of treatment with danazol and leuprolide acetate depot injection. Human Reproduction1995;10(4):942-946. [DOI: 10.1093/oxfordjournals.humrep.a136067]">Odukoya 1995</a>).  </p> <p>See <a href="#CD014788-fig-0002">Figure 2</a> for the risk of bias graph and <a href="#CD014788-fig-0003">Figure 3</a> for the risk of bias summary.  </p> <div class="figure" id="CD014788-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD014788-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD014788-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD014788-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD014788-sec-0045"> <h4 class="title">Allocation</h4> <p>Twenty‐two trials were at low risk of selection bias related to random sequence generation, as they used computer randomisation or random number tables (<a href="./references#CD014788-bbs2-0001" title="AbdouAM , AmmarIMM , AlenmrAAA , AbdelrhmanAA . Dienogest versus leuprolide acetate for recurrent pelvic pain following laparoscopic treatment of endometriosis. Journal of Obstetrics and Gynecology of India Aug 2018;4:306-13. [PMID: DOI: 10.1007/s13224-018-1119-3]">Abdou 2018</a>; <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0014" title="CrosignaniPG , De CeccoL , GastaldiA , VenturiniPL , OldaniS , VegettiW , et al. Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study. Human Reproduction1996;11(12):2732-5. [DOI: 10.1093/oxfordjournals.humrep.a019199]">Crosignani 1996</a>; <a href="./references#CD014788-bbs2-0021" title="FerreiraRA , VieiraC , Rosa-e-SilavaJ , Rosa-e-SilvaA , NogueiraA , FerrianiR . Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception2010;81:117-122. [DOI: 10.1016/j.contraception.2009.08.003]">Ferreira 2010</a>; <a href="./references#CD014788-bbs2-0022" title="FinkelsteinJS , KlibanskiA , ArnoldAL , TothTL , HornsteinMD , NeerRM . Prevention of estrogen deficiency–related bone loss with human parathyroid hormone–(1-34). Journal of the American Medical Association1998;280:1067-1073. [DOI: 10.1001/jama.280.12.1067]">Finkelstein 1998</a>; <a href="./references#CD014788-bbs2-0023" title="FinkelsteinJS , Arnold AL . Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. Journal of Clinical Endocrinology &amp; Metabolism1999;84:1214-1219. [DOI: 10.1210/jcem.84.4.5643]">Finkelstein 1999</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>; <a href="./references#CD014788-bbs2-0029" title="GomesMK , FerrianiRA , Rosa e SilvaJC , Japur de Sa Rosa e SilvaAC , VieiraCS , Candido dos ReisFJ . The levonorgestrel-releasing intrauterine system and endometriosis staging. Fertility &amp; Sterility2007;87(5):1231-4. [DOI: 10.1016/j.fertnstert.2006.11.044]">Gomes 2007</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0040" title="LemayA , MaheuxR , HuotC , BlanchetJ , FaureN . Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1988;158(2):233-6. [DOI: 10.1016/0002-9378(88)90128-7]LemayA , MaheuxR , QuesnelG , Bureau M, FaureN , MeratP . LH-RH agonist treatment of endometriosis. Contributions to Gynecology and Obstetrics1987;16:247-53. ">Lemay 1988</a>; <a href="./references#CD014788-bbs2-0041" title="LingFW . Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic pain study group. Obstetrics &amp; Gynecology1999;93(1):51-58. [DOI: 10.1016/s0029-7844(98)00341-x]">Ling 1999</a>; <a href="./references#CD014788-bbs2-0043" title="MillerJD . Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. American Journal of Obstetrics &amp; Gynecology2000;182(6):1483-1488. [DOI: 10.1067/mob.2000.106846]">Miller 2000</a>; <a href="./references#CD014788-bbs2-0047" title="OdukoyaOA , BansalA , WilsonAP , WeetmanAP , CookeID . Serum-soluble CD23 in patients with endometriosis and the effect of treatment with danazol and leuprolide acetate depot injection. Human Reproduction1995;10(4):942-946. [DOI: 10.1093/oxfordjournals.humrep.a136067]">Odukoya 1995</a>; <a href="./references#CD014788-bbs2-0049" title="OzakiR ,  KumakiriJ , JinushiM , IkumaS , MurakamiK , KawasakiY , et al. Comparison of effect of preoperative dienogest and gonadotropin‑releasing hormone agonist administration on laparoscopic cystectomy for ovarian endometriomas. Archives of Gynecology and Obstetrics  July 2020;302:969-976. [DOI: 10.1007/s00404-020-05691-3]">Ozaki 2020</a>; <a href="./references#CD014788-bbs2-0051" title="PettaCA , FerrianiRA , AbraoMS , HassanD , RosaESJC , PodgaecS , et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Human Reproduction2005;20(7):1993-8. [DOI: 10.1093/humrep/deh869]VieiraCS , FerreiraRA , Rosa e SilvaJC , Rosa e SilvaACJS , GomesMK , FerrianiRA . Comparative study of the influence of the levonorgestrel intra-uterine system and the GnRH analogues on cardiovascular risk markers in patients with endometriosis. Fertility &amp; Sterility2007;88(Suppl 1):211. deSa Rosa e SilvaAC , Rosa e SilvaJC , NogueiraAA , PettaCA , AbraoMS , FerrianiRA . The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis. Fertility &amp; Sterility2006;86(3):742-4. ">Petta 2005</a>; <a href="./references#CD014788-bbs2-0060" title="SkrzypulecV , WalaszekA , DrosdzolA , NowosielskiK , PielaB , Rozmus-WarcholinskaW . Influence of GnRH analogue on the intensification of endometriosis symptoms and infertility treatment. Wiadomosci Lekarskie2004;57 Suppl 1:301-4. [PMID: 15884262]">Skrzypulec 2004</a>; <a href="./references#CD014788-bbs2-0062" title="SurreyES , JuddHL . Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial. Journal of Clinical Endocrinology and Metabolism1992;75(2):558-563. [DOI: 10.1210/jcem.75.2.1386374]">Surrey 1992</a>; <a href="./references#CD014788-bbs2-0063" title="SurreyES , HornsteinMD . Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstetrics and Gynecology2002;99(5 Pt 1):709-719. [DOI: 10.1016/s0029-7844(02)01945-2]">Surrey 2002</a>; <a href="./references#CD014788-bbs2-0064" title='TaharaM , MatsuokaT , YokoiT , TasakaK , KurachiH , MurataY . Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy). Fertility &amp; Sterility2000;73(4):799-804. [DOI: 10.1016/s0015-0282(99)00636-6]'>Tahara 2000</a>; <a href="./references#CD014788-bbs2-0068" title="VercelliniP , TrespidiL , PanazzaS , BramanteT , MauroF , CrosignaniPG . Very low dose danazol for relief of endometriosis-associated pelvic pain: a pilot study. Fertility &amp; Sterility1994;62(6):1136-42. [PMID: 7525359]">Vercellini 1994</a>;  <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>. The remaining trials were at unclear risk of selection bias as they did not describe the method of randomisation used.  </p> <p>Twelve trials were at low risk of selection bias related to allocation concealment (<a href="./references#CD014788-bbs2-0001" title="AbdouAM , AmmarIMM , AlenmrAAA , AbdelrhmanAA . Dienogest versus leuprolide acetate for recurrent pelvic pain following laparoscopic treatment of endometriosis. Journal of Obstetrics and Gynecology of India Aug 2018;4:306-13. [PMID: DOI: 10.1007/s13224-018-1119-3]">Abdou 2018</a>; <a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>; <a href="./references#CD014788-bbs2-0011" title="ChangSP , NgHT . A randomized comparative study of the effect of leuprorelin acetate depot and danazol in the treatment of endometriosis. Chung Hua i Hsueh Tsa Chih - Chinese Medical Journal1996;57(6):431-7. ">Chang 1996</a>;  <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0017" title="DlugiAM , MillerJD , KnittleJ . Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertility &amp; Sterility1990;54(3):419-27. [DOI: 10.1016/s0015-0282(16)53755-8]">Dlugi 1990</a>; <a href="./references#CD014788-bbs2-0022" title="FinkelsteinJS , KlibanskiA , ArnoldAL , TothTL , HornsteinMD , NeerRM . Prevention of estrogen deficiency–related bone loss with human parathyroid hormone–(1-34). Journal of the American Medical Association1998;280:1067-1073. [DOI: 10.1001/jama.280.12.1067]">Finkelstein 1998</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0037" title="JelleyRY , MagillPJ . The effect of LHRH agonist therapy in the treatment of endometriosis (English experience). Progress in Clinical &amp; Biological Research1986;225:227-38. JelleyRY . Multicentre open comparative study of buserelin and danazol in the treatment of endometriosis. British Journal of Clinical Practice1986;48(Suppl):64-8. ">Jelley 1986</a>; <a href="./references#CD014788-bbs2-0040" title="LemayA , MaheuxR , HuotC , BlanchetJ , FaureN . Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1988;158(2):233-6. [DOI: 10.1016/0002-9378(88)90128-7]LemayA , MaheuxR , QuesnelG , Bureau M, FaureN , MeratP . LH-RH agonist treatment of endometriosis. Contributions to Gynecology and Obstetrics1987;16:247-53. ">Lemay 1988</a>; <a href="./references#CD014788-bbs2-0041" title="LingFW . Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic pain study group. Obstetrics &amp; Gynecology1999;93(1):51-58. [DOI: 10.1016/s0029-7844(98)00341-x]">Ling 1999</a>; <a href="./references#CD014788-bbs2-0047" title="OdukoyaOA , BansalA , WilsonAP , WeetmanAP , CookeID . Serum-soluble CD23 in patients with endometriosis and the effect of treatment with danazol and leuprolide acetate depot injection. Human Reproduction1995;10(4):942-946. [DOI: 10.1093/oxfordjournals.humrep.a136067]">Odukoya 1995</a>;  <a href="./references#CD014788-bbs2-0069" title="VercelliniP , SomaM , MoroGL . Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertility &amp; Sterility 196;66(6):911-919. [DOI: 10.1016/s0015-0282(16)58682-8]">Vercellini 1996</a>). The remaining trials did not describe allocation concealment and were at unclear risk of this bias. </p> </section> <section id="CD014788-sec-0046"> <h4 class="title">Blinding</h4> <p>Thirty‐six studies described blinding of patients and personnel, and they were judged to be at low risk of performance bias (<a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>; <a href="./references#CD014788-bbs2-0003" title="AgarwalSK , HamrangC , HenzlMR , JuddHL . Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. Journal of Reproductive Medicine1997;42(7):413-23. ">Agarwal 1997</a>; <a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a>; <a href="./references#CD014788-bbs2-0007" title="BergqvistA , BerghT , HogstromL , MattssonS , NordenskjoldF , RasmussenC . Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertility &amp; Sterility1998;69(4):702-8. ">Bergqvist 1998</a>; <a href="./references#CD014788-bbs2-0009" title="BurryKA , PattonPE , IllingworthDR . Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.. American Journal of Obstetrics &amp; Gynecology1989;160(6):1454-9; discussion 1459-61. ">Burry 1989</a>; <a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>; <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0016" title="DawoodMY , RamosJ , Khan-DawoodF . Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertility &amp; Sterility1995;63:1177-1183. [DOI: 10.1016/s0015-0282(16)57593-1]">Dawood 1995</a>; <a href="./references#CD014788-bbs2-0017" title="DlugiAM , MillerJD , KnittleJ . Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertility &amp; Sterility1990;54(3):419-27. [DOI: 10.1016/s0015-0282(16)53755-8]">Dlugi 1990</a>; <a href="./references#CD014788-bbs2-0024" title="FrankeHR , Van der WeijerPHM , PenningsTMM , Van der MoorenMJ . Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertility &amp; Sterility Sept 2000;74:534-539. [DOI: 10.1016/s0015-0282(00)00690-7]">Franke 2000</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>; <a href="./references#CD014788-bbs2-0026" title="FreundlG , GödtkeK , GnothaC , GodehardtE , Kienle E. Steroidal ‘Add-Back’ Therapy in Patients Treated with GnRH Agonists. Gynecologic and Obstetric Investigation1998;45:22-30. [DOI: 10.1159/000052848]">Freundl 1998</a>; <a href="./references#CD014788-bbs2-0028" title="GnothC , GödtkeK , FreundlG , GodehardtE , KienleE . Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists. Gynecologic and Obstetric Investigation1999;47:37-41. [DOI: 10.1159/000010059]">Gnoth 1999</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a>; <a href="./references#CD014788-bbs2-0032" title="HornsteinM , YuzpeA , BurryK , HeinrichsL , OrwollE . A prospective randomised double-blind trial of 3 versus 6 months nafarelin therapy for symptoms of endometriosis. Fertility &amp; Sterility1992;58:S84. HornsteinMD , YuzpeAA , BurryKA , HeinrichsLR , Buttram VL Jr, et al. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertility &amp; Sterility1995;63(5):955-62. [PMID: 7720940]">Hornstein 1995</a>; <a href="./references#CD014788-bbs2-0033" title="HornsteinMD , SurreyES , WeisbergGW , Casino LA LUPRON add-back study group. Leuprolide acetate depot and hormonal add-back in endometriosis: A 12- month study. Obstetrics and Gynecology Jan 1998;1:16-24. [DOI: 10.1016/s0029-7844(97)00620-0]">Hornstein 1998</a>; <a href="./references#CD014788-bbs2-0035" title="HurstBS , GardnerSC , TuckerKE , AwoniyiCA , SchlaffWD . Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. Journal of the Society of Laparoendoscopic Surgeons2000;4:97-101. [PMID: PMC3015370]">Hurst 2000</a>; <a href="./references#CD014788-bbs2-0038" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility June 1990;53(6):998-1003. [DOI: 10.1016/s0015-0282(16)53574-2]">Kennedy 1990</a>; <a href="./references#CD014788-bbs2-0039" title="KiilholmaP , TuimalaR , KivinenS , KorhonenM , Hagman E. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertility &amp; Sterility1995;64(5):903-908. [DOI: 10.1016/s0015-0282(16)57900-x]">Kiilholma 1995</a>; <a href="./references#CD014788-bbs2-0041" title="LingFW . Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic pain study group. Obstetrics &amp; Gynecology1999;93(1):51-58. [DOI: 10.1016/s0029-7844(98)00341-x]">Ling 1999</a>; <a href="./references#CD014788-bbs2-0042" title="MakarainenL , RönnbergL , KauppilaA . Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertility &amp; Sterility1996;65(1):29-34. [DOI: 10.1016/s0015-0282(16)58023-6]">Mäkäräinen 1996</a>; <a href="./references#CD014788-bbs2-0043" title="MillerJD . Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. American Journal of Obstetrics &amp; Gynecology2000;182(6):1483-1488. [DOI: 10.1067/mob.2000.106846]">Miller 2000</a>; <a href="./references#CD014788-bbs2-0045" title="MoghissiKS , SchlaffWD , OliveDL , SkinnerMA , YinH . Goserelin acetate (Zoladex) with or without hormone replacement. Therapy for the treatment of endometriosis. Fertility &amp; Sterility June 1998;69(6):1056-1062. [DOI: 10.1016/s0015-0282(98)00086-7]">Moghissi 1998</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>; <a href="./references#CD014788-bbs2-0048" title="OrwollES , YuzpeAA , BurryKA , HeinrichsL , ButtramVC ,  HornsteinMD . Nafarelin therapy in endometriosis: long-term effects on bone mineral density. American Journal of Obstetrics and Gynecology Nov 1994;171(5):1221-1225. [DOI: 10.1016/0002-9378(94)90136-8]">Orwoll 1994</a>; <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>; <a href="./references#CD014788-bbs2-0055" title="RouxC , PelissierC , ListratV , KoltaS , SimonettaC , GuignardM , et al. Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. Osteoporosis International1995;5:185-190. [DOI: 10.1007/BF02106098]">Roux 1995</a>; <a href="./references#CD014788-bbs2-0058" title="ShawRW . Nafarelin in the treatment of pelvic pain caused by endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):574-6. [DOI: 10.1016/0002-9378(90)90433-8]">Shaw 1990</a>; <a href="./references#CD014788-bbs2-0059" title="SillemM , ParvizM , WoitgeHW , KieselL , UlrichU , vonHolstT , et al. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. Experimental and Clinical Endocrinology &amp; Diabetes1999;107:379-385. [DOI: 10.1055/s-0029-1212129]">Sillem 1999</a>; <a href="./references#CD014788-bbs2-0060" title="SkrzypulecV , WalaszekA , DrosdzolA , NowosielskiK , PielaB , Rozmus-WarcholinskaW . Influence of GnRH analogue on the intensification of endometriosis symptoms and infertility treatment. Wiadomosci Lekarskie2004;57 Suppl 1:301-4. [PMID: 15884262]">Skrzypulec 2004</a>; <a href="./references#CD014788-bbs2-0062" title="SurreyES , JuddHL . Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial. Journal of Clinical Endocrinology and Metabolism1992;75(2):558-563. [DOI: 10.1210/jcem.75.2.1386374]">Surrey 1992</a>; <a href="./references#CD014788-bbs2-0063" title="SurreyES , HornsteinMD . Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstetrics and Gynecology2002;99(5 Pt 1):709-719. [DOI: 10.1016/s0029-7844(02)01945-2]">Surrey 2002</a>; <a href="./references#CD014788-bbs2-0069" title="VercelliniP , SomaM , MoroGL . Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertility &amp; Sterility 196;66(6):911-919. [DOI: 10.1016/s0015-0282(16)58682-8]">Vercellini 1996</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>; <a href="./references#CD014788-bbs2-0071" title="WhitehouseRW , AdamsJE , BancroftK , Vaughan-WilliamsCA , ElsteinM . The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clinical Endocrinology1990;33(3):365-373. [DOI: 10.1016/s0015-0282(16)58682-8]">Whitehouse 1990</a>). The remaining trials were assigned as having unclear risk of bias.  </p> <p>Forty‐two studies described blinding of outcome assessors, and they were judged to be at low risk of detection bias (<a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>; <a href="./references#CD014788-bbs2-0003" title="AgarwalSK , HamrangC , HenzlMR , JuddHL . Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. Journal of Reproductive Medicine1997;42(7):413-23. ">Agarwal 1997</a>; <a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a>; <a href="./references#CD014788-bbs2-0007" title="BergqvistA , BerghT , HogstromL , MattssonS , NordenskjoldF , RasmussenC . Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertility &amp; Sterility1998;69(4):702-8. ">Bergqvist 1998</a>; <a href="./references#CD014788-bbs2-0009" title="BurryKA , PattonPE , IllingworthDR . Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.. American Journal of Obstetrics &amp; Gynecology1989;160(6):1454-9; discussion 1459-61. ">Burry 1989</a>; <a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>; <a href="./references#CD014788-bbs2-0011" title="ChangSP , NgHT . A randomized comparative study of the effect of leuprorelin acetate depot and danazol in the treatment of endometriosis. Chung Hua i Hsueh Tsa Chih - Chinese Medical Journal1996;57(6):431-7. ">Chang 1996</a>; <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0016" title="DawoodMY , RamosJ , Khan-DawoodF . Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertility &amp; Sterility1995;63:1177-1183. [DOI: 10.1016/s0015-0282(16)57593-1]">Dawood 1995</a>; <a href="./references#CD014788-bbs2-0017" title="DlugiAM , MillerJD , KnittleJ . Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertility &amp; Sterility1990;54(3):419-27. [DOI: 10.1016/s0015-0282(16)53755-8]">Dlugi 1990</a>; <a href="./references#CD014788-bbs2-0024" title="FrankeHR , Van der WeijerPHM , PenningsTMM , Van der MoorenMJ . Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertility &amp; Sterility Sept 2000;74:534-539. [DOI: 10.1016/s0015-0282(00)00690-7]">Franke 2000</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>; <a href="./references#CD014788-bbs2-0026" title="FreundlG , GödtkeK , GnothaC , GodehardtE , Kienle E. Steroidal ‘Add-Back’ Therapy in Patients Treated with GnRH Agonists. Gynecologic and Obstetric Investigation1998;45:22-30. [DOI: 10.1159/000052848]">Freundl 1998</a>; <a href="./references#CD014788-bbs2-0027" title="FukushimaM , ShindoM , SatoK . Hormone treatment related bone mineral content changes in Japanese women with endometriosis. Asia-Oceania Journal of Obstetrics and Gynaecology1993;19(3):299-307. [DOI: 10.1111/j.1447-0756.1993.tb00389.x]Fukushima M . Changes in bone mineral content following hormone treatment for endometriosis. . International Journal of Gynecology &amp; Obstetrics1995;50:S17-S21. [DOI: 10.1016/0020-7292(95)02510-j]">Fukushima 1993</a>; <a href="./references#CD014788-bbs2-0028" title="GnothC , GödtkeK , FreundlG , GodehardtE , KienleE . Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists. Gynecologic and Obstetric Investigation1999;47:37-41. [DOI: 10.1159/000010059]">Gnoth 1999</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a>; <a href="./references#CD014788-bbs2-0032" title="HornsteinM , YuzpeA , BurryK , HeinrichsL , OrwollE . A prospective randomised double-blind trial of 3 versus 6 months nafarelin therapy for symptoms of endometriosis. Fertility &amp; Sterility1992;58:S84. HornsteinMD , YuzpeAA , BurryKA , HeinrichsLR , Buttram VL Jr, et al. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertility &amp; Sterility1995;63(5):955-62. [PMID: 7720940]">Hornstein 1995</a>; <a href="./references#CD014788-bbs2-0033" title="HornsteinMD , SurreyES , WeisbergGW , Casino LA LUPRON add-back study group. Leuprolide acetate depot and hormonal add-back in endometriosis: A 12- month study. Obstetrics and Gynecology Jan 1998;1:16-24. [DOI: 10.1016/s0029-7844(97)00620-0]">Hornstein 1998</a>; <a href="./references#CD014788-bbs2-0035" title="HurstBS , GardnerSC , TuckerKE , AwoniyiCA , SchlaffWD . Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. Journal of the Society of Laparoendoscopic Surgeons2000;4:97-101. [PMID: PMC3015370]">Hurst 2000</a>; <a href="./references#CD014788-bbs2-0038" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility June 1990;53(6):998-1003. [DOI: 10.1016/s0015-0282(16)53574-2]">Kennedy 1990</a>; <a href="./references#CD014788-bbs2-0039" title="KiilholmaP , TuimalaR , KivinenS , KorhonenM , Hagman E. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertility &amp; Sterility1995;64(5):903-908. [DOI: 10.1016/s0015-0282(16)57900-x]">Kiilholma 1995</a>; <a href="./references#CD014788-bbs2-0040" title="LemayA , MaheuxR , HuotC , BlanchetJ , FaureN . Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1988;158(2):233-6. [DOI: 10.1016/0002-9378(88)90128-7]LemayA , MaheuxR , QuesnelG , Bureau M, FaureN , MeratP . LH-RH agonist treatment of endometriosis. Contributions to Gynecology and Obstetrics1987;16:247-53. ">Lemay 1988</a>; <a href="./references#CD014788-bbs2-0041" title="LingFW . Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic pain study group. Obstetrics &amp; Gynecology1999;93(1):51-58. [DOI: 10.1016/s0029-7844(98)00341-x]">Ling 1999</a>; <a href="./references#CD014788-bbs2-0042" title="MakarainenL , RönnbergL , KauppilaA . Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertility &amp; Sterility1996;65(1):29-34. [DOI: 10.1016/s0015-0282(16)58023-6]">Mäkäräinen 1996</a>; <a href="./references#CD014788-bbs2-0043" title="MillerJD . Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. American Journal of Obstetrics &amp; Gynecology2000;182(6):1483-1488. [DOI: 10.1067/mob.2000.106846]">Miller 2000</a>; <a href="./references#CD014788-bbs2-0045" title="MoghissiKS , SchlaffWD , OliveDL , SkinnerMA , YinH . Goserelin acetate (Zoladex) with or without hormone replacement. Therapy for the treatment of endometriosis. Fertility &amp; Sterility June 1998;69(6):1056-1062. [DOI: 10.1016/s0015-0282(98)00086-7]">Moghissi 1998</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>; <a href="./references#CD014788-bbs2-0048" title="OrwollES , YuzpeAA , BurryKA , HeinrichsL , ButtramVC ,  HornsteinMD . Nafarelin therapy in endometriosis: long-term effects on bone mineral density. American Journal of Obstetrics and Gynecology Nov 1994;171(5):1221-1225. [DOI: 10.1016/0002-9378(94)90136-8]">Orwoll 1994</a>; <a href="./references#CD014788-bbs2-0051" title="PettaCA , FerrianiRA , AbraoMS , HassanD , RosaESJC , PodgaecS , et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Human Reproduction2005;20(7):1993-8. [DOI: 10.1093/humrep/deh869]VieiraCS , FerreiraRA , Rosa e SilvaJC , Rosa e SilvaACJS , GomesMK , FerrianiRA . Comparative study of the influence of the levonorgestrel intra-uterine system and the GnRH analogues on cardiovascular risk markers in patients with endometriosis. Fertility &amp; Sterility2007;88(Suppl 1):211. deSa Rosa e SilvaAC , Rosa e SilvaJC , NogueiraAA , PettaCA , AbraoMS , FerrianiRA . The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis. Fertility &amp; Sterility2006;86(3):742-4. ">Petta 2005</a>; <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>; <a href="./references#CD014788-bbs2-0055" title="RouxC , PelissierC , ListratV , KoltaS , SimonettaC , GuignardM , et al. Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. Osteoporosis International1995;5:185-190. [DOI: 10.1007/BF02106098]">Roux 1995</a>; <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>; <a href="./references#CD014788-bbs2-0058" title="ShawRW . Nafarelin in the treatment of pelvic pain caused by endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):574-6. [DOI: 10.1016/0002-9378(90)90433-8]">Shaw 1990</a>; <a href="./references#CD014788-bbs2-0059" title="SillemM , ParvizM , WoitgeHW , KieselL , UlrichU , vonHolstT , et al. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. Experimental and Clinical Endocrinology &amp; Diabetes1999;107:379-385. [DOI: 10.1055/s-0029-1212129]">Sillem 1999</a>; <a href="./references#CD014788-bbs2-0060" title="SkrzypulecV , WalaszekA , DrosdzolA , NowosielskiK , PielaB , Rozmus-WarcholinskaW . Influence of GnRH analogue on the intensification of endometriosis symptoms and infertility treatment. Wiadomosci Lekarskie2004;57 Suppl 1:301-4. [PMID: 15884262]">Skrzypulec 2004</a>; <a href="./references#CD014788-bbs2-0062" title="SurreyES , JuddHL . Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial. Journal of Clinical Endocrinology and Metabolism1992;75(2):558-563. [DOI: 10.1210/jcem.75.2.1386374]">Surrey 1992</a>; <a href="./references#CD014788-bbs2-0063" title="SurreyES , HornsteinMD . Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstetrics and Gynecology2002;99(5 Pt 1):709-719. [DOI: 10.1016/s0029-7844(02)01945-2]">Surrey 2002</a>; <a href="./references#CD014788-bbs2-0069" title="VercelliniP , SomaM , MoroGL . Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertility &amp; Sterility 196;66(6):911-919. [DOI: 10.1016/s0015-0282(16)58682-8]">Vercellini 1996</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>; <a href="./references#CD014788-bbs2-0071" title="WhitehouseRW , AdamsJE , BancroftK , Vaughan-WilliamsCA , ElsteinM . The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clinical Endocrinology1990;33(3):365-373. [DOI: 10.1016/s0015-0282(16)58682-8]">Whitehouse 1990</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>). The remaining trials were assigned as having unclear risk of bias.  </p> </section> <section id="CD014788-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>Eight trials were considered to be at high risk of attrition bias due to high loss to follow‐up (<a href="./references#CD014788-bbs2-0004" title="AN Zoladex. Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(1):55-60. ">AN Zoladex 1996</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0017" title="DlugiAM , MillerJD , KnittleJ . Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertility &amp; Sterility1990;54(3):419-27. [DOI: 10.1016/s0015-0282(16)53755-8]">Dlugi 1990</a>; <a href="./references#CD014788-bbs2-0027" title="FukushimaM , ShindoM , SatoK . Hormone treatment related bone mineral content changes in Japanese women with endometriosis. Asia-Oceania Journal of Obstetrics and Gynaecology1993;19(3):299-307. [DOI: 10.1111/j.1447-0756.1993.tb00389.x]Fukushima M . Changes in bone mineral content following hormone treatment for endometriosis. . International Journal of Gynecology &amp; Obstetrics1995;50:S17-S21. [DOI: 10.1016/0020-7292(95)02510-j]">Fukushima 1993</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>; <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>; <a href="./references#CD014788-bbs2-0063" title="SurreyES , HornsteinMD . Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstetrics and Gynecology2002;99(5 Pt 1):709-719. [DOI: 10.1016/s0029-7844(02)01945-2]">Surrey 2002</a>). Five trials were considered to be at unclear risk of bias due to insufficient data (<a href="./references#CD014788-bbs2-0011" title="ChangSP , NgHT . A randomized comparative study of the effect of leuprorelin acetate depot and danazol in the treatment of endometriosis. Chung Hua i Hsueh Tsa Chih - Chinese Medical Journal1996;57(6):431-7. ">Chang 1996</a>; <a href="./references#CD014788-bbs2-0048" title="OrwollES , YuzpeAA , BurryKA , HeinrichsL , ButtramVC ,  HornsteinMD . Nafarelin therapy in endometriosis: long-term effects on bone mineral density. American Journal of Obstetrics and Gynecology Nov 1994;171(5):1221-1225. [DOI: 10.1016/0002-9378(94)90136-8]">Orwoll 1994</a>; <a href="./references#CD014788-bbs2-0059" title="SillemM , ParvizM , WoitgeHW , KieselL , UlrichU , vonHolstT , et al. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. Experimental and Clinical Endocrinology &amp; Diabetes1999;107:379-385. [DOI: 10.1055/s-0029-1212129]">Sillem 1999</a>; <a href="./references#CD014788-bbs2-0065" title="TangH , WuR , LiX , ZhouY , LiuZ , WangC , ChenY , et al. Curative effect of 1.88-mg and 3.75-mg gonadotrophin-releasing hormone agonist on stage III–IV endometriosis: Randomized controlled study. The Journal of Obstetrics and Gynaecology Research October 2017;43(10):1550-1554. [DOI: 10.1111/jog.13420]">Tang 2017</a>; <a href="./references#CD014788-bbs2-0066" title="TummonIS , AliA , PeppingME , RadwanskaE , BinorZ , DmowskiWP . Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertility &amp; Sterility May 1988;49(5):792-796. [PMID: 3129312]">Tummon 1988</a>) and the rest of the trials were assigned as having low risk of bias.  </p> </section> <section id="CD014788-sec-0048"> <h4 class="title">Selective reporting</h4> <p>None of the protocols from the original review were viewed but almost all the published reports of all included articles included all expected outcomes and were therefore judged to be at low risk of reporting bias. Only <a href="./references#CD014788-bbs2-0009" title="BurryKA , PattonPE , IllingworthDR . Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.. American Journal of Obstetrics &amp; Gynecology1989;160(6):1454-9; discussion 1459-61. ">Burry 1989</a>, <a href="./references#CD014788-bbs2-0019" title="EdmondsDK , HowellR . Can hormone replacement therapy be used during medical therapy of endometriosis?British Journal of Obstetrics and Gynaecology May 1994;101:24-26. [DOI: 10.1111/j.1471-0528.1994.tb13681.x]">Edmonds 1994</a> and <a href="./references#CD014788-bbs2-0057" title="ShawRW , MattaW . Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis - comparison of two dose regimens. Clinical Reproduction and Fertility1986;4(5):329-36. [PMID: 3100012]">Shaw 1986</a> did not report any results of changes in symptoms, while this had been asked and reported during follow‐up; they were assessed as being at high risk of reporting bias. </p> </section> <section id="CD014788-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>There was no evidence of other potential sources of bias identified.</p> </section> </section> <section id="CD014788-sec-0050"> <h3 class="title" id="CD014788-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD014788-tbl-0001"><b>Summary of findings 1</b> GnRHas compared to no treatment for relief of overall pain associated with endometriosis and its related adverse effects</a>; <a href="./full#CD014788-tbl-0002"><b>Summary of findings 2</b> GnRHas compared to placebo for relief of overall pain associated with endometriosis and its related adverse effects</a>; <a href="./full#CD014788-tbl-0003"><b>Summary of findings 3</b> GnRHas compared to analgesics for relief of overall pain associated with endometriosis and its related adverse effects</a>; <a href="./full#CD014788-tbl-0004"><b>Summary of findings 4</b> GnRHas compared to danazol for relief of overall pain associated with endometriosis and its related adverse effects</a>; <a href="./full#CD014788-tbl-0005"><b>Summary of findings 5</b> GnRHas compared to intra‐uterine progestogens device for relief of overall pain associated with endometriosis and its related adverse effects</a>; <a href="./full#CD014788-tbl-0006"><b>Summary of findings 6</b> Effect of GnRHas versus other hormonal treatment on bone mineral density</a> </p> <p>We identified six studies at low risk of selection bias and not at high risk of any other bias (<a href="./references#CD014788-bbs2-0001" title="AbdouAM , AmmarIMM , AlenmrAAA , AbdelrhmanAA . Dienogest versus leuprolide acetate for recurrent pelvic pain following laparoscopic treatment of endometriosis. Journal of Obstetrics and Gynecology of India Aug 2018;4:306-13. [PMID: DOI: 10.1007/s13224-018-1119-3]">Abdou 2018</a>; <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0022" title="FinkelsteinJS , KlibanskiA , ArnoldAL , TothTL , HornsteinMD , NeerRM . Prevention of estrogen deficiency–related bone loss with human parathyroid hormone–(1-34). Journal of the American Medical Association1998;280:1067-1073. [DOI: 10.1001/jama.280.12.1067]">Finkelstein 1998</a>; <a href="./references#CD014788-bbs2-0040" title="LemayA , MaheuxR , HuotC , BlanchetJ , FaureN . Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1988;158(2):233-6. [DOI: 10.1016/0002-9378(88)90128-7]LemayA , MaheuxR , QuesnelG , Bureau M, FaureN , MeratP . LH-RH agonist treatment of endometriosis. Contributions to Gynecology and Obstetrics1987;16:247-53. ">Lemay 1988</a>; <a href="./references#CD014788-bbs2-0041" title="LingFW . Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic pain study group. Obstetrics &amp; Gynecology1999;93(1):51-58. [DOI: 10.1016/s0029-7844(98)00341-x]">Ling 1999</a>; <a href="./references#CD014788-bbs2-0047" title="OdukoyaOA , BansalA , WilsonAP , WeetmanAP , CookeID . Serum-soluble CD23 in patients with endometriosis and the effect of treatment with danazol and leuprolide acetate depot injection. Human Reproduction1995;10(4):942-946. [DOI: 10.1093/oxfordjournals.humrep.a136067]">Odukoya 1995</a>). The results of these studies were included in the original reviews. We also performed a sensitivity analysis, which included all studies. Results are stated below.   </p> <section id="CD014788-sec-0051"> <h4 class="title">1. GnRHas versus no treatment for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>In a previous version of this review, there was only one study which compared GnRHas with no treatment (<a href="./references#CD014788-bbs2-0091" title="FedeleL , BianchiS , BoccioloneL , Di NolaG , FranchiD . Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study. Fertility &amp; Sterility1993;59(3):516-21. ">Fedele 1993</a>) for the outcome of overall pain, reported as relief of painful symptoms (dysmenorrhoea). We have excluded this study from the current review because it was not possible to read this article in full text. No further studies comparing GnRHas versus no treatment were identified.  </p> </section> <section id="CD014788-sec-0052"> <h4 class="title">2. GnRHas versus placebo for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>Five studies were identified which compared GnRHas with placebo, all with a different outcome measure (<a href="./references#CD014788-bbs2-0007" title="BergqvistA , BerghT , HogstromL , MattssonS , NordenskjoldF , RasmussenC . Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertility &amp; Sterility1998;69(4):702-8. ">Bergqvist 1998</a>; <a href="./references#CD014788-bbs2-0017" title="DlugiAM , MillerJD , KnittleJ . Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertility &amp; Sterility1990;54(3):419-27. [DOI: 10.1016/s0015-0282(16)53755-8]">Dlugi 1990</a>; <a href="./references#CD014788-bbs2-0041" title="LingFW . Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic pain study group. Obstetrics &amp; Gynecology1999;93(1):51-58. [DOI: 10.1016/s0029-7844(98)00341-x]">Ling 1999</a>; <a href="./references#CD014788-bbs2-0043" title="MillerJD . Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. American Journal of Obstetrics &amp; Gynecology2000;182(6):1483-1488. [DOI: 10.1067/mob.2000.106846]">Miller 2000</a>; <a href="./references#CD014788-bbs2-0060" title="SkrzypulecV , WalaszekA , DrosdzolA , NowosielskiK , PielaB , Rozmus-WarcholinskaW . Influence of GnRH analogue on the intensification of endometriosis symptoms and infertility treatment. Wiadomosci Lekarskie2004;57 Suppl 1:301-4. [PMID: 15884262]">Skrzypulec 2004</a>). Only <a href="./references#CD014788-bbs2-0041" title="LingFW . Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic pain study group. Obstetrics &amp; Gynecology1999;93(1):51-58. [DOI: 10.1016/s0029-7844(98)00341-x]">Ling 1999</a> was at low risk of bias. </p> <p>Four were included in sensitivity analysis, however, these results should be interpreted with caution. <a href="./references#CD014788-bbs2-0060" title="SkrzypulecV , WalaszekA , DrosdzolA , NowosielskiK , PielaB , Rozmus-WarcholinskaW . Influence of GnRH analogue on the intensification of endometriosis symptoms and infertility treatment. Wiadomosci Lekarskie2004;57 Suppl 1:301-4. [PMID: 15884262]">Skrzypulec 2004</a> did not provide usable data.  </p> <p>2.1 Relief of overall pain </p> <p>Relief of overall pain (reported as decrease in pain scores) was reported by three studies (<a href="./references#CD014788-bbs2-0007" title="BergqvistA , BerghT , HogstromL , MattssonS , NordenskjoldF , RasmussenC . Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertility &amp; Sterility1998;69(4):702-8. ">Bergqvist 1998</a>; <a href="./references#CD014788-bbs2-0041" title="LingFW . Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic pain study group. Obstetrics &amp; Gynecology1999;93(1):51-58. [DOI: 10.1016/s0029-7844(98)00341-x]">Ling 1999</a>; <a href="./references#CD014788-bbs2-0043" title="MillerJD . Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. American Journal of Obstetrics &amp; Gynecology2000;182(6):1483-1488. [DOI: 10.1067/mob.2000.106846]">Miller 2000</a>), but only one study (<a href="./references#CD014788-bbs2-0041" title="LingFW . Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic pain study group. Obstetrics &amp; Gynecology1999;93(1):51-58. [DOI: 10.1016/s0029-7844(98)00341-x]">Ling 1999</a>) was included in the primary analysis.  GnRHas may improve pelvic pain compared to placebo (RR 2.14; 95% CI 1.41 to 3.24, 1 RCT, n = 87), dysmenorrhoea (RR 2.25; 95% CI 1.59 to 3.16, 1 RCT, n = 87), dyspareunia (RR 2.21; 95% CI 1.39 to 3.54, 1 RCT, n = 59) and pelvic tenderness (RR 2.28; 95% CI 1.48 to 3.50,1 RCT, n = 85) after three months of treatment. We are uncertain of the effect of GnRHas compared to placebo for pelvic induration, based on the results after three months of treatment (RR 1.07; 95% CI 0.64 to 1.79, 1 RCT, n = 81). We graded all outcomes as having low‐certainty evidence; <a href="./references#CD014788-fig-0004" title="">Analysis 1.1</a>. </p> <p>The sensitivity analysis including the studies with unclear or high risk of bias suggested treatment with GnRHas compared to placebo (<a href="./references#CD014788-fig-0006" title="">Analysis 2.1</a>, <a href="./references#CD014788-bbs2-0007" title="BergqvistA , BerghT , HogstromL , MattssonS , NordenskjoldF , RasmussenC . Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertility &amp; Sterility1998;69(4):702-8. ">Bergqvist 1998</a>) at six months follow up may improve the relief of dyspareunia (RR 0.28; 95% CI 0.09 to 0.89, 1 RCT, n = 49) and pelvic tenderness (RR 0.22; 95% CI 0. 09 to 0.55, 1 RCT, n = 49). We are uncertain of the effect of GnRHas compared to placebo for dyschezia (RR 0.26 95%CI 0.03 to 2.17, 1 RCT, n = 49). One study (<a href="./references#CD014788-fig-0006" title="">Analysis 2.1</a>.; <a href="./references#CD014788-bbs2-0043" title="MillerJD . Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. American Journal of Obstetrics &amp; Gynecology2000;182(6):1483-1488. [DOI: 10.1067/mob.2000.106846]">Miller 2000</a>) found pain, using the Endometriosis Symptom Severity Score (ESSS), may improve following GnRHa therapy compared to placebo with an MD 2.90 (95% CI 2.80 to 3.00, 1 RCT, n = 120, <a href="./references#CD014788-fig-0008" title="">Analysis 2.3</a>), as measured one month after treatment. </p> <p>2.2 Bone mineral density </p> <p>No studies at overall low risk of bias were included in this analysis.</p> <p>In the sensitivity analysis including unclear or high risk of bias studies, <a href="./references#CD014788-bbs2-0017" title="DlugiAM , MillerJD , KnittleJ . Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertility &amp; Sterility1990;54(3):419-27. [DOI: 10.1016/s0015-0282(16)53755-8]">Dlugi 1990</a> was the only study that reported effects on BMD. "Due to the variety of different methodologies and anatomic sites used to assess changes in bone mineral density, sample sizes were small. In addition, very few placebo patients had data included in the analysis. Consequently, between treatment group data could not be adequately evaluated. Nevertheless, 15 patients treated with leuprolide acetate, who had spinal bone mineral density assessed by dual photon absorptiometry demonstrated a mean decrease of 3.6% (P = 0.001) from baseline to the end of treatment. Eight patients treated with leuprolide acetate had spinal bone mineral density measured by quantitative computed tomography. These patients had a mean decrease in their bone mineral density of 11.8% (P &lt; 0.001)".  </p> <p>2.3 Adverse effects </p> <p>Again, only <a href="./references#CD014788-bbs2-0041" title="LingFW . Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic pain study group. Obstetrics &amp; Gynecology1999;93(1):51-58. [DOI: 10.1016/s0029-7844(98)00341-x]">Ling 1999</a> was included in the primary analysis. Treatment with GnRHas may be associated with greater incidence of hot flushes at three months of treatment (RR 3.08; 95% CI 1.89 to 5.01, 1 RCT, n = 100, low‐certainty evidence) (<a href="./references#CD014788-fig-0005" title="">Analysis 1.2</a>). </p> <p>We performed a sensitivity analysis including the studies with unclear or high risk of bias and found treatment with GnRHas may also be associated with greater incidence of vasodilatation (RR 2.69; 95% CI 1.51 to 4.81, 1 RCT, n = 63) and headache (RR 3.55; 95% CI 1.09 to 11.53, 1 RCT, n = 63) at six months of treatment (<a href="./references#CD014788-bbs2-0017" title="DlugiAM , MillerJD , KnittleJ . Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertility &amp; Sterility1990;54(3):419-27. [DOI: 10.1016/s0015-0282(16)53755-8]">Dlugi 1990</a>) and sleep disturbances at 12 months treatment (RR 2.31; 95% CI 1.33 to 4.02, 1 RCT, n = 49, <a href="./references#CD014788-bbs2-0007" title="BergqvistA , BerghT , HogstromL , MattssonS , NordenskjoldF , RasmussenC . Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertility &amp; Sterility1998;69(4):702-8. ">Bergqvist 1998</a>) compared to placebo. We are uncertain of the effect of GnRHas compared to placebo, for hot flushes at 12 months treatment (RR 1.62; 95% CI 0.87 to 3.02, 1 RCT, n = 49, <a href="./references#CD014788-bbs2-0007" title="BergqvistA , BerghT , HogstromL , MattssonS , NordenskjoldF , RasmussenC . Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertility &amp; Sterility1998;69(4):702-8. ">Bergqvist 1998</a>) (<a href="./references#CD014788-fig-0009" title="">Analysis 2.4</a>). Nevertheless, these results should be interpreted with caution in view of the high risk of bias in these studies. </p> <p>2.4 Quality of life </p> <p>No studies with overall low risk of bias were included in this analysis.</p> <p>One high risk of bias study reported on quality of life (<a href="./references#CD014788-bbs2-0043" title="MillerJD . Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. American Journal of Obstetrics &amp; Gynecology2000;182(6):1483-1488. [DOI: 10.1067/mob.2000.106846]">Miller 2000</a>).  At one month of follow‐up, GnRHas treatment resulted in lower physical and mental health according to the Short Form (36) Health Survey (SF‐36) questionnaire (MD ‐0.46; 95% CI ‐0.48 ‐ 0.44, 1 RCT, n = 120, <a href="./references#CD014788-fig-0010" title="">Analysis 2.5</a>).  </p> </section> <section id="CD014788-sec-0053"> <h4 class="title">3. GnRHas versus analgesics for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>No studies comparing GnRHas and analgesics were identified. </p> </section> <section id="CD014788-sec-0054"> <h4 class="title">4. GnRHas versus danazol for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>Twenty‐nine studies were identified which compared GnRHas with danazol (<a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>; <a href="./references#CD014788-bbs2-0004" title="AN Zoladex. Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(1):55-60. ">AN Zoladex 1996</a>; <a href="./references#CD014788-bbs2-0005" title="AudebertA , LucasC , Joubert-CollinM . Efficacy and safety of slow-release leuprorelin 3,75 mg compared to danazol treatment.  [Efficacite et tolerance de la leuproreline 3,75 MG a liberation prolongeedans le traitement de l'endometriose en comparaison au danazol]. References en Gynecologie Obstetrique1997;5(1):49-57. ">Audebert 1997</a>; <a href="./references#CD014788-bbs2-0009" title="BurryKA , PattonPE , IllingworthDR . Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.. American Journal of Obstetrics &amp; Gynecology1989;160(6):1454-9; discussion 1459-61. ">Burry 1989</a>; <a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>; <a href="./references#CD014788-bbs2-0011" title="ChangSP , NgHT . A randomized comparative study of the effect of leuprorelin acetate depot and danazol in the treatment of endometriosis. Chung Hua i Hsueh Tsa Chih - Chinese Medical Journal1996;57(6):431-7. ">Chang 1996</a>; <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0016" title="DawoodMY , RamosJ , Khan-DawoodF . Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertility &amp; Sterility1995;63:1177-1183. [DOI: 10.1016/s0015-0282(16)57593-1]">Dawood 1995</a>; <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>; <a href="./references#CD014788-bbs2-0020" title="FedeleL , BianchiS , ArcainiL , VercelliniP , CandianiGB . Buserelin versus danazol in the treatment of endometriosis-associated infertility. American Journal of Obstetrics &amp; Gynecology1989;161(4):871-6. [DOI: 10.1016/0002-9378(89)90739-4]FedeleL , MarchiniM , BianchiS , BaglioniA , ZanottiF . Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fertility &amp; Sterility1993;59(6):1191-5. ">Fedele 1989</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>; <a href="./references#CD014788-bbs2-0027" title="FukushimaM , ShindoM , SatoK . Hormone treatment related bone mineral content changes in Japanese women with endometriosis. Asia-Oceania Journal of Obstetrics and Gynaecology1993;19(3):299-307. [DOI: 10.1111/j.1447-0756.1993.tb00389.x]Fukushima M . Changes in bone mineral content following hormone treatment for endometriosis. . International Journal of Gynecology &amp; Obstetrics1995;50:S17-S21. [DOI: 10.1016/0020-7292(95)02510-j]">Fukushima 1993</a>; <a href="./references#CD014788-bbs2-0028" title="GnothC , GödtkeK , FreundlG , GodehardtE , KienleE . Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists. Gynecologic and Obstetric Investigation1999;47:37-41. [DOI: 10.1159/000010059]">Gnoth 1999</a>; <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a>; <a href="./references#CD014788-bbs2-0037" title="JelleyRY , MagillPJ . The effect of LHRH agonist therapy in the treatment of endometriosis (English experience). Progress in Clinical &amp; Biological Research1986;225:227-38. JelleyRY . Multicentre open comparative study of buserelin and danazol in the treatment of endometriosis. British Journal of Clinical Practice1986;48(Suppl):64-8. ">Jelley 1986</a>; <a href="./references#CD014788-bbs2-0038" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility June 1990;53(6):998-1003. [DOI: 10.1016/s0015-0282(16)53574-2]">Kennedy 1990</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>; <a href="./references#CD014788-bbs2-0047" title="OdukoyaOA , BansalA , WilsonAP , WeetmanAP , CookeID . Serum-soluble CD23 in patients with endometriosis and the effect of treatment with danazol and leuprolide acetate depot injection. Human Reproduction1995;10(4):942-946. [DOI: 10.1093/oxfordjournals.humrep.a136067]">Odukoya 1995</a>; <a href="./references#CD014788-bbs2-0050" title="PalagianoA , CapuanoV . Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol. Minerva Ginecologica1994;46(4):173-7. [PMID: 8065590]">Palagiano 1994</a>; <a href="./references#CD014788-bbs2-0052" title="AllenTW . Zoladex versus danazol in endometriosis therapy. Journal of the American Osteopathic Association1993;93(10):1013. RockJA , TrugliaJA , CaplanRJ . Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstetrics &amp; Gynecology1993;82(2):198-205. [PMID: 8336864]RockJA . A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis . Fertility &amp; Sterility1991;56(pp.s49). ">Rock 1993</a>; <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>; <a href="./references#CD014788-bbs2-0054" title="RotondiM , LabriolaD , AmmaturoFP , AmatoG , CarellaC , IzzoA , et al. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. European Journal of Gynaecological Oncology2002;23(6):523-526. [PMID: 12556096]">Rotondi 2002</a>; <a href="./references#CD014788-bbs2-0058" title="ShawRW . Nafarelin in the treatment of pelvic pain caused by endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):574-6. [DOI: 10.1016/0002-9378(90)90433-8]">Shaw 1990</a>; <a href="./references#CD014788-bbs2-0066" title="TummonIS , AliA , PeppingME , RadwanskaE , BinorZ , DmowskiWP . Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertility &amp; Sterility May 1988;49(5):792-796. [PMID: 3129312]">Tummon 1988</a>; <a href="./references#CD014788-bbs2-0067" title="TummonIS , PeppingME , BinorZ , RadwanskaE , DmowskiWP . A randomized, prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis. Fertility &amp; Sterility1989;51(3):390-4. [DOI: 10.1016/s0015-0282(16)60542-3]">Tummon 1989</a>; <a href="./references#CD014788-bbs2-0068" title="VercelliniP , TrespidiL , PanazzaS , BramanteT , MauroF , CrosignaniPG . Very low dose danazol for relief of endometriosis-associated pelvic pain: a pilot study. Fertility &amp; Sterility1994;62(6):1136-42. [PMID: 7525359]">Vercellini 1994</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>; <a href="./references#CD014788-bbs2-0071" title="WhitehouseRW , AdamsJE , BancroftK , Vaughan-WilliamsCA , ElsteinM . The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clinical Endocrinology1990;33(3):365-373. [DOI: 10.1016/s0015-0282(16)58682-8]">Whitehouse 1990</a>). </p> <p>Of these twenty‐nine studies, only two were low risk of selection bias (<a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0047" title="OdukoyaOA , BansalA , WilsonAP , WeetmanAP , CookeID . Serum-soluble CD23 in patients with endometriosis and the effect of treatment with danazol and leuprolide acetate depot injection. Human Reproduction1995;10(4):942-946. [DOI: 10.1093/oxfordjournals.humrep.a136067]">Odukoya 1995</a>). All twenty‐nine studies were included in sensitivity analysis, nevertheless, these results should be interpreted with caution.  </p> <p>4.1 Relief of overall pain </p> <p>Relief of overall pain was reported by <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a> and <a href="./references#CD014788-bbs2-0047" title="OdukoyaOA , BansalA , WilsonAP , WeetmanAP , CookeID . Serum-soluble CD23 in patients with endometriosis and the effect of treatment with danazol and leuprolide acetate depot injection. Human Reproduction1995;10(4):942-946. [DOI: 10.1093/oxfordjournals.humrep.a136067]">Odukoya 1995</a>.  </p> <p>Dichotomous data suggested very low‐certainty evidence of the effect of GnRHas versus danazol on relief of overall pain, reported as partly and completely resolved pelvic tenderness, after six months of treatment ((RR 1.15, 95% CI 0.49 to 2.73, 1 RCT, n = 41) and (RR 1.10, 95% CI 0.67 to 1.81, 1 RCT, n = 41)), respectively (<a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>).  One study reported that "there was no difference between the two drugs (aka leuprolide acetate versus danazol) in the relief of pain symptoms at the end of three months, but the mean score was lower at the end of three months with leuprolide acetate injections" (<a href="./references#CD014788-bbs2-0047" title="OdukoyaOA , BansalA , WilsonAP , WeetmanAP , CookeID . Serum-soluble CD23 in patients with endometriosis and the effect of treatment with danazol and leuprolide acetate depot injection. Human Reproduction1995;10(4):942-946. [DOI: 10.1093/oxfordjournals.humrep.a136067]">Odukoya 1995</a>). </p> <p>Continuous data suggested very low‐certainty evidence of the effect of GnRHas versus danazol on relief of overall pain (MD ‐0.13, 95% CI ‐0.74 to 0.49, 1 RCT, n = 41), pelvic pain (MD 0.26, 95% CI ‐0.35 to 0.88, 1 RCT, n = 41), dysmenorrhoea (MD 0.10, 95% CI ‐0.51 to 0.72, 1 RCT, n = 41), dyspareunia (MD ‐0.20, 95% CI ‐0.82 to 0.41, 1 RCT, n = 41), pelvic induration (MD ‐0.12, 95% CI ‐0.73 to 0.49, 1 RCT, n = 41 (<a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>)) and pelvic tenderness (MD ‐0.21, 95% CI ‐0.82 to 0.41, 1 RCT, n = 41), all after three months of treatment (<a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>).  </p> <p>Similarly, after six months of treatment, we found very low‐certainty evidence of the effect of GnRHas versus danazol on relief of overall pain (MD 0.40, 95% CI ‐0.86 to 1.66, 1 RCT, n = 41), pelvic pain (MD 0.50, 95% CI 0.10 to 0.90, 1 RCT, n = 41), dysmenorrhoea (MD 0.40, 95% CI ‐0.12 to 0.792, 1 RCT, n = 41), dyspareunia (MD ‐0.40, 95% CI ‐0.90 to 0.10, 1 RCT, n = 41) and pelvic tenderness (MD ‐0.20, 95% CI ‐0.75 to 0.35, 1 RCT, n = 41) (<a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>).  </p> <p>We performed a sensitivity analysis including unclear or high risk of bias studies and found pain scores were reported by twenty‐two studies (<a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>; <a href="./references#CD014788-bbs2-0005" title="AudebertA , LucasC , Joubert-CollinM . Efficacy and safety of slow-release leuprorelin 3,75 mg compared to danazol treatment.  [Efficacite et tolerance de la leuproreline 3,75 MG a liberation prolongeedans le traitement de l'endometriose en comparaison au danazol]. References en Gynecologie Obstetrique1997;5(1):49-57. ">Audebert 1997</a>; <a href="./references#CD014788-bbs2-0011" title="ChangSP , NgHT . A randomized comparative study of the effect of leuprorelin acetate depot and danazol in the treatment of endometriosis. Chung Hua i Hsueh Tsa Chih - Chinese Medical Journal1996;57(6):431-7. ">Chang 1996</a>; <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>; <a href="./references#CD014788-bbs2-0020" title="FedeleL , BianchiS , ArcainiL , VercelliniP , CandianiGB . Buserelin versus danazol in the treatment of endometriosis-associated infertility. American Journal of Obstetrics &amp; Gynecology1989;161(4):871-6. [DOI: 10.1016/0002-9378(89)90739-4]FedeleL , MarchiniM , BianchiS , BaglioniA , ZanottiF . Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fertility &amp; Sterility1993;59(6):1191-5. ">Fedele 1989</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>; <a href="./references#CD014788-bbs2-0027" title="FukushimaM , ShindoM , SatoK . Hormone treatment related bone mineral content changes in Japanese women with endometriosis. Asia-Oceania Journal of Obstetrics and Gynaecology1993;19(3):299-307. [DOI: 10.1111/j.1447-0756.1993.tb00389.x]Fukushima M . Changes in bone mineral content following hormone treatment for endometriosis. . International Journal of Gynecology &amp; Obstetrics1995;50:S17-S21. [DOI: 10.1016/0020-7292(95)02510-j]">Fukushima 1993</a>; <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a>; <a href="./references#CD014788-bbs2-0037" title="JelleyRY , MagillPJ . The effect of LHRH agonist therapy in the treatment of endometriosis (English experience). Progress in Clinical &amp; Biological Research1986;225:227-38. JelleyRY . Multicentre open comparative study of buserelin and danazol in the treatment of endometriosis. British Journal of Clinical Practice1986;48(Suppl):64-8. ">Jelley 1986</a>;  <a href="./references#CD014788-bbs2-0038" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility June 1990;53(6):998-1003. [DOI: 10.1016/s0015-0282(16)53574-2]">Kennedy 1990</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>; <a href="./references#CD014788-bbs2-0047" title="OdukoyaOA , BansalA , WilsonAP , WeetmanAP , CookeID . Serum-soluble CD23 in patients with endometriosis and the effect of treatment with danazol and leuprolide acetate depot injection. Human Reproduction1995;10(4):942-946. [DOI: 10.1093/oxfordjournals.humrep.a136067]">Odukoya 1995</a>; <a href="./references#CD014788-bbs2-0050" title="PalagianoA , CapuanoV . Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol. Minerva Ginecologica1994;46(4):173-7. [PMID: 8065590]">Palagiano 1994</a>; <a href="./references#CD014788-bbs2-0052" title="AllenTW . Zoladex versus danazol in endometriosis therapy. Journal of the American Osteopathic Association1993;93(10):1013. RockJA , TrugliaJA , CaplanRJ . Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstetrics &amp; Gynecology1993;82(2):198-205. [PMID: 8336864]RockJA . A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis . Fertility &amp; Sterility1991;56(pp.s49). ">Rock 1993</a>; <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>; <a href="./references#CD014788-bbs2-0054" title="RotondiM , LabriolaD , AmmaturoFP , AmatoG , CarellaC , IzzoA , et al. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. European Journal of Gynaecological Oncology2002;23(6):523-526. [PMID: 12556096]">Rotondi 2002</a>; <a href="./references#CD014788-bbs2-0067" title="TummonIS , PeppingME , BinorZ , RadwanskaE , DmowskiWP . A randomized, prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis. Fertility &amp; Sterility1989;51(3):390-4. [DOI: 10.1016/s0015-0282(16)60542-3]">Tummon 1989</a>; <a href="./references#CD014788-bbs2-0068" title="VercelliniP , TrespidiL , PanazzaS , BramanteT , MauroF , CrosignaniPG . Very low dose danazol for relief of endometriosis-associated pelvic pain: a pilot study. Fertility &amp; Sterility1994;62(6):1136-42. [PMID: 7525359]">Vercellini 1994</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>; <a href="./references#CD014788-bbs2-0071" title="WhitehouseRW , AdamsJE , BancroftK , Vaughan-WilliamsCA , ElsteinM . The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clinical Endocrinology1990;33(3):365-373. [DOI: 10.1016/s0015-0282(16)58682-8]">Whitehouse 1990</a>), but only thirteen of them could be included in meta‐analyses (<a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>; <a href="./references#CD014788-bbs2-0005" title="AudebertA , LucasC , Joubert-CollinM . Efficacy and safety of slow-release leuprorelin 3,75 mg compared to danazol treatment.  [Efficacite et tolerance de la leuproreline 3,75 MG a liberation prolongeedans le traitement de l'endometriose en comparaison au danazol]. References en Gynecologie Obstetrique1997;5(1):49-57. ">Audebert 1997</a>; <a href="./references#CD014788-bbs2-0011" title="ChangSP , NgHT . A randomized comparative study of the effect of leuprorelin acetate depot and danazol in the treatment of endometriosis. Chung Hua i Hsueh Tsa Chih - Chinese Medical Journal1996;57(6):431-7. ">Chang 1996</a>; <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>; <a href="./references#CD014788-bbs2-0020" title="FedeleL , BianchiS , ArcainiL , VercelliniP , CandianiGB . Buserelin versus danazol in the treatment of endometriosis-associated infertility. American Journal of Obstetrics &amp; Gynecology1989;161(4):871-6. [DOI: 10.1016/0002-9378(89)90739-4]FedeleL , MarchiniM , BianchiS , BaglioniA , ZanottiF . Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fertility &amp; Sterility1993;59(6):1191-5. ">Fedele 1989</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>; <a href="./references#CD014788-bbs2-0037" title="JelleyRY , MagillPJ . The effect of LHRH agonist therapy in the treatment of endometriosis (English experience). Progress in Clinical &amp; Biological Research1986;225:227-38. JelleyRY . Multicentre open comparative study of buserelin and danazol in the treatment of endometriosis. British Journal of Clinical Practice1986;48(Suppl):64-8. ">Jelley 1986</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>; <a href="./references#CD014788-bbs2-0050" title="PalagianoA , CapuanoV . Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol. Minerva Ginecologica1994;46(4):173-7. [PMID: 8065590]">Palagiano 1994</a>; <a href="./references#CD014788-bbs2-0067" title="TummonIS , PeppingME , BinorZ , RadwanskaE , DmowskiWP . A randomized, prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis. Fertility &amp; Sterility1989;51(3):390-4. [DOI: 10.1016/s0015-0282(16)60542-3]">Tummon 1989</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>). Dichotomous data showed probably little or no difference in the effect of GnRHas versus danazol on overall pain relief after six months of treatment: reported as pelvic pain (RR 0.96, 95% CI 0.83 to 1.11, I<sup>2</sup> = 0%, 6 RCTs, n = 625, (<a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0020" title="FedeleL , BianchiS , ArcainiL , VercelliniP , CandianiGB . Buserelin versus danazol in the treatment of endometriosis-associated infertility. American Journal of Obstetrics &amp; Gynecology1989;161(4):871-6. [DOI: 10.1016/0002-9378(89)90739-4]FedeleL , MarchiniM , BianchiS , BaglioniA , ZanottiF . Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fertility &amp; Sterility1993;59(6):1191-5. ">Fedele 1989</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>; <a href="./references#CD014788-bbs2-0050" title="PalagianoA , CapuanoV . Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol. Minerva Ginecologica1994;46(4):173-7. [PMID: 8065590]">Palagiano 1994</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>)), dysmenorrhoea (RR 1.01, 95% CI 0.96 to 1.06, I<sup>2</sup> = 0%, 6 RCTs, n = 644, (<a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0020" title="FedeleL , BianchiS , ArcainiL , VercelliniP , CandianiGB . Buserelin versus danazol in the treatment of endometriosis-associated infertility. American Journal of Obstetrics &amp; Gynecology1989;161(4):871-6. [DOI: 10.1016/0002-9378(89)90739-4]FedeleL , MarchiniM , BianchiS , BaglioniA , ZanottiF . Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fertility &amp; Sterility1993;59(6):1191-5. ">Fedele 1989</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>; <a href="./references#CD014788-bbs2-0050" title="PalagianoA , CapuanoV . Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol. Minerva Ginecologica1994;46(4):173-7. [PMID: 8065590]">Palagiano 1994</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>)), dyspareunia (RR 1.10, 95% CI 0.90 to 1.34, I<sup>2</sup> = 13%, 5 RCTs, n = 342, (<a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0020" title="FedeleL , BianchiS , ArcainiL , VercelliniP , CandianiGB . Buserelin versus danazol in the treatment of endometriosis-associated infertility. American Journal of Obstetrics &amp; Gynecology1989;161(4):871-6. [DOI: 10.1016/0002-9378(89)90739-4]FedeleL , MarchiniM , BianchiS , BaglioniA , ZanottiF . Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fertility &amp; Sterility1993;59(6):1191-5. ">Fedele 1989</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>; <a href="./references#CD014788-bbs2-0050" title="PalagianoA , CapuanoV . Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol. Minerva Ginecologica1994;46(4):173-7. [PMID: 8065590]">Palagiano 1994</a>)), pelvic induration (RR 0.78, 95% CI 0.32 to 1.89, I<sup>2</sup> = 0%, 2 RCTs, n = 151, (<a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>), pelvic tenderness partly resolved (RR 1.28, 95% CI 0.59 to 2.76, I<sup>2</sup> = 0%, 2 RCTs, n = 96, (<a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>) and pelvic tenderness completely resolved (RR 0.97, 95% CI 0.84 to 1.12, I<sup>2</sup> = 0%, 2 RCTs, n = 194 (<a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>)). Also, we are uncertain of the effect on pain reduction when pelvic induration and pelvic tenderness were combined (<a href="./references#CD014788-bbs2-0038" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility June 1990;53(6):998-1003. [DOI: 10.1016/s0015-0282(16)53574-2]">Kennedy 1990</a>; <a href="./references#CD014788-fig-0014" title="">Analysis 4.1</a>).  </p> <p>Continuous data suggested very low‐certainty evidence of the effect of GnRHas versus danazol on relief of overall pain (SMD 0.00, 95% CI ‐0.46 to 0.46, I<sup>2</sup> = 81%, 3 RCTs, n = 85 (<a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>; <a href="./references#CD014788-bbs2-0067" title="TummonIS , PeppingME , BinorZ , RadwanskaE , DmowskiWP . A randomized, prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis. Fertility &amp; Sterility1989;51(3):390-4. [DOI: 10.1016/s0015-0282(16)60542-3]">Tummon 1989</a>)), pelvic pain (SMD 0.35, 95% CI ‐0.08 to 0.79, I<sup>2</sup> = 65%, 2 RCTs, n = 90 (<a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>)), dyspareunia (SMD 0.25, 95% CI ‐0.19 to 0.69, I<sup>2</sup> = 90%, 2 RCTs, n = 90 (<a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>)) and pelvic induration (SMD 0.40 95% CI ‐0.04 to 0.83, I<sup>2</sup> = 73%, 2 RCTs, n = 90 (<a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>)), all after six months of treatment. Pelvic tenderness after six months of treatment with GnRHas compared to danazol may be decreased  in favour of GnRHas with SMD ‐0.59 (95% CI ‐1.03 to ‐0.15, I<sup>2</sup> = 66%, 2 RCTs, n = 90 (<a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>)) (<a href="./references#CD014788-fig-0015" title="">Analysis 4.2</a>). Two studies that could not be included in the meta‐analyses of continuous pain outcomes reported similar results. One study reported "The investigators' symptom severity scores also dropped after 6 months for both the nafarelin and danazol groups. There were no symptoms in 57% of the patients in the nafarelin group or 48% of patients in the danazol group" (<a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>). This is comparable with <a href="./references#CD014788-bbs2-0054" title="RotondiM , LabriolaD , AmmaturoFP , AmatoG , CarellaC , IzzoA , et al. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. European Journal of Gynaecological Oncology2002;23(6):523-526. [PMID: 12556096]">Rotondi 2002</a>, who stated that "Both treatments were associated with a significant reduction in mean total subjective scores but with no difference between the treatments", respectively.  Nevertheless, as we included all types of risk of bias, these results should be interpreted with caution.  </p> <p>No usable data could be extracted from <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a>, <a href="./references#CD014788-bbs2-0052" title="AllenTW . Zoladex versus danazol in endometriosis therapy. Journal of the American Osteopathic Association1993;93(10):1013. RockJA , TrugliaJA , CaplanRJ . Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstetrics &amp; Gynecology1993;82(2):198-205. [PMID: 8336864]RockJA . A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis . Fertility &amp; Sterility1991;56(pp.s49). ">Rock 1993</a> and <a href="./references#CD014788-bbs2-0068" title="VercelliniP , TrespidiL , PanazzaS , BramanteT , MauroF , CrosignaniPG . Very low dose danazol for relief of endometriosis-associated pelvic pain: a pilot study. Fertility &amp; Sterility1994;62(6):1136-42. [PMID: 7525359]">Vercellini 1994</a>.  </p> <p>4.2 Bone mineral density </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>When we included all studies in the analysis, six studies reported data on BMD (<a href="./references#CD014788-bbs2-0016" title="DawoodMY , RamosJ , Khan-DawoodF . Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertility &amp; Sterility1995;63:1177-1183. [DOI: 10.1016/s0015-0282(16)57593-1]">Dawood 1995</a>; <a href="./references#CD014788-bbs2-0027" title="FukushimaM , ShindoM , SatoK . Hormone treatment related bone mineral content changes in Japanese women with endometriosis. Asia-Oceania Journal of Obstetrics and Gynaecology1993;19(3):299-307. [DOI: 10.1111/j.1447-0756.1993.tb00389.x]Fukushima M . Changes in bone mineral content following hormone treatment for endometriosis. . International Journal of Gynecology &amp; Obstetrics1995;50:S17-S21. [DOI: 10.1016/0020-7292(95)02510-j]">Fukushima 1993</a>; <a href="./references#CD014788-bbs2-0052" title="AllenTW . Zoladex versus danazol in endometriosis therapy. Journal of the American Osteopathic Association1993;93(10):1013. RockJA , TrugliaJA , CaplanRJ . Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstetrics &amp; Gynecology1993;82(2):198-205. [PMID: 8336864]RockJA . A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis . Fertility &amp; Sterility1991;56(pp.s49). ">Rock 1993</a>; <a href="./references#CD014788-bbs2-0066" title="TummonIS , AliA , PeppingME , RadwanskaE , BinorZ , DmowskiWP . Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertility &amp; Sterility May 1988;49(5):792-796. [PMID: 3129312]">Tummon 1988</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>; <a href="./references#CD014788-bbs2-0071" title="WhitehouseRW , AdamsJE , BancroftK , Vaughan-WilliamsCA , ElsteinM . The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clinical Endocrinology1990;33(3):365-373. [DOI: 10.1016/s0015-0282(16)58682-8]">Whitehouse 1990</a>). Two studies (<a href="./references#CD014788-bbs2-0016" title="DawoodMY , RamosJ , Khan-DawoodF . Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertility &amp; Sterility1995;63:1177-1183. [DOI: 10.1016/s0015-0282(16)57593-1]">Dawood 1995</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>) reported the percentage change values of BMD at the lumbar spine after six months of treatment.  Three studies (<a href="./references#CD014788-bbs2-0027" title="FukushimaM , ShindoM , SatoK . Hormone treatment related bone mineral content changes in Japanese women with endometriosis. Asia-Oceania Journal of Obstetrics and Gynaecology1993;19(3):299-307. [DOI: 10.1111/j.1447-0756.1993.tb00389.x]Fukushima M . Changes in bone mineral content following hormone treatment for endometriosis. . International Journal of Gynecology &amp; Obstetrics1995;50:S17-S21. [DOI: 10.1016/0020-7292(95)02510-j]">Fukushima 1993</a>; <a href="./references#CD014788-bbs2-0066" title="TummonIS , AliA , PeppingME , RadwanskaE , BinorZ , DmowskiWP . Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertility &amp; Sterility May 1988;49(5):792-796. [PMID: 3129312]">Tummon 1988</a>; <a href="./references#CD014788-bbs2-0071" title="WhitehouseRW , AdamsJE , BancroftK , Vaughan-WilliamsCA , ElsteinM . The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clinical Endocrinology1990;33(3):365-373. [DOI: 10.1016/s0015-0282(16)58682-8]">Whitehouse 1990</a>) reported absolute values of BMD at the lumbar spine after six months of treatment. We are uncertain of the effect of GnRHas or danazol between the two groups for absolute values of BMD (SMD 0.21 95% CI ‐0.31 to 0.73, I<sup>2</sup> = 94%, 3 RCTs, n = 81) (<a href="./references#CD014788-fig-0016" title="">Analysis 4.3</a>).  </p> <p>Data reported by <a href="./references#CD014788-bbs2-0052" title="AllenTW . Zoladex versus danazol in endometriosis therapy. Journal of the American Osteopathic Association1993;93(10):1013. RockJA , TrugliaJA , CaplanRJ . Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstetrics &amp; Gynecology1993;82(2):198-205. [PMID: 8336864]RockJA . A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis . Fertility &amp; Sterility1991;56(pp.s49). ">Rock 1993</a> could not be used in a meta‐analysis; it was reported that "the mean percent loss following 12 and 24 weeks of Zoladex therapy was 3.6% (n = 37; 95% CI ‐5.0 to ‐2.2) and 5.4% (n = 38; 95% CI ‐7.2 to ‐3.6), respectively. Danazol‐treated women showed a mean percent loss in bone mineral density at week 12 of 0.4% (n = 17; 95% CI ‐2.9 to +2.1) and a mean percent increase in 1.0% (n = 17; 95% CI ‐1.4 to +3.4) at week 24".  </p> <p>4.3 Adverse effects </p> <p><a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a> reported adverse effects. We are uncertain about the effect of GnRHas compared to danazol on adverse effects reported by patients treated for six months. The adverse effects mentioned were vaginal dryness (RR 1.45, 95% CI 0.52 to 4.05, 1 RCT, n = 59), hot flushes (RR 15.50, 95% CI 0.93 to 259.61, 1 RCT, n = 59), gastrointestinal complaints (RR 0.15, 95% CI 0.01 to 2.74, 1 RCT, n = 59), weight gain (RR 0.26, 95% CI 0.08 to 0.82, 1 RCT, n = 59) acne (RR 0.08, 95% CI 0.00 to 1.35, 1 RCT, n = 59) and generalised spasm (RR 0.08, 95% CI 0.00 to 1.35, 1 RCT, n = 59), all very low‐certainty evidence. </p> <p>We performed a sensitivity analysis including  unclear or high risk of bias studies and found eighteen studies that reported on adverse effects (<a href="./references#CD014788-bbs2-0004" title="AN Zoladex. Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(1):55-60. ">AN Zoladex 1996</a>; <a href="./references#CD014788-bbs2-0005" title="AudebertA , LucasC , Joubert-CollinM . Efficacy and safety of slow-release leuprorelin 3,75 mg compared to danazol treatment.  [Efficacite et tolerance de la leuproreline 3,75 MG a liberation prolongeedans le traitement de l'endometriose en comparaison au danazol]. References en Gynecologie Obstetrique1997;5(1):49-57. ">Audebert 1997</a>; <a href="./references#CD014788-bbs2-0009" title="BurryKA , PattonPE , IllingworthDR . Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.. American Journal of Obstetrics &amp; Gynecology1989;160(6):1454-9; discussion 1459-61. ">Burry 1989</a>; <a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>; <a href="./references#CD014788-bbs2-0011" title="ChangSP , NgHT . A randomized comparative study of the effect of leuprorelin acetate depot and danazol in the treatment of endometriosis. Chung Hua i Hsueh Tsa Chih - Chinese Medical Journal1996;57(6):431-7. ">Chang 1996</a>; <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>; <a href="./references#CD014788-bbs2-0020" title="FedeleL , BianchiS , ArcainiL , VercelliniP , CandianiGB . Buserelin versus danazol in the treatment of endometriosis-associated infertility. American Journal of Obstetrics &amp; Gynecology1989;161(4):871-6. [DOI: 10.1016/0002-9378(89)90739-4]FedeleL , MarchiniM , BianchiS , BaglioniA , ZanottiF . Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fertility &amp; Sterility1993;59(6):1191-5. ">Fedele 1989</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>; <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a>; <a href="./references#CD014788-bbs2-0037" title="JelleyRY , MagillPJ . The effect of LHRH agonist therapy in the treatment of endometriosis (English experience). Progress in Clinical &amp; Biological Research1986;225:227-38. JelleyRY . Multicentre open comparative study of buserelin and danazol in the treatment of endometriosis. British Journal of Clinical Practice1986;48(Suppl):64-8. ">Jelley 1986</a>; <a href="./references#CD014788-bbs2-0038" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility June 1990;53(6):998-1003. [DOI: 10.1016/s0015-0282(16)53574-2]">Kennedy 1990</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>; <a href="./references#CD014788-bbs2-0052" title="AllenTW . Zoladex versus danazol in endometriosis therapy. Journal of the American Osteopathic Association1993;93(10):1013. RockJA , TrugliaJA , CaplanRJ . Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstetrics &amp; Gynecology1993;82(2):198-205. [PMID: 8336864]RockJA . A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis . Fertility &amp; Sterility1991;56(pp.s49). ">Rock 1993</a>; <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>; <a href="./references#CD014788-bbs2-0054" title="RotondiM , LabriolaD , AmmaturoFP , AmatoG , CarellaC , IzzoA , et al. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. European Journal of Gynaecological Oncology2002;23(6):523-526. [PMID: 12556096]">Rotondi 2002</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>). A total of forty different types of adverse effects were reported, of which a meta‐analysis could be performed in twenty‐three studies. Eight of the most commonly reported adverse effects were vaginal dryness, hot flushes, headaches, muscle cramps/myalgia, sleep disturbance/insomnia, altered libido, weight gain and acne. Adverse effects were more frequently reported in groups receiving GnRHas than those receiving danazol. The evidence suggested that, compared to danazol, GnRHas probably lead to more vaginal dryness (RR 1.82, 95% CI 1.53 to 2.18, I<sup>2</sup> = 11%, 12 RCTs, n = 1340 (<a href="./references#CD014788-bbs2-0004" title="AN Zoladex. Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(1):55-60. ">AN Zoladex 1996</a>; <a href="./references#CD014788-bbs2-0005" title="AudebertA , LucasC , Joubert-CollinM . Efficacy and safety of slow-release leuprorelin 3,75 mg compared to danazol treatment.  [Efficacite et tolerance de la leuproreline 3,75 MG a liberation prolongeedans le traitement de l'endometriose en comparaison au danazol]. References en Gynecologie Obstetrique1997;5(1):49-57. ">Audebert 1997</a>; <a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>; <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>; <a href="./references#CD014788-bbs2-0020" title="FedeleL , BianchiS , ArcainiL , VercelliniP , CandianiGB . Buserelin versus danazol in the treatment of endometriosis-associated infertility. American Journal of Obstetrics &amp; Gynecology1989;161(4):871-6. [DOI: 10.1016/0002-9378(89)90739-4]FedeleL , MarchiniM , BianchiS , BaglioniA , ZanottiF . Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fertility &amp; Sterility1993;59(6):1191-5. ">Fedele 1989</a>; <a href="./references#CD014788-bbs2-0037" title="JelleyRY , MagillPJ . The effect of LHRH agonist therapy in the treatment of endometriosis (English experience). Progress in Clinical &amp; Biological Research1986;225:227-38. JelleyRY . Multicentre open comparative study of buserelin and danazol in the treatment of endometriosis. British Journal of Clinical Practice1986;48(Suppl):64-8. ">Jelley 1986</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>; <a href="./references#CD014788-bbs2-0050" title="PalagianoA , CapuanoV . Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol. Minerva Ginecologica1994;46(4):173-7. [PMID: 8065590]">Palagiano 1994</a>; <a href="./references#CD014788-bbs2-0052" title="AllenTW . Zoladex versus danazol in endometriosis therapy. Journal of the American Osteopathic Association1993;93(10):1013. RockJA , TrugliaJA , CaplanRJ . Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstetrics &amp; Gynecology1993;82(2):198-205. [PMID: 8336864]RockJA . A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis . Fertility &amp; Sterility1991;56(pp.s49). ">Rock 1993</a>; <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>)), more hot flushes (RR 1.50, 95% CI 1.42 to 1.60, I<sup>2</sup> = 69%, 16 RCTs, n = 1998 (<a href="./references#CD014788-bbs2-0004" title="AN Zoladex. Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(1):55-60. ">AN Zoladex 1996</a>; <a href="./references#CD014788-bbs2-0005" title="AudebertA , LucasC , Joubert-CollinM . Efficacy and safety of slow-release leuprorelin 3,75 mg compared to danazol treatment.  [Efficacite et tolerance de la leuproreline 3,75 MG a liberation prolongeedans le traitement de l'endometriose en comparaison au danazol]. References en Gynecologie Obstetrique1997;5(1):49-57. ">Audebert 1997</a>; <a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>; <a href="./references#CD014788-bbs2-0011" title="ChangSP , NgHT . A randomized comparative study of the effect of leuprorelin acetate depot and danazol in the treatment of endometriosis. Chung Hua i Hsueh Tsa Chih - Chinese Medical Journal1996;57(6):431-7. ">Chang 1996</a>; <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>; <a href="./references#CD014788-bbs2-0020" title="FedeleL , BianchiS , ArcainiL , VercelliniP , CandianiGB . Buserelin versus danazol in the treatment of endometriosis-associated infertility. American Journal of Obstetrics &amp; Gynecology1989;161(4):871-6. [DOI: 10.1016/0002-9378(89)90739-4]FedeleL , MarchiniM , BianchiS , BaglioniA , ZanottiF . Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fertility &amp; Sterility1993;59(6):1191-5. ">Fedele 1989</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>; <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a>; <a href="./references#CD014788-bbs2-0037" title="JelleyRY , MagillPJ . The effect of LHRH agonist therapy in the treatment of endometriosis (English experience). Progress in Clinical &amp; Biological Research1986;225:227-38. JelleyRY . Multicentre open comparative study of buserelin and danazol in the treatment of endometriosis. British Journal of Clinical Practice1986;48(Suppl):64-8. ">Jelley 1986</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>; <a href="./references#CD014788-bbs2-0050" title="PalagianoA , CapuanoV . Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol. Minerva Ginecologica1994;46(4):173-7. [PMID: 8065590]">Palagiano 1994</a>; <a href="./references#CD014788-bbs2-0052" title="AllenTW . Zoladex versus danazol in endometriosis therapy. Journal of the American Osteopathic Association1993;93(10):1013. RockJA , TrugliaJA , CaplanRJ . Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstetrics &amp; Gynecology1993;82(2):198-205. [PMID: 8336864]RockJA . A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis . Fertility &amp; Sterility1991;56(pp.s49). ">Rock 1993</a>; <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>; <a href="./references#CD014788-bbs2-0054" title="RotondiM , LabriolaD , AmmaturoFP , AmatoG , CarellaC , IzzoA , et al. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. European Journal of Gynaecological Oncology2002;23(6):523-526. [PMID: 12556096]">Rotondi 2002</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>)), more headaches (RR 1.43, 95% CI 1.21 to 1.69, I<sup>2</sup> = 0%, 12 RCTs, n = 1103 (<a href="./references#CD014788-bbs2-0004" title="AN Zoladex. Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(1):55-60. ">AN Zoladex 1996</a>; <a href="./references#CD014788-bbs2-0005" title="AudebertA , LucasC , Joubert-CollinM . Efficacy and safety of slow-release leuprorelin 3,75 mg compared to danazol treatment.  [Efficacite et tolerance de la leuproreline 3,75 MG a liberation prolongeedans le traitement de l'endometriose en comparaison au danazol]. References en Gynecologie Obstetrique1997;5(1):49-57. ">Audebert 1997</a>; <a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>; <a href="./references#CD014788-bbs2-0020" title="FedeleL , BianchiS , ArcainiL , VercelliniP , CandianiGB . Buserelin versus danazol in the treatment of endometriosis-associated infertility. American Journal of Obstetrics &amp; Gynecology1989;161(4):871-6. [DOI: 10.1016/0002-9378(89)90739-4]FedeleL , MarchiniM , BianchiS , BaglioniA , ZanottiF . Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fertility &amp; Sterility1993;59(6):1191-5. ">Fedele 1989</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>; <a href="./references#CD014788-bbs2-0050" title="PalagianoA , CapuanoV . Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol. Minerva Ginecologica1994;46(4):173-7. [PMID: 8065590]">Palagiano 1994</a>; <a href="./references#CD014788-bbs2-0052" title="AllenTW . Zoladex versus danazol in endometriosis therapy. Journal of the American Osteopathic Association1993;93(10):1013. RockJA , TrugliaJA , CaplanRJ . Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstetrics &amp; Gynecology1993;82(2):198-205. [PMID: 8336864]RockJA . A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis . Fertility &amp; Sterility1991;56(pp.s49). ">Rock 1993</a>; <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>; <a href="./references#CD014788-bbs2-0054" title="RotondiM , LabriolaD , AmmaturoFP , AmatoG , CarellaC , IzzoA , et al. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. European Journal of Gynaecological Oncology2002;23(6):523-526. [PMID: 12556096]">Rotondi 2002</a>)), more sleep disturbance/insomnia (RR 2.04, 95% CI 1.61 to 2.59, I<sup>2</sup> = 45%, 7 RCTs, n = 881, <a href="./references#CD014788-bbs2-0004" title="AN Zoladex. Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(1):55-60. ">AN Zoladex 1996</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>; <a href="./references#CD014788-bbs2-0037" title="JelleyRY , MagillPJ . The effect of LHRH agonist therapy in the treatment of endometriosis (English experience). Progress in Clinical &amp; Biological Research1986;225:227-38. JelleyRY . Multicentre open comparative study of buserelin and danazol in the treatment of endometriosis. British Journal of Clinical Practice1986;48(Suppl):64-8. ">Jelley 1986</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>; <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>)), and more altered libido (RR 1.58, 95% CI 1.30 to 1.92, I<sup>2</sup> = 58%, 9 RCTs, n = 1286).  On the other hand, compared to danazol, GnRHas probably lead to fewer muscle cramps/myalgia (RR 0.16, 95% CI 0.09 to 0.29, I<sup>2</sup> = 0%, 8 RCTs, n = 884 (<a href="./references#CD014788-bbs2-0004" title="AN Zoladex. Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(1):55-60. ">AN Zoladex 1996</a>; <a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0020" title="FedeleL , BianchiS , ArcainiL , VercelliniP , CandianiGB . Buserelin versus danazol in the treatment of endometriosis-associated infertility. American Journal of Obstetrics &amp; Gynecology1989;161(4):871-6. [DOI: 10.1016/0002-9378(89)90739-4]FedeleL , MarchiniM , BianchiS , BaglioniA , ZanottiF . Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fertility &amp; Sterility1993;59(6):1191-5. ">Fedele 1989</a>; <a href="./references#CD014788-bbs2-0025" title="FraserIS , ShearmanRP , JansenRP , SutherlandPD . A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1991;31(2):158-63. [DOI: 10.1111/j.1479-828x.1991.tb01807.x]">Fraser 1991</a>; <a href="./references#CD014788-bbs2-0037" title="JelleyRY , MagillPJ . The effect of LHRH agonist therapy in the treatment of endometriosis (English experience). Progress in Clinical &amp; Biological Research1986;225:227-38. JelleyRY . Multicentre open comparative study of buserelin and danazol in the treatment of endometriosis. British Journal of Clinical Practice1986;48(Suppl):64-8. ">Jelley 1986</a>; <a href="./references#CD014788-bbs2-0046" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility1990;53(6):998-1003. NEET. Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up The Nafarelin European Endometriosis Trial Group (NEET) . Fertility &amp; Sterility1992;57(3):514-22. [PMID: 1531464]">NEET 1992</a>; <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>)), less weight gain (RR 0.38 (95% CI 0.29 to 0.49, I<sup>2</sup> = 65%, 9 RCTs, n = 1081 (<a href="./references#CD014788-bbs2-0005" title="AudebertA , LucasC , Joubert-CollinM . Efficacy and safety of slow-release leuprorelin 3,75 mg compared to danazol treatment.  [Efficacite et tolerance de la leuproreline 3,75 MG a liberation prolongeedans le traitement de l'endometriose en comparaison au danazol]. References en Gynecologie Obstetrique1997;5(1):49-57. ">Audebert 1997</a>; <a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>; <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0020" title="FedeleL , BianchiS , ArcainiL , VercelliniP , CandianiGB . Buserelin versus danazol in the treatment of endometriosis-associated infertility. American Journal of Obstetrics &amp; Gynecology1989;161(4):871-6. [DOI: 10.1016/0002-9378(89)90739-4]FedeleL , MarchiniM , BianchiS , BaglioniA , ZanottiF . Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fertility &amp; Sterility1993;59(6):1191-5. ">Fedele 1989</a>; <a href="./references#CD014788-bbs2-0037" title="JelleyRY , MagillPJ . The effect of LHRH agonist therapy in the treatment of endometriosis (English experience). Progress in Clinical &amp; Biological Research1986;225:227-38. JelleyRY . Multicentre open comparative study of buserelin and danazol in the treatment of endometriosis. British Journal of Clinical Practice1986;48(Suppl):64-8. ">Jelley 1986</a>; <a href="./references#CD014788-bbs2-0050" title="PalagianoA , CapuanoV . Medical treatment of endometriosis: comparative study of leuprolide acetate and danazol. Minerva Ginecologica1994;46(4):173-7. [PMID: 8065590]">Palagiano 1994</a>; <a href="./references#CD014788-bbs2-0052" title="AllenTW . Zoladex versus danazol in endometriosis therapy. Journal of the American Osteopathic Association1993;93(10):1013. RockJA , TrugliaJA , CaplanRJ . Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstetrics &amp; Gynecology1993;82(2):198-205. [PMID: 8336864]RockJA . A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis . Fertility &amp; Sterility1991;56(pp.s49). ">Rock 1993</a>; <a href="./references#CD014788-bbs2-0054" title="RotondiM , LabriolaD , AmmaturoFP , AmatoG , CarellaC , IzzoA , et al. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. European Journal of Gynaecological Oncology2002;23(6):523-526. [PMID: 12556096]">Rotondi 2002</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>)) and less acne (RR 0.59, 95% CI 0.47 to 0.73, I<sup>2</sup> = 29%, 10 RCTs, n = 1040 (<a href="./references#CD014788-bbs2-0005" title="AudebertA , LucasC , Joubert-CollinM . Efficacy and safety of slow-release leuprorelin 3,75 mg compared to danazol treatment.  [Efficacite et tolerance de la leuproreline 3,75 MG a liberation prolongeedans le traitement de l'endometriose en comparaison au danazol]. References en Gynecologie Obstetrique1997;5(1):49-57. ">Audebert 1997</a>; <a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>; <a href="./references#CD014788-bbs2-0012" title="ChengMH , YuBK , ChangSP , WangPH . A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Journal of the Chinese Medical Association2005;68(7):307-14. ">Cheng 2005</a>; <a href="./references#CD014788-bbs2-0013" title="CirkelU , OchsH , SchneiderHP . A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology1995;59(1):61-9. CirkelU , OchsH , SchneiderHPG . GnRH analogue depot (triptorelin) versus danazol in the treatment of endometriosis. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. OchsH , CirkelU , SchneiderHP . Correlation between extent of ovarian suppression and regression of endometriosis: decapeptyl vs danazol. Gynecological Endocrinology (3rd International Symposium)1993;7(Supp 2):43. ">Cirkel 1995</a>; <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>; <a href="./references#CD014788-bbs2-0020" title="FedeleL , BianchiS , ArcainiL , VercelliniP , CandianiGB . Buserelin versus danazol in the treatment of endometriosis-associated infertility. American Journal of Obstetrics &amp; Gynecology1989;161(4):871-6. [DOI: 10.1016/0002-9378(89)90739-4]FedeleL , MarchiniM , BianchiS , BaglioniA , ZanottiF . Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fertility &amp; Sterility1993;59(6):1191-5. ">Fedele 1989</a>; <a href="./references#CD014788-bbs2-0037" title="JelleyRY , MagillPJ . The effect of LHRH agonist therapy in the treatment of endometriosis (English experience). Progress in Clinical &amp; Biological Research1986;225:227-38. JelleyRY . Multicentre open comparative study of buserelin and danazol in the treatment of endometriosis. British Journal of Clinical Practice1986;48(Suppl):64-8. ">Jelley 1986</a>; <a href="./references#CD014788-bbs2-0052" title="AllenTW . Zoladex versus danazol in endometriosis therapy. Journal of the American Osteopathic Association1993;93(10):1013. RockJA , TrugliaJA , CaplanRJ . Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstetrics &amp; Gynecology1993;82(2):198-205. [PMID: 8336864]RockJA . A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis . Fertility &amp; Sterility1991;56(pp.s49). ">Rock 1993</a>; <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>; <a href="./references#CD014788-bbs2-0054" title="RotondiM , LabriolaD , AmmaturoFP , AmatoG , CarellaC , IzzoA , et al. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. European Journal of Gynaecological Oncology2002;23(6):523-526. [PMID: 12556096]">Rotondi 2002</a>)). All adverse effects reported in the previously mentioned eighteen articles, are reported in <a href="./references#CD014788-fig-0017" title="">Analysis 4.4</a>.  </p> <p>The results, reported by <a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>, <a href="./references#CD014788-bbs2-0009" title="BurryKA , PattonPE , IllingworthDR . Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.. American Journal of Obstetrics &amp; Gynecology1989;160(6):1454-9; discussion 1459-61. ">Burry 1989</a> and <a href="./references#CD014788-bbs2-0038" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility June 1990;53(6):998-1003. [DOI: 10.1016/s0015-0282(16)53574-2]">Kennedy 1990</a>, could not be extracted for current analyses. </p> <p>4.4 Quality of life </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>For the sensitivity analysis, including all studies, only one study mentioned the effect of GnRHas compared to danazol on quality of life (<a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>), but results could not be extracted for current analyses. "The quality of life measurements in the U.S. study were obtained by a questionnaire composed of 22 simple questions that comprised the Psychological General Well‐Being Index plus a modification of Part II of the Nottingham Health Profile, which requires only a patient's visual qualification of psychological state rather than a numerical quantification. The results of these questionnaires failed to reveal statistically significant differences between the entire treatment group." </p> <p>4.5 Improvement of most troublesome symptoms </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>In the sensitivity analysis, including studies with unclear or high risk of bias, six studies could be included that reported on "improvement of most troublesome symptom" (<a href="./references#CD014788-bbs2-0004" title="AN Zoladex. Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(1):55-60. ">AN Zoladex 1996</a>; <a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>; <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a>; <a href="./references#CD014788-bbs2-0038" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility June 1990;53(6):998-1003. [DOI: 10.1016/s0015-0282(16)53574-2]">Kennedy 1990</a>; <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>; <a href="./references#CD014788-bbs2-0058" title="ShawRW . Nafarelin in the treatment of pelvic pain caused by endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):574-6. [DOI: 10.1016/0002-9378(90)90433-8]">Shaw 1990</a>). A distinction was made between overall improvement and complete resolution, both after six months of treatment. We are uncertain of the effect between the two groups (RR 1.08, 95% CI 0.99 to 1.18, I<sup>2</sup> = 39%,  RCTs, n = 747 (<a href="./references#CD014788-bbs2-0004" title="AN Zoladex. Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(1):55-60. ">AN Zoladex 1996</a>; <a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>; <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a>; <a href="./references#CD014788-bbs2-0038" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility June 1990;53(6):998-1003. [DOI: 10.1016/s0015-0282(16)53574-2]">Kennedy 1990</a>; <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>; <a href="./references#CD014788-bbs2-0058" title="ShawRW . Nafarelin in the treatment of pelvic pain caused by endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):574-6. [DOI: 10.1016/0002-9378(90)90433-8]">Shaw 1990</a>) and RR 1.14, 95% CI 0.99 to 1.32, I<sup>2</sup> = 43%, 5 RCTs, n = 534, (<a href="./references#CD014788-bbs2-0004" title="AN Zoladex. Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1996;36(1):55-60. ">AN Zoladex 1996</a>; <a href="./references#CD014788-bbs2-0010" title="BurryK . Nafarelin in the management of endometriosis: quality of life assessment. American Journal of Obstetrics &amp; Gynecology1992;166:735-9. BurryKA , ButtramV , MoghissiKMF . Quality of life during and after treatment of endometriosis with Nafarelin or Danazol (abstract). Fertility &amp; Sterility1990;54(pp.s13):0-029. ">Burry 1992</a>; <a href="./references#CD014788-bbs2-0038" title="KennedySH , WilliamsIA , BrodribbJ , BarlowDH , ShawRW . A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertility &amp; Sterility June 1990;53(6):998-1003. [DOI: 10.1016/s0015-0282(16)53574-2]">Kennedy 1990</a>; <a href="./references#CD014788-bbs2-0053" title="RollandR , van derHeijdenPF . Nafarelin versus danazol in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):586-8. [DOI: 10.1016/0002-9378(90)90437-c]">Rolland 1990</a>; <a href="./references#CD014788-bbs2-0058" title="ShawRW . Nafarelin in the treatment of pelvic pain caused by endometriosis. American Journal of Obstetrics &amp; Gynecology1990;162(2):574-6. [DOI: 10.1016/0002-9378(90)90433-8]">Shaw 1990</a>), respectively) (<a href="./references#CD014788-fig-0018" title="">Analysis 4.5</a>). </p> </section> <section id="CD014788-sec-0055"> <h4 class="title">5. GnRHas versus intra‐uterine progestogens for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>Three studies assessed outcome measures when GnRHas were compared to intra‐uterine progestogens (<a href="./references#CD014788-bbs2-0021" title="FerreiraRA , VieiraC , Rosa-e-SilavaJ , Rosa-e-SilvaA , NogueiraA , FerrianiR . Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception2010;81:117-122. [DOI: 10.1016/j.contraception.2009.08.003]">Ferreira 2010</a>; <a href="./references#CD014788-bbs2-0029" title="GomesMK , FerrianiRA , Rosa e SilvaJC , Japur de Sa Rosa e SilvaAC , VieiraCS , Candido dos ReisFJ . The levonorgestrel-releasing intrauterine system and endometriosis staging. Fertility &amp; Sterility2007;87(5):1231-4. [DOI: 10.1016/j.fertnstert.2006.11.044]">Gomes 2007</a>; <a href="./references#CD014788-bbs2-0051" title="PettaCA , FerrianiRA , AbraoMS , HassanD , RosaESJC , PodgaecS , et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Human Reproduction2005;20(7):1993-8. [DOI: 10.1093/humrep/deh869]VieiraCS , FerreiraRA , Rosa e SilvaJC , Rosa e SilvaACJS , GomesMK , FerrianiRA . Comparative study of the influence of the levonorgestrel intra-uterine system and the GnRH analogues on cardiovascular risk markers in patients with endometriosis. Fertility &amp; Sterility2007;88(Suppl 1):211. deSa Rosa e SilvaAC , Rosa e SilvaJC , NogueiraAA , PettaCA , AbraoMS , FerrianiRA . The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis. Fertility &amp; Sterility2006;86(3):742-4. ">Petta 2005</a>).  </p> <p>5.1 Relief of overall pain </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including high risk of bias studies and found very low‐certainty evidence for an effect on relief of overall pain between groups for the effectiveness of pain relief, measured after six months of treatment with GnRHas or intra‐uterine progestogens (MD ‐0.76, 95% CI ‐1.62 to 0.10, I<sup>2</sup> = 22%, 2 RCTs, n = 58 (<a href="./references#CD014788-bbs2-0021" title="FerreiraRA , VieiraC , Rosa-e-SilavaJ , Rosa-e-SilvaA , NogueiraA , FerrianiR . Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception2010;81:117-122. [DOI: 10.1016/j.contraception.2009.08.003]">Ferreira 2010</a>; <a href="./references#CD014788-bbs2-0029" title="GomesMK , FerrianiRA , Rosa e SilvaJC , Japur de Sa Rosa e SilvaAC , VieiraCS , Candido dos ReisFJ . The levonorgestrel-releasing intrauterine system and endometriosis staging. Fertility &amp; Sterility2007;87(5):1231-4. [DOI: 10.1016/j.fertnstert.2006.11.044]">Gomes 2007</a>)) (<a href="./references#CD014788-fig-0019" title="">Analysis 5.1</a>). </p> <p>5.2 Quality of life </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including high risk of bias studies and found very low‐certainty evidence for an effect on quality of life scores, measured by the psychological well‐being questionnaire index (PGWBI) between both groups, after six months of treatment (MD ‐2.00, 95% CI ‐10.26 to 6.26, 1 RCT, n = 82, <a href="./references#CD014788-bbs2-0051" title="PettaCA , FerrianiRA , AbraoMS , HassanD , RosaESJC , PodgaecS , et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Human Reproduction2005;20(7):1993-8. [DOI: 10.1093/humrep/deh869]VieiraCS , FerreiraRA , Rosa e SilvaJC , Rosa e SilvaACJS , GomesMK , FerrianiRA . Comparative study of the influence of the levonorgestrel intra-uterine system and the GnRH analogues on cardiovascular risk markers in patients with endometriosis. Fertility &amp; Sterility2007;88(Suppl 1):211. deSa Rosa e SilvaAC , Rosa e SilvaJC , NogueiraAA , PettaCA , AbraoMS , FerrianiRA . The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis. Fertility &amp; Sterility2006;86(3):742-4. ">Petta 2005</a>) (<a href="./references#CD014788-fig-0020" title="">Analysis 5.2</a>). </p> </section> <section id="CD014788-sec-0056"> <h4 class="title">6. GnRHas versus oral or injectable progestogens for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>Seven studies were identified which compared GnRHas with oral or injectable progestogens (<a href="./references#CD014788-bbs2-0001" title="AbdouAM , AmmarIMM , AlenmrAAA , AbdelrhmanAA . Dienogest versus leuprolide acetate for recurrent pelvic pain following laparoscopic treatment of endometriosis. Journal of Obstetrics and Gynecology of India Aug 2018;4:306-13. [PMID: DOI: 10.1007/s13224-018-1119-3]">Abdou 2018</a>; <a href="./references#CD014788-bbs2-0015" title="CrosignaniPG , LucianoA , RayA , BergqvistA . Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction Sep 2006;21:248-56. [DOI: 10.1093/humrep/dei290]">Crosignani 2006</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0049" title="OzakiR ,  KumakiriJ , JinushiM , IkumaS , MurakamiK , KawasakiY , et al. Comparison of effect of preoperative dienogest and gonadotropin‑releasing hormone agonist administration on laparoscopic cystectomy for ovarian endometriomas. Archives of Gynecology and Obstetrics  July 2020;302:969-976. [DOI: 10.1007/s00404-020-05691-3]">Ozaki 2020</a>; <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>; <a href="./references#CD014788-bbs2-0061" title="StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. International Journal of Gynecology and Obstetrics2012;117(3):228-233. [DOI: 10.1016/j.ijgo.2012.01.009]StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Human Reproduction January 2010;25(3):633-641. [DOI: 10.1093/humrep/dep46]">Strowitzki 2012</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>). <a href="./references#CD014788-bbs2-0015" title="CrosignaniPG , LucianoA , RayA , BergqvistA . Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction Sep 2006;21:248-56. [DOI: 10.1093/humrep/dei290]">Crosignani 2006</a> did not provide usable data on relief of overall pain and changes in BMD. Data about adverse effects were provided, and included in meta‐analysis. <a href="./references#CD014788-bbs2-0001" title="AbdouAM , AmmarIMM , AlenmrAAA , AbdelrhmanAA . Dienogest versus leuprolide acetate for recurrent pelvic pain following laparoscopic treatment of endometriosis. Journal of Obstetrics and Gynecology of India Aug 2018;4:306-13. [PMID: DOI: 10.1007/s13224-018-1119-3]">Abdou 2018</a> was considered at low risk of selection bias, and was included in the original review.  </p> <p>6.1 Relief of overall pain </p> <p>Only one study reported relief of overall pain, after three months of treatment with either GnRHas or oral progestogens (<a href="./references#CD014788-bbs2-0001" title="AbdouAM , AmmarIMM , AlenmrAAA , AbdelrhmanAA . Dienogest versus leuprolide acetate for recurrent pelvic pain following laparoscopic treatment of endometriosis. Journal of Obstetrics and Gynecology of India Aug 2018;4:306-13. [PMID: DOI: 10.1007/s13224-018-1119-3]">Abdou 2018</a>).  </p> <p>There may be an improvement in overall pain, reported as pelvic pain (MD ‐2.50, 95% CI ‐3.55 to ‐1.45, 1 RCT, n = 261, low certainty of evidence) and dyspareunia (MD ‐2.10, 95% CI ‐2.83 to ‐1.37, 1 RCT, n = 261, low certainty of evidence) after three months of treatment, in favour of oral progestogens. We are uncertain about the effect on back pain of both GnRHas and oral progestogens (MD 0.50, 95% CI ‐0.40 to 1.40, 1 RCT, n = 261) (<a href="./references#CD014788-fig-0021" title="">Analysis 6.1</a>). </p> <p>We performed a sensitivity analysis including all studies. Two studies (<a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>; <a href="./references#CD014788-bbs2-0061" title="StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. International Journal of Gynecology and Obstetrics2012;117(3):228-233. [DOI: 10.1016/j.ijgo.2012.01.009]StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Human Reproduction January 2010;25(3):633-641. [DOI: 10.1093/humrep/dep46]">Strowitzki 2012</a>) reported relief of overall pain in dichotomous data, comparing GnRHas with oral or injectable progestogens. <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a> did not provide usable data on relief of overall pain, except for pelvic tenderness, but stated that, "treatment with DMPA‐SC 104 was statistically equivalent (P &lt; 0.02) to treatment with leuprolide at month 6 for the reduction of four of the five signs and symptoms, namely dysmenorrhoea, dyspareunia, pelvic pain, and pelvic tenderness". <a href="./references#CD014788-bbs2-0061" title="StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. International Journal of Gynecology and Obstetrics2012;117(3):228-233. [DOI: 10.1016/j.ijgo.2012.01.009]StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Human Reproduction January 2010;25(3):633-641. [DOI: 10.1093/humrep/dep46]">Strowitzki 2012</a> reported results on different outcome measurements, namely pelvic pain, dysmenorrhoea, dyspareunia, pelvic induration and pelvic tenderness. For both, all reported outcomes were after six months of treatment. Therefore, a meta‐analysis could only be performed for pelvic tenderness; we are uncertain whether the two groups differ in effects on pelvic tenderness (RR 1.11, 95% CI 0.95 to 1.29, I<sup>2</sup> = 0%, 2 RCTs, n = 419) (<a href="./references#CD014788-fig-0023" title="">Analysis 7.1</a>). </p> <p>Continuous outcome data were reported by four studies (<a href="./references#CD014788-bbs2-0001" title="AbdouAM , AmmarIMM , AlenmrAAA , AbdelrhmanAA . Dienogest versus leuprolide acetate for recurrent pelvic pain following laparoscopic treatment of endometriosis. Journal of Obstetrics and Gynecology of India Aug 2018;4:306-13. [PMID: DOI: 10.1007/s13224-018-1119-3]">Abdou 2018</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0061" title="StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. International Journal of Gynecology and Obstetrics2012;117(3):228-233. [DOI: 10.1016/j.ijgo.2012.01.009]StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Human Reproduction January 2010;25(3):633-641. [DOI: 10.1093/humrep/dep46]">Strowitzki 2012</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>). However, these studies had different specific outcome measurements and treatment periods. Consequently, meta‐analysis could only be performed for dyspareunia after six months of treatment with GnRHas or oral or injectable progestogens. The results of <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a> and <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a> were combined, and we are uncertain about the effect of GnRHas or oral or injectable progestogens between both groups (MD ‐0.10 95% CI ‐0.10 to 0.22, I<sup>2</sup> = 0%, 2 RCTs, n = 180) (<a href="./references#CD014788-fig-0024" title="">Analysis 7.2</a>). </p> <p><a href="./references#CD014788-bbs2-0015" title="CrosignaniPG , LucianoA , RayA , BergqvistA . Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction Sep 2006;21:248-56. [DOI: 10.1093/humrep/dei290]">Crosignani 2006</a> only mentioned the results of overall pain in figures, but stated that "6 months of treatment with subcutaneous formulation of depot medroxyprogesterone acetate 104 mg/0.65 mL (DMPA‐SC 104) resulted in statistically equivalent (P &lt; 0.02) reductions of all five signs and symptoms of endometriosis (dysmenorrhoea, dyspareunia, pelvic pain, pelvic tenderness and induration) compared with leuprolide treatment. Similarly, scores for all three prespecified scales of the SF‐36 (physical function, role physical and social functioning) significantly improved at month 6 relative to pre‐treatment in both treatment groups, (P ≤ 0.001)".  </p> <p>6.2 Bone mineral density </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including high risk of bias studies. Four studies reported the effect of GnRHas and oral versus injectable progestogens on bone mineral density (<a href="./references#CD014788-bbs2-0015" title="CrosignaniPG , LucianoA , RayA , BergqvistA . Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction Sep 2006;21:248-56. [DOI: 10.1093/humrep/dei290]">Crosignani 2006</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>). Again, however, different outcome measures have been used, namely percentage change in BMD and absolute values after six and 12 months of treatment. This means that a meta‐analysis could not be undertaken. The difference in percentage change values after six months of treatment may decrease according to one study (MD ‐1.60, 95% CI ‐2.57 to ‐0.63, 1 RCT, n = 87, <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>). One study found an uncertain difference (<a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>) after six months (MD ‐0.04 95% CI ‐0.08 to 0.01, 1 RCT, n = 87), but BMD may decrease following GnRHas versus oral or injectable progestogens after 12 months of treatment (MD ‐0.05 95% CI ‐0.10 to ‐0.01, 1 RCT, n = 87) (<a href="./references#CD014788-fig-0025" title="">Analysis 7.3</a>).  </p> <p><a href="./references#CD014788-bbs2-0015" title="CrosignaniPG , LucianoA , RayA , BergqvistA . Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction Sep 2006;21:248-56. [DOI: 10.1093/humrep/dei290]">Crosignani 2006</a> could not be included in meta‐analysis, but "In the leuprolide group, significant (P &lt; 0.001) reductions from pre‐treatment in both total hip and lumbar spine BMD (median percentage changes of –2.10 and –4.00, respectively) were observed at month 6. However, the DMPA‐SC 104 group showed significant reduction from pre‐treatment (P &lt; 0.001) only in lumbar spine BMD (median percentage changes: total hip, –0.50; lumbar spine, –1.00). Compared with the leuprolide group, reductions in both total hip and lumbar spine BMD were significantly smaller (P &lt; 0.001) in the DMPA‐SC 104 group".  </p> <p>"The leuprolide group experienced significant (P &lt; 0.001) reductions from baseline in both total hip and lumbar spine BMD at month 6 (median percentage changes of ‐1.65 and ‐3.95, respectively). In comparison, the DMPA‐SC 104 group showed a significant reduction from baseline in lumbar spine BMD only (median percentage changes were as follows: total hip BMD, ‐0.30 [P = 0.063]; lumbar spine BMD, ‐1.10 [P &lt; 0.001]). Compared with leuprolide, reductions in both total hip and lumbar spine BMD were significantly less (P &lt; 0.001) for the DMPA‐SC 104 group" (<a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>).  </p> <p>6.3 Adverse effects </p> <p>Only one study was included in the original analysis (<a href="./references#CD014788-bbs2-0001" title="AbdouAM , AmmarIMM , AlenmrAAA , AbdelrhmanAA . Dienogest versus leuprolide acetate for recurrent pelvic pain following laparoscopic treatment of endometriosis. Journal of Obstetrics and Gynecology of India Aug 2018;4:306-13. [PMID: DOI: 10.1007/s13224-018-1119-3]">Abdou 2018</a>); it had with low‐certainty evidence. </p> <p>There may be a decrease of vaginal bleeding seen in women treated with GnRHas, compared to oral progestogens (RR 0.33, 95% CI 0.23 to 0.48, 1 RCT, n = 242). Also, there may be less weight gain in women treated with GnRHas instead of oral progestogens (RR 0.31, 95% CI 0.10 to 0.92, 1 RCT, n = 242). We are uncertain about the effect of GnRHas compared to oral progestogens, for headache, after three months of treatment (RR 1.53, 95% CI 0.88 to 2.67, 1 RCT, n = 242) (<a href="./references#CD014788-fig-0022" title="">Analysis 6.2</a>). </p> <p>We performed a sensitivity analysis including high risk of bias studies. All the seven studies who were identified, mentioned adverse effects when comparing GnRHas with oral or injectable progestogens (<a href="./references#CD014788-bbs2-0001" title="AbdouAM , AmmarIMM , AlenmrAAA , AbdelrhmanAA . Dienogest versus leuprolide acetate for recurrent pelvic pain following laparoscopic treatment of endometriosis. Journal of Obstetrics and Gynecology of India Aug 2018;4:306-13. [PMID: DOI: 10.1007/s13224-018-1119-3]">Abdou 2018</a>; <a href="./references#CD014788-bbs2-0015" title="CrosignaniPG , LucianoA , RayA , BergqvistA . Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction Sep 2006;21:248-56. [DOI: 10.1093/humrep/dei290]">Crosignani 2006</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0049" title="OzakiR ,  KumakiriJ , JinushiM , IkumaS , MurakamiK , KawasakiY , et al. Comparison of effect of preoperative dienogest and gonadotropin‑releasing hormone agonist administration on laparoscopic cystectomy for ovarian endometriomas. Archives of Gynecology and Obstetrics  July 2020;302:969-976. [DOI: 10.1007/s00404-020-05691-3]">Ozaki 2020</a>; <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>; <a href="./references#CD014788-bbs2-0061" title="StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. International Journal of Gynecology and Obstetrics2012;117(3):228-233. [DOI: 10.1016/j.ijgo.2012.01.009]StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Human Reproduction January 2010;25(3):633-641. [DOI: 10.1093/humrep/dep46]">Strowitzki 2012</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>). A meta‐analysis could be performed for headache, intermenstrual bleeding and hot flushes after six months of treatment.  </p> <p>For headache, an improvement was found between both groups in favour of GnRHas compared to oral or injectable progestogens (RR 1.46 95% CI 1.04 to 2.03, I<sup>2</sup> = 0%, 3 RCTs, n = 110, (<a href="./references#CD014788-bbs2-0015" title="CrosignaniPG , LucianoA , RayA , BergqvistA . Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction Sep 2006;21:248-56. [DOI: 10.1093/humrep/dei290]">Crosignani 2006</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>)). Hot flushes may improve in women treated with GnRHas, compared to oral or injectable progestogens (RR 2.11, 95% CI 1.70 to 2.62, I<sup>2</sup> = 88%, 4 RCTs, n = 902, (<a href="./references#CD014788-bbs2-0015" title="CrosignaniPG , LucianoA , RayA , BergqvistA . Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction Sep 2006;21:248-56. [DOI: 10.1093/humrep/dei290]">Crosignani 2006</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>)). In contrast, intermenstrual bleeding was decreased in women treated with GnRHas, compared to oral or injectable progestogens (RR 0.58 95% CI 0.50 to 0.67, I<sup>2</sup> = 84%, 4 RCTs, n = 902, (<a href="./references#CD014788-bbs2-0015" title="CrosignaniPG , LucianoA , RayA , BergqvistA . Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction Sep 2006;21:248-56. [DOI: 10.1093/humrep/dei290]">Crosignani 2006</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>)) (<a href="./references#CD014788-fig-0026" title="">Analysis 7.4</a>). </p> <p>There may be an increase in the number of menopausal symptoms by the Kupperman Index (MD 6.80, 95% CI 2.37 to 11.23, 1 RCT, n = 70) and hot flushes (MD 1.10, 95% CI 0.71 to 1.49, 1 RCT, n = 70) in favour of GnRHas, and a decrease of breast pain (MD ‐0.20, 95% CI ‐0.39 to ‐0.01, 1 RCT, n = 70), and metrorrhagia (MD ‐0.90, 95% CI ‐1.31 to ‐0.49, 1 RCT, n = 70). We are uncertain about the effect of GnRH compared to oral or injectable progestogens, when results are reported after four months of treatment, when compared for depression (MD 0.20, 95% CI ‐0.18 to 0.58, 1 RCT, n = 70), oedema (MD 0.20, 95% CI ‐0.14 to 0.54, 1 RCT, n = 70), and headache (MD 0.10, 95% CI ‐0.32 to 0.52, 1 RCT, n = 70) (<a href="./references#CD014788-fig-0027" title="">Analysis 7.5</a>). </p> <p>6.4 Quality of life </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including high risk of bias studies. Quality of life, measured by SF‐36 was reported by four studies (<a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>; <a href="./references#CD014788-bbs2-0061" title="StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. International Journal of Gynecology and Obstetrics2012;117(3):228-233. [DOI: 10.1016/j.ijgo.2012.01.009]StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Human Reproduction January 2010;25(3):633-641. [DOI: 10.1093/humrep/dep46]">Strowitzki 2012</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>). <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a> reported results after six months of treatment and for all domains, but we are uncertain about the effect found between two groups. After 12 months of treatment, <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a> also reported no significant differences in the results of the SF‐36 (<a href="./references#CD014788-fig-0028" title="">Analysis 7.6</a>). </p> <p><a href="./references#CD014788-bbs2-0015" title="CrosignaniPG , LucianoA , RayA , BergqvistA . Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction Sep 2006;21:248-56. [DOI: 10.1093/humrep/dei290]">Crosignani 2006</a> data were not usable for meta‐analysis, but stated that "mean scores for all four prespecified Endometriosis Health Profile‐30 (EHP‐30) scales (pain, emotional well‐being, self‐image and intercourse) as well as the two remaining scales (social support, control and powerlessness), significantly improved in both groups at month six compared with pretreatment. Similarly, scores for all three prespecified scales of the SF‐36 (physical function, role physical and social functioning) significantly improved at month six relative to pretreatment". In addition, "mean scores for all four prespecified EHP‐30 scales (pain, emotional well‐being, self‐image, and intercourse) and two additional EHP‐30 scales (social support as well as control and powerlessness) significantly improved in both groups at month six compared with the case of baseline (P &lt; 0.05), and these improvements were maintained at the 12‐month post‐treatment follow‐up. Similarly, scores for all three prespecified scales of the SF‐36 (physical function, role‐physical, and social functioning) significantly improved at month six relative to baseline, with improvements maintained through 12 months of follow‐up, in both groups (P &lt; 0.05)" (<a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>). <a href="./references#CD014788-bbs2-0061" title="StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. International Journal of Gynecology and Obstetrics2012;117(3):228-233. [DOI: 10.1016/j.ijgo.2012.01.009]StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Human Reproduction January 2010;25(3):633-641. [DOI: 10.1093/humrep/dep46]">Strowitzki 2012</a> stated that "at the end of treatment, QoL showed more pronounced absolute improvements in the dienogest (DNG) group than in the leuprolide acetate group, including both the physical health (DNG, 10.2 points; LA, 7.0 points) and the mental health (DNG, 3.3 points; LA, 1.9 points) summary scale scores. Compared with LA, DNG was also associated with greater relative improvements in specific SF‐36 scale categories. In particular, DNG produced greater improvements in the categories 'physical functioning' (DNG, 18.0%; LA, 6.8%), 'role‐physical' (DNG, 75.7%; LA, 33.6%), 'vitality' (DNG, 28.3%; LA, 12.3%), and 'social functioning' (DNG, 21.4%; LA, 8.7%), which relate to everyday physical activity, productivity at work, energy levels, and ability to interact in society, respectively".  </p> <p>6.5 Improvement of most troublesome symptom </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>For the sensitivity analysis, <a href="./references#CD014788-bbs2-0061" title="StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. International Journal of Gynecology and Obstetrics2012;117(3):228-233. [DOI: 10.1016/j.ijgo.2012.01.009]StrowitzkiT , MarrJ , GerlingerC , FaustmannT , SeitzC . Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Human Reproduction January 2010;25(3):633-641. [DOI: 10.1093/humrep/dep46]">Strowitzki 2012</a> was the only study that reported dichotomous results on improvement of the most troublesome symptom. We are uncertain about the effect between the two groups after six months of treatment (RR 1.00, 95% CI 0.79 to 1.28, 1 RCT, n = 229) (<a href="./references#CD014788-fig-0029" title="">Analysis 7.7</a>). </p> <p><a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a> and <a href="./references#CD014788-bbs2-0049" title="OzakiR ,  KumakiriJ , JinushiM , IkumaS , MurakamiK , KawasakiY , et al. Comparison of effect of preoperative dienogest and gonadotropin‑releasing hormone agonist administration on laparoscopic cystectomy for ovarian endometriomas. Archives of Gynecology and Obstetrics  July 2020;302:969-976. [DOI: 10.1007/s00404-020-05691-3]">Ozaki 2020</a> both reported values for overall symptoms. <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a> reported no difference between two groups, after six months of treatment (MD ‐0.70, 95% CI ‐1.52 to 0.12, 1 RCT, n = 253). <a href="./references#CD014788-bbs2-0049" title="OzakiR ,  KumakiriJ , JinushiM , IkumaS , MurakamiK , KawasakiY , et al. Comparison of effect of preoperative dienogest and gonadotropin‑releasing hormone agonist administration on laparoscopic cystectomy for ovarian endometriomas. Archives of Gynecology and Obstetrics  July 2020;302:969-976. [DOI: 10.1007/s00404-020-05691-3]">Ozaki 2020</a> reported results after four months of treatment, and used a numerical rating scale (NRS) and a verbal rating scale (VRS). For GnRHas compared to oral or injectable progestogens, there may be an improvement for NRS after four months of treatment (MD 2.60, 95% CI 0.37 to 4.83, 1 RCT, n = 70) and also for "improvement of most troublesome symptom" measured by VRS (MD 0.70, 95% CI 0.06 to 1.34, 1 RCT, n = 70) (<a href="./references#CD014788-fig-0030" title="">Analysis 7.8</a>).   </p> </section> <section id="CD014788-sec-0057"> <h4 class="title">7. GnRHas versus gestrinone for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>Only one study compared GnRHas with gestrinone (<a href="./references#CD014788-bbs2-0069" title="VercelliniP , SomaM , MoroGL . Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertility &amp; Sterility 196;66(6):911-919. [DOI: 10.1016/s0015-0282(16)58682-8]">Vercellini 1996</a>), with unclear and low risk for selection bias. This study was not included in the original review, but results below are from the sensitivity analyses. </p> <p>7.1 Relief of overall pain </p> <p><a href="./references#CD014788-bbs2-0069" title="VercelliniP , SomaM , MoroGL . Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertility &amp; Sterility 196;66(6):911-919. [DOI: 10.1016/s0015-0282(16)58682-8]">Vercellini 1996</a> reported relief of overall pain on a continuous scale, after three and six months of treatment with GnRHas or gestrinone. We are uncertain about the effect found for overall pain, reported as dysmenorrhoea, dyspareunia, and non‐menstrual pelvic pain, all measured on a NRS and VRS scale (<a href="./references#CD014788-fig-0031" title="">Analysis 8.1</a>). </p> <p>7.2 Bone mineral density </p> <p>BMD was measured by <a href="./references#CD014788-bbs2-0069" title="VercelliniP , SomaM , MoroGL . Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertility &amp; Sterility 196;66(6):911-919. [DOI: 10.1016/s0015-0282(16)58682-8]">Vercellini 1996</a>, who reported the percentage of change after six and 12 months of treatment with either GnRHas or gestrinone. After both treatment periods, there may be a decrease found in favour of GnRHas ((MD ‐1.96 95% CI ‐3.62 to ‐0.30, 1 RCT, n = 41) and (MD ‐5.10 95% CI ‐7.39 to ‐2.81, 1 RCT, n = 41), respectively) (<a href="./references#CD014788-fig-0032" title="">Analysis 8.2</a>). </p> <p>7.3 Adverse effects </p> <p>After six months of treatment, there may be an improvement for hot flushes after treatment with GnRHas, compared to gestrinone (RR 2.29 95% CI 1.21 to 4.32, 1 RCT, n = 55). For the remainder of all the reported adverse effects, we are uncertain about the effect on BMD between the two groups (<a href="./references#CD014788-fig-0033" title="">Analysis 8.3</a>). </p> </section> <section id="CD014788-sec-0058"> <h4 class="title">8. Trials comparing different doses of GnRHas for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>A total of eight trials compared different doses of GnRHas (<a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>; <a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a>; <a href="./references#CD014788-bbs2-0009" title="BurryKA , PattonPE , IllingworthDR . Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.. American Journal of Obstetrics &amp; Gynecology1989;160(6):1454-9; discussion 1459-61. ">Burry 1989</a>; <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a>; <a href="./references#CD014788-bbs2-0044" title="MinaguchiH , UemuraT , ShirasuK . Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis--multicenter trial in Japan. Progress in Clinical &amp; Biological Research1986;225:211-25. [PMID: 3097667]">Minaguchi 1986</a>; <a href="./references#CD014788-bbs2-0057" title="ShawRW , MattaW . Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis - comparison of two dose regimens. Clinical Reproduction and Fertility1986;4(5):329-36. [PMID: 3100012]">Shaw 1986</a>; <a href="./references#CD014788-bbs2-0064" title='TaharaM , MatsuokaT , YokoiT , TasakaK , KurachiH , MurataY . Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy). Fertility &amp; Sterility2000;73(4):799-804. [DOI: 10.1016/s0015-0282(99)00636-6]'>Tahara 2000</a>; <a href="./references#CD014788-bbs2-0065" title="TangH , WuR , LiX , ZhouY , LiuZ , WangC , ChenY , et al. Curative effect of 1.88-mg and 3.75-mg gonadotrophin-releasing hormone agonist on stage III–IV endometriosis: Randomized controlled study. The Journal of Obstetrics and Gynaecology Research October 2017;43(10):1550-1554. [DOI: 10.1111/jog.13420]">Tang 2017</a>). <a href="./references#CD014788-bbs2-0064" title='TaharaM , MatsuokaT , YokoiT , TasakaK , KurachiH , MurataY . Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy). Fertility &amp; Sterility2000;73(4):799-804. [DOI: 10.1016/s0015-0282(99)00636-6]'>Tahara 2000</a><i> </i>and <a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a><i> </i>both compared 200 μg nafarelin with 400 μg nafarelin for a treatment period of six months. <a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>, <a href="./references#CD014788-bbs2-0009" title="BurryKA , PattonPE , IllingworthDR . Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.. American Journal of Obstetrics &amp; Gynecology1989;160(6):1454-9; discussion 1459-61. ">Burry 1989</a><i> </i> and<i> </i><a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a><i> </i>all compared 400 μg nafarelin with 800 μg nafarelin for a treatment period of six months. <a href="./references#CD014788-bbs2-0065" title="TangH , WuR , LiX , ZhouY , LiuZ , WangC , ChenY , et al. Curative effect of 1.88-mg and 3.75-mg gonadotrophin-releasing hormone agonist on stage III–IV endometriosis: Randomized controlled study. The Journal of Obstetrics and Gynaecology Research October 2017;43(10):1550-1554. [DOI: 10.1111/jog.13420]">Tang 2017</a> compared 1.88 mg leuprorelin with 3.75 mg leuprorelin for a treatment period of six months. As this comparison only included studies with unclear or high risk of bias, results stated below are results of the sensitivity analysis. Results from <a href="./references#CD014788-bbs2-0044" title="MinaguchiH , UemuraT , ShirasuK . Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis--multicenter trial in Japan. Progress in Clinical &amp; Biological Research1986;225:211-25. [PMID: 3097667]">Minaguchi 1986</a> and <a href="./references#CD014788-bbs2-0057" title="ShawRW , MattaW . Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis - comparison of two dose regimens. Clinical Reproduction and Fertility1986;4(5):329-36. [PMID: 3100012]">Shaw 1986</a> could not be used for meta‐analysis.  </p> <p>8.1 Relief of overall pain </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including all studies suited for meta‐analysis. We are uncertain about the effect found for overall pain, reported as pelvic pain after two months (MD 0.20, 95% CI ‐1.07 to 1.47, 1 RCT, n = 15), four months (MD ‐0.10, 95% CI ‐1.07 to 0.87, 1 RCT, n = 15) and six months (MD 0.30, 95% CI ‐0.61 to 1.21, 1 RCT, n = 15) of treatment with 200 μg nafarelin compared to 400 μg nafarelin (<a href="./references#CD014788-bbs2-0064" title='TaharaM , MatsuokaT , YokoiT , TasakaK , KurachiH , MurataY . Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy). Fertility &amp; Sterility2000;73(4):799-804. [DOI: 10.1016/s0015-0282(99)00636-6]'>Tahara 2000</a>) (<a href="./references#CD014788-fig-0034" title="">Analysis 9.1</a>).  </p> <p>Besides, we are also uncertain about the effect found for overall pain, reported as pelvic pain (RR 1.24, 95% CI 0.71 to 2.16, 1 RCT, n = 77), dysmenorrhoea (RR 3.00, 95% CI 0.13 to 71.74, 1 RCT, n = 90), and dyspareunia (RR 1.05, 95% CI 0.49 to 2.26, 1 RCT, n = 57) after six months of treatment with 400 μg nafarelin compared to 800 μg nafarelin (<a href="./references#CD014788-bbs2-0002" title="AdamsonGD , KweiL , EdgrenRA . Pain of endometriosis: effects of nafarelin and danazol therapy. International Journal of Fertility &amp; Menopausal Studies1994;39(4):215-7. ">Adamson 1994</a>) (<a href="./references#CD014788-fig-0035" title="">Analysis 9.2</a>).  </p> <p><a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a>, <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a> and <a href="./references#CD014788-bbs2-0065" title="TangH , WuR , LiX , ZhouY , LiuZ , WangC , ChenY , et al. Curative effect of 1.88-mg and 3.75-mg gonadotrophin-releasing hormone agonist on stage III–IV endometriosis: Randomized controlled study. The Journal of Obstetrics and Gynaecology Research October 2017;43(10):1550-1554. [DOI: 10.1111/jog.13420]">Tang 2017</a> did not provide sufficient data to include them in the meta‐analysis. </p> <p>8.2 Bone mineral density </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including all studies suited for meta‐analysis. In one study, it was reported that "bone mineral density of the lumbar spine at 24 weeks of treatment was significantly lower than before treatment in the control group, with a mean bone loss of 5.56%. The decrease in bone mineral content was less in the half‐dose group, with a mean bone loss of 1.38%. It has been reported that nafarelin at a dosage of 200 mg daily does not cause the significant reduction in bone density that is seen with a dosage of 400 mg daily. Our data show that loss of BMD was largely eliminated with half‐dose nafarelin during 6 months of GnRH agonist therapy" (<a href="./references#CD014788-bbs2-0064" title='TaharaM , MatsuokaT , YokoiT , TasakaK , KurachiH , MurataY . Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy). Fertility &amp; Sterility2000;73(4):799-804. [DOI: 10.1016/s0015-0282(99)00636-6]'>Tahara 2000</a>).  </p> <p><a href="./references#CD014788-bbs2-0065" title="TangH , WuR , LiX , ZhouY , LiuZ , WangC , ChenY , et al. Curative effect of 1.88-mg and 3.75-mg gonadotrophin-releasing hormone agonist on stage III–IV endometriosis: Randomized controlled study. The Journal of Obstetrics and Gynaecology Research October 2017;43(10):1550-1554. [DOI: 10.1111/jog.13420]">Tang 2017</a> stated that "the BMD was decreased in both groups at 20 weeks after treatment, and the degree of loss of BMD in the control group <i>(= 3.75 mg leuprorelin)</i> (5.6%) was higher than in the research group <i>(= 1.88 mg leuprorelin)</i>(1.2%; P &lt; 0.05)".  </p> <p>8.3 Adverse effects </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including all studies suited for meta‐analysis. We are uncertain about the effect found for vasomotor symptoms after two months, four months and six months of treatment with 200 μg nafarelin compared to 400 μg nafarelin (<a href="./references#CD014788-bbs2-0064" title='TaharaM , MatsuokaT , YokoiT , TasakaK , KurachiH , MurataY . Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy). Fertility &amp; Sterility2000;73(4):799-804. [DOI: 10.1016/s0015-0282(99)00636-6]'>Tahara 2000</a>). In addition, rhinitis, upper respiratory infections, and irregular bleeding were reported without any significant difference between either group (<a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a>) (<a href="./references#CD014788-fig-0036" title="">Analysis 9.3</a>). </p> <p><a href="./references#CD014788-bbs2-0065" title="TangH , WuR , LiX , ZhouY , LiuZ , WangC , ChenY , et al. Curative effect of 1.88-mg and 3.75-mg gonadotrophin-releasing hormone agonist on stage III–IV endometriosis: Randomized controlled study. The Journal of Obstetrics and Gynaecology Research October 2017;43(10):1550-1554. [DOI: 10.1111/jog.13420]">Tang 2017</a> compared 1.88 mg leuprorelin with 3.75 mg leuprorelin for a treatment period of two, three, four and six months. After two months, there was no difference in menopausal symptoms, measured by the Kupperman Index (MD 1.20, 95% CI ‐3.14 to 5.54, 1 RCT, n = 50). However, after three, four and six months, there may be a difference in favour of 3.75 mg leuprorelin compared to 1.88 mg leuprorelin ((MD 5.70, 95% CI 2.12 to 9.28, 1 RCT, n = 50) (MD 9.50, 95% CI 6.55 to 12.45, 1 RCT, n = 50) (MD 13.20, 95% CI 10.22 to 16.18, 1 RCT, n = 50), respectively) (<a href="./references#CD014788-fig-0037" title="">Analysis 9.4</a>). </p> <p><a href="./references#CD014788-bbs2-0009" title="BurryKA , PattonPE , IllingworthDR . Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.. American Journal of Obstetrics &amp; Gynecology1989;160(6):1454-9; discussion 1459-61. ">Burry 1989</a> reported the results of weight gain during treatment, but it was not possible to extract data for meta‐analysis.  </p> <p>8.4 Improvement of most troublesome symptom </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including all studies. <a href="./references#CD014788-bbs2-0031" title="HenzlMR , CorsonSL , MoghissiK , ButtramVC , BerqvistC , JacobsonJ . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. New England Journal of Medicine1988;318(8):485-9. HenzlMR . Role of nafarelin in the management of endometriosis. Journal of Reproductive Medicine1989;34(12 Suppl):1021-4. JacobsL , FieldC , ThieJ , CoulamC . Treatment of endometriosis with the GnRH agonist naferelin acetate. International Journal of Fertility1991;36:30-5. MoghissiKS , CorsonSL , ButtramV , HenzlMR . Evaluation of a GnRH agonist (nafarelin) versus danazol for treatment of endometriosis. Contributions to Gynecology &amp; Obstetrics1987;16:266. ">Henzl 1988</a> measured overall improvement, and we are uncertain about the effect between 400 μg nafarelin with 80 0μg nafarelin for a treatment period of six months (RR 0.94, 95% CI 0.78 to 1.14, 1 RCT, n = 143) (<a href="./references#CD014788-fig-0038" title="">Analysis 9.5</a>).  </p> </section> <section id="CD014788-sec-0059"> <h4 class="title">9. Trials comparing different treatment duration of GnRHas for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>Two trial mentioned the effect of different treatment duration of GnRHas (two trials; <a href="./references#CD014788-bbs2-0032" title="HornsteinM , YuzpeA , BurryK , HeinrichsL , OrwollE . A prospective randomised double-blind trial of 3 versus 6 months nafarelin therapy for symptoms of endometriosis. Fertility &amp; Sterility1992;58:S84. HornsteinMD , YuzpeAA , BurryKA , HeinrichsLR , Buttram VL Jr, et al. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertility &amp; Sterility1995;63(5):955-62. [PMID: 7720940]">Hornstein 1995</a>; <a href="./references#CD014788-bbs2-0048" title="OrwollES , YuzpeAA , BurryKA , HeinrichsL , ButtramVC ,  HornsteinMD . Nafarelin therapy in endometriosis: long-term effects on bone mineral density. American Journal of Obstetrics and Gynecology Nov 1994;171(5):1221-1225. [DOI: 10.1016/0002-9378(94)90136-8]">Orwoll 1994</a>). As this comparison only included studies with unclear or high risk of bias, results stated below are the results of the sensitivity analysis.  </p> <p><a href="./references#CD014788-bbs2-0032" title="HornsteinM , YuzpeA , BurryK , HeinrichsL , OrwollE . A prospective randomised double-blind trial of 3 versus 6 months nafarelin therapy for symptoms of endometriosis. Fertility &amp; Sterility1992;58:S84. HornsteinMD , YuzpeAA , BurryKA , HeinrichsLR , Buttram VL Jr, et al. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertility &amp; Sterility1995;63(5):955-62. [PMID: 7720940]">Hornstein 1995</a><i> </i>and <a href="./references#CD014788-bbs2-0048" title="OrwollES , YuzpeAA , BurryKA , HeinrichsL , ButtramVC ,  HornsteinMD . Nafarelin therapy in endometriosis: long-term effects on bone mineral density. American Journal of Obstetrics and Gynecology Nov 1994;171(5):1221-1225. [DOI: 10.1016/0002-9378(94)90136-8]">Orwoll 1994</a> both compared a total treatment period of three months with intranasal 200 μg nafarelin twice daily combined with three consecutive months of placebo use, with a total treatment period of six months with intranasal 200 μg nafarelin twice daily.  </p> <p>9.1 Relief of overall pain </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including all studies. <a href="./references#CD014788-bbs2-0032" title="HornsteinM , YuzpeA , BurryK , HeinrichsL , OrwollE . A prospective randomised double-blind trial of 3 versus 6 months nafarelin therapy for symptoms of endometriosis. Fertility &amp; Sterility1992;58:S84. HornsteinMD , YuzpeAA , BurryKA , HeinrichsLR , Buttram VL Jr, et al. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertility &amp; Sterility1995;63(5):955-62. [PMID: 7720940]">Hornstein 1995</a> measured relief of overall pain, with a comparison of a total treatment period of three months with a total treatment period of six months with intranasal 200 μg nafarelin twice daily. There may be an improvement  for pelvic pain (MD 0.16, 95% CI 0.13 to 0.19, 1 RCT, n = 179) and pelvic tenderness (MD 0.05, 95% CI 0.03 to 0.07, 1 RCT, n = 179) after six months of treatment, in favour of six months treatment compared to three months of treatment (with intranasal 200 μg nafarelin twice daily and three months of placebo). For overall pain, reported as dysmenorrhoea (MD ‐0.09, 95% CI ‐0.11 to ‐0.07, 1 RCT, n = 179) and dyspareunia (MD ‐0.14, 95% CI ‐0.17 to ‐0.11, 1 RCT, n = 179), the opposite results were found. There may be a slight decrease after six months of treatment, in favour of three months treatment, compared to six months of treatment with intranasal 200 μg nafarelin twice daily. No significant difference was found for pelvic induration between the two groups (MD ‐0.03, 95% CI ‐0.06 to 0.00, 1 RCT, n = 179) (<a href="./references#CD014788-fig-0039" title="">Analysis 10.1</a>). </p> <p>9.2 Bone mineral density </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including all studies. For BMD, after a total treatment period of three months with intranasal 200 μg nafarelin twice daily combined with three consecutive months of placebo use, there might be a decrease in BMD, compared with a total treatment period of six months with intranasal 200 μg nafarelin twice daily. This applied to both spinal bone mass (MD 1.60, 95% CI 1.51 to 1.69, 1 RCT, n = 183) and proximal femoral bone (MD 1.90, 95% CI 1.72 to 2.08, 1 RCT, n = 183) (<a href="./references#CD014788-bbs2-0048" title="OrwollES , YuzpeAA , BurryKA , HeinrichsL , ButtramVC ,  HornsteinMD . Nafarelin therapy in endometriosis: long-term effects on bone mineral density. American Journal of Obstetrics and Gynecology Nov 1994;171(5):1221-1225. [DOI: 10.1016/0002-9378(94)90136-8]">Orwoll 1994</a>) (<a href="./references#CD014788-fig-0040" title="">Analysis 10.2</a> and <a href="./references#CD014788-fig-0041" title="">Analysis 10.3</a>).  </p> </section> <section id="CD014788-sec-0060"> <h4 class="title">10. Trials comparing different route of administration of GnRHas for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>Four trials comparing different route of administration of GnRHas were included in this comparison (<a href="./references#CD014788-bbs2-0003" title="AgarwalSK , HamrangC , HenzlMR , JuddHL . Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. Journal of Reproductive Medicine1997;42(7):413-23. ">Agarwal 1997</a>; <a href="./references#CD014788-bbs2-0008" title="Bergqvist A and SCANDET group. A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis. Gynecological Endocrinology Aug 2000;14:425-432. [DOI: https://doi.org/10.3109/09513590009167714]">Bergqvist 2000</a>; <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a>; <a href="./references#CD014788-bbs2-0040" title="LemayA , MaheuxR , HuotC , BlanchetJ , FaureN . Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1988;158(2):233-6. [DOI: 10.1016/0002-9378(88)90128-7]LemayA , MaheuxR , QuesnelG , Bureau M, FaureN , MeratP . LH-RH agonist treatment of endometriosis. Contributions to Gynecology and Obstetrics1987;16:247-53. ">Lemay 1988</a>). </p> <p><a href="./references#CD014788-bbs2-0008" title="Bergqvist A and SCANDET group. A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis. Gynecological Endocrinology Aug 2000;14:425-432. [DOI: https://doi.org/10.3109/09513590009167714]">Bergqvist 2000</a><i> </i>compared subcutaneously administered goserelin depot with intranasal nafarelin 200 μg twice daily. <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a> and <a href="./references#CD014788-bbs2-0040" title="LemayA , MaheuxR , HuotC , BlanchetJ , FaureN . Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1988;158(2):233-6. [DOI: 10.1016/0002-9378(88)90128-7]LemayA , MaheuxR , QuesnelG , Bureau M, FaureN , MeratP . LH-RH agonist treatment of endometriosis. Contributions to Gynecology and Obstetrics1987;16:247-53. ">Lemay 1988</a> both compared subcutaneously administered buserelin depot 200 μg once daily with intranasal buserelin 200 μg thrice daily.  </p> <p>The results of <a href="./references#CD014788-bbs2-0018" title="DmowskiWP , RadwanskaE , BinorZ , TummonI , PeppingP . Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertility &amp; Sterility1989;51(3):395-400. [DOI: 10.1016/s0015-0282(16)60543-5]">Dmowski 1989a</a> could not be used, because no distinction was made in the article between subcutaneously administered buserelin depot 200 μg once daily and intranasal nafarelin 200 μg buserelin thrice daily. </p> <p>10.1 Relief of overall pain </p> <p><a href="./references#CD014788-bbs2-0040" title="LemayA , MaheuxR , HuotC , BlanchetJ , FaureN . Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1988;158(2):233-6. [DOI: 10.1016/0002-9378(88)90128-7]LemayA , MaheuxR , QuesnelG , Bureau M, FaureN , MeratP . LH-RH agonist treatment of endometriosis. Contributions to Gynecology and Obstetrics1987;16:247-53. ">Lemay 1988</a> compared subcutaneously administered buserelin depot 200 μg once daily with intranasal 400 μg buserelin thrice daily. We are uncertain about the effect on pelvic pain (RR 1.00, 95% CI 0.53 to 1.87, 1 RCT, n = 5), dysmenorrhoea (RR 1.22, 95% CI 0.73 to 2.06, 1 RCT, n = 9), dyspareunia (RR 1.00, 95% CI 0.57 to 1.75, 1 RCT, n = 7), pelvic induration (RR 0.86, 95% CI 0.47 to 1.55, 1 RCT, n = 8) and pelvic tenderness (RR 1.50, 95% CI 0.69 to 3.27, 1 RCT, n = 10) between either group, after six months of treatment (<a href="./references#CD014788-fig-0042" title="">Analysis 11.1</a>). As this comparison included only one low‐risk study, a sensitivity analysis reported comparable results. </p> <p><a href="./references#CD014788-bbs2-0003" title="AgarwalSK , HamrangC , HenzlMR , JuddHL . Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. Journal of Reproductive Medicine1997;42(7):413-23. ">Agarwal 1997</a> compared intramuscularly administered leuprolide acetate depot 3.75 mg once monthly with intranasal nafarelin 200 μg twice daily. We are uncertain about the effect on overall pain, reported as pelvic pain (RR 0.96, 95% CI 0.73 to 1.26, 1 RCT, n = 192), dysmenorrhoea (RR 1.29, 95% CI 0.72 to 2.30, 1 RCT, n = 192), dyspareunia (RR 0.88, 95% CI 0.62 to 1.25, 1 RCT, n = 166), pelvic induration (RR 1.41, 95% CI 0.82 to 2.41, 1 RCT, n = 192) and pelvic tenderness (RR 1.23, 95% CI 0.88 to 1.73, 1 RCT, n = 192) between either group, after six months of treatment (<a href="./references#CD014788-fig-0044" title="">Analysis 12.1</a>; <a href="./references#CD014788-fig-0045" title="">Analysis 12.2</a>).  </p> <p><a href="./references#CD014788-bbs2-0008" title="Bergqvist A and SCANDET group. A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis. Gynecological Endocrinology Aug 2000;14:425-432. [DOI: https://doi.org/10.3109/09513590009167714]">Bergqvist 2000</a> reported that "the total pain score, i.e. the three parameters dysmenorrhoea, dyspareunia and pelvic pain, was reduced in both groups, for goserelin by 45% and for nafarelin by 43% 3 months after the end of treatment". </p> <p>10.2 Adverse effects </p> <p><a href="./references#CD014788-bbs2-0040" title="LemayA , MaheuxR , HuotC , BlanchetJ , FaureN . Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. American Journal of Obstetrics &amp; Gynecology1988;158(2):233-6. [DOI: 10.1016/0002-9378(88)90128-7]LemayA , MaheuxR , QuesnelG , Bureau M, FaureN , MeratP . LH-RH agonist treatment of endometriosis. Contributions to Gynecology and Obstetrics1987;16:247-53. ">Lemay 1988</a> compared subcutaneously administered buserelin depot 200 μg once daily with intranasal 400 μg buserelin thrice daily. For hot flushes (RR 0.86, 95% CI 0.48 to 1.55, 1 RCT, n = 13), vaginal dryness (RR 0.86, 95% CI 0.17 to 4.37, 1 RCT, n = 13), decreased libido (RR 0.86, 95% CI 0.07 to 10.96,  1 RCT, n = 13) and headaches (RR 1.71, 95% CI 0.20 to 14.55, 1 RCT, n = 13), we are uncertain about the effects found between the two groups (<a href="./references#CD014788-fig-0043" title="">Analysis 11.2</a>). As this comparison included only one low‐risk study, a sensitivity analysis reported comparable results (<a href="./references#CD014788-fig-0046" title="">Analysis 12.3</a>). </p> <p><a href="./references#CD014788-bbs2-0008" title="Bergqvist A and SCANDET group. A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis. Gynecological Endocrinology Aug 2000;14:425-432. [DOI: https://doi.org/10.3109/09513590009167714]">Bergqvist 2000</a> and <a href="./references#CD014788-bbs2-0003" title="AgarwalSK , HamrangC , HenzlMR , JuddHL . Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. Journal of Reproductive Medicine1997;42(7):413-23. ">Agarwal 1997</a> reported adverse effects after comparing intramuscular administered goserelin or leoprolide acetate depot with intranasal nafarelin 200 μg twice daily. For hot flushes (RR 0.95, 95% CI 0.88 to 1.02, I<sup>2</sup> = 38%, 2 RCTs, n = 404), headaches (RR 0.83, 95% CI 0.63 to 1.10, 1 RCT, n = 213), sweating (RR 1.13, 95% CI 0.71 to 1.79, 1 RCT, n = 213), and vaginal dryness (RR 0.52, 95% CI 0.27 to 1.00, 1 RCT, n = 213), we are uncertain about the effect found between the two groups. This is in contrast with the results of vaginal bleeding, because there may be an improvement in favour of subcutaneously administered goserelin depot compared to intranasal nafarelin 200 μg twice daily (RR 19.19, 95% CI 1.12 to 328.28, 1 RCT, n = 213) (<a href="./references#CD014788-fig-0047" title="">Analysis 12.4</a>). </p> <p>10.3  Bone mineral density </p> <p><a href="./references#CD014788-bbs2-0003" title="AgarwalSK , HamrangC , HenzlMR , JuddHL . Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. Journal of Reproductive Medicine1997;42(7):413-23. ">Agarwal 1997</a> stated the percentage of decrease of BMD when intranasal nafarelin was compared to intramuscular leuprolide acetate. After six months of treatment, there may be a reduction in BMD in favour of nafarelin (MD ‐2.00, 95% CI ‐2.10 to ‐1.90, 1 RCT, n = 152).  </p> </section> <section id="CD014788-sec-0061"> <h4 class="title">11. Trials comparing different GnRHas treatment regimens for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>There was only one trial included, comparing different GnRHa treatment regimens (<a href="./references#CD014788-bbs2-0014" title="CrosignaniPG , De CeccoL , GastaldiA , VenturiniPL , OldaniS , VegettiW , et al. Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study. Human Reproduction1996;11(12):2732-5. [DOI: 10.1093/oxfordjournals.humrep.a019199]">Crosignani 1996</a>). <a href="./references#CD014788-bbs2-0014" title="CrosignaniPG , De CeccoL , GastaldiA , VenturiniPL , OldaniS , VegettiW , et al. Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study. Human Reproduction1996;11(12):2732-5. [DOI: 10.1093/oxfordjournals.humrep.a019199]">Crosignani 1996</a><i> </i>compared a monthly injection of leuprolide with a three‐monthly injection of leuprolide. As this comparison only included one study with an unclear risk of bias, the results stated below are the results of the sensitivity analysis.  </p> <p>11.1 Relief of overall pain </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including all studies. Only <a href="./references#CD014788-bbs2-0014" title="CrosignaniPG , De CeccoL , GastaldiA , VenturiniPL , OldaniS , VegettiW , et al. Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study. Human Reproduction1996;11(12):2732-5. [DOI: 10.1093/oxfordjournals.humrep.a019199]">Crosignani 1996</a> was included in the comparison 'Trials comparing different GnRHa treatment regimens for revealing painful symptoms associated with endometriosis and its related adverse effects'. We are uncertain about the effect found for overall pain, reported as pain symptom scores after three and six months of treatment. Results were subdivided into non‐menstrual pelvic pain (MD ‐0.20, 95% CI ‐0.52 to 0.12, 1 RCT, n = 30), dyspareunia (MD ‐0.10, 95% CI ‐0.51 to 0.31, 1 RCT, n = 30), pelvic induration (MD 0.10, 95% CI ‐0.40 to 0.60, 1 RCT, n = 30) and pelvic tenderness (MD ‐0.30, 95% CI ‐0.71 to 0.11, 1 RCT, n = 30), during a treatment period of three months. For a treatment period of six months, the results were similar for non‐menstrual pelvic pain (MD 0.10, 95% CI ‐0.15 to 0.35, 1 RCT, n = 30), dyspareunia (MD 0.00, 95% CI ‐0.50 to 0.50, 1 RCT, n = 30), and pelvic tenderness (MD 0.40, 95% CI ‐0.10 to 0.90, 1 RCT, n = 30). However, for pelvic induration after six months of treatment, there may be a difference between the two groups (MD 0.40, 95% CI 0.10 to 0.70, 1 RCT, n = 30) (<a href="./references#CD014788-fig-0049" title="">Analysis 13.1</a>).  </p> <p>11.2 Adverse effects </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including all studies. Adverse effects were reported by <a href="./references#CD014788-bbs2-0014" title="CrosignaniPG , De CeccoL , GastaldiA , VenturiniPL , OldaniS , VegettiW , et al. Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study. Human Reproduction1996;11(12):2732-5. [DOI: 10.1093/oxfordjournals.humrep.a019199]">Crosignani 1996</a>; we are uncertain about the effect on hot flushes (RR 1.00, 95% CI 0.70 to 1.43, 1 RCT, n = 24), vaginal dryness (RR 0.67, 95% CI 0.13 to 3.44, 1 RCT, n = 30), abdominal pain (RR 3.00, 95% CI 0.13 to 68.26, 1 RCT, n = 30), arthralgia (RR 3.00, 95% CI 0.13 to 68.26, 1 RCT, n = 30) and depression (RR 3.00, 95% CI 0.13 to 68.26, 1 RCT, n = 30), after six months of treatment when a monthly injection of leuprolide was compared with a three‐monthly injection of leuprolide (<a href="./references#CD014788-fig-0050" title="">Analysis 13.2</a>). </p> <p>11.3 Bone mineral density </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including all studies. <a href="./references#CD014788-bbs2-0014" title="CrosignaniPG , De CeccoL , GastaldiA , VenturiniPL , OldaniS , VegettiW , et al. Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study. Human Reproduction1996;11(12):2732-5. [DOI: 10.1093/oxfordjournals.humrep.a019199]">Crosignani 1996</a> reported the results of monthly versus three‐monthly doses of leuprolide acetate on BMD. The trial stated that there might be a slight variation of lumbar spine bone mineral density observed at the end of GnRHa treatment in both study groups (P &lt; 0.01), the percentage decrease over basal being 5.2% and 4.9%, respectively. But the study did not provide sufficient data for comparison of the groups; authors were contacted for the previous version of the review, but have not replied to date. </p> </section> <section id="CD014788-sec-0062"> <h4 class="title">12. Trials comparing GnRHas versus GnRHas in conjunction with add‐back therapy (hormonal or non‐hormonal) for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>Sixteen trials compared GnRHas versus GnRHas in conjunction with add‐back therapy (hormonal or non‐hormonal) (<a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a>; <a href="./references#CD014788-bbs2-0019" title="EdmondsDK , HowellR . Can hormone replacement therapy be used during medical therapy of endometriosis?British Journal of Obstetrics and Gynaecology May 1994;101:24-26. [DOI: 10.1111/j.1471-0528.1994.tb13681.x]">Edmonds 1994</a>; <a href="./references#CD014788-bbs2-0024" title="FrankeHR , Van der WeijerPHM , PenningsTMM , Van der MoorenMJ . Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertility &amp; Sterility Sept 2000;74:534-539. [DOI: 10.1016/s0015-0282(00)00690-7]">Franke 2000</a>; <a href="./references#CD014788-bbs2-0026" title="FreundlG , GödtkeK , GnothaC , GodehardtE , Kienle E. Steroidal ‘Add-Back’ Therapy in Patients Treated with GnRH Agonists. Gynecologic and Obstetric Investigation1998;45:22-30. [DOI: 10.1159/000052848]">Freundl 1998</a>; <a href="./references#CD014788-bbs2-0028" title="GnothC , GödtkeK , FreundlG , GodehardtE , KienleE . Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists. Gynecologic and Obstetric Investigation1999;47:37-41. [DOI: 10.1159/000010059]">Gnoth 1999</a>; <a href="./references#CD014788-bbs2-0033" title="HornsteinMD , SurreyES , WeisbergGW , Casino LA LUPRON add-back study group. Leuprolide acetate depot and hormonal add-back in endometriosis: A 12- month study. Obstetrics and Gynecology Jan 1998;1:16-24. [DOI: 10.1016/s0029-7844(97)00620-0]">Hornstein 1998</a>; <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>; <a href="./references#CD014788-bbs2-0035" title="HurstBS , GardnerSC , TuckerKE , AwoniyiCA , SchlaffWD . Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. Journal of the Society of Laparoendoscopic Surgeons2000;4:97-101. [PMID: PMC3015370]">Hurst 2000</a>; <a href="./references#CD014788-bbs2-0036" title="IraharaM ,  UemuraH , YasuiT , KinoshitaH , YamadaM , TezukaM , et al. Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis. Gynecologic and Obstetric Investigation2001;52:217-222. [DOI: 10.1159/000052978]">Irahara 2001</a>; <a href="./references#CD014788-bbs2-0039" title="KiilholmaP , TuimalaR , KivinenS , KorhonenM , Hagman E. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertility &amp; Sterility1995;64(5):903-908. [DOI: 10.1016/s0015-0282(16)57900-x]">Kiilholma 1995</a>; <a href="./references#CD014788-bbs2-0042" title="MakarainenL , RönnbergL , KauppilaA . Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertility &amp; Sterility1996;65(1):29-34. [DOI: 10.1016/s0015-0282(16)58023-6]">Mäkäräinen 1996</a>; <a href="./references#CD014788-bbs2-0045" title="MoghissiKS , SchlaffWD , OliveDL , SkinnerMA , YinH . Goserelin acetate (Zoladex) with or without hormone replacement. Therapy for the treatment of endometriosis. Fertility &amp; Sterility June 1998;69(6):1056-1062. [DOI: 10.1016/s0015-0282(98)00086-7]">Moghissi 1998</a>; <a href="./references#CD014788-bbs2-0059" title="SillemM , ParvizM , WoitgeHW , KieselL , UlrichU , vonHolstT , et al. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. Experimental and Clinical Endocrinology &amp; Diabetes1999;107:379-385. [DOI: 10.1055/s-0029-1212129]">Sillem 1999</a>; <a href="./references#CD014788-bbs2-0062" title="SurreyES , JuddHL . Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial. Journal of Clinical Endocrinology and Metabolism1992;75(2):558-563. [DOI: 10.1210/jcem.75.2.1386374]">Surrey 1992</a>; <a href="./references#CD014788-bbs2-0063" title="SurreyES , HornsteinMD . Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstetrics and Gynecology2002;99(5 Pt 1):709-719. [DOI: 10.1016/s0029-7844(02)01945-2]">Surrey 2002</a>; <a href="./references#CD014788-bbs2-0068" title="VercelliniP , TrespidiL , PanazzaS , BramanteT , MauroF , CrosignaniPG . Very low dose danazol for relief of endometriosis-associated pelvic pain: a pilot study. Fertility &amp; Sterility1994;62(6):1136-42. [PMID: 7525359]">Vercellini 1994</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>). As this comparison only included studies with unclear or high risk of bias, the results stated below are the results of the sensitivity analysis.  </p> <p>12.1 Relief of overall pain </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including all studies. A total of ten studies reported relief of overall pain as a primary or secondary outcome measure (<a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a>; <a href="./references#CD014788-bbs2-0026" title="FreundlG , GödtkeK , GnothaC , GodehardtE , Kienle E. Steroidal ‘Add-Back’ Therapy in Patients Treated with GnRH Agonists. Gynecologic and Obstetric Investigation1998;45:22-30. [DOI: 10.1159/000052848]">Freundl 1998</a>; <a href="./references#CD014788-bbs2-0033" title="HornsteinMD , SurreyES , WeisbergGW , Casino LA LUPRON add-back study group. Leuprolide acetate depot and hormonal add-back in endometriosis: A 12- month study. Obstetrics and Gynecology Jan 1998;1:16-24. [DOI: 10.1016/s0029-7844(97)00620-0]">Hornstein 1998</a>; <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>; <a href="./references#CD014788-bbs2-0035" title="HurstBS , GardnerSC , TuckerKE , AwoniyiCA , SchlaffWD . Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. Journal of the Society of Laparoendoscopic Surgeons2000;4:97-101. [PMID: PMC3015370]">Hurst 2000</a>; <a href="./references#CD014788-bbs2-0042" title="MakarainenL , RönnbergL , KauppilaA . Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertility &amp; Sterility1996;65(1):29-34. [DOI: 10.1016/s0015-0282(16)58023-6]">Mäkäräinen 1996</a>; <a href="./references#CD014788-bbs2-0045" title="MoghissiKS , SchlaffWD , OliveDL , SkinnerMA , YinH . Goserelin acetate (Zoladex) with or without hormone replacement. Therapy for the treatment of endometriosis. Fertility &amp; Sterility June 1998;69(6):1056-1062. [DOI: 10.1016/s0015-0282(98)00086-7]">Moghissi 1998</a>; <a href="./references#CD014788-bbs2-0063" title="SurreyES , HornsteinMD . Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstetrics and Gynecology2002;99(5 Pt 1):709-719. [DOI: 10.1016/s0029-7844(02)01945-2]">Surrey 2002</a>; <a href="./references#CD014788-bbs2-0068" title="VercelliniP , TrespidiL , PanazzaS , BramanteT , MauroF , CrosignaniPG . Very low dose danazol for relief of endometriosis-associated pelvic pain: a pilot study. Fertility &amp; Sterility1994;62(6):1136-42. [PMID: 7525359]">Vercellini 1994</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>).  </p> <p>Relief of overall pain was presented both as a dichotomous and as a continuous outcome measure. <a href="./references#CD014788-bbs2-0026" title="FreundlG , GödtkeK , GnothaC , GodehardtE , Kienle E. Steroidal ‘Add-Back’ Therapy in Patients Treated with GnRH Agonists. Gynecologic and Obstetric Investigation1998;45:22-30. [DOI: 10.1159/000052848]">Freundl 1998</a> was the only study that reported dichotomous outcomes; we are uncertain about the effect between GnRHas and GnRHas in conjunction with add‐back therapy (dysmenorrhoea, RR 0.63, 95% CI 0.58 to 159.04, 1 RCT, n = 28; dyspareunia, RR 6.07, 95% CI 0.86 to 43.04, 1 RCT, n = 28; and non‐menstrual pelvic pain, RR 1.30, 95% CI 0.26 to 6.62, 1 RCT, n = 28) (<a href="./references#CD014788-fig-0051" title="">Analysis 14.1</a>). <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a> reported continuous outcomes; we are uncertain about the effect found between groups for overall pain, reported as dysmenorrhoea after six months of treatment (not estimable), dyspareunia after six months of treatment (MD ‐0.20, 95% CI ‐0.40 to 0.80, 1 RCT, n = 90), and overall pain (MD ‐1.50, 95% CI ‐7.92 to 4.92, 1 RCT, n = 90); or dysmenorrhoea (not estimable) and dyspareunia (MD 0.20, 95% CI ‐0.03 to 0.43, 1 RCT, n = 90) both after 12 months of treatment. In contrast, values for pelvic pain may improve slightly in favour of GnRHas in conjunction with add‐back therapy. This applied to both six months of treatment (MD ‐0.20, 95% CI ‐0.39 to ‐0.01, 1 RCT, n = 90) and 12 months of treatment (MD ‐0.10, 95% CI ‐0.14 to ‐0.06, 1 RCT, n = 90) (<a href="./references#CD014788-fig-0052" title="">Analysis 14.2</a>). This corresponds partly to the data extracted from <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>, which stated that "both groups showed similar improvement in pelvic symptoms (dysmenorrhoea, dyspareunia, and other pelvic pain) and pelvic signs (tenderness and induration) during the course of treatment with no significant difference between the two groups (P &gt; 0.05)". </p> <p> <a href="./references#CD014788-bbs2-0033" title="HornsteinMD , SurreyES , WeisbergGW , Casino LA LUPRON add-back study group. Leuprolide acetate depot and hormonal add-back in endometriosis: A 12- month study. Obstetrics and Gynecology Jan 1998;1:16-24. [DOI: 10.1016/s0029-7844(97)00620-0]">Hornstein 1998</a> did not include data in the meta‐analysis, but no significant difference was found between GnRHas alone (group A), compared with three different add‐back groups (group B received daily oral norethindrone acetate 5 mg with placebo for oestrogen; group C received norethindrone 5 mg and conjugated equine oestrogens 0.625 mg; group D received norethindrone 5 mg and conjugated equine oestrogens 1.25 mg), comparing dysmenorrhoea, non‐menstrual pelvic pain, and pelvic tenderness. "The mean decreases in group D were significantly less than those of group A at week 4, 8 (P &lt; 0.05), 12 (P &lt; 0.01), and 48 (P &lt; 0.05)" (<a href="./references#CD014788-bbs2-0033" title="HornsteinMD , SurreyES , WeisbergGW , Casino LA LUPRON add-back study group. Leuprolide acetate depot and hormonal add-back in endometriosis: A 12- month study. Obstetrics and Gynecology Jan 1998;1:16-24. [DOI: 10.1016/s0029-7844(97)00620-0]">Hornstein 1998</a>). All participants in the study of <a href="./references#CD014788-bbs2-0039" title="KiilholmaP , TuimalaR , KivinenS , KorhonenM , Hagman E. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertility &amp; Sterility1995;64(5):903-908. [DOI: 10.1016/s0015-0282(16)57900-x]">Kiilholma 1995</a> showed subjective improvement on goserelin acetate therapy. The authors reported that "the response was equally good in patients with or without HRT (P = not significant [NS]). The pelvic symptoms score decreased from 4.7 and 4.7 in goserelin acetate plus HRT and goserelin acetate plus placebo patients to 0.9 and 0.5 after 6 months, respectively".  </p> <p><a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a>, <a href="./references#CD014788-bbs2-0035" title="HurstBS , GardnerSC , TuckerKE , AwoniyiCA , SchlaffWD . Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. Journal of the Society of Laparoendoscopic Surgeons2000;4:97-101. [PMID: PMC3015370]">Hurst 2000</a>, <a href="./references#CD014788-bbs2-0042" title="MakarainenL , RönnbergL , KauppilaA . Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertility &amp; Sterility1996;65(1):29-34. [DOI: 10.1016/s0015-0282(16)58023-6]">Mäkäräinen 1996</a>, <a href="./references#CD014788-bbs2-0045" title="MoghissiKS , SchlaffWD , OliveDL , SkinnerMA , YinH . Goserelin acetate (Zoladex) with or without hormone replacement. Therapy for the treatment of endometriosis. Fertility &amp; Sterility June 1998;69(6):1056-1062. [DOI: 10.1016/s0015-0282(98)00086-7]">Moghissi 1998</a> and <a href="./references#CD014788-bbs2-0068" title="VercelliniP , TrespidiL , PanazzaS , BramanteT , MauroF , CrosignaniPG . Very low dose danazol for relief of endometriosis-associated pelvic pain: a pilot study. Fertility &amp; Sterility1994;62(6):1136-42. [PMID: 7525359]">Vercellini 1994</a> did not provide sufficient data to include their data in the meta‐analysis.  </p> <p><a href="./references#CD014788-bbs2-0063" title="SurreyES , HornsteinMD . Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstetrics and Gynecology2002;99(5 Pt 1):709-719. [DOI: 10.1016/s0029-7844(02)01945-2]">Surrey 2002</a> compared four different groups, all receiving GnRHas. Group A received daily oral placebos for oestrogen and progestin add‐back. Patients included in group B received daily oral norethindrone acetate 5 mg and placebo for oestrogen. Patients in group C received oral norethindrone acetate 5 mg and conjugated equine oestrogens 0.625 mg daily. Those in group D received oral norethindrone acetate 5 mg and conjugated equine oestrogens 1.25 mg daily. The authors reported that "the median changes in overall pelvic pain, dysmenorrhoea, and dyspareunia scores from pre‐therapy baseline throughout the follow‐up period for the four groups are displayed in Figures 1–3, respectively. Decreases in symptom scores from baseline remained statistically significant through month 12 of follow‐up for all groups with the exceptions of dysmenorrhoea for groups A and D and deep dyspareunia for group D, which all remained suppressed through month 8 of follow‐up. The only significant difference between groups regarding return to baseline scores occurred between groups A and D for dysmenorrhoea, where group D patients returned to baseline levels sooner".  </p> <p>12.2 Bone mineral density </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including all studies. The effect of add‐back therapy on the GnRHas‐induced loss of bone mineral density was reported by thirteen studies (<a href="./references#CD014788-bbs2-0019" title="EdmondsDK , HowellR . Can hormone replacement therapy be used during medical therapy of endometriosis?British Journal of Obstetrics and Gynaecology May 1994;101:24-26. [DOI: 10.1111/j.1471-0528.1994.tb13681.x]">Edmonds 1994</a>, <a href="./references#CD014788-bbs2-0024" title="FrankeHR , Van der WeijerPHM , PenningsTMM , Van der MoorenMJ . Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertility &amp; Sterility Sept 2000;74:534-539. [DOI: 10.1016/s0015-0282(00)00690-7]">Franke 2000</a>; <a href="./references#CD014788-bbs2-0026" title="FreundlG , GödtkeK , GnothaC , GodehardtE , Kienle E. Steroidal ‘Add-Back’ Therapy in Patients Treated with GnRH Agonists. Gynecologic and Obstetric Investigation1998;45:22-30. [DOI: 10.1159/000052848]">Freundl 1998</a>; <a href="./references#CD014788-bbs2-0028" title="GnothC , GödtkeK , FreundlG , GodehardtE , KienleE . Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists. Gynecologic and Obstetric Investigation1999;47:37-41. [DOI: 10.1159/000010059]">Gnoth 1999</a>; <a href="./references#CD014788-bbs2-0033" title="HornsteinMD , SurreyES , WeisbergGW , Casino LA LUPRON add-back study group. Leuprolide acetate depot and hormonal add-back in endometriosis: A 12- month study. Obstetrics and Gynecology Jan 1998;1:16-24. [DOI: 10.1016/s0029-7844(97)00620-0]">Hornstein 1998</a>; <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>; <a href="./references#CD014788-bbs2-0036" title="IraharaM ,  UemuraH , YasuiT , KinoshitaH , YamadaM , TezukaM , et al. Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis. Gynecologic and Obstetric Investigation2001;52:217-222. [DOI: 10.1159/000052978]">Irahara 2001</a>; <a href="./references#CD014788-bbs2-0045" title="MoghissiKS , SchlaffWD , OliveDL , SkinnerMA , YinH . Goserelin acetate (Zoladex) with or without hormone replacement. Therapy for the treatment of endometriosis. Fertility &amp; Sterility June 1998;69(6):1056-1062. [DOI: 10.1016/s0015-0282(98)00086-7]">Moghissi 1998</a>; <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>; <a href="./references#CD014788-bbs2-0059" title="SillemM , ParvizM , WoitgeHW , KieselL , UlrichU , vonHolstT , et al. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. Experimental and Clinical Endocrinology &amp; Diabetes1999;107:379-385. [DOI: 10.1055/s-0029-1212129]">Sillem 1999</a>; <a href="./references#CD014788-bbs2-0062" title="SurreyES , JuddHL . Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial. Journal of Clinical Endocrinology and Metabolism1992;75(2):558-563. [DOI: 10.1210/jcem.75.2.1386374]">Surrey 1992</a>; <a href="./references#CD014788-bbs2-0063" title="SurreyES , HornsteinMD . Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstetrics and Gynecology2002;99(5 Pt 1):709-719. [DOI: 10.1016/s0029-7844(02)01945-2]">Surrey 2002</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>).  </p> <p>A meta‐analysis was undertaken for continuous outcome measures, and subdivided into percentage change values and absolute values. The percentage change may improve when treated with GnRHas compared with GnRHas in conjunction with add‐back therapy (MD ‐3.88, 95% CI ‐4.27 to ‐3.49, I<sup>2</sup> = 93%, 2 RCTs, n = 46, <a href="./references#CD014788-bbs2-0026" title="FreundlG , GödtkeK , GnothaC , GodehardtE , Kienle E. Steroidal ‘Add-Back’ Therapy in Patients Treated with GnRH Agonists. Gynecologic and Obstetric Investigation1998;45:22-30. [DOI: 10.1159/000052848]">Freundl 1998</a>; <a href="./references#CD014788-bbs2-0062" title="SurreyES , JuddHL . Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial. Journal of Clinical Endocrinology and Metabolism1992;75(2):558-563. [DOI: 10.1210/jcem.75.2.1386374]">Surrey 1992</a>). <a href="./references#CD014788-bbs2-0028" title="GnothC , GödtkeK , FreundlG , GodehardtE , KienleE . Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists. Gynecologic and Obstetric Investigation1999;47:37-41. [DOI: 10.1159/000010059]">Gnoth 1999</a> also mentioned a significant loss of BMD in the lumbar spine for the GnRHa + placebo group compared to that for the GnRHa + add‐back group (6.5 vs. 2.0%, respectively, P = 0.001). For absolute values, after six months of treatment with either GnRHas or GnRHas in conjunction with add‐back therapy, there may be a difference in change in favour of GnRHas in conjunction with add‐back therapy (MD 0.02, 95% CI 0.02 to 0.02, I<sup>2</sup> = 70%, 5 RCTs, n = 199, <a href="./references#CD014788-bbs2-0028" title="GnothC , GödtkeK , FreundlG , GodehardtE , KienleE . Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists. Gynecologic and Obstetric Investigation1999;47:37-41. [DOI: 10.1159/000010059]">Gnoth 1999</a>; <a href="./references#CD014788-bbs2-0059" title="SillemM , ParvizM , WoitgeHW , KieselL , UlrichU , vonHolstT , et al. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. Experimental and Clinical Endocrinology &amp; Diabetes1999;107:379-385. [DOI: 10.1055/s-0029-1212129]">Sillem 1999</a>; <a href="./references#CD014788-bbs2-0062" title="SurreyES , JuddHL . Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial. Journal of Clinical Endocrinology and Metabolism1992;75(2):558-563. [DOI: 10.1210/jcem.75.2.1386374]">Surrey 1992</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>). Only <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a> reported results after 12 months of treatment, without any changes between either group (<a href="./references#CD014788-fig-0053" title="">Analysis 14.3</a>). </p> <p>Bone mineral density loss is reduced by 50% to 2.5% overall by the addition of add‐back therapy and there may be an improvement in the rate of return to normal of bone mineral density during post‐treatment follow‐up (<a href="./references#CD014788-bbs2-0019" title="EdmondsDK , HowellR . Can hormone replacement therapy be used during medical therapy of endometriosis?British Journal of Obstetrics and Gynaecology May 1994;101:24-26. [DOI: 10.1111/j.1471-0528.1994.tb13681.x]">Edmonds 1994</a>). We are uncertain about the effect on BMD after six months of treatment with GnRHas, compared to GnRHas in conjunction with add‐back therapy (<a href="./references#CD014788-bbs2-0024" title="FrankeHR , Van der WeijerPHM , PenningsTMM , Van der MoorenMJ . Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertility &amp; Sterility Sept 2000;74:534-539. [DOI: 10.1016/s0015-0282(00)00690-7]">Franke 2000</a>). Another study, <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>, reported a "reduction of bone mineral density at the lumbar spine in group 1 (= GnRHas) of ‐4.1% compared with ‐2.3% in group 2 (= GnRHas + add‐back)". There was for both groups a reduction compared to baseline.  A comparison between the two groups has not been made. <a href="./references#CD014788-bbs2-0033" title="HornsteinMD , SurreyES , WeisbergGW , Casino LA LUPRON add-back study group. Leuprolide acetate depot and hormonal add-back in endometriosis: A 12- month study. Obstetrics and Gynecology Jan 1998;1:16-24. [DOI: 10.1016/s0029-7844(97)00620-0]">Hornstein 1998</a> compared GnRHas alone (group A), and three different add‐back groups (group B: received daily oral norethindrone acetate 5 mg with placebo for oestrogen; group C: received norethindrone 5 mg and conjugated equine oestrogens 0.625 mg; group D: received norethindrone 5 mg and conjugated equine oestrogens 1.25 mg). "All three add‐back groups had significantly less bone loss than the agonist‐only group at 24‐ and 52‐week measurements (P ≤ 0.001)". This corresponds to the results found by <a href="./references#CD014788-bbs2-0036" title="IraharaM ,  UemuraH , YasuiT , KinoshitaH , YamadaM , TezukaM , et al. Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis. Gynecologic and Obstetric Investigation2001;52:217-222. [DOI: 10.1159/000052978]">Irahara 2001</a> and <a href="./references#CD014788-bbs2-0059" title="SillemM , ParvizM , WoitgeHW , KieselL , UlrichU , vonHolstT , et al. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. Experimental and Clinical Endocrinology &amp; Diabetes1999;107:379-385. [DOI: 10.1055/s-0029-1212129]">Sillem 1999</a>. "The control group (= GnRHas alone) significantly (P &lt; 0.01) decreased BMD of the lumber spine (mean percentage change: –6.3%) after six months of treatment; however, add‐back therapy prevented this BMD reduction (mean percentage change: –0.8%)" (<a href="./references#CD014788-bbs2-0036" title="IraharaM ,  UemuraH , YasuiT , KinoshitaH , YamadaM , TezukaM , et al. Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis. Gynecologic and Obstetric Investigation2001;52:217-222. [DOI: 10.1159/000052978]">Irahara 2001</a>) and "both groups, a significant decrease in lumbar bone mineral density (LBMD) was observed after six months of treatment. When compared to baseline values, the mean relative bone loss was 4%, in both groups equally (P &lt; 0.01, 0 months vs. 6 months). Absolute values decreased from 1.28 ± 0.18 g/cm<sup>2</sup> (mean ± standard deviation) to 1.23 ± 0.16 g/cm<sup>2</sup> in group A and from 1.19 ± 0.11 g/cm<sup>2</sup> to 1.14 ± 0.1 g/cm<sup>2</sup> in group B. No change in bone mineral density was observed at the femoral neck or Ward's triangle" (<a href="./references#CD014788-bbs2-0059" title="SillemM , ParvizM , WoitgeHW , KieselL , UlrichU , vonHolstT , et al. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. Experimental and Clinical Endocrinology &amp; Diabetes1999;107:379-385. [DOI: 10.1055/s-0029-1212129]">Sillem 1999</a>). <a href="./references#CD014788-bbs2-0045" title="MoghissiKS , SchlaffWD , OliveDL , SkinnerMA , YinH . Goserelin acetate (Zoladex) with or without hormone replacement. Therapy for the treatment of endometriosis. Fertility &amp; Sterility June 1998;69(6):1056-1062. [DOI: 10.1016/s0015-0282(98)00086-7]">Moghissi 1998</a> reported that the mean percentage loss was significantly higher in the group without add‐back therapy than in either group with once daily doses of 0.3 mg of conjugated oestrogen and 5 mg of medroxyprogesterone acetate, or once daily doses of 0.625 mg of conjugated oestrogen and 5 mg of medroxyprogesterone acetate at week 12 (P &lt; 0.001). Data could not be included in meta‐analyses.  </p> <p>12.3 Adverse effects </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including all studies. Eleven studies reported adverse effects when comparing GnRHas with GnRHas in conjunction with add‐back therapy (<a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a>; <a href="./references#CD014788-bbs2-0019" title="EdmondsDK , HowellR . Can hormone replacement therapy be used during medical therapy of endometriosis?British Journal of Obstetrics and Gynaecology May 1994;101:24-26. [DOI: 10.1111/j.1471-0528.1994.tb13681.x]">Edmonds 1994</a>; <a href="./references#CD014788-bbs2-0024" title="FrankeHR , Van der WeijerPHM , PenningsTMM , Van der MoorenMJ . Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertility &amp; Sterility Sept 2000;74:534-539. [DOI: 10.1016/s0015-0282(00)00690-7]">Franke 2000</a>; <a href="./references#CD014788-bbs2-0026" title="FreundlG , GödtkeK , GnothaC , GodehardtE , Kienle E. Steroidal ‘Add-Back’ Therapy in Patients Treated with GnRH Agonists. Gynecologic and Obstetric Investigation1998;45:22-30. [DOI: 10.1159/000052848]">Freundl 1998</a>; <a href="./references#CD014788-bbs2-0033" title="HornsteinMD , SurreyES , WeisbergGW , Casino LA LUPRON add-back study group. Leuprolide acetate depot and hormonal add-back in endometriosis: A 12- month study. Obstetrics and Gynecology Jan 1998;1:16-24. [DOI: 10.1016/s0029-7844(97)00620-0]">Hornstein 1998</a>; <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>; <a href="./references#CD014788-bbs2-0035" title="HurstBS , GardnerSC , TuckerKE , AwoniyiCA , SchlaffWD . Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. Journal of the Society of Laparoendoscopic Surgeons2000;4:97-101. [PMID: PMC3015370]">Hurst 2000</a>; <a href="./references#CD014788-bbs2-0039" title="KiilholmaP , TuimalaR , KivinenS , KorhonenM , Hagman E. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertility &amp; Sterility1995;64(5):903-908. [DOI: 10.1016/s0015-0282(16)57900-x]">Kiilholma 1995</a>; <a href="./references#CD014788-bbs2-0042" title="MakarainenL , RönnbergL , KauppilaA . Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertility &amp; Sterility1996;65(1):29-34. [DOI: 10.1016/s0015-0282(16)58023-6]">Mäkäräinen 1996</a>; <a href="./references#CD014788-bbs2-0045" title="MoghissiKS , SchlaffWD , OliveDL , SkinnerMA , YinH . Goserelin acetate (Zoladex) with or without hormone replacement. Therapy for the treatment of endometriosis. Fertility &amp; Sterility June 1998;69(6):1056-1062. [DOI: 10.1016/s0015-0282(98)00086-7]">Moghissi 1998</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>). Only six of them could be included in meta‐analysis, namely for assessment of hot flushes, loss of libido, vaginal dryness, headache and vaginal bleeding, all after six months of treatment. For hot flushes and vaginal dryness, there may be an improvement in both groups, in favour of GnRHas (RR 1.59, 95% CI 1.32 to 1.93, I<sup>2</sup> = 92%, 4 RCTs, n = 215 (<a href="./references#CD014788-bbs2-0019" title="EdmondsDK , HowellR . Can hormone replacement therapy be used during medical therapy of endometriosis?British Journal of Obstetrics and Gynaecology May 1994;101:24-26. [DOI: 10.1111/j.1471-0528.1994.tb13681.x]">Edmonds 1994</a>; <a href="./references#CD014788-bbs2-0026" title="FreundlG , GödtkeK , GnothaC , GodehardtE , Kienle E. Steroidal ‘Add-Back’ Therapy in Patients Treated with GnRH Agonists. Gynecologic and Obstetric Investigation1998;45:22-30. [DOI: 10.1159/000052848]">Freundl 1998</a>; <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>) and RR 1.40, 95% CI 1.11 to 1.76, I<sup>2</sup> = 30%, 3 RCTs, n = 404 (<a href="./references#CD014788-bbs2-0019" title="EdmondsDK , HowellR . Can hormone replacement therapy be used during medical therapy of endometriosis?British Journal of Obstetrics and Gynaecology May 1994;101:24-26. [DOI: 10.1111/j.1471-0528.1994.tb13681.x]">Edmonds 1994</a>; <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>; <a href="./references#CD014788-bbs2-0045" title="MoghissiKS , SchlaffWD , OliveDL , SkinnerMA , YinH . Goserelin acetate (Zoladex) with or without hormone replacement. Therapy for the treatment of endometriosis. Fertility &amp; Sterility June 1998;69(6):1056-1062. [DOI: 10.1016/s0015-0282(98)00086-7]">Moghissi 1998</a>), respectively). "Hot flushes were reported more frequently by the patients receiving goserelin acetate plus placebo than by those receiving HRT. The difference was significant (P &lt; 0.01) after 4 weeks of trial medication and highly significant at 6 months (P &lt; 0.0001)" (<a href="./references#CD014788-bbs2-0039" title="KiilholmaP , TuimalaR , KivinenS , KorhonenM , Hagman E. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertility &amp; Sterility1995;64(5):903-908. [DOI: 10.1016/s0015-0282(16)57900-x]">Kiilholma 1995</a>). In addition, <a href="./references#CD014788-bbs2-0033" title="HornsteinMD , SurreyES , WeisbergGW , Casino LA LUPRON add-back study group. Leuprolide acetate depot and hormonal add-back in endometriosis: A 12- month study. Obstetrics and Gynecology Jan 1998;1:16-24. [DOI: 10.1016/s0029-7844(97)00620-0]">Hornstein 1998</a>, who compared the GnRHas alone (group A) with three different add‐back groups (group B: received daily oral norethindrone acetate 5 mg with placebo for oestrogen; group C: received norethindrone 5 mg and conjugated equine oestrogens 0.625 mg; group D: received norethindrone 5 mg and conjugated equine oestrogens 1.25 mg) stated that "the percentage of patients experiencing hot flashes was dramatically less in the three add‐back groups than in group A", after 52 weeks of treatment. We are uncertain of the effect found between GnRHas and GnRHas in conjunction with add‐back therapy for loss of libido (RR 1.07, 95% CI 0.58 to 1.97, I<sup>2</sup> = 89%, 2 RCTs, n = 96, <a href="./references#CD014788-bbs2-0019" title="EdmondsDK , HowellR . Can hormone replacement therapy be used during medical therapy of endometriosis?British Journal of Obstetrics and Gynaecology May 1994;101:24-26. [DOI: 10.1111/j.1471-0528.1994.tb13681.x]">Edmonds 1994</a>; <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>) and headache (RR 0.91, 95% CI 0.67 to 1.24, I<sup>2</sup> = 0%, 3 RCTs, n = 126, <a href="./references#CD014788-bbs2-0019" title="EdmondsDK , HowellR . Can hormone replacement therapy be used during medical therapy of endometriosis?British Journal of Obstetrics and Gynaecology May 1994;101:24-26. [DOI: 10.1111/j.1471-0528.1994.tb13681.x]">Edmonds 1994</a>; <a href="./references#CD014788-bbs2-0026" title="FreundlG , GödtkeK , GnothaC , GodehardtE , Kienle E. Steroidal ‘Add-Back’ Therapy in Patients Treated with GnRH Agonists. Gynecologic and Obstetric Investigation1998;45:22-30. [DOI: 10.1159/000052848]">Freundl 1998</a>; <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>). Vaginal bleeding was seen more commonly in women treated with GnRH in conjunction with add‐back therapy (RR 0.57, 95% CI 0.35 to 0.93, I<sup>2</sup> = 70%, 3 RCTs, n = 185, <a href="./references#CD014788-bbs2-0006" title="BergqvistA , JacobsonJ , HarrisS . A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology1997;11(3):187-94. [DOI: 10.3109/09513599709152533]">Bergqvist 1997</a>; <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>) (<a href="./references#CD014788-fig-0054" title="">Analysis 14.4</a>). This is comparable to the results of <a href="./references#CD014788-bbs2-0042" title="MakarainenL , RönnbergL , KauppilaA . Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertility &amp; Sterility1996;65(1):29-34. [DOI: 10.1016/s0015-0282(16)58023-6]">Mäkäräinen 1996</a>, who stated: "significantly fewer patients in the MPA group (=GnRHas + add‐back) had hot flushes and sweating at 3 and 6 months than in the placebo group (=GnRHas alone). Other side effects recorded occurred with similar frequency in both groups". The results mentioned above, are partly in contrast to <a href="./references#CD014788-bbs2-0035" title="HurstBS , GardnerSC , TuckerKE , AwoniyiCA , SchlaffWD . Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. Journal of the Society of Laparoendoscopic Surgeons2000;4:97-101. [PMID: PMC3015370]">Hurst 2000</a>, who reported "as expected, hot flush and headache mean scores during time period three are usually lower for the oestradiol group than for the placebo group, although these differences were not statistically significant". Besides these outcome measures, "in the GnRH agonist plus placebo group, the Kupperman index score decreased by 75% at 4 weeks, 129% at 12 weeks, and 113% at 24 weeks (P = 0.0004). The difference between groups at 24 weeks was statistically significant (P = 0.003)" (<a href="./references#CD014788-bbs2-0024" title="FrankeHR , Van der WeijerPHM , PenningsTMM , Van der MoorenMJ . Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertility &amp; Sterility Sept 2000;74:534-539. [DOI: 10.1016/s0015-0282(00)00690-7]">Franke 2000</a>). </p> <p>The results reported by <a href="./references#CD014788-bbs2-0063" title="SurreyES , HornsteinMD . Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstetrics and Gynecology2002;99(5 Pt 1):709-719. [DOI: 10.1016/s0029-7844(02)01945-2]">Surrey 2002</a> could not be extracted for current analyses. </p> <p>12.4 Quality of life </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including all studies. Quality of life, measured by SF‐36, was reported by only one study (<a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>). After 12 months of treatment, <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a> reported that there may be a slight difference in the results of the SF‐36, in the domains 'physical function' and 'vitality'.  Both domains reported better quality of life in women treated with GnRHas in conjunction with add‐back therapy.  For the other domains, we are uncertain of the effect after 12 months of treatment (<a href="./references#CD014788-fig-0055" title="">Analysis 14.5</a>). </p> <p>12.5 Improvement of most troublesome symptom </p> <p>No studies with overall low risk of bias were identified for this analysis.</p> <p>We performed a sensitivity analysis including all studies. <a href="./references#CD014788-bbs2-0062" title="SurreyES , JuddHL . Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial. Journal of Clinical Endocrinology and Metabolism1992;75(2):558-563. [DOI: 10.1210/jcem.75.2.1386374]">Surrey 1992</a> reported results of improvement of overall pain, after four weeks of treatment with either GnRHas of GnRHas in conjunction with add‐back therapy. There may be a greater improvement in women treated with GnRHas, compared to GnRHas in conjunction with add‐back (<a href="./references#CD014788-fig-0056" title="">Analysis 14.6</a>). </p> <p>This is in contrast to <a href="./references#CD014788-bbs2-0019" title="EdmondsDK , HowellR . Can hormone replacement therapy be used during medical therapy of endometriosis?British Journal of Obstetrics and Gynaecology May 1994;101:24-26. [DOI: 10.1111/j.1471-0528.1994.tb13681.x]">Edmonds 1994</a>, which reported no difference in pain scores after six months of treatment with GnRHas or with GnRHas in conjunction with add‐back therapy.  </p> </section> <section id="CD014788-sec-0063"> <h4 class="title">13. Trials comparing GnRHas versus GnRHas in conjunction with calcium‐regulating agents for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>A total of three trials compared GnRHas versus GnRHas in conjunction with calcium‐regulating agents (<a href="./references#CD014788-bbs2-0022" title="FinkelsteinJS , KlibanskiA , ArnoldAL , TothTL , HornsteinMD , NeerRM . Prevention of estrogen deficiency–related bone loss with human parathyroid hormone–(1-34). Journal of the American Medical Association1998;280:1067-1073. [DOI: 10.1001/jama.280.12.1067]">Finkelstein 1998</a>; <a href="./references#CD014788-bbs2-0023" title="FinkelsteinJS , Arnold AL . Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. Journal of Clinical Endocrinology &amp; Metabolism1999;84:1214-1219. [DOI: 10.1210/jcem.84.4.5643]">Finkelstein 1999</a>; <a href="./references#CD014788-bbs2-0055" title="RouxC , PelissierC , ListratV , KoltaS , SimonettaC , GuignardM , et al. Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. Osteoporosis International1995;5:185-190. [DOI: 10.1007/BF02106098]">Roux 1995</a>). </p> <p>Since <a href="./references#CD014788-bbs2-0022" title="FinkelsteinJS , KlibanskiA , ArnoldAL , TothTL , HornsteinMD , NeerRM . Prevention of estrogen deficiency–related bone loss with human parathyroid hormone–(1-34). Journal of the American Medical Association1998;280:1067-1073. [DOI: 10.1001/jama.280.12.1067]">Finkelstein 1998</a> reported the same results for BMD as <a href="./references#CD014788-bbs2-0023" title="FinkelsteinJS , Arnold AL . Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. Journal of Clinical Endocrinology &amp; Metabolism1999;84:1214-1219. [DOI: 10.1210/jcem.84.4.5643]">Finkelstein 1999</a>, only <a href="./references#CD014788-bbs2-0022" title="FinkelsteinJS , KlibanskiA , ArnoldAL , TothTL , HornsteinMD , NeerRM . Prevention of estrogen deficiency–related bone loss with human parathyroid hormone–(1-34). Journal of the American Medical Association1998;280:1067-1073. [DOI: 10.1001/jama.280.12.1067]">Finkelstein 1998</a> was included in the analysis on BMD. As this comparison only included one study with a low risk of bias, the results stated below are the results of the sensitivity analysis.  </p> <p>13.1 Bone mineral density </p> <p><a href="./references#CD014788-bbs2-0022" title="FinkelsteinJS , KlibanskiA , ArnoldAL , TothTL , HornsteinMD , NeerRM . Prevention of estrogen deficiency–related bone loss with human parathyroid hormone–(1-34). Journal of the American Medical Association1998;280:1067-1073. [DOI: 10.1001/jama.280.12.1067]">Finkelstein 1998</a> reported that there may be a slight decrease in BMD after 12 months treatment (MD ‐7.00 95% CI ‐7.53 to ‐6.47, 1 RCT, n = 43) with GnRHas, compared to GnRHas in conjunction with calcium‐regulating agents (<a href="./references#CD014788-fig-0057" title="">Analysis 15.1</a>; <a href="./references#CD014788-fig-0059" title="">Analysis 16.1</a>). </p> <p><a href="./references#CD014788-bbs2-0055" title="RouxC , PelissierC , ListratV , KoltaS , SimonettaC , GuignardM , et al. Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. Osteoporosis International1995;5:185-190. [DOI: 10.1007/BF02106098]">Roux 1995</a> compared triptorelin alone (group 0) with triptorelin and salmon calcitonin 100 IU daily (group 1) and triptorelin and salmon calcitonin 200 IU daily (group 2). After six months of treatment, the mean values (± SD) of BMD (g/cm<sup>2</sup>) of group 0 were 1.031 ± 0.091, compared to 1.009 ± 0.152 in group 1 and 0.987 ± 0.143 in group 2.  </p> <p>13.2 Adverse effects </p> <p><a href="./references#CD014788-bbs2-0022" title="FinkelsteinJS , KlibanskiA , ArnoldAL , TothTL , HornsteinMD , NeerRM . Prevention of estrogen deficiency–related bone loss with human parathyroid hormone–(1-34). Journal of the American Medical Association1998;280:1067-1073. [DOI: 10.1001/jama.280.12.1067]">Finkelstein 1998</a> reported results about adverse effects, but it was not possible to report these outcomes in a meta‐analysis. "Mild nausea (P &lt; 0.001) and arthralgias (P = 0.05) were reported more common in the women who received human parathyroid hormone, although only 1 woman reported that these symptoms affected her routine activities".  </p> <p>Data of <a href="./references#CD014788-bbs2-0055" title="RouxC , PelissierC , ListratV , KoltaS , SimonettaC , GuignardM , et al. Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. Osteoporosis International1995;5:185-190. [DOI: 10.1007/BF02106098]">Roux 1995</a> could not be used in the meta‐analysis, but "[t]here was no difference in side effects in the three groups (GnRHas combined with placebo (group 0), salmon calcitonin 100 IU daily (group 1) and salmon calcitonin 200 IU daily (group 2)). Nasal symptoms were reported by 12 (31%) patients. Thirty patients (75%) experienced hot flushes, which were attributed to the menopausal status rather than the spray. However, 11 of 40 patients (27.5%) experienced arthralgia, predominantly of the hand joints, including 3 patients with a clinical diagnosis of carpal syndrome and 1 patient with spontaneous knee effusion".  </p> <p>13.3 Improvement of most troublesome symptom </p> <p>We are uncertain about the effect mentioned by <a href="./references#CD014788-bbs2-0022" title="FinkelsteinJS , KlibanskiA , ArnoldAL , TothTL , HornsteinMD , NeerRM . Prevention of estrogen deficiency–related bone loss with human parathyroid hormone–(1-34). Journal of the American Medical Association1998;280:1067-1073. [DOI: 10.1001/jama.280.12.1067]">Finkelstein 1998</a> related to improvement of the most troublesome symptom, both overall improvement (RR 0.96, 95% CI 0.84 to 1.08, 1 RCT, n = 43) and complete resolution (RR 0.95, 95% CI 0.64 to 1.41, 1 RCT, n = 43), when GnRHas were compared to GnRHas in conjunction with calcium‐regulating agents for a treatment period of 12 months (<a href="./references#CD014788-fig-0058" title="">Analysis 15.2</a>; <a href="./references#CD014788-fig-0060" title="">Analysis 16.2</a>). </p> </section> <section id="CD014788-sec-0064"> <h4 class="title">14. Trials assessing the effect of GnRHas on BMD</h4> <p>Thirty‐one trials were included, across the 13 comparisons (<a href="./references#CD014788-bbs2-0003" title="AgarwalSK , HamrangC , HenzlMR , JuddHL . Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. Journal of Reproductive Medicine1997;42(7):413-23. ">Agarwal 1997</a>; <a href="./references#CD014788-bbs2-0014" title="CrosignaniPG , De CeccoL , GastaldiA , VenturiniPL , OldaniS , VegettiW , et al. Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot study. Human Reproduction1996;11(12):2732-5. [DOI: 10.1093/oxfordjournals.humrep.a019199]">Crosignani 1996</a>; <a href="./references#CD014788-bbs2-0015" title="CrosignaniPG , LucianoA , RayA , BergqvistA . Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction Sep 2006;21:248-56. [DOI: 10.1093/humrep/dei290]">Crosignani 2006</a>; <a href="./references#CD014788-bbs2-0016" title="DawoodMY , RamosJ , Khan-DawoodF . Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertility &amp; Sterility1995;63:1177-1183. [DOI: 10.1016/s0015-0282(16)57593-1]">Dawood 1995</a>; <a href="./references#CD014788-bbs2-0017" title="DlugiAM , MillerJD , KnittleJ . Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertility &amp; Sterility1990;54(3):419-27. [DOI: 10.1016/s0015-0282(16)53755-8]">Dlugi 1990</a>; <a href="./references#CD014788-bbs2-0019" title="EdmondsDK , HowellR . Can hormone replacement therapy be used during medical therapy of endometriosis?British Journal of Obstetrics and Gynaecology May 1994;101:24-26. [DOI: 10.1111/j.1471-0528.1994.tb13681.x]">Edmonds 1994</a>; <a href="./references#CD014788-bbs2-0022" title="FinkelsteinJS , KlibanskiA , ArnoldAL , TothTL , HornsteinMD , NeerRM . Prevention of estrogen deficiency–related bone loss with human parathyroid hormone–(1-34). Journal of the American Medical Association1998;280:1067-1073. [DOI: 10.1001/jama.280.12.1067]">Finkelstein 1998</a>; <a href="./references#CD014788-bbs2-0023" title="FinkelsteinJS , Arnold AL . Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. Journal of Clinical Endocrinology &amp; Metabolism1999;84:1214-1219. [DOI: 10.1210/jcem.84.4.5643]">Finkelstein 1999</a>; <a href="./references#CD014788-bbs2-0024" title="FrankeHR , Van der WeijerPHM , PenningsTMM , Van der MoorenMJ . Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertility &amp; Sterility Sept 2000;74:534-539. [DOI: 10.1016/s0015-0282(00)00690-7]">Franke 2000</a>; <a href="./references#CD014788-bbs2-0026" title="FreundlG , GödtkeK , GnothaC , GodehardtE , Kienle E. Steroidal ‘Add-Back’ Therapy in Patients Treated with GnRH Agonists. Gynecologic and Obstetric Investigation1998;45:22-30. [DOI: 10.1159/000052848]">Freundl 1998</a>; <a href="./references#CD014788-bbs2-0027" title="FukushimaM , ShindoM , SatoK . Hormone treatment related bone mineral content changes in Japanese women with endometriosis. Asia-Oceania Journal of Obstetrics and Gynaecology1993;19(3):299-307. [DOI: 10.1111/j.1447-0756.1993.tb00389.x]Fukushima M . Changes in bone mineral content following hormone treatment for endometriosis. . International Journal of Gynecology &amp; Obstetrics1995;50:S17-S21. [DOI: 10.1016/0020-7292(95)02510-j]">Fukushima 1993</a>; <a href="./references#CD014788-bbs2-0028" title="GnothC , GödtkeK , FreundlG , GodehardtE , KienleE . Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists. Gynecologic and Obstetric Investigation1999;47:37-41. [DOI: 10.1159/000010059]">Gnoth 1999</a>; <a href="./references#CD014788-bbs2-0030" title="HaradaT , MomoedaM , TaketaniY , AsoT , FukunagaM , HaginoH , et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertility &amp; Sterility2009;91(3):675-681. [DOI: 10.1016/j.fertnstert.2007.12.080]">Harada 2009</a>; <a href="./references#CD014788-bbs2-0033" title="HornsteinMD , SurreyES , WeisbergGW , Casino LA LUPRON add-back study group. Leuprolide acetate depot and hormonal add-back in endometriosis: A 12- month study. Obstetrics and Gynecology Jan 1998;1:16-24. [DOI: 10.1016/s0029-7844(97)00620-0]">Hornstein 1998</a>; <a href="./references#CD014788-bbs2-0034" title="HowellR , EdmondsDK , DowsettM , CrookD , LeesB , StevensonJC . Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertility &amp; Sterility1995;64(3):474-481. [DOI: 10.1016/s0015-0282(16)57779-6.]">Howell 1995</a>; <a href="./references#CD014788-bbs2-0036" title="IraharaM ,  UemuraH , YasuiT , KinoshitaH , YamadaM , TezukaM , et al. Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis. Gynecologic and Obstetric Investigation2001;52:217-222. [DOI: 10.1159/000052978]">Irahara 2001</a>; <a href="./references#CD014788-bbs2-0045" title="MoghissiKS , SchlaffWD , OliveDL , SkinnerMA , YinH . Goserelin acetate (Zoladex) with or without hormone replacement. Therapy for the treatment of endometriosis. Fertility &amp; Sterility June 1998;69(6):1056-1062. [DOI: 10.1016/s0015-0282(98)00086-7]">Moghissi 1998</a>; <a href="./references#CD014788-bbs2-0048" title="OrwollES , YuzpeAA , BurryKA , HeinrichsL , ButtramVC ,  HornsteinMD . Nafarelin therapy in endometriosis: long-term effects on bone mineral density. American Journal of Obstetrics and Gynecology Nov 1994;171(5):1221-1225. [DOI: 10.1016/0002-9378(94)90136-8]">Orwoll 1994</a>; <a href="./references#CD014788-bbs2-0052" title="AllenTW . Zoladex versus danazol in endometriosis therapy. Journal of the American Osteopathic Association1993;93(10):1013. RockJA , TrugliaJA , CaplanRJ . Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstetrics &amp; Gynecology1993;82(2):198-205. [PMID: 8336864]RockJA . A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis . Fertility &amp; Sterility1991;56(pp.s49). ">Rock 1993</a>; <a href="./references#CD014788-bbs2-0055" title="RouxC , PelissierC , ListratV , KoltaS , SimonettaC , GuignardM , et al. Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. Osteoporosis International1995;5:185-190. [DOI: 10.1007/BF02106098]">Roux 1995</a>; <a href="./references#CD014788-bbs2-0056" title="SchlaffWD , CarsonSA , LucianoA , RossD , BergqvistA . Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility &amp; Sterility February 2006;85(2):314-325. [DOI: 10.1016/j.fertnstert.2005.07.1315.]">Schlaff 2006</a>; <a href="./references#CD014788-bbs2-0059" title="SillemM , ParvizM , WoitgeHW , KieselL , UlrichU , vonHolstT , et al. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. Experimental and Clinical Endocrinology &amp; Diabetes1999;107:379-385. [DOI: 10.1055/s-0029-1212129]">Sillem 1999</a>; <a href="./references#CD014788-bbs2-0062" title="SurreyES , JuddHL . Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial. Journal of Clinical Endocrinology and Metabolism1992;75(2):558-563. [DOI: 10.1210/jcem.75.2.1386374]">Surrey 1992</a>; <a href="./references#CD014788-bbs2-0063" title="SurreyES , HornsteinMD . Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstetrics and Gynecology2002;99(5 Pt 1):709-719. [DOI: 10.1016/s0029-7844(02)01945-2]">Surrey 2002</a>; <a href="./references#CD014788-bbs2-0064" title='TaharaM , MatsuokaT , YokoiT , TasakaK , KurachiH , MurataY . Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy). Fertility &amp; Sterility2000;73(4):799-804. [DOI: 10.1016/s0015-0282(99)00636-6]'>Tahara 2000</a>; <a href="./references#CD014788-bbs2-0065" title="TangH , WuR , LiX , ZhouY , LiuZ , WangC , ChenY , et al. Curative effect of 1.88-mg and 3.75-mg gonadotrophin-releasing hormone agonist on stage III–IV endometriosis: Randomized controlled study. The Journal of Obstetrics and Gynaecology Research October 2017;43(10):1550-1554. [DOI: 10.1111/jog.13420]">Tang 2017</a>; <a href="./references#CD014788-bbs2-0066" title="TummonIS , AliA , PeppingME , RadwanskaE , BinorZ , DmowskiWP . Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertility &amp; Sterility May 1988;49(5):792-796. [PMID: 3129312]">Tummon 1988</a>; <a href="./references#CD014788-bbs2-0069" title="VercelliniP , SomaM , MoroGL . Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertility &amp; Sterility 196;66(6):911-919. [DOI: 10.1016/s0015-0282(16)58682-8]">Vercellini 1996</a>; <a href="./references#CD014788-bbs2-0070" title="WheelerJM , KnittleJD , MillerJD . Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. American Journal of Obstetrics &amp; Gynecology1993;169(1):26-33. WheelerJM , KnittleJD , MillerJD . Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. American Journal of Obstetrics &amp; Gynecology1992;167(5):1367-71. [DOI: 10.1016/0002-9378(93)90126-4.]">Wheeler 1992</a>; <a href="./references#CD014788-bbs2-0071" title="WhitehouseRW , AdamsJE , BancroftK , Vaughan-WilliamsCA , ElsteinM . The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clinical Endocrinology1990;33(3):365-373. [DOI: 10.1016/s0015-0282(16)58682-8]">Whitehouse 1990</a>; <a href="./references#CD014788-bbs2-0072" title="ZupiE , SbraciaM , MarconiD , SorrentiG , ZulloF , PalombaS . Role of medical therapy in the treatment of endometriosis associated pelvic pain: a randomized controlled study. Journal of Minimally Invasive Gynecology2005;12(5):S6. [DOI: 10.3390/jcm10051085]">Zupi 2005</a>). The effects on BMD are reported separately in the relevant comparisons and are also visible in <a href="./references#CD014788-fig-0016" title="">Analysis 4.3</a>; <a href="./references#CD014788-fig-0025" title="">Analysis 7.3</a>; <a href="./references#CD014788-fig-0032" title="">Analysis 8.2</a>; <a href="./references#CD014788-fig-0040" title="">Analysis 10.2</a>; <a href="./references#CD014788-fig-0041" title="">Analysis 10.3</a>; <a href="./references#CD014788-fig-0048" title="">Analysis 12.5</a>; <a href="./references#CD014788-fig-0053" title="">Analysis 14.3</a>; <a href="./references#CD014788-fig-0057" title="">Analysis 15.1</a>; <a href="./references#CD014788-fig-0059" title="">Analysis 16.1</a>.  </p> <p> </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD014788-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD014788-sec-0065"></div> <section id="CD014788-sec-0066"> <h3 class="title" id="CD014788-sec-0066">Summary of main results</h3> <p>There were no studies found comparing GnRHas with either no treatment or analgesics. </p> <section id="CD014788-sec-0067"> <h4 class="title">Trials comparing GnRHas versus placebo for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>There may be a decrease in reported pelvic pain scores, dysmenorrhoea scores, dyspareunia scores, and pelvic tenderness scores after three months of treatment. We are uncertain of the effect of GnRHas compared to placebo for pelvic induration, based on the results found after three months of treatment.  </p> <p>Additionally, treatment with GnRHas may be associated slightly with a greater incidence of hot flushes at three months of treatment. </p> </section> <section id="CD014788-sec-0068"> <h4 class="title">Trials comparing GnRHas versus danazol for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>For pelvic pain in women treated with either GnRHas or danazol, a subdivision was made between pelvic tenderness, partly resolved and completely resolved. These dichotomous data indicated the uncertainty of the effect of GnRHas or danazol for the effectiveness of pelvic tenderness after six months of treatment with either GnRHas or danazol.  </p> <p>We are uncertain about the effect of GnRHas compared to danazol for relief of overall pain, when a subdivision was made for overall pain, pelvic pain, dysmenorrhoea, dyspareunia, pelvic induration, and pelvic tenderness. For all results, this was after three months of treatment. After six months of treatment, we are still uncertain about the effect of GnRHas or danazol on overall pain, dysmenorrhoea, dyspareunia, and pelvic tenderness. For pelvic pain and pelvic induration, these complaints may decrease after treatment with GnRHas, compared to danazol, during six months of treatment. </p> </section> <section id="CD014788-sec-0069"> <h4 class="title">Trials comparing GnRHas versus intra‐uterine progestogens for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>We are uncertain about the effect on VAS scores between groups after six months of treatment. Besides, we are also uncertain about the effect of GnRHas compared to intra‐uterine progestogens for relief of overall pain after six months of treatment.  </p> <p>For quality of life, we are uncertain about the effects, measured by the psychological well‐being questionnaire index (PGWBI) between groups, after six months of treatment. </p> </section> <section id="CD014788-sec-0070"> <h4 class="title">Trials comparing GnRHas versus oral or injectable progestogens for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>There may be an improvement in pelvic pain and dyspareunia after three months of treatment, in favour of oral progestogens. We are uncertain about the effects on back pain of both GnRHas and oral progestogens after three months of treatment.  </p> <p>Additionally, there may be a decrease of vaginal bleeding in women treated with GnRHas, compared to oral progestogens. Also, there may be slightly less weight gain in women treated with GnRHas instead of oral progestogens. We are uncertain about the effect of GnRHas compared to oral progestogens, for headache, after three months of treatment. </p> </section> <section id="CD014788-sec-0071"> <h4 class="title">Trials comparing GnRHas versus gestrinone for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>We are uncertain about the effects found for dysmenorrhoea, dyspareunia, and non‐menstrual pelvic pain, all measured on NRS and VRS scales.  </p> <p>For BMD, there may be a decrease found in favour of GnRHas after six and 12 months of treatment with either GnRHas or gestrinone.  </p> <p>After six months of treatment, there may be an improvement in hot flushes after treatment with GnRHas compared to gestrinone.  </p> </section> <section id="CD014788-sec-0072"> <h4 class="title">Trials comparing different route of administration of GnRHas for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>We are uncertain about the effect on pelvic pain, dysmenorrhoea, dyspareunia, pelvic induration and pelvic tenderness when comparing buserelin depot 200 μg once daily with intranasal buserelin 200 μg thrice daily, after six months of treatment.  </p> <p>When comparing subcutaneously administered buserelin depot 200 μg once daily with intranasal buserelin 200 μg thrice daily, for hot flushes, vaginal dryness, decreased libido and headaches, we are uncertain about the effects found between the two groups.  </p> </section> <section id="CD014788-sec-0073"> <h4 class="title">Trials comparing GnRHas versus GnRHas in conjunction with calcium‐regulating agents for relief of overall pain associated with endometriosis and its related adverse effects </h4> <p>There may be a slightly bigger decrease in BMD after 12 months treatment with GnRHas, compared to GnRHas in conjunction with calcium‐regulating agents.  </p> <p>We are uncertain about the effect related to improvement of the most troublesome symptom, both overall improvement and complete resolution, when GnRHas were compared to GnRHas in conjunction with calcium‐regulating agents for a treatment period of 12 months.  </p> </section> </section> <section id="CD014788-sec-0074"> <h3 class="title" id="CD014788-sec-0074">Overall completeness and applicability of evidence</h3> <p>Unfortunately, some data are still missing. Despite the attempts made to contact the authors, the missing data could not be included in the review. Nevertheless, it is believed that, due to the large number of patients included (7355 in total), the evidence is comprehensive and has covered a variety of treatment options and outcome measurements. In particular, the comparisons comparing GnRHas with danazol, including 23 studies, and GnRHas compared with GnRHas in conjunction with add‐back therapy, including 17 studies, cover a wide number of studies.  </p> <p>One issue of concern is the methods of reporting relief of overall pain in the trials. Some trials report overall pain whilst others provide details of specific endometriosis‐associated pain such as dysmenorrhoea, dyspareunia, pelvic pain, pelvic induration, and pelvic tenderness. In addition, these outcome measures were requested at many different follow‐up periods. This means that a meta‐analysis was impossible at times. When it was possible, the analysis contained only a limited amount of studies.  </p> <p>In addition, it should be noted that not all hormonal treatment options (e.g. gestrinone and danazol) reported in this review are still common treatment options for women with endometriosis. Since they are still treatment options that might be available, it has been decided to include these comparisons in the current review. </p> </section> <section id="CD014788-sec-0075"> <h3 class="title" id="CD014788-sec-0075">Quality of the evidence</h3> <p>This was a systematic review of 72 trials including 7355 women.</p> <p>We prepared Summary of findings tables using GRADEpro and Cochrane methods. We judged the evidence for the comparisons included in the main analysis as low quality. This is primarily due to few studies with small sizes reporting each outcome. For the sensitivity analysis, due to poorly reported methods, the quality of evidence reviewed was either very low or low. Overall, the quality of the evidence was very mixed with only six of 72 trials reporting adequate details on all assessed categories, and so the evidence has therefore been declared as having an overall low risk of bias. A total of nine studies were at low risk for selection bias, without having high risk of bias in other domains, and were therefore included in the original analysis. Ten of 72 studies reported high risk of bias on one category, and most of the studies reported unclear risk of bias, due to missing data, mainly for 'selection bias'.  </p> <p>A strength of this review is that all the included studies involved premenopausal women with symptoms of endometriosis. The diagnosis of endometriosis was made by direct visualisation (laparoscopically or laparotomically diagnosed endometriosis) or from ultrasonographic imaging/MRI. In this way, an attempt was made to include all women with complaints, with a clear diagnosis of endometriosis. Women without complaints, for example, women with only infertility, were not included. This is especially important for the outcome measures 'relief of overall pain', 'quality of life', 'improvement of most troublesome symptom' and 'patient satisfaction'. Weaknesses of this review are that the included studies were small and many were at unclear of high risk of bias.  </p> <p>In addition to the above points, the form of reporting results by some included articles is debatable. Some included articles have described the results for continuous outcome measures (such as pain complaints) as a dichotomous outcome measure (improvement, yes/no). This can cause the results to be interpreted incorrectly and the effects to be underestimated or overestimated. We would therefore recommend that continuous outcomes should not be reported as dichotomous outcomes.  This allows for a more careful way of reporting results. </p> </section> <section id="CD014788-sec-0076"> <h3 class="title" id="CD014788-sec-0076">Potential biases in the review process</h3> <p>The searches for this review included electronic searching by multiple sources and is felt to be comprehensive. At least two review authors independently extracted data and conducted the risk of bias assessment. The publications included spanned over 34 years (from 1988 to 2022) during which time the methods and data reporting practices have changed significantly. Especially for older publications, attempts to contact authors were often unsuccessful, resulting in poor scoring in risk of bias assessment due to inadequate information. Inaccessibility to useful information available with these authors, but not included in papers, might have also limited the meta‐analysis and especially the Summary of findings tables.  </p> </section> <section id="CD014788-sec-0077"> <h3 class="title" id="CD014788-sec-0077">Agreements and disagreements with other studies or reviews</h3> <p>Other reviews concerning the use of GnRHas in treating endometriosis‐associated pain agree with GnRHas being effective in reducing overall pain (<a href="./references#CD014788-bbs2-0151" title="JacksonB , TelnerDE . Managing the misplaced: approach to endometriosis. Canadian Family Physician 2006;11:1420-1424. [PMID: PMC1783710]">Jackson 2006</a>; <a href="./references#CD014788-bbs2-0152" title="KalaitzopoulosDR , SamartzisN , KolovosGN , MaretiE , SamartzisEP , EberhardM , DinasK , DaniilidisA . Treatment of endometriosis: a review with comparison of 8 guidelines. BMC Womens Health2021;1:397. [DOI: 10.1186/s12905-021-01545-5]">Kalaitzopoulos 2021</a>; <a href="./references#CD014788-bbs2-0160" title="RafiqueS , DecherneyAH . Medical Management of Endometriosis. Clinical Obstetrics and Gynecology2017;3:485-496. [DOI: 10.1097/GRF.0000000000000292]">Rafique 2017</a>). There are several proposals within reviews and guidelines on the specific duration of treatment available, varying between six and 12 months. This does not completely correlate with the findings of our review, as we as well have found that GnRHas could be effective in reducing pelvic tenderness. However, our evidence is still of very low certainty.  </p> <p>Most reviews describe danazol as an effective orally used treatment in reducing endometriosis‐associated pain. However, in the current ESHRE, WES and SOGC guidelines, danazol is no longer described as a recommended treatment option because of a high risk of quality of life‐reducing side effects. ACOG is the only guideline that still recommends danazol as a treatment option (<a href="./references#CD014788-bbs2-0152" title="KalaitzopoulosDR , SamartzisN , KolovosGN , MaretiE , SamartzisEP , EberhardM , DinasK , DaniilidisA . Treatment of endometriosis: a review with comparison of 8 guidelines. BMC Womens Health2021;1:397. [DOI: 10.1186/s12905-021-01545-5]">Kalaitzopoulos 2021</a>).  </p> <p> </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD014788-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD014788-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD014788-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD014788-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: GnRHas versus placebo, Outcome 1: Relief of overall pain ‐ dichotomous ‐ decrease of pain" data-id="CD014788-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: GnRHas versus placebo, Outcome 1: Relief of overall pain ‐ dichotomous ‐ decrease of pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: GnRHas versus placebo, Outcome 2: Adverse effects ‐ dichotomous" data-id="CD014788-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: GnRHas versus placebo, Outcome 2: Adverse effects ‐ dichotomous</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: GnRHas versus placebo ‐ all studies included, Outcome 1: Relief of overall pain ‐ dichotomous" data-id="CD014788-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: GnRHas versus placebo ‐ all studies included, Outcome 1: Relief of overall pain ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: GnRHas versus placebo ‐ all studies included, Outcome 2: Relief of overall pain ‐ dichotomous ‐ decrease of pain" data-id="CD014788-fig-0007" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: GnRHas versus placebo ‐ all studies included, Outcome 2: Relief of overall pain ‐ dichotomous ‐ decrease of pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: GnRHas versus placebo ‐ all studies included, Outcome 3: Relief of overall pain ‐ continuous" data-id="CD014788-fig-0008" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: GnRHas versus placebo ‐ all studies included, Outcome 3: Relief of overall pain ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: GnRHas versus placebo ‐ all studies included, Outcome 4: Adverse effects ‐ dichotomous" data-id="CD014788-fig-0009" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: GnRHas versus placebo ‐ all studies included, Outcome 4: Adverse effects ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: GnRHas versus placebo ‐ all studies included, Outcome 5: Quality of life ‐ continuous" data-id="CD014788-fig-0010" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: GnRHas versus placebo ‐ all studies included, Outcome 5: Quality of life ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: GnRHas versus danazol, Outcome 1: Relief of overall pain ‐ dichotomous" data-id="CD014788-fig-0011" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: GnRHas versus danazol, Outcome 1: Relief of overall pain ‐ dichotomous</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: GnRHas versus danazol, Outcome 2: Relief of overall pain ‐ continuous" data-id="CD014788-fig-0012" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: GnRHas versus danazol, Outcome 2: Relief of overall pain ‐ continuous</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: GnRHas versus danazol, Outcome 3: Adverse effects ‐ dichotomous" data-id="CD014788-fig-0013" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: GnRHas versus danazol, Outcome 3: Adverse effects ‐ dichotomous</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: GnRHas versus danazol ‐ all studies included, Outcome 1: Relief of overall pain ‐ dichotomous" data-id="CD014788-fig-0014" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: GnRHas versus danazol ‐ all studies included, Outcome 1: Relief of overall pain ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: GnRHas versus danazol ‐ all studies included, Outcome 2: Relief of overall pain ‐ continuous" data-id="CD014788-fig-0015" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: GnRHas versus danazol ‐ all studies included, Outcome 2: Relief of overall pain ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: GnRHas versus danazol ‐ all studies included, Outcome 3: Bone mineral density of spinal bone mass ‐ continuous" data-id="CD014788-fig-0016" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: GnRHas versus danazol ‐ all studies included, Outcome 3: Bone mineral density of spinal bone mass ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: GnRHas versus danazol ‐ all studies included, Outcome 4: Adverse effects ‐ dichotomous" data-id="CD014788-fig-0017" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: GnRHas versus danazol ‐ all studies included, Outcome 4: Adverse effects ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: GnRHas versus danazol ‐ all studies included, Outcome 5: Improvement of most troublesome symptoms ‐ dichotomous" data-id="CD014788-fig-0018" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: GnRHas versus danazol ‐ all studies included, Outcome 5: Improvement of most troublesome symptoms ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: GnRHas versus intra‐uterine progestagen device ‐ all studies included, Outcome 1: Relief of overall pain ‐ continuous" data-id="CD014788-fig-0019" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: GnRHas versus intra‐uterine progestagen device ‐ all studies included, Outcome 1: Relief of overall pain ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: GnRHas versus intra‐uterine progestagen device ‐ all studies included, Outcome 2: Quality of life ‐ continuous" data-id="CD014788-fig-0020" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: GnRHas versus intra‐uterine progestagen device ‐ all studies included, Outcome 2: Quality of life ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: GnRHas versus oral or injectable progestogens, Outcome 1: Relief of overall pain ‐ continuous" data-id="CD014788-fig-0021" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: GnRHas versus oral or injectable progestogens, Outcome 1: Relief of overall pain ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: GnRHas versus oral or injectable progestogens, Outcome 2: Adverse effects ‐ dichotomous" data-id="CD014788-fig-0022" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: GnRHas versus oral or injectable progestogens, Outcome 2: Adverse effects ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: GnRHas versus oral or injectable progestogens ‐ all studies included, Outcome 1: Relief of overall pain ‐ dichotomous" data-id="CD014788-fig-0023" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: GnRHas versus oral or injectable progestogens ‐ all studies included, Outcome 1: Relief of overall pain ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: GnRHas versus oral or injectable progestogens ‐ all studies included, Outcome 2: Relief of overall pain ‐ continuous" data-id="CD014788-fig-0024" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: GnRHas versus oral or injectable progestogens ‐ all studies included, Outcome 2: Relief of overall pain ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: GnRHas versus oral or injectable progestogens ‐ all studies included, Outcome 3: Bone mineral density of spinal bone mass ‐ continuous" data-id="CD014788-fig-0025" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: GnRHas versus oral or injectable progestogens ‐ all studies included, Outcome 3: Bone mineral density of spinal bone mass ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: GnRHas versus oral or injectable progestogens ‐ all studies included, Outcome 4: Adverse effects ‐ dichotomous" data-id="CD014788-fig-0026" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: GnRHas versus oral or injectable progestogens ‐ all studies included, Outcome 4: Adverse effects ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: GnRHas versus oral or injectable progestogens ‐ all studies included, Outcome 5: Adverse effects ‐ continuous" data-id="CD014788-fig-0027" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: GnRHas versus oral or injectable progestogens ‐ all studies included, Outcome 5: Adverse effects ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: GnRHas versus oral or injectable progestogens ‐ all studies included, Outcome 6: Quality of life ‐ continuous" data-id="CD014788-fig-0028" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: GnRHas versus oral or injectable progestogens ‐ all studies included, Outcome 6: Quality of life ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: GnRHas versus oral or injectable progestogens ‐ all studies included, Outcome 7: Improvement of most troublesome symptoms ‐ dichotomous" data-id="CD014788-fig-0029" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: GnRHas versus oral or injectable progestogens ‐ all studies included, Outcome 7: Improvement of most troublesome symptoms ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-007.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: GnRHas versus oral or injectable progestogens ‐ all studies included, Outcome 8: Improvement of most troublesome symptoms ‐ continuous" data-id="CD014788-fig-0030" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-007.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-007.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7: GnRHas versus oral or injectable progestogens ‐ all studies included, Outcome 8: Improvement of most troublesome symptoms ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-007.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: GnRHas versus gestrinone ‐ all studies included, Outcome 1: Relief of overall pain ‐ continuous" data-id="CD014788-fig-0031" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: GnRHas versus gestrinone ‐ all studies included, Outcome 1: Relief of overall pain ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: GnRHas versus gestrinone ‐ all studies included, Outcome 2: Bone mineral density of spinal bone mass ‐ continuous" data-id="CD014788-fig-0032" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: GnRHas versus gestrinone ‐ all studies included, Outcome 2: Bone mineral density of spinal bone mass ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: GnRHas versus gestrinone ‐ all studies included, Outcome 3: Adverse effects ‐ dichotomous" data-id="CD014788-fig-0033" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: GnRHas versus gestrinone ‐ all studies included, Outcome 3: Adverse effects ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: GnRHas versus GnRHas (varying dosage) ‐ all studies included, Outcome 1: Relief of overall pain ‐ 200 μg versus 400 μg nafarelin ‐ continuous" data-id="CD014788-fig-0034" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: GnRHas versus GnRHas (varying dosage) ‐ all studies included, Outcome 1: Relief of overall pain ‐ 200 μg versus 400 μg nafarelin ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: GnRHas versus GnRHas (varying dosage) ‐ all studies included, Outcome 2: Relief of overall pain ‐ 400 μg versus 800 μg nafarelin ‐ dichotomous" data-id="CD014788-fig-0035" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: GnRHas versus GnRHas (varying dosage) ‐ all studies included, Outcome 2: Relief of overall pain ‐ 400 μg versus 800 μg nafarelin ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: GnRHas versus GnRHas (varying dosage) ‐ all studies included, Outcome 3: Adverse effects ‐ 200 μg versus 400 μg nafarelin ‐ dichotomous" data-id="CD014788-fig-0036" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: GnRHas versus GnRHas (varying dosage) ‐ all studies included, Outcome 3: Adverse effects ‐ 200 μg versus 400 μg nafarelin ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: GnRHas versus GnRHas (varying dosage) ‐ all studies included, Outcome 4: Adverse effects ‐ 3.75 mg versus 1.88 mg leuprolide acetate ‐ continuous" data-id="CD014788-fig-0037" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: GnRHas versus GnRHas (varying dosage) ‐ all studies included, Outcome 4: Adverse effects ‐ 3.75 mg versus 1.88 mg leuprolide acetate ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: GnRHas versus GnRHas (varying dosage) ‐ all studies included, Outcome 5: Improvement of most troublesome symptoms ‐ 400 μg versus 800 μg nafarelin ‐ dichotomous" data-id="CD014788-fig-0038" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: GnRHas versus GnRHas (varying dosage) ‐ all studies included, Outcome 5: Improvement of most troublesome symptoms ‐ 400 μg versus 800 μg nafarelin ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: GnRHas versus GnRHas (duration of treatment) ‐ all studies included, Outcome 1: Relief of overall pain ‐ 3 months vs 6 months ‐ continuous" data-id="CD014788-fig-0039" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: GnRHas versus GnRHas (duration of treatment) ‐ all studies included, Outcome 1: Relief of overall pain ‐ 3 months vs 6 months ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: GnRHas versus GnRHas (duration of treatment) ‐ all studies included, Outcome 2: Bone mineral density of spinal bone mass ‐ 3 months vs 6 months ‐ continuous" data-id="CD014788-fig-0040" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: GnRHas versus GnRHas (duration of treatment) ‐ all studies included, Outcome 2: Bone mineral density of spinal bone mass ‐ 3 months vs 6 months ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: GnRHas versus GnRHas (duration of treatment) ‐ all studies included, Outcome 3: Bone mineral density of proximal femoral bone ‐ 3 months vs 6 months ‐ continuous" data-id="CD014788-fig-0041" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: GnRHas versus GnRHas (duration of treatment) ‐ all studies included, Outcome 3: Bone mineral density of proximal femoral bone ‐ 3 months vs 6 months ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: GnRHas versus GnRHas (route of administration), Outcome 1: Relief of overall pain ‐ IN versus SC ‐ dichotomous" data-id="CD014788-fig-0042" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: GnRHas versus GnRHas (route of administration), Outcome 1: Relief of overall pain ‐ IN versus SC ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: GnRHas versus GnRHas (route of administration), Outcome 2: Adverse effects ‐ IN vs SC ‐ dichotomous" data-id="CD014788-fig-0043" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: GnRHas versus GnRHas (route of administration), Outcome 2: Adverse effects ‐ IN vs SC ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: GnRHas versus GnRHas (route of administration) ‐ all studies included, Outcome 1: Relief of overall pain ‐ IN versus SC ‐ dichotomous" data-id="CD014788-fig-0044" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: GnRHas versus GnRHas (route of administration) ‐ all studies included, Outcome 1: Relief of overall pain ‐ IN versus SC ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: GnRHas versus GnRHas (route of administration) ‐ all studies included, Outcome 2: Relief of overall pain ‐ IN versus IM ‐ dichotomous" data-id="CD014788-fig-0045" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: GnRHas versus GnRHas (route of administration) ‐ all studies included, Outcome 2: Relief of overall pain ‐ IN versus IM ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: GnRHas versus GnRHas (route of administration) ‐ all studies included, Outcome 3: Adverse effects ‐ IN vs SC ‐ dichotomous" data-id="CD014788-fig-0046" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: GnRHas versus GnRHas (route of administration) ‐ all studies included, Outcome 3: Adverse effects ‐ IN vs SC ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-012.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: GnRHas versus GnRHas (route of administration) ‐ all studies included, Outcome 4: Adverse effects ‐ IN versus IM depot ‐ dichotomous" data-id="CD014788-fig-0047" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-012.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-012.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: GnRHas versus GnRHas (route of administration) ‐ all studies included, Outcome 4: Adverse effects ‐ IN versus IM depot ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-012.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-012.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: GnRHas versus GnRHas (route of administration) ‐ all studies included, Outcome 5: Bone mineral density of spinal bone mass ‐ IN vs IM depot ‐ continuous" data-id="CD014788-fig-0048" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-012.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-012.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12: GnRHas versus GnRHas (route of administration) ‐ all studies included, Outcome 5: Bone mineral density of spinal bone mass ‐ IN vs IM depot ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-012.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: GnRHas versus GnRHas (different treatment regimens) ‐ all studies included, Outcome 1: Relief of overall pain ‐ monthly versus 3‐monthly depot leuprolide acetate ‐ continuous" data-id="CD014788-fig-0049" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: GnRHas versus GnRHas (different treatment regimens) ‐ all studies included, Outcome 1: Relief of overall pain ‐ monthly versus 3‐monthly depot leuprolide acetate ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: GnRHas versus GnRHas (different treatment regimens) ‐ all studies included, Outcome 2: Adverse effects ‐ monthly versus 3‐monthly depot leuprolide acetate ‐ dichotomous" data-id="CD014788-fig-0050" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: GnRHas versus GnRHas (different treatment regimens) ‐ all studies included, Outcome 2: Adverse effects ‐ monthly versus 3‐monthly depot leuprolide acetate ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: GnRHas versus GnRHas in conjunction with add‐back therapy ‐ all studies included, Outcome 1: Relief of overall pain ‐ dichotomous" data-id="CD014788-fig-0051" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: GnRHas versus GnRHas in conjunction with add‐back therapy ‐ all studies included, Outcome 1: Relief of overall pain ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: GnRHas versus GnRHas in conjunction with add‐back therapy ‐ all studies included, Outcome 2: Relief of overall pain ‐ continuous" data-id="CD014788-fig-0052" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: GnRHas versus GnRHas in conjunction with add‐back therapy ‐ all studies included, Outcome 2: Relief of overall pain ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: GnRHas versus GnRHas in conjunction with add‐back therapy ‐ all studies included, Outcome 3: Bone mineral density of spinal bone mass ‐ continuous" data-id="CD014788-fig-0053" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: GnRHas versus GnRHas in conjunction with add‐back therapy ‐ all studies included, Outcome 3: Bone mineral density of spinal bone mass ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-014.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: GnRHas versus GnRHas in conjunction with add‐back therapy ‐ all studies included, Outcome 4: Adverse effects ‐ dichotomous" data-id="CD014788-fig-0054" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-014.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-014.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14: GnRHas versus GnRHas in conjunction with add‐back therapy ‐ all studies included, Outcome 4: Adverse effects ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-014.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-014.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: GnRHas versus GnRHas in conjunction with add‐back therapy ‐ all studies included, Outcome 5: Quality of life ‐ continuous" data-id="CD014788-fig-0055" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-014.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-014.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.5</div> <div class="figure-caption"> <p>Comparison 14: GnRHas versus GnRHas in conjunction with add‐back therapy ‐ all studies included, Outcome 5: Quality of life ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-014.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-014.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: GnRHas versus GnRHas in conjunction with add‐back therapy ‐ all studies included, Outcome 6: Improvement of most troublesome symptoms ‐ continuous " data-id="CD014788-fig-0056" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-014.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-014.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.6</div> <div class="figure-caption"> <p>Comparison 14: GnRHas versus GnRHas in conjunction with add‐back therapy ‐ all studies included, Outcome 6: Improvement of most troublesome symptoms ‐ continuous  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-014.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: GnRHas versus GnRHas in conjunction with calcium‐regulating agents, Outcome 1: Bone mineral density of spinal bone mass ‐ continuous" data-id="CD014788-fig-0057" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: GnRHas versus GnRHas in conjunction with calcium‐regulating agents, Outcome 1: Bone mineral density of spinal bone mass ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-015.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: GnRHas versus GnRHas in conjunction with calcium‐regulating agents, Outcome 2: Improvement of most troublesome symptoms ‐ dichotomous" data-id="CD014788-fig-0058" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-015.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-015.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15: GnRHas versus GnRHas in conjunction with calcium‐regulating agents, Outcome 2: Improvement of most troublesome symptoms ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-015.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-016.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: GnRHas versus GnRHas in conjunction with calcium‐regulating agents ‐ all studies included, Outcome 1: Bone mineral density of spinal bone mass ‐ continuous" data-id="CD014788-fig-0059" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-016.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-016.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: GnRHas versus GnRHas in conjunction with calcium‐regulating agents ‐ all studies included, Outcome 1: Bone mineral density of spinal bone mass ‐ continuous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-016.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014788-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/urn:x-wiley:14651858:media:CD014788:CD014788-CMP-016.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: GnRHas versus GnRHas in conjunction with calcium‐regulating agents ‐ all studies included, Outcome 2: Improvement of most troublesome symptoms ‐ dichotomous" data-id="CD014788-fig-0060" src="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-016.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_t/tCD014788-CMP-016.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16: GnRHas versus GnRHas in conjunction with calcium‐regulating agents ‐ all studies included, Outcome 2: Improvement of most troublesome symptoms ‐ dichotomous </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/media/CDSR/CD014788/image_n/nCD014788-CMP-016.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD014788-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">GnRHas compared to no treatment for relief of overall pain associated with endometriosis and its related adverse effects</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GnRHas compared to no treatment for relief of overall pain associated with endometriosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> Women with endometriosis<br/><b>Settings:</b> Gynaecology clinics<br/><b>Intervention:</b> GnRHas<br/><b>Comparison:</b> No treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>GnRHas</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies included for any outcomes</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">GnRHas compared to no treatment for relief of overall pain associated with endometriosis and its related adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014788-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">GnRHas compared to placebo for relief of overall pain associated with endometriosis and its related adverse effects</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GnRHas compared to placebo for relief of overall pain associated with endometriosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> Women with endometriosis<br/><b>Settings:</b> Gynaecology clinic<br/><b>Intervention:</b> GnRHas<br/><b>Comparison:</b> Placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>GnRHas</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ reported as pelvic pain ‐ 3 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>372 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>796 per 1000</b> </p> <p>(525 to 1205)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.14</b> </p> <p>(1.41 to 3.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relief of overall pain ‐ reported as dysmenorrhoea ‐ 3 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>439 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>988 per 1000</b> </p> <p>(698 to 1387)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.25</b> </p> <p>(1.59 to 3.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ reported as dyspareunia ‐ 3 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>387 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>855 per 1000</b> </p> <p>(538 to 1370)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.21</b> </p> <p>(1.39 to 3.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ reported as pelvic tenderness scores‐ 3 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>357 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>814 per 1000</b> </p> <p>(529 to 1250)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.28</b> </p> <p>(1.48 to 3.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ reported as pelvic induration scores ‐ 3 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>405 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>434 per 1000</b> </p> <p>(259 to 726)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.07</b> </p> <p>(0.64 to 1.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Evidence based on a single trial </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">GnRHas compared to placebo for relief of overall pain associated with endometriosis and its related adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014788-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">GnRHas compared to analgesics for relief of overall pain associated with endometriosis and its related adverse effects</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GnRHas compared to analgesics for relief of overall pain associated with endometriosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> Women with pain due to endometriosis<br/><b>Settings:</b> Gynaecological clinics<br/><b>Intervention:</b> GnRHas<br/><b>Comparison:</b> Analgesics </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Analgesics</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>GnRHas</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies included for any outcomes</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">GnRHas compared to analgesics for relief of overall pain associated with endometriosis and its related adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014788-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">GnRHas compared to danazol for relief of overall pain associated with endometriosis and its related adverse effects</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GnRHas compared to danazol for relief of overall pain associated with endometriosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> Women with pain due to endometriosis<br/><b>Settings:</b> Gynaecological clinics<br/><b>Intervention:</b> GnRHas<br/><b>Comparison:</b> Danazol </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Danazol</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>GnRHas</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relief of overall pain ‐ reported as pelvic tenderness, partly resolved ‐ 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>316 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>363 per 1000</b><br/>(155 to 862) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.15</b><br/>(0.49 to 2.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relief of overall pain ‐ reported as pelvic tenderness, complete resolved ‐ 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>579 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>637 per 1000</b><br/>(388 to 1048) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10 </b><br/>(0.67 to 1.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of overall pain in the control groups was ‐4.6</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of overall pain in the intervention group was <b>0.4 higher</b> </p> <p>(‐0.86 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ reported as pelvic pain ‐ 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of pelvic pain in the control groups was ‐0.5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of pelvic pain in the intervention group was <b>0.5 higher</b> </p> <p>(0.10 to 0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ reported as dysmenorrhoea ‐ 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of dysmenorrhoea in the control groups was ‐2.4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of dysmenorrhoea in the intervention group was <b>0.4 higher</b> </p> <p>(‐0.12 to 0.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ reported as pelvic induration ‐ 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of pelvic induration in the control groups was ‐0.7</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of pelvic induration in the intervention group was <b>0.7 higher</b> </p> <p>(0.21 to 1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relief of overall pain ‐ reported as pelvic tenderness ‐ 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of pelvic tenderness in the control groups was ‐0.7</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of pelvic tenderness in the intervention group was <b>0.2 lower</b> </p> <p>(‐0.75 to 0.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Evidence based on a single trial </p> <p><sup>2</sup> Small number of events </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">GnRHas compared to danazol for relief of overall pain associated with endometriosis and its related adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014788-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">GnRHas compared to intra‐uterine progestogens device for relief of overall pain associated with endometriosis and its related adverse effects</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GnRHas compared to intra‐uterine progestogens device for relief of overall pain associated with endometriosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> Women with pain due to endometriosis<br/><b>Settings:</b> Gynaecological clinics<br/><b>Intervention:</b> GnRHas<br/><b>Comparison: I</b>ntra‐uterine progestogens device </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intra‐uterine progestogens device</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>GnRHas</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies included with only low risk of bias</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">GnRHas compared to intra‐uterine progestogens device for relief of overall pain associated with endometriosis and its related adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014788-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Effect of GnRHas versus other hormonal treatment on bone mineral density</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Effect of GnRHas versus other hormonal treatment on bone mineral density</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population</b>: Women with endometriosis, treated with GnRHas with effect on bone mineral density </p> <p><b>Settings</b>: Gynaecological clinics  </p> <p><b>Intervention</b>: GnRHas </p> <p><b>Comparison</b>: Other hormonal treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Illustrative comparative risks* 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Relative effect  </b> </p> <p><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>No of participants</b> </p> <p><b>(studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Quality of the evidence</b> </p> <p><b>(GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Other hormonal treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>GnRHas</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GnRHas vs gestrinone</b> </p> <p><b>Percentage change values ‐ 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean percentage change in BMD in the control groups was 0.88</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean percentage change in BMD in the intervention group was <b>1.96 lower</b> </p> <p>(3.62 to 0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GnRHas vs gestrinone</b> </p> <p><b>Percentage change values ‐ 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean percentage change in BMD in the control groups was 2.06</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean percentage change in BMD in the intervention group was <b>5.10 lower</b> </p> <p>(7.39 to 2.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>GnRHas vs GnRHas in conjunction with calcium‐regulating agents</b> </p> <p><b>Anterior‐posterior spine ‐ 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in BMD in the control groups was 2.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in BMD in the intervention group was <b>7.00 lower</b> </p> <p>(7.53 to 6.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>GnRHas vs GnRHas in conjunction with calcium‐regulating agents</b> </p> <p><b>Lateral spine ‐ 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean change in BMD in the control groups was 7.5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean relief of pelvic pain in the intervention group was <b>12.40</b> <b>lower</b> </p> <p>(13.31 to 11.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Evidence based on a single trial </p> <p><sup>2</sup> Small number of events </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Effect of GnRHas versus other hormonal treatment on bone mineral density</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/full#CD014788-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014788-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">GnRHas versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Relief of overall pain ‐ dichotomous ‐ decrease of pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Decreases in pelvic pain scores ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [1.41, 3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Decreases in dysmenorrhoea scores ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [1.59, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Decreases in dyspareunia scores ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [1.39, 3.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 Decreases in pelvic tenderness scores ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [1.48, 3.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.5 Decreases in pelvic induration scores ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.64, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Adverse effects ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Hot flushes/flashes ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.08 [1.89, 5.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">GnRHas versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014788-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">GnRHas versus placebo ‐ all studies included</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Relief of overall pain ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Dyspareunia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.09, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Dyschezia/ bowel pressure ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.03, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Pelvic tenderness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.09, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Relief of overall pain ‐ dichotomous ‐ decrease of pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Decreases in pelvic pain scores ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [1.41, 3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Decreases in dysmenorrhoea scores ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [1.59, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 Decreases in dyspareunia scores ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [1.39, 3.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.4 Decreases in pelvic tenderness scores ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [1.48, 3.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.5 Decreases in pelvic induration scores ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.64, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Relief of overall pain ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Decrease of overall pain by Severity scale mean scores ‐ 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [2.80, 3.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Adverse effects ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Hot flushes/flashes ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.08 [1.89, 5.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Vasodilatation ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [1.51, 4.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 Headache‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.55 [1.09, 11.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.4 Hot flushes/flashes ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.87, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.5 Sleep disturbances ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.31 [1.33, 4.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Quality of life ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Physical component ‐ 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.48, ‐0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Mental component ‐ 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.48, ‐0.44]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">GnRHas versus placebo ‐ all studies included</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014788-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">GnRHas versus danazol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Relief of overall pain ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Pelvic tenderness, partly resolved ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.49, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Pelvic tenderness, complete resolved ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.67, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Relief of overall pain ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Relief of overall pain‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.66, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Pelvic pain ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.26, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 Dysmenorrhoea ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.49, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.4 Dyspareunia ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.77, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.5 Pelvic induration ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.59, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.6 Pelvic tenderness ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.78, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.7 Relief of overall pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.86, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.8 Pelvic pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.10, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.9 Dysmenorrhoea ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.12, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.10 Dyspareunia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.90, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.11 Pelvic induration ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.21, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.12 Pelvic tenderness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.75, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Adverse effects ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Vaginal dryness/vaginitis ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.52, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Hot flushes/flashes ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.50 [0.93, 259.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 Gastrointestinal ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.4 Weight gain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.08, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.5 Acne ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.6 Generalised spasm ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 1.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">GnRHas versus danazol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014788-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">GnRHas versus danazol ‐ all studies included</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Relief of overall pain ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Pelvic pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.83, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Dysmenorrhoea ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 Dyspareunia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.90, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.4 Pelvic induration ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.32, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.5 Pelvic tenderness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.39, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.6 Pelvic tenderness, partly resolved ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.59, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.7 Pelvic tenderness, complete resolved ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.84, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.8 Pelvic tenderness and induration combined, complete resolved ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.59, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.9 Pelvic tenderness and induration combined, partly resolved ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.35, 6.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Relief of overall pain ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Relief of overall pain‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.74, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Pelvic pain ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [‐0.35, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.3 Dysmenorrhoea ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.51, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.4 Dyspareunia ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.82, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.5 Pelvic induration ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.73, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.6 Pelvic tenderness ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.82, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.7 Relief of overall pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.46, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.8 Pelvic pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [‐0.08, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.9 Dysmenorrhoea ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [‐0.16, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.10 Dyspareunia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [‐0.19, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.11 Pelvic induration ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.04, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.12 Pelvic tenderness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.59 [‐1.03, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Bone mineral density of spinal bone mass ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Absolute values ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐0.31, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Adverse effects ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Vaginal dryness/vaginitis ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.53, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Hot flushes/flashes ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.42, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 Headaches ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.21, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.4 Infections and flu like symptoms ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.60 [1.31, 9.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.5 Muscle cramps/myalgia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>884</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.09, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.6 Sleep disturbance/insomnia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [1.61, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.7 Skin rash ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.8 Gastrointestinal ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.15, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.9 Weight gain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1081</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.29, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.10 Acne ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1040</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.47, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.11 Breast atrophy/changes ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.52, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.12 Emotional lability/altered mood ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.66 [1.12, 6.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.13 Oedema/fluid retention ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.12, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.14 Asthenia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.09, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.15 Depression ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.20, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.16 Generalised spasm ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.17 Voice alteration ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 3.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.18 Hirsutism ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.09, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.19 Seborrhoea ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.19, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.20 Alopecia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.02, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.21 Altered libido ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.30, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.22 Sweating ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.03, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.23 Breast tenderness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.04, 4.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.24 Fatigue ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.40, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.25 Arthralgia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.61 [1.08, 286.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.26 Hunger ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.01, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.27 Nervousness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.07, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.28 Irritability ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.74 [1.67, 13.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.29 Nausea ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.35, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.30 Breast pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.56 [0.19, 66.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.31 Back distress ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.15, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.32 Paraesthesia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.18, 3.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.33 Agressiveness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 3.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.34 Pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.11, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.35 Oily hair and skin ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.26, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.36 Bleeding ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.22, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.37 Malaise ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.12, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.38 Chest  aches ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.15, 6.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.39 Dizzy spells ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.01, 3.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.40 PMS feelings ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.32, 5.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Improvement of most troublesome symptoms ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Overall improvement ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.63, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 Overall improvement ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.99, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.3 Complete resolution ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.99, 1.32]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">GnRHas versus danazol ‐ all studies included</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014788-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">GnRHas versus intra‐uterine progestagen device ‐ all studies included</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Relief of overall pain ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Relief of overall pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.76 [‐1.62, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Decrease of VAS score ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.11, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Quality of life ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Psychological Well‐Being Questionnaire index (PGWBI) ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐10.26, 6.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">GnRHas versus intra‐uterine progestagen device ‐ all studies included</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014788-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">GnRHas versus oral or injectable progestogens</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Relief of overall pain ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Pelvic pain ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.50 [‐3.55, ‐1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 Dyspareunia ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐2.83, ‐1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.3 Back pain ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐0.40, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Adverse effects ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Vaginal bleeding ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.23, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Headache ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.88, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.3 Weight gain ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.10, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.4 Vaginal dryness ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.75 [1.66, 13.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.5 Hot flushes ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [1.87, 4.65]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">GnRHas versus oral or injectable progestogens</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014788-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">GnRHas versus oral or injectable progestogens ‐ all studies included</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Relief of overall pain ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Pelvic pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.83, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 Dysmenorrhoea ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.28, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.3 Dyspareunia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.67, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.4 Pelvic induration ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.95, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.5 Pelvic tenderness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.78, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Relief of overall pain ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Pelvic pain ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.50 [‐3.55, ‐1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 Dyspareunia ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐2.83, ‐1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.3 Back pain ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐0.40, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.4 Overall pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.48, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.5 Pelvic pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐0.88, ‐0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.6 Absolute reduction mean VAS ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐8.49, 5.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.7 Dysmenorrhoea ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.8 Dyspareunia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.42, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.9 Lumbago‐ mean change ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐8.20, 5.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.10 Lumbago ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.39, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.11 Lower abdominal pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.45, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.12 Dyschezia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.14, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.13 Pain on internal examination ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.33, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.14 Lower abdominal pain, mean change ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [‐5.19, 10.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.15 Pelvic induration ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.04, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.16 Pelvic tenderness‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.33, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.17 Pelvic pain ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐0.75, ‐0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.18 Overall pain ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [‐2.13, 9.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.19 Dysmenorrhoea ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.20 Dyspareunia ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.13, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Bone mineral density of spinal bone mass ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 Percentage change values ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐2.57, ‐0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.2 Absolute values ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.08, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.3 Absolute values ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.10, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Adverse effects ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.1 Vaginal bleeding ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.23, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.2 Headache ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.88, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.3 Weight gain ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.10, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.4 Vaginal dryness ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.75 [1.66, 13.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.5 Hot flushes ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [1.87, 4.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.6 Acne ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.40, 3.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.7 Alopecia ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.49, 3.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.8 Decreased libido ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.48, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.9 Vaginal dryness ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.54, 7.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.10 Weight gain ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.68, 4.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.11 Nausea ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.30, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.12 Headache ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>815</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.04, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.13 Breast pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.22, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.14 Intermenstrual bleeding ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>902</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.50, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.15 Hot flushes/flashes ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>902</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [1.70, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.16 Emotional changes ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.21 [1.64, 16.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.17 Insomnia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.59, 8.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.18 Decreased libido ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.59, 8.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Adverse effects ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.1 Climacteric symptoms by Kupperman index ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.80 [2.37, 11.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.2 Hot flushes/flashes ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.71, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.3 Depression ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.18, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.4 Oedema ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.14, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.5 Headache ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.32, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.6 Breast pain ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.39, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.7 Metrorrhagia ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.31, ‐0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Quality of life ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.1 Bodily pain ‐ 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.70 [‐10.81, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.2 General health ‐ 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐2.58, 3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.3 Physical function ‐ 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐3.66, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.4 Role physical ‐ 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.50 [‐12.01, 5.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.5 Role emotional ‐ 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.80 [‐16.67, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.6 Mental health ‐ 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐4.04, 4.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.7 Social function ‐ 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.80 [‐9.98, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.8 Vitality ‐ 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐5.41, 4.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.9 General health ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.70 [‐1.97, 9.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.10 Physical function ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [‐3.72, 7.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.11 Role physical ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [‐4.15, 6.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.12 Role emotional‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.20 [‐1.60, 10.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.13 Mental health‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐4.39, 5.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.14 Social function ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐6.93, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.15 Vitality ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐4.94, 8.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Improvement of most troublesome symptoms ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.1 Complete resolution ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.79, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.8 Improvement of most troublesome symptoms ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.1 Overall symptoms by numerical rating scale ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [0.37, 4.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.2 Overall symptoms by verbal rating scale ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.06, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8.3 Overall symptoms ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐1.52, 0.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">GnRHas versus oral or injectable progestogens ‐ all studies included</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014788-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">GnRHas versus gestrinone ‐ all studies included</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Relief of overall pain ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 Dysmenorrhoea, visual analog scale ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 Dysmenorrhoea, verbal rating scale ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.3 Dyspareunia, visual analog scale ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.04, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.4 Dyspareunia, verbal rating scale ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [‐0.12, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.5 Non‐menstrual pain, visual analog scale ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [‐0.59, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.6 Non‐menstrual pain, verbal rating scale ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.36, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.7 Dysmenorrhoea, visual analog scale ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.82 [‐1.49, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.8 Dysmenorrhoea, verbal rating scale ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐0.58, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.9 Dyspareunia, visual analog scale ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.25, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.10 Dyspareunia, verbal rating scale ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.11 Non‐menstrual pain, visual analog scale ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [‐0.94, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.12 Non‐menstrual pain, verbal rating scale ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.20, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Bone mineral density of spinal bone mass ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Percentage change values ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.96 [‐3.62, ‐0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 Percentage change values ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.10 [‐7.39, ‐2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Adverse effects ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 Hot flushes/flashes ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.21, 4.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.2 Headache ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.41 [0.51, 11.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.3 Asthenia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.03, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.4 Mood change ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.26, 7.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.5 Dermatitis ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.6 Dizziness‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.05, 5.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.7 Joint pain‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.05, 5.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.8 Drowsiness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.05, 5.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.9 Swelling ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.01, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.10 Nausea‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.05, 5.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.11 Tachycardia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.05, 5.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.12 Vaginal dryness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.83 [0.24, 96.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.13 Insomnia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.14 Hypertrichosis ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.15 Seborrhea‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.16 Skin rash ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.17 Constipation ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.18 Itching ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [0.12, 68.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.19 Vaginal discharge ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [0.12, 68.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.20 Paresthesia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [0.12, 68.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.21 Cramps ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [0.12, 68.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">GnRHas versus gestrinone ‐ all studies included</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014788-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">GnRHas versus GnRHas (varying dosage) ‐ all studies included</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Relief of overall pain ‐ 200 μg versus 400 μg nafarelin ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 Pelvic pain ‐ 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐1.07, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.2 Pelvic pain ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐1.07, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.3 Pelvic pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.61, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Relief of overall pain ‐ 400 μg versus 800 μg nafarelin ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 Pelvic pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.71, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.2 Dysmenorrhea ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 71.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.3 Dyspareunia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.49, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Adverse effects ‐ 200 μg versus 400 μg nafarelin ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.1 Vasomotor symptoms (hot flashes or dizziness) ‐ 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.17, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.2 Vasomotor symptoms (hot flashes or dizziness) ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.10, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.3 Vasomotor symptoms (hot flashes or dizziness) ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.08, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.4 Rhinitis ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.10, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.5 Upper respiratory infection ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.03, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.6 Irregular bleeding ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.31, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Adverse effects ‐ 3.75 mg versus 1.88 mg leuprolide acetate ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.1 Menopausal symptoms by Kupperman Index ‐ 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐3.14, 5.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.2 Menopausal symptoms by Kupperman Index ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.70 [2.12, 9.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.3 Menopausal symptoms by Kupperman Index ‐ 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.50 [6.55, 12.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.4 Menopausal symptoms by Kupperman Index ‐ 5 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.20 [10.22, 16.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 Improvement of most troublesome symptoms ‐ 400 μg versus 800 μg nafarelin ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.1 Overall improvement ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.78, 1.14]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">GnRHas versus GnRHas (varying dosage) ‐ all studies included</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014788-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">GnRHas versus GnRHas (duration of treatment) ‐ all studies included</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Relief of overall pain ‐ 3 months vs 6 months ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 Pelvic pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.13, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.2 Dysmenorrhoea ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.11, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.3 Dyspareunia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.17, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.4 Pelvic induration ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.06, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.5 Pelvic tenderness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.03, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Bone mineral density of spinal bone mass ‐ 3 months vs 6 months ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 Percentage change values ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.51, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Bone mineral density of proximal femoral bone ‐ 3 months vs 6 months ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.1 Percentage change values ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [1.72, 2.08]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">GnRHas versus GnRHas (duration of treatment) ‐ all studies included</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014788-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">GnRHas versus GnRHas (route of administration)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Relief of overall pain ‐ IN versus SC ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 Pelvic pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.53, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.2 Dysmenorrhea ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.73, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.3 Dyspareunia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.57, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.4 Pelvic induration ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.47, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.5 Pelvic tenderness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.69, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Adverse effects ‐ IN vs SC ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.1 Hot flushes/flashes ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.48, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.2 Vaginal dryness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.17, 4.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.3 Decreased libido ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.07, 10.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.4 Headaches ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.20, 14.55]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">GnRHas versus GnRHas (route of administration)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014788-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">GnRHas versus GnRHas (route of administration) ‐ all studies included</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Relief of overall pain ‐ IN versus SC ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 Pelvic pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.53, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.2 Dysmenorrhoea ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.73, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.3 Dyspareunia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.57, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.4 Pelvic induration ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.47, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.5 Pelvic tenderness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.69, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Relief of overall pain ‐ IN versus IM ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.1 Pelvic pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.73, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.2 Dysmenorrhoea ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.72, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.3 Dyspareunia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.62, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.4 Pelvic induration ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.82, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.5 Pelvic tenderness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.88, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Adverse effects ‐ IN vs SC ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.1 Hot flushes/flashes ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.48, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.2 Vaginal dryness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.17, 4.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.3 Decreased libido ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.07, 10.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.4 Headaches ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.20, 14.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 Adverse effects ‐ IN versus IM depot ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.1 Hot flushes/flashes ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.2 Headache ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.63, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.3 Sweating ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.71, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.4 Vaginal dryness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.27, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.5 Vaginal bleeding ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.19 [1.12, 328.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.5 Bone mineral density of spinal bone mass ‐ IN vs IM depot ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5.1 Percentage decrease of BMD ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐2.10, ‐1.90]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">GnRHas versus GnRHas (route of administration) ‐ all studies included</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014788-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">GnRHas versus GnRHas (different treatment regimens) ‐ all studies included</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Relief of overall pain ‐ monthly versus 3‐monthly depot leuprolide acetate ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 Non‐menstrual pelvic pain ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.52, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.2 Dyspareunia ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.51, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.3 Pelvic induration ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.40, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.4 Pelvic tenderness ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.71, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.5 Non‐menstrual pelvic pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.15, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.6 Dyspareunia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.50, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.7 Pelvic induration ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.10, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.8 Pelvic tenderness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.10, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Adverse effects ‐ monthly versus 3‐monthly depot leuprolide acetate ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.1 Hot flushes/flashes ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.70, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.2 Vaginal dryness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.13, 3.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.3 Abdominal pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 68.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.4 Arthralgia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 68.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.5 Depression ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 68.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">GnRHas versus GnRHas (different treatment regimens) ‐ all studies included</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014788-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">GnRHas versus GnRHas in conjunction with add‐back therapy ‐ all studies included</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Relief of overall pain ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.1 Dysmenorrhoea ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.62 [0.58, 159.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.2 Dyspareunia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.07 [0.86, 43.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.3 Non‐menstrual pelvic pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.26, 6.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Relief of overall pain ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.1 Pelvic pain ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.39, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.2 Dysmenorrhoea ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.3 Dyspareunia ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.40, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.4 Pelvic pain ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.14, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.5 Overall pain ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐7.92, 4.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.6 Dysmenorrhoea ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.7 Dyspareunia ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.03, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Bone mineral density of spinal bone mass ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.1 Percentage change values ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.88 [‐4.27, ‐3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.2 Absolute values ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.02, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.3 Absolute values ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.06, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.4 Adverse effects ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.1 Hot flushes/flashes ‐ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.61, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.2 Hot flushes/flashes ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.32, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.3 Loss of libido ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.58, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.4 Vaginal dryness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.11, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.5 Headaches ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.67, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.6 Sweating ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.31, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.7 Sleeplessness ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.18, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.8 Peripheral oedema ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [0.54, 9.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.9 Vaginal bleeding ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.35, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.10 Rhinitis ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.36, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.11 Upper respiratory infection ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.27, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4.12 Emotional changes ‐ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [1.26, 7.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.5 Quality of life ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.1 General health ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.70 [‐10.15, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.2 Physical function ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.80 [‐14.81, ‐2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.3 Role physical ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [‐3.13, 8.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.4 Role emotional ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [‐3.82, 8.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.5 Mental health ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐6.17, 5.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.6 Social function ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.80 [‐8.80, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5.7 Vitality ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.20 [‐15.18, ‐5.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.6 Improvement of most troublesome symptoms ‐ continuous  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.6.1 Improvement overall pain ‐ 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.00 [5.59, 18.41]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">GnRHas versus GnRHas in conjunction with add‐back therapy ‐ all studies included</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014788-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">GnRHas versus GnRHas in conjunction with calcium‐regulating agents</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Bone mineral density of spinal bone mass ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.1 Anterior‐posterior spine ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.00 [‐7.53, ‐6.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.2 Lateral spine ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.40 [‐13.31, ‐11.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.2 Improvement of most troublesome symptoms ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.1 Overall improvement ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.84, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.2 Complete resolution ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.64, 1.41]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">GnRHas versus GnRHas in conjunction with calcium‐regulating agents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014788-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">GnRHas versus GnRHas in conjunction with calcium‐regulating agents ‐ all studies included</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 Bone mineral density of spinal bone mass ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.1 Anterior‐posterior spine ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.00 [‐7.53, ‐6.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.2 Lateral spine ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.40 [‐13.31, ‐11.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.2 Improvement of most troublesome symptoms ‐ dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.1 Overall improvement ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.84, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.2 Complete resolution ‐ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.64, 1.41]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">GnRHas versus GnRHas in conjunction with calcium‐regulating agents ‐ all studies included</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014788.pub2/references#CD014788-tbl-0022">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD014788.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD014788-note-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD014788-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD014788-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD014788-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hu#CD014788-note-0013">Magyar</a> </li> <li class="section-language"> <a class="" href="ms#CD014788-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ro#CD014788-note-0014">Română</a> </li> <li class="section-language"> <a class="" href="th#CD014788-note-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD014788-note-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD014788-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014788\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014788\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014788\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014788\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014788\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014788\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014788\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014788\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014788\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014788\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014788\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014788\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014788\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014788\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014788\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014788\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014788\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014788\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014788.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014788.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD014788.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD014788.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014788.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714279425"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014788.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714279429"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014788.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6ac4ab3bf3cd',t:'MTc0MDcxNDI3OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 